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Abstract 
 
The downstream of tyrosine kinase (Dok) protein family has seven members, Dok 1-7. 
The precise role of these proteins is not entirely clear although some authors have 
suggested a potential tumour suppressor role. The aims of this clinically oriented PhD 
were to determine the expression profile and role of DOK7 in human colorectal cancer, 
to determine whether DOK7 expression is associated with tumour pathology and clinical 
outcome data, to determine the functional role of DOK7 in colorectal cancer cells and to 
evaluate DOK7 coordinated cell signalling in colorectal cancer.  
 
Initial work revealed that DOK7 mRNA expression is significantly reduced in colorectal 
cancer tissue compared with normal colorectal tissue and is associated with overall 
survival in patients with colorectal cancer. DOK7 is variably expressed in colorectal 
cancer cell lines with high expression in HRT-18 cells and low expression in HT-115 
and RKO cells. Difficulties in obtaining DOK7 knockdown and expression subsequently 
revealed that DOK7 has several splice variants coding for different isoforms.  
 
Further work investigating DOK7 variants 1-3 (DOK7V1-3) revealed that DOK7V1 
mRNA expression is significantly reduced in colorectal cancer tissue compared with 
normal colorectal tissue and is associated with disease-free status and length of disease-
free survival. In contrast, DOK7V2 and DOK7V3 mRNA expression is significantly 
increased in colorectal cancer tissue compared with normal colorectal tissue.  
 
Functional assays using a DOK7V2 overexpression model did not show a significant 
difference in colorectal cancer cell growth, adhesion or invasion in RKO DOK7V2 
overexpression cells compared to the control cell line.  
 
 XXIII 
However, antibody based protein microarray revealed that DOK7V2 overexpression is 
associated with significant changes in the expression and phosphorylation (activation) of 
numerous proteins in RKO cells. Cell signalling pathways potentially implicated include 
PI-3K-Akt, mTOR, MAPK, Jak/STAT and angiogenesis signalling pathways.  
 
Our findings suggest that DOK7 plays an important role in colorectal carcinogenesis and 
that DOK7 isoforms may play different and possibly opposing roles. Protein microarray 
data provides a number of potential avenues for further work to elucidate the interaction 
of Dok7 with other cell signalling proteins and may help identify future potential 
therapeutic targets.  
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1.1 Colorectal cancer 
 
1.1.1 Introduction  
 
Colorectal cancer is one of commonest cancers worldwide, with 1,361,000 cases in 2012 (1). 
It remains the third commonest cancer in men (746,000 cases in 2012, 10.1% of all cancers) 
and the second commonest cancer in women (614,000, 9.2% of all cancers) (1). The 
estimated age-standardised incidences of colorectal cancer per 100,000 of the population by 
gender from the most recent GLOBOCAN figures are illustrated in Figure 1.1. 
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A. 
 
 
B. 
 
Figure 1.1 Age-standardised colorectal cancer incidence worldwide in 2012 A. Age-
standardised incidence per 100,000 men B. Age-standardised incidence per 100,000 women. 
Map from most recent GLOBOCAN figures (IARC) 2012 (1) 
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There is wide geographical variation in incidence, with the majority of cases (54.2%) 
occurring in more developed countries (1).  The highest incidence rates are seen in Australia 
and New Zealand, with the lowest incidence seen in Western Africa (1). Potential causes for 
the geographical variation seen include differences in diet (particularly with regard to 
consumption of meat, fibre and animal fats), levels of physical activity and obesity and 
possibly differences in genetic susceptibility to dietary carcinogens (2, 3).  
 
In the UK, colorectal carcinoma is the fourth commonest cancer with 41,300 newly diagnosed 
cases in 2014 and accounts for 12% of all new cancers diagnosed in the UK per year (4). It is 
the third most common cancer in both men (22,800 cases diagnosed in 2014, 12% of all nale 
cancers) and women (18,400 cases diagnosed in 2014, 10% of all female cancers) (4). The 
crude incidence rate for men and women in the UK is 72 and 56 per 100,000 respectively, 
giving a male: female ratio of approximately 12:10 (4). In the UK, the European Age-
Standardised incidence of colorectal cancer has risen by 6% over the last decade and World 
Health Organisation figures predict that the incidence of colorectal cancer will continue to 
rise, with a forecasted incidence of 58,119 in the year 2035 (1, 4). In the UK, the European 
age-standardised incidence rates of bowel cancer in people aged 60-69 years rose by 14% 
between 2004-2006 and 2008-2012 (4). It is likely that this is due to the introduction of bowel 
screening during that period (4).   
 
In 2012, the lifetime risk of developing bowel cancer was 1 in 14 for men and 1 in 19 for 
women, highlighting the important public health problem that this cancer poses (4).  
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1.1.2 Mortality 
 
Five-year survival rates for colorectal cancer have doubled over the last 40 years. For men 
with bowel cancer, 1-year age standardised net survival has increased from 47% to 77% and 
the 5-year age-standardised net survival has increased from 25% to 59% over the time period 
from 1971-1972 to 2010-2011 (5). For women with bowel cancer, 1-year age-standardised net 
survival has increased from 45% to 74% and 5-year age-standardised net survival has 
increased from 24% to 58% over the same time period (5). The most recent Cancer Research 
UK figures for the age-standardised one-, five- and ten-year net survival rates for adults with 
bowel cancer in England and Wales are shown in Table 1.1.   
 
Table 1.1 Age-standardised one-, five- and ten-year net survival for adults aged 15-99 with 
bowel cancer in England and Wales in 2010-2011. Data from Cancer Research UK: Bowel 
cancer survival statistics (5). 
 
Net survival  1-year survival (%) 5-year survival (%) 10-year survival (%) 
Men 77.4 59.2 56.0 
Women 73.9 58.2 57.2 
Both sexes 75.7 58.7 56.6 
 
 
Despite improvements in survival, colorectal cancer resulted in 694,000 deaths worldwide in 
2012 (1). In the UK, it remains the second commonest cause of cancer related death 
accounting for 10% of all cancer deaths and in 2014, 15,900 patients died of the disease – 44 
each day (6). Worldwide, mortality rates from colorectal cancer vary with the highest 
estimated mortality rates seen in Central and Eastern Europe and the lowest in Western Africa 
(1).  
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Within Europe, 5-year survival is highest in Central European countries (over 60%), followed 
by Northern Europe and Italy, with levels significantly lower in the UK and Slovenia (around 
50%) and lowest in Eastern European countries (7). It has been suggested that poorer 
colorectal cancer survival in the UK may be due to more advanced disease at presentation, 
although this assertion has been challenged (8, 9). Nevertheless, a significant proportion of 
patients present with advanced disease (at the time of diagnosis, 55% of patients have stage 
III or IV disease and 26% have metastases) and this is related to survival outcomes (4).  
 
Currently, there is great variation worldwide in screening strategies for colorectal cancer and 
their implementation (10). Strategies for screening include non-invasive stool tests such as 
guaiac faecal occult blood test (gFOBT) and faecal immunochemical test for haemoglobin 
(FIT), and invasive tests such as flexible sigmoidoscopy, colonoscopy and CT colonography 
(10). More recently, newer screening strategies to detect DNA, RNA or protein in blood or 
stool have become available alongside imaging tests such as colon capsule endoscopy and 
magnetic resonance colonography (10). Globally, there are also differences in the delivery of 
screening with some countries offering an organised screening programme and others, taking 
a more opportunistic approach. Generally, the implementation of organised screening 
programmes has been higher in Western countries with higher incidences of colorectal cancer 
(10). Analysis of 2012 GLOBOCAN incidence and mortality statistics has revealed that 
countries with formal colorectal cancer screening programmes have lower than expected 
mortality-to-incidence ratios for colorectal cancer whereas countries with no screening 
programmes have higher than expected mortality-to-incidence ratios (11). This suggests that 
global differences in screening strategies may have an effect on global variations in colorectal 
cancer mortality. 
 
Five-year relative survival by stage at diagnosis is shown in Table 1.2. As the data shows, 
survival decreases markedly with increasing stage of disease, highlighting the importance of 
early diagnosis. 
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Table 1.2 Five-year relative survival (%) by stage of disease at diagnosis in adults aged 15-99 
presenting with colorectal cancer in the former Anglia Cancer Network, UK from 2006-2010. 
Data from Cancer Research UK: Bowel cancer survival statistics (5).   
 
Stage  Men Women 
Stage I 94.6 100.2 
Stage II 83.5 85.9 
Stage III 62.6 62.7 
Stage IV 6.9 8.1 
All Stages 58.2 61.1 
Stage not known 18.7 15.1 
 
 
Advanced colorectal cancers may present as an emergency. Recent data from Public Health 
England shows that 25% of colorectal cancers present as an emergency and that this is 
associated with reduced survival (12). One-year relative survival is estimated to be 49% for 
patients presenting as an emergency compared to 82% for those patients presenting via the 
urgent suspected two-week wait outpatient clinic (12). Factors contributing to a late or 
emergency presentation include patient factors such as older age, female gender, high 
deprivation index, and unmarried, divorced or widowed marital status and hospital or 
physician associated factors such as incomplete colonic imaging, false-negative 
investigations, inappropriate surgical treatment, administrative delays and the commencement 
of iron therapy in patients with iron deficiency anaemia without investigation to establish a 
cause for blood loss (13, 14).   
 
Overall, differences in cancer survival rates may be attributed to four main factors: (1) stage 
at diagnosis, which may be influenced by diagnostic delay (2) the outcomes of treatments 
including surgery, chemotherapy, hormonal therapy or radiotherapy, (3) patient factors such 
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as age, fitness, co-morbidities and socio-economic factors and (4) the characteristics of the 
tumour (15).  
 
1.1.3 Anatomy of the colon and rectum 
 
The large intestine is approximately 1.5m in length and extends from the caecum to the anus 
(16). It comprises the caecum, appendix, colon, rectum and anal canal and its primary 
function is to absorb fluid from the bowel content resulting in formed stools (16). This study 
focuses on cancers affecting the large intestine from the caecum to the rectum (referred to 
interchangeably as colorectal or bowel cancers) but excludes those affecting the anal canal 
(anal cancers).  
 
The large intestine begins at the caecum, located in the right iliac fossa (16). Bowel content 
enters the caecum from the terminal ileum via the ileocaecal valve (16). From the caecum, the 
large intestine continues upwards as the ascending colon and then bends to the left at the right 
colic flexure (or hepatic flexure) becoming the transverse colon which runs transversely 
across the upper abdomen (16). In the left upper quadrant, the large intestine bends 
downwards at the left colic flexure (or splenic flexure) and continues as the descending colon 
(16). At the pelvis, it becomes the sigmoid colon and at the third sacral vertebra the sigmoid 
colon ends and the large intestine continues as the rectum (16). The large intestine has a 
number of structural characteristics that help to differentiate it from the small intestine. It has 
a wider lumen, it’s longitudinal muscle is separated into three bands called taeniae coli, it has 
appendices of fat on its outer surface called appendices epiploicae and it is drawn into 
sacculations giving rise to colonic haustra (16).  
 
The caecum, transverse colon and sigmoid colon are intraperitoneal structures, meaning that 
they are mobile within the peritoneal cavity and the transverse and sigmoid colon are also 
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suspended on a mesocolon (16). By comparison, the ascending and descending colon and the 
rectum are retroperitoneal structures (16). 
 
The blood supply to the colon is split according to the embryological origin of the large 
intestine. The large intestine from the caecum as far round as the latter two-thirds of the 
transverse colon arises from the embryonic midgut and is therefore supplied by branches of 
the superior mesenteric artery, namely the ileocolic artery (giving rise to the anterior and 
posterior caecal arteries, the appendicular artery and the colic artery), the right colic artery 
and the middle colic artery (16). The remainder of the large intestine from the latter one-third 
of the transverse colon as far down as the dentate line arises from the embryological hindgut 
and consequently is supplied by branches of the inferior mesenteric artery, namely the left 
colic artery, the sigmoidal arteries and the superior rectal artery (16). The blood supply of the 
lower one-third of the anal canal arises from branches of the internal iliac artery, namely the 
middle rectal artery and the internal pudendal artery which gives rise to the inferior rectal 
artery (16). The superior and inferior mesenteric veins provide the venous drainage of the 
large intestine above the dentate line and drain the territories supplied by the corresponding 
arteries into the portal vein. Venous blood from the lower one-third of the anal canal drains 
into the internal iliac veins and from there into the common iliac veins and subsequently the 
inferior vena cava. Consequently the rectum is one of several sites in the body where there are 
porto-systemic anastomoses. 
 
1.1.4 Anatomical site of colorectal cancer 
 
The majority of bowel cancers occur in the left side of the bowel with around 57% of cases 
diagnosed between 2007-2009 being located in the descending colon, sigmoid colon, 
rectosigmoid junction or rectum (4). The anatomical distribution of bowel cancers diagnosed 
in Great Britain between 2007-2009 is illustrated in Figure 1.2.  
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Figure 1.2 Anatomical distribution of large bowel cancers diagnosed in Great Britain between 
2007-2009. Figure obtained from Cancer Research UK: Bowel cancer incidence statistics (4).    
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Although left-sided bowel cancers remain more prevalent, several authors report a shift 
towards more proximal tumours over recent decades in several countries emphasizing the 
importance of complete colonic assessment (17-20). Furthermore, previous studies have 
identified a number of differences in the presentation, prognosis and underlying genetic and 
epigenetic changes between proximal and distal colonic tumours leading some authors to 
speculate that left- and right-sided colonic cancers may represent different tumours (21). For 
example, microsatellite instability is more common in tumours located proximal to the splenic 
flexure whereas chromosomal instability is more common in more distal tumours (22, 23). 
The causes of these differences in tumours of different anatomical location and the apparent 
“proximal shift” of colon cancer are uncertain but causes may include differences in 
embryological origin or physiology or differences in exposure to environmental factors or 
susceptibility to dietary factors or alcohol (23).  
 
1.1.5 Histopathological features of colorectal cancer 
 
More than 95% of colorectal cancers are adenocarcinomas, which originate in the glandular 
lining of the bowel wall. Most adenocarcinomas arise within pre-existing adenomatous polyps 
or adenomas, which have an estimated prevalence of around 35% in Western countries and 
around 10-15% in Asia and Africa (24). Adenomas can be further classified according to their 
architecture as tubular, villous, tubulovillous or serrated (24). It is estimated that around 5% 
of adenomatous polyps become malignant over a period of 5-10 years and features associated 
with higher malignant potential include villous architecture, large size, and high-grade 
epithelial dysplasia (24).   
 
Histological subtypes of colorectal adenocarcinomas include mucinous adenocarcinomas, 
which account for 5-15% of all colorectal cancers, and signet ring tumours, which account for 
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around 1% of colorectal cancers (25, 26). These are treated in the same way as other 
adenocarcinomas (25). 
 
Other rare types of colorectal cancer include squamous cell carcinomas, carcinoid tumours, 
sarcomas and lymphomas (25). The full WHO histological classification of tumours of the 
colon and rectum is shown in Table 1.3. The work discussed in this thesis focuses on 
colorectal adenocarcinomas and therefore, these rarer types will not be discussed further. 
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Table 1.3 WHO histological classification of tumours of the colon and rectum.  Adapted from 
Hamilton SR, Aaltonen LA (Eds.): World Health Organisation Classification of Tumours. 
Pathology and Genetics of Tumours of the Digestive System. IARC Press: Lyon 2000 (27). 
 
Epithelial 
tumours 
Adenoma 
 
 
 
 
 
 
 
 
 
Intraepithelial 
neoplasia 
(dysplasia)  
 
 
 
 
 
Carcinoma 
 
 
 
 
 
 
 
 
 
 
Carcinoid 
 
 
 
 
 
 
Mixed 
carcinoid-
adenocarcinoma 
 
Others 
 
 
 
Tubular 
Villous 
Tubulovillous 
Serrated 
 
 
 
 
 
Low-grade glandular 
intraepithelial neoplasia 
High-grade glandular 
intraepithelial neoplasia 
 
 
Adenocarcinoma 
Mucinous adenocarcinoma 
Signet-ring cell carcinoma 
Small cell carcinoma 
Squamous cell carcinoma 
Adenosquamous carcinoma 
Medullary carcinoma 
Undifferentiated carcinoma 
 
 
 
EC-cell, serotonin-producing 
neoplasm 
L-cell glucagon-like peptide 
and PP/PYY producing tumour 
Others 
 
 
 
Non-epithelial tumours 
Lipoma 
Leiomyoma 
Gastrointestinal stromal 
tumour 
Leiomyosarcoma 
Angiosarcoma 
Kaposi sarcoma 
Malignant melanoma 
Others 
 
 
Malignant lymphomas 
 
 
 
 
 
 
 
 
 
 
Secondary tumours 
 
 
Polyps 
Hyperplastic (metaplastic) 
Peutz-Jeghers 
Juvenile 
 
 
 
 
 
 
 
Marginal zone B-
cell lymphoma of 
MALT type 
Mantle cell 
lymphoma 
Diffuse large B-cell 
lymphoma 
Burkitt lymphoma 
Burkitt-like/atypical 
Burkitt-lymphoma 
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1.1.6 Histopathological grading of colorectal cancer 
  
The histopathological grading of colorectal cancers is based on the extent of glandular 
appearance (27). Well-differentiated tumours are those in which glandular structures are 
exhibited in >95% of the tumour, moderately differentiated tumours are those in which 
glandular structures are seen in 50-95% of the tumour and poorly differentiated tumours are 
those in which 5-50% of the tumour has glandular structures (27). Mucinous and signet-ring 
cell carcinomas are considered to be poorly differentiated carcinomas.  
 
1.1.7 Colorectal cancer spread 
 
Colorectal carcinomas may breach the muscularis propria and spread directly to involve 
adjacent structures or perforate, resulting in transcoelomic spread to the peritoneal cavity 
(27). Alternatively, spread may occur via the blood or lymphatic vessels resulting in systemic 
disease. Common distant metastatic sites include the liver and lungs. 
 
1.1.8 Adenoma-carcinoma sequence 
 
The process of colorectal cancer development from normal tissue is amongst the best 
understood of all cancers. It has long been recognised that colorectal carcinomas often arise 
from pre-existing benign tumours known as adenomas, and the age-linked incidence of cancer 
suggests that tumour development occurs as a result of mutations acquired in a multistep 
fashion (28).  
 
Over recent decades, the molecular and histopathological changes occurring during various 
stages of tumour development from tiny adenoma to advanced metastatic carcinoma have 
been studied and we now understand colorectal carcinogenesis to be a complex multistep 
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process that involves numerous genetic and epigenetic modifications. This knowledge has 
generated a model of colorectal cancer development usually referred to as the adenoma-
carcinoma sequence. 
 
The genetic model of colorectal tumourigenesis proposed by Fearon and Vogelstein is shown 
in Figure 1.3. Tumourigenesis occurs as a result of accumulated (inherited or acquired) 
genetic mutations in oncogenes (such as Ras) and tumour suppressor genes (such as those 
found on chromosomes 5q, 17p and 18q) resulting in their activation and suppression, 
respectively (29).  Although temporal relationships in the occurrence of genetic mutations can 
be inferred from studies of normal, adenomatous and carcinomatous tissue, it is the 
progressive accumulation of these defects, rather than their order of occurrence, that is most 
crucial to the process of tumourigenesis (29). 
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Figure 1.3 Genetic model for colorectal tumourigenesis. Adapted from ‘A Genetic Model for 
Colorectal Tumourigenesis’ Fearon & Vogelstein (1990) (29).  
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1.1.9 Aetiology and risk factors 
 
The development and progression of colorectal cancer is dependent on the complex 
interaction of genetic, epigenetic and environmental factors.   
 
1.1.9.1 Genetic/epigenetic factors 
 
The genetic factors contributing to colorectal cancer development can be divided into those 
relating to chromosomal instability, where there are mutations in oncogenes or tumour 
suppressor genes, and those relating to microsatellite instability, due to mutations in mismatch 
repair genes. Epigenetic changes such as hyper/hypomethylation may also play a role in 
cancer development by altering the stability of the genome, increasing the rate of 
accumulation of genetic defects within the cell (29).  
 
1.1.9.1.1 Oncogenes in colorectal cancer 
 
Oncogenes are activated by “gain of function” mutations resulting in over, or aberrant, 
expression of their gene product resulting in the subsequent stimulation of cell growth or 
inhibition of cell death (30).  
 
1.1.9.1.1.1 Ras (Rat sarcoma) oncogenes 
 
The Ras proteins are involved in cell signal transduction acting as effectors in the mitogen-
activated protein kinase (MAPK) pathway downstream of epidermal growth factor receptor 
(EGFR) (31). EGFR is a tyrosine kinase receptor that, via its interaction with its ligand 
epidermal growth factor (EGF) stimulates cell proliferation, differentiation and survival (32, 
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33). The ras proteins were discovered as a result of observations made by Jennifer Harvey in 
1964, that the injection of mice with Moloney’s leukaemogenic virus resulted in the 
development of tumours (34).  
 
The three human ras genes, HRAS, KRAS and NRAS, are the commonest oncogenes 
implicated in human cancer and studies have shown that mutations of the ras genes are 
important in the development of pancreatic, thyroid and lung cancer, amongst other human 
cancers (32, 35, 36).  
 
The first studies of the Ras oncogenes in colorectal cancer date back to the early 1980s when 
Feinberg and Vogelstein reported the hypomethylation of HRAS and KRAS in colonic 
adenocarcinomas (37). Later, in 1984, Spandidos and Kerr confirmed that KRAS and HRAS 
are overexpressed in pre-malignant adenomatous polyps and malignant colorectal tumours 
(38).    
  
Ras gene mutations are found in over a third of colorectal cancers, as well as in over 50% of 
adenomas greater than 1cm in size suggesting they precede cancer development and play a 
role in the early stages of tumourigenesis (33, 39, 40). However, ras gene mutations are less 
common in small adenomas less than 1cm, where prevalence is less than 10% (40). Mutations 
of the KRAS gene result in activation of the MAPK pathway and in metastatic colorectal 
cancer, they have been shown to predict treatment resistance to anti-EGFR monoclonal 
antibodies (31).    
 
1.1.9.1.2 Tumour suppressor genes in colorectal cancer 
 
Tumour suppressor genes are affected by “loss of function” mutations in cancer resulting in 
reduced expression of a gene product that usually stimulates apoptosis or differentiation, or 
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which inhibits cell growth (30). Knudson hypothesized that both maternal and paternal copies 
of a tumour suppressor gene must be inactivated in order to eliminate their function but in 
practice, it is likely that some tumour suppressor genes act in a dominant negative fashion, 
exerting their phenotypic effect even in the presence of a wild-type allele (29).   
 
1.1.9.1.2.1 Adenomatous polyposis coli (APC) gene 
 
The adenomatous polyposis coli (APC) gene is a tumour suppressor gene located on 
chromosome 5q21 (41).  It encodes a 312kDa protein, involved in the control of cell 
proliferation and differentiation via the Wnt signalling pathway, which is inactivated in the 
early stages of colorectal cancer (30). In patients with familial adenomatous polyposis (FAP), 
there is an inherited mutation in the APC gene but mutation or loss of this gene may also 
occur sporadically at an early stage in the process of colorectal tumourigenesis in patients 
without FAP (29).  
 
1.1.9.1.2.2 p53 
 
The TP53 gene is located on chromosome 17p. Loss of p53 is observed in over 75% of 
colorectal cancers (and a smaller proportion of colorectal adenomas) and is associated with 
the presence of distant metastases and cancer-related death (40, 42). 
 
1.1.9.1.2.3 Deleted in colorectal cancer (DCC) gene 
 
The deleted in colorectal cancer (DCC) gene is a tumour suppressor gene located on 
chromosome 18q (29). Loss of this allele is found in over 70% of colorectal carcinomas, 47% 
of advanced adenomas, but less than 15% of early adenomas (40).   
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1.1.9.1.3 Microsatellite instability 
 
Microsatellite instability occurs as a result of impaired DNA mismatch repair (MMR), such 
that the correction of spontaneous errors occurring during DNA replication does not take 
place. Consequently, cells with defective MMR accumulate errors and contain novel 
microsatellite sequences in their DNA. Microsatellites are repeated sequences of up to six 
base pairs in length, which usually occur in introns but may also occur in coding regions.   
 
Inactivation of DNA MMR is associated with hereditary non-polyposis colorectal cancer 
(HNPCC) and is also seen in around 20% of sporadic colorectal cancers (43). The majority of 
patients with HNPCC have a germline mutation in one of the MMR genes (hMSH2 or 
hMLH1), whereas the majority of sporadic MSI cases are due to hypermethylation of the 
hMLH1 promoter (43). Germline mutations in hMSH6 are also seen but are associated with 
late-onset familial colorectal cancer and extra-colonic tumours (43).   
 
1.1.9.1.4 Inherited colorectal cancer syndromes 
 
The two most common inherited colorectal cancer syndromes are HNPCC and FAP, which 
together account for approximately 5% of all colorectal cancers (44). Other inherited 
syndromes associated with an increased risk of colorectal cancer include Peutz-Jeghers 
syndrome and Juvenile polyposis syndrome. As well as these defined inherited syndromes, 
around 20% of bowel cancers are associated with hereditary factors, likely due to as-yet-
undiscovered susceptibility genes with lower penetrance (45, 46).  
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1.1.9.1.4.1 Familial adenomatous polyposis (FAP) 
 
Familial adenomatous polyposis is an autosomal dominant condition, caused by a germline 
mutation in the APC gene on chromosome 5, that accounts for less than 1% of bowel cancers 
(47). It is characterised by the development of hundreds of thousands of adenomatous polyps 
in the colon and rectum beginning in childhood or adolescence. Colorectal cancer develops in 
almost 100% of patients by the age of 50, with an average age of onset of 39 years (48). 
Depending on the nature of the mutation, extra-colonic manifestations may also be found and 
these include gastric and duodenal polyps, desmoid tumours, osteomas, retinal lesions and 
brain tumours (30). Classical FAP, described above, differs clinically from attenuated FAP (a 
subtype of FAP) in that attenuated FAP is associated with the later development of colonic 
polyps, reduced polyp number and the later development of colorectal cancer. 
 
In patients with classical FAP, colectomy is recommended once adenomas emerge to prevent 
the almost inevitable development of colorectal cancer. Operative strategies include 
colectomy with ileorectal anastomosis, total proctocolectomy with permanent ileostomy or 
restorative proctocolectomy with pouch formation. 
 
1.1.9.1.4.2 Hereditary non-polyposis colorectal cancer (HNPCC)  
 
Hereditary non-polyposis colorectal cancer (HNPCC, also known as Lynch syndrome) is the 
commonest cause of inherited colorectal cancer and is also associated with an increased risk 
of other cancers including endometrial, ovarian, gastric, pancreatic, small bowel, ureteric and 
renal cancer (49). It accounts for 1-4% of colon cancers (47). HNPCC occurs due to inherited 
mutations in one of seven mismatch repair genes, shown in Table 1.4. Currently predictive 
testing in the UK focuses on four of these genes: MLH1, MSH2, MSH6 and PMS2 (50). 
Individuals at risk due to their family history or identified by predictive genetic testing are 
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offered additional bowel screening by colonoscopy, are educated about the symptoms of 
bowel cancer and are offered prophylactic colectomy. 
 
Table 1.4 Mismatch repair genes associated with HNPCC and their associated frequency in 
HNPCC. Data obtained from Medscape: Hereditary Colorectal Cancer webpage (51).  
 
Mismatch repair gene Chromosomal location Frequency of HNPCC cases  
MSH2 2p16 45-50% 
MLH1 3p22.3 20% 
MSH6 2p16 10% 
PMS2 7p22.1 1% 
PMS1 2q32.2 Rare 
MSH3 5q14.1 Rare 
EXO1 1q43 Rare 
Unidentified genes  20-25% 
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1.1.9.2 Individual patient factors 
 
1.1.9.2.1 Age 
 
The incidence of colorectal cancer is strongly related to age. Ninety five percent of patients 
diagnosed with bowel cancer are aged 50 or over, and roughly half of these (43% of all cases) 
are aged over 75 years (4). The age-specific incidence for colorectal cancer in the UK is 
shown in Figure 1.4.  
 
 
 
Figure 1.4 Average number of new cases per year and age-specific incidence rate for bowel 
cancer in the UK (2010-2012). Source: cruk.org/cancerstats (4).  
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1.1.9.2.2 Socio-economic factors 
 
There is an association between increasing socio-economic deprivation and bowel cancer 
incidence in men in England but no evidence for a similar association in females (4).  
 
1.1.9.2.3 Ethnicity 
 
The age-standardised incidence of bowel cancer is significantly higher in white males and 
females than for Asians or Black men and women (4). 
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1.1.9.3 Lifestyle and other risk factors 
 
It is estimated that 54% of cases of bowel cancer are associated with lifestyle or other 
environmental risk factors (52) The lifestyle or environmental factors associated with bowel 
cancer risk are shown in Table 1.5. 
 
Table 1.5 Lifestyle or environmental risk factors implicated in colorectal cancer.  
 
Risk factor Effect on bowel cancer risk 
a
 Percentage of bowel cancers in 
UK attributable to factor 
X radiation 
b
 
Gamma radiation 
b
 
Increases risk 2% 
Drinking alcohol 
c
 Increases risk 11% 
Tobacco smoking Increases risk 8% 
Red/processed meat Increases risk 21% 
Overweight/obesity Increases risk 13% 
Abdominal fatness Increases risk NQ 
Height Increases risk NQ 
Haem iron Possibly increases risk NQ 
Cheese Possibly increases risk NQ 
Dietary sugars Possibly increases risk NQ 
Dietary animal fat Possibly increases risk NQ 
Asbestos May increase risk NQ 
Schistosoma japonicum May increase risk NQ 
Physical activity 
d
 Decreases risk 3% due to inadequate physical 
activity 
Dietary fibre May decrease risk 12% due to inadequate dietary 
fibre 
Garlic May decrease risk NQ 
Calcium May decrease risk NQ 
Milk May decrease risk NQ 
Non-starchy vegetables Possibly decrease risk NQ 
Fruit Possibly decrease risk NQ 
Dietary folate Possibly decrease risk NQ 
Dietary/supplementary selenium Possibly decrease risk NQ 
Fish Possibly decrease risk NQ 
Dietary vitamin D Possibly decrease risk NQ 
 
NQ = not quantified 
a
 As classified by the World Cancer Research Fund/American Institute for Cancer Research 
(WCRF/AICR) 
b
 Evidence sufficient for colon but limited for rectum 
c
 Evidence convincing for males and probable for females 
d
 Evidence stronger for colon than rectum 
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1.1.9.4 Medical conditions 
 
The risk of developing colorectal cancer is increased in individuals with colorectal adenomas, 
inflammatory bowel disease, complicated diverticulitis, previous cancer, sarcoidosis, 
gallstones, metabolic syndrome and type II diabetes, though risk is actually lower in diabetics 
taking metformin. Furthermore, infection with the human papillomavirus (HPV) and 
Helicobacter pylori (H. pylori) are also associated with elevated bowel cancer risk. 
 
1.1.9.4.1 Inflammatory bowel diseases 
 
Patients with inflammatory bowel diseases have an increased risk of colorectal cancer (pooled 
standardized incidence ratio 1.7, 95% CI =1.2-2.2) with risk highest in those patients with 
IBD diagnosis before age 30, those with extensive disease and those with longer disease 
duration (53).  
 
1.1.10 Diagnosis of colorectal cancer 
 
The diagnosis of colorectal cancer begins with thorough history taking and a systematic 
examination of the patient, which includes a digital rectal examination and rigid 
sigmoidoscopy. The majority of patients present symptomatically, although the introduction 
of bowel screening in recent years will inevitably result in increasing numbers of diagnoses in 
asymptomatic individuals. 
 
  
 67 
1.1.10.1 Mode of presentation and symptomatology 
 
1.1.10.1.1 Bowel screening 
 
The English Bowel Cancer Screening pilot conducted between 2000 and 2002 assessed the 
feasibility of a faecal occult blood (FOB) screening tool for the detection of colorectal cancer. 
This study revealed that the positive predictive value of FOB screening was 10.9% for cancer 
and 35% for adenoma (54). Of all screen detected cancers, 48% were Dukes’ stage A and 
only 1% had metastasised at the time of diagnosis (54). The NHS Bowel Cancer Screening 
programme was subsequently introduced in England in 2006, in Scotland in 2007 and in 2007 
in Wales.  
 
The current Bowel Screening Wales programme invites men and women aged 60 to 74 for 
screening every two years (55). The initial test kit is a guaiac faecal occult blood (FOB) test 
kit, which is completed by participants at home and returned to the screening laboratory. 
Participants with a negative FOB are returned to routine recall, those with equivocal results 
are sent a faecal immunochemical test to complete and those with a positive FOB result are 
invited for telephone assessment with Specialist Screening Practitioners who assess their 
fitness for colonoscopy. If the participant is fit, they are offered a colonoscopy in their local 
assessment centre and dependent on the results of the colonoscopy, they are then returned to 
routine colonoscopy entered into a polyp surveillance programme or, if cancer is diagnosed, 
they are referred to the multidisciplinary team. Those unfit for colonscopy are usually offered 
a CT scan. 
  
The aim of the Bowel Screening Wales programme is to reduce deaths from bowel cancer by 
15% in the group of people invited for screening by the year 2020 (55). In the most recent 
Annual Statistical Report published in January 2017, uptake for invited participants was 
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54.4% (55). Of 164,400 test kits that were validated, 151,800 were given a definitive result of 
which 98.7% were negative and 1.3% were positive (55). Attendance at index colonoscopy or 
flexible sigmoidoscopy was 97.3% and of these procedures, the cancer detection rate was 
12.0%, the polyp detection rate was 67.0% and the adenoma detection rate was 52.8% (55). In 
the year 2015-2016, a total of 205 participants were diagnosed with cancer and 1149 had 
polyps detected and removed (55).     
 
1.1.10.1.2 Symptomatic presentation 
 
Colorectal cancer may present with symptoms including change in bowel habit, rectal 
bleeding, abdominal pain and weight loss or symptomatic anaemia. 
 
1.1.10.1.2.1 Emergency symptomatic presentation 
 
Unfortunately, 21% of all patients with colorectal cancer present as an emergency with a 
tendency for this group to represent the more elderly, frail, co-morbid patients and those with 
advanced disease (56). Consequently, the mortality in this group is much higher and 1 in 7 
(13.7%) of those undergoing emergency surgical resection do not survive beyond the first 90 
post-operative days (57).  Increasing bowel cancer awareness amongst the general population 
and bowel screening are strategies aimed at reducing these numbers. 
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1.1.11 Investigation of suspected colorectal cancer 
 
1.1.11.1 Colonoscopy 
 
Colonoscopy is the ‘gold standard’ investigation for suspected colorectal cancer and National 
Institute for Health and Care Excellence (NICE) guidelines, updated in 2014, state that it 
should be offered as the first-line investigation for all patients suspected to have colorectal 
cancer who do not have a major comorbidity (58). Colonoscopy offers several advantages 
over alternative diagnostic investigations, not least the opportunity to obtain histological 
diagnosis by biopsy.  
 
Magnetic endoscopic imaging devices (MEIs) are adjuncts to colonoscopy that demonstrate 
the configuration of the colonoscopy in three dimensions. The aim of these devices is to allow 
the colonoscopist to adjust the colonoscope to prevent looping thereby potentially reducing 
pain and increasing caecal intubation rates. A recent systematic review and meta-analysis of 
13 randomised studies found that use of MEI increased the caecal intubation rate, particularly 
for procedures performed by inexperienced colonoscopists (59). Although procedure time and 
pain were reduced, the difference was not felt by the authors to be clinically significant (59). 
Moreover, further studies to determine the effect on complication rate and cost-benefit 
analyses are required.    
 
1.1.11.2 Computerised tomography pneumocolon (CT pneumocolon) 
 
CT pneumocolon (also known as CT colonography) approaches colonoscopy in terms of its 
sensitivity and specificity and in the short term, is more acceptable to patients (60). However, 
30% of CT pneumocolons will detect a lesion that requires a colonoscopy for further 
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evaluation and longer-term follow up suggests that overall, there is greater patient satisfaction 
with colonoscopy as the first line investigation (60).  
 
1.1.11.3 Minimal-preparation CT 
 
Minimal-preparation CT is a valuable tool in the investigation of frail or elderly patients with 
suspected colorectal cancer who are not fit enough to undergo colonoscopy or CT 
pneumocolon (61).  A study of 1077 CT studies in 1031 patients found that CT correctly 
identified 83/98 colorectal cancers, with a sensitivity of 85% (CI: 78-92%) and a specificity 
of 91% (CI: 90-93%)(61).  
 
1.1.11.4 Flexible sigmoidoscopy 
 
Flexible sigmoidoscopy is used to investigate fresh rectal bleeding or other symptoms 
suggestive of anal outlet pathology in patients for whom there is a low suspicion of 
malignancy. 
 
1.1.11.5 Barium enema 
 
The results of the multicentre Special Interest Group in Gastrointestinal and Abdominal 
Radiology (SIGGAR) 1 trial show that CT colonography is significantly better at detecting 
colorectal cancer than barium enema (62). Therefore, the Royal College of Radiologists no 
longer recommends the use of barium enema as a method of investigation for patients with 
symptoms suggestive of colorectal cancer (63).  
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1.1.12 Staging of colorectal cancer 
 
Staging is essential in determining what treatment strategies are appropriate, whether 
treatment will be curative or palliative in intent and the patient’s likely prognosis. In addition, 
proper staging is essential in recording and comparing outcomes and in determining the 
success of established or novel treatments. There are a number of staging systems in use, 
namely Dukes’ staging, Tumour Node Metastasis (TNM) classification or the Union for 
International Cancer Control (UICC) stage grouping. 
 
1.1.12.1 Dukes’ staging 
 
Cuthbert Dukes (1890-1977) was a Pathologist at St. Mark’s hospital in London who 
specialised in the pathology of rectal cancer and pioneered work on familial polyposis of the 
colon resulting in the establishment of the national polyposis registry (64). In 1932, he 
developed the Dukes’ classification for rectal cancers (see Table 1.6), although it was 
extended for broader use across all colorectal cancers in due course.  
 
Table 1.6 Dukes’ staging of rectal cancer (65).  
 
Stage Definition 
A Growth confined to the rectum, no extra-rectal spread, no lymphatic metastases 
B Spread by direct continuity into extra-rectal tissues, no lymph node spread 
C Lymphatic metastases present 
 
“Modified” Dukes’ classification includes an additional stage ‘D’ which is defined by the 
presence of distant metastasis. Dukes’ stage is closely associated with survival as illustrated 
in Table 1.7.  
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Table 1.7 Colorectal cancer 5-year relative survival rate by Dukes’ stage at diagnosis, 
England 1996-2002. 
 
Dukes stage at diagnosis Percentage of cases 5 year relative survival 
A 8.7% 93.2% 
B 24.2% 77.0% 
C 23.6% 47.7% 
D 9.2% 6.6% 
Unknown 34.3% 35.4% 
Source: Cancer Research UK, Original data: Colorectal Survival by Stage, NCIN Publication, accessed May 2012. 
 
 
1.1.12.2 TNM classification 
 
The most common staging system used for colorectal cancer is the TNM 
(tumour/node/metastasis) system developed by the American Joint Committee on Cancer 
(AJCC) and updated most recently as its 7
th
 edition in 2010. A number is assigned to each of 
the three categories based on the degree of bowel wall invasion (T), involvement of lymph 
nodes (N) and presence of metastatic disease (M). The TNM staging definitions for colorectal 
cancer are shown in Table 1.8.     
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Table 1.8 TNM Colon and Rectum Cancer Staging Definitions. From AJCC Colon and 
Rectum Cancer Staging 7
th
 Edition (66). 
 
 
Primary Tumour (T) 
 
  
Tx  
T0  
Tis 
T1 
T2 
T3 
T4a 
T4b  
 
Primary tumour cannot be assessed 
No evidence of primary tumour 
Carcinoma in situ 
Tumour invades submucosa 
Tumour invades muscularis propria 
Tumour invades into pericolorectal tissues 
Tumour penetrates to surface of visceral peritoneum 
Tumour directly invades/is adherent to other organs 
 
 
Regional lymph nodes (N) 
  
Nx 
N0 
N1 
N1a 
N1b 
N1c 
 
 
N2 
N2a 
N2b 
 
 
Regional lymph nodes cannot be assessed 
No regional lymph node metastasis 
Metastasis in 1-3 regional lymph nodes 
Metastasis in one regional lymph node 
Metastasis in 2-3 regional lymph nodes 
Tumour in subserosa, mesentery, non peritonealised 
pericolic/perirectal tissue without regional nodal metastasis 
Metastasis in 4 or more regional lymph nodes 
Metastasis in 4-6 regional lymph nodes 
Metastasis in 7 or more regional lymph nodes 
 
Distant metastasis (M) 
  
M0 
M1 
M1a 
M1b 
 
No distant metastasis 
Distant metastasis 
Metastasis confined to one organ or site 
Metastases in more than one organ/site or peritoneum 
 
Note: cTNM = clinical classification, pTNM = pathological classification, rTNM = classification of 
recurrent disease 
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1.1.12.3 UICC stage grouping for colorectal cancer 
 
The TNM stage can be further grouped into UICC/AJCC stage grouping. This, along with its 
association with Dukes’ staging is shown in Table 1.9. 
 
Table 1.9 UICC stage and its association with TNM stage and Dukes’ stage. Taken from 
AJCC 7
th
 Edition Colon and Rectum Cancer Staging (66).  
 
 
Stage 
 
T 
 
N 
 
M 
 
Dukes’ stage 
 
0 
 
Tis 
 
N0 
 
M0 
 
- 
I T1 N0 M0 A 
 T2 N0 M0 A 
IIA T3 N0 M0 B 
IIB T4a N0 M0 B 
IIC T4b N0 M0 B 
IIIA T1-2 N1/N1c M0 C 
 T1 N2a M0 C 
IIIB T3-T4a N1/N1c M0 C 
 T2-T3 N2a M0 C 
 T1-T2 N2b M0 C 
IIIC T4a N2a M0 C 
 T3-T4a N2b M0 C 
 T4b N1-N2 M0 C 
IVA Any T Any N M1a - 
IVB Any T Any N M1b  
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1.1.13 Staging investigations 
 
1.1.13.1 Computerised tomography 
 
All patients with colorectal cancer should undergo contrast-enhanced CT scan of the chest, 
abdomen and pelvis for the purposes of staging (67).  
 
1.1.13.2 Magnetic resonance (MR) imaging 
 
In addition to CT scan, all patients with rectal cancer should also undergo MR imaging to 
determine whether the circumferential resection margin (CRM) is threatened by the tumour 
(67). Furthermore, the Royal College of Radiologists recommends MR imaging with liver-
specific contrast agents as the technique of choice in staging patients with colorectal liver 
metastases, as MR has greater sensitivity for the detection of metastatic disease than either 
CT or positron emission tomography CT (PET-CT) (68).    
 
1.1.13.3 Endorectal ultrasound scan (USS) 
 
Endorectal USS can be a useful adjunct to MRI imaging in patients with potentially resectable 
rectal cancer or can be used as an alternative in patients in whom MRI is contraindicated (67).  
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1.1.13.4 Positron emission tomography –CT (PET-CT) 
 
18-fluorodeoxyglucose positron emission tomography-CT (
18
FDG PET-CT) may be used for 
the further assessment of extra-hepatic metastases that may be amenable to radical surgery 
and a recent meta-analysis has confirmed that it is a useful tool to help predict survival 
outcomes in patients with colorectal cancer liver metastases (67, 69). 
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1.1.13.5 Stratification of local recurrence risk of rectal cancers  
 
The risk of local recurrence of rectal cancers can be predicted by MRI as shown in Table 
1.10. A high risk of systemic recurrence may also be predicted by the presence of extramural 
vascular invasion on MRI (67). 
 
Table 1.10 Risk of local recurrence for rectal tumours based on characteristics of tumour 
predicted by MRI. Taken from NICE guideline CG131 (Colorectal cancer: The diagnosis and 
management of colorectal cancer) (67). 
 
Risk of local 
recurrence 
Characteristic of rectal tumour predicted by MRI 
High risk Threatened (<1mm) or breached CRM 
Low tumours with inter-sphincteric or levator involvement 
Moderate risk  cT3b or greater without threatened CRM 
Suspicious lymph node without threatened CRM 
Extramural vascular invasion 
Low risk cT1/cT2/cT3a without lymph node involvement 
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1.1.14 Management of colorectal cancer 
 
1.1.14.1 The role of the multidisciplinary team  
 
The multidisciplinary team (MDT) is central to the modern management of colorectal cancer. 
The team, which includes surgeons, gastroenterologists, colorectal nurse specialists, 
radiologists, oncologists and pathologists, meet regularly to discuss new cases, decide 
management plans, record patient outcomes and undertake data collection for purposes of 
local and national audit. The MDT is usually surgeon led, with patients being assigned to, and 
being the responsibility of, a named consultant surgeon though their care may be transferred 
to the oncologists as required. During the MDT meeting, information is shared and through 
collaborative decision-making, recommendations for the patient’s management are made. 
These recommendations can then be discussed with the patient enabling them to make 
informed decisions about their care.  
 
The aim of the MDT is to enable timely diagnosis and treatment, to ensure evidence-based 
recommendations for patient management, to allow continuity of care, to facilitate 
information exchange, to identify patients who may be eligible for inclusion in trials and to 
provide education and learning to members (70). The evidence for the effectiveness of cancer 
MDT meetings is weak and limited but there are more studies that suggest MDTs have a 
positive impact than those suggesting they have a negative impact (70). One large study 
looking at patients with all cancers found that MDT meetings were associated with a 
significant improvement in 5 year survival and in another study looking at colorectal cancer 
in particular, MDT working was associated with an increase in recruitment of patients to trials 
(71, 72). Given the fact that MDT meetings are the cornerstone of cancer management in 
current UK practice, it seems unlikely that further randomised controlled trials will be 
undertaken.      
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1.1.14.2 Surgery for colorectal cancer 
 
Surgical resection remains the cornerstone of curative management of locally confined 
colorectal cancers and the most recent National Bowel Cancer Audit shows that just over 60% 
of patients with colorectal cancer undergo major resectional surgery (57). 
 
Although the proportion of patients undergoing major resection has remained around 60-65% 
over the last 5 years, the 90-day mortality rate has decreased from 5.8% to 3.8% overall (73). 
Over this time period, the proportion of colorectal cancer patients has remained at just over 
21% and 16% of patients with a colorectal cancer have their major resectional surgery 
performed as an urgent or emergency procedure (73). Emergent/urgent surgery is associated 
with an increased 90-day mortality of 12.1% compared to 2.3% for those patients undergoing 
elective or scheduled surgery (73).    
 
1.1.14.2.1 Selection of patients for surgery 
 
The suitability for surgery of a patient with colorectal cancer depends both of the stage of the 
disease and also on the patients fitness for surgery. Cardiopulmonary exercise (CPEx) testing 
is a non-invasive assessment of a patients exercise capacity that is used to estimate their 
fitness prior to undertaking major resectional surgery. 
 
1.1.14.2.2 Surgical approaches 
 
The surgical resection of a colorectal cancer can be undertaken via an open or laparoscopic 
approach. Laparoscopic surgery is associated with reduced length of hospital stay and NICE 
and the Association of Coloproctology of Great Britain and Ireland (ACPGBI) recommend 
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that laparoscopic resection should be offered as an alternative to open resection to suitable 
patients (57). In 2011/2012, 40% of bowel resections in England and Wales were performed 
via a laparoscopic approach, compared to 25% in 2008/2009 (57).  
 
1.1.14.2.3 Resection of hepatic metastases 
 
Historically, the presence of liver metastases was tantamount to a death sentence. Fortunately, 
this is no longer the case and now nearly 7% of all patients with distant colorectal metastases 
confined to the liver are being considered for liver resection with curative intent (67).  
 
1.1.14.3 Colonic stents for acute large bowel obstruction 
 
In patients presenting as an emergency with acute left-sided colonic obstruction, a colonic 
stent can be employed to manage the obstruction in patients with unresectable disease or who 
are unfit for major surgery, or can be used as a ‘bridge’ to manage relieve obstruction and 
convert an emergency admission to a planned resection (73). 
 
1.1.14.4 Chemotherapy 
 
Adjuvant chemotherapy with capecitabine monotherapy or combination therapy with 
oxaliplatin, 5-fluorouracil and folinic acid is offered to patients with high risk Stage II and 
Stage III colon cancer (67).   
 
Neo-adjuvant chemotherapy is offered to patients with advanced and metastatic colorectal 
cancer. Current NICE guidelines suggest folinic acid plus fluorouracil plus oxaliplatin 
(FOLFOX) as first-line treatment followed by either irinotecan alone or folinic acid plus 
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fluorouracil plus irinotecan (FOLFIRI) as second-line treatment (67). Alternatively, 
capecitabine plus oxaliplatin (XELOX) may be used as first-line treatment followed by 
FOLFIRI as second-line treatment (67).   
 
1.1.14.5 Neo-adjuvant therapy for rectal cancer 
 
The use of neo-adjuvant therapy in rectal cancer depends on the risk of local recurrence 
predicted from staging MR imaging. Patients with low risk rectal cancer do not require neo-
adjuvant therapy and proceed directly to surgical resection (67). For patients with high-risk 
rectal tumours, neo-adjuvant chemoradiotherapy with an interval prior to surgery is advised to 
allow tumour response and shrinkage (67).  
 
The management of those with moderate risk rectal cancers is more contentious. There are 
essentially two options for this group, (i) short-course pre-operative radiotherapy followed by 
immediate surgery and (ii) pre-operative chemoradiotherapy with an interval before surgery. 
Current NICE guidelines recommend the former option in those with moderate-risk rectal 
tumours and the latter option in those with borderline moderate/high risk MR findings (67).    
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1.1.14.6 Biological agents in the treatment of metastatic colorectal cancer 
 
1.1.14.6.1 Anti-EGFR monoclonal antibody 
 
Anti-EGFR monoclonal antibodies (mAbs), such as cetuximab, now play a role in the 
management of patients with metastatic colorectal cancer (mCRC). Current NICE guidelines 
recommend the use of anti-EGFR mAbs in patients with EGFR-expressing KRAS wild-type 
mCRC in combination with chemotherapy, or as a single agent in patients who have failed 
chemotherapy (74).  
 
A recent study by Sorich et al suggests that patients with KRAS exon 3 and 4, and NRAS 
exon 2, 3 and 4 mutations may also benefit less from anti-EGFR mAbs than patients who are 
wild-type for these additional RAS activating mutations and that testing for these further 
mutations should form part of patient work up when deciding whether anti-EGFR therapy is 
appropriate (31).   
 
1.1.14.7 Palliation of advanced disease 
 
Palliation of symptoms is the primary aim of treatment for patients with advanced colorectal 
cancer and may encompass palliative surgery or stenting to prevent or alleviate obstruction, 
chemotherapy, radiotherapy and medications including analgesics and antiemetics.   
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1.1.14.8 Challenges in the management of colorectal cancer 
 
Despite advances in treatment, colorectal cancer accounts for a significant proportion of 
cancer related deaths. It is likely that this is due, in part at least, to the high proportion of 
patients presenting with advanced disease or as an emergency. Population based screening is 
one strategy aimed at addressing this problem but limitations of current UK screening include 
the possibility of false negative FOB test, cost and the fact that colonoscopy is invasive and is 
associated with complications such as bleeding and colonic perforation.  
 
There is a real need to develop non-invasive or minimally invasive diagnostic tests, which 
could identify patients at higher risk of developing colorectal cancer or identify those with 
early changes or early stage cancer, which is associated with better prognosis. Consequently 
there has been increasing interest in the development of blood or faecal-based biomarker tests 
that can detect the presence of altered genes associated with colorectal cancer.  
 
Biomarkers are defined as ‘molecular indicators of exposure or disease state’(75).  In cancer, 
they may arise from the tumour itself or from the response of the body to cancer and may 
have a role in identifying populations at increased risk, in cancer prevention, diagnosis and 
prognosis and in predicting tumour responsiveness to therapy and the risk of relapse. 
There has been huge interest in the identification of genetic, epigenetic and proteomic 
biomarkers in relation to all cancers and a number of biomarkers have been identified which 
are shown in Table 1.11. 
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Table 1.11 Examples of cancer biomarkers 
 
Biomarker Name Disease 
AFP Alpha-fetoprotein Liver cancer 
BCR-ABL Philadelphia chromosome Chronic myeloid leukaemia 
BRCA1/BRCA2 Breast cancer 1/Breast cancer 2 Breast/ovarian cancer 
BRAF V600E Proto-oncogene B-Raf Melanoma/colorectal cancer 
CA-125 Cancer antigen 125 Ovarian cancer 
CA19-9 Cancer antigen 19-9 Pancreatic cancer 
CEA Carcinoembryonic antigen Colorectal cancer 
EGFR Epidermal growth factor receptor Non-small cell lung cancer 
HER-2 Human epidermal growth factor receptor 
2 
Breast cancer 
KIT Proto-oncogene c-Kit Gastrointestinal stromal 
tumour 
PSA Prostate specific antigen Prostate cancer 
S100 S100 protein Melanoma 
 
One recently identified biomarker is Septin9 DNA, which is hypermethylated in colorectal 
cancer. A molecular DNA test for this (Epi proColon®) was the first blood-based test for 
colorectal cancer screening to be approved by the FDA in April 2016. It is hoped that further 
biomarkers will be identified that may aid not only in the diagnosis of colorectal cancer, but 
in its management, either by stratifying patients according to their likely response to adjuvant 
therapies or through the development of novel molecular therapies.  
 
This thesis is concerned with the investigation of an adaptor protein called Dok-7, its 
association with colorectal cancer with a view to its potential use as a diagnostic and 
prognostic marker in colorectal cancer and its potential as a novel therapeutic target. The Dok 
proteins are discussed in detail in Section 1.3.  
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1.1.14.9 Follow up 
 
All patients with colorectal cancer undergoing treatment with curative intent should be 
offered follow up starting with clinical follow up 4-6 weeks after treatment. Within the first 
three years after treatment, patients should undergo two CT scans of the chest, abdomen and 
pelvis and serum carcinoembryonic antigen (CEA) should be checked every six months (67). 
Surveillance colonoscopy is usually performed 1 year and 5 years after initial treatment (67). 
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1.2 The Hallmarks of Cancer and the molecular basis of cancer progression 
 
1.2.1 The Hallmarks of Cancer 
 
In their seminal paper ‘The Hallmarks of Cancer’ published in Nature in 2000, Hanahan and 
Weinberg identified a number of characteristics shared by cancer cells (76). These 
characteristics are (i) self-sufficiency in growth signals, (ii) insensitivity to antigrowth 
signals, (iii) evasion of apoptosis, (iv) limitless replicative potential, (v) sustained 
angiogenesis and (vi) tissue invasion and metastasis (76). As previously discussed, outcomes 
in patients with colorectal cancer are closely related to stage of disease, which is defined by 
the degree of local tumour invasion and the presence of local and distant metastases, and the 
majority of cancer-related deaths occur as a consequence of metastatic disease.  
     
1.2.2 The molecular basis of cancer progression 
 
1.2.2.1 Epithelial-mesenchymal transition 
 
Enhanced cancer cell motility plays an important role in both invasion and metastasis (77).   
Firstly, primary tumour cells invade local tissues in a process known as epithelial-
mesenchymal transition (EMT). EMT is seen during normal foetal and postnatal development 
and is regulated by transcription factors such as Twist1, Snail1 and Slug, which inhibit E-
cadherin expression, zonaoccludens 1 (ZO1) and Beta4-integrin (78). It results in the 
reorganisation of cytoskeletal structures and the upregulation of fibroblast markers and genes 
such as vimentin, N-cadherin, Twist and α-smooth muscle actin (α-SMA). Cells consequently 
become more mobile, plastic, isolated and resistant to apoptosis. Several molecules have been 
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implicated in EMT, including TGF-β, which has been shown to induce EMT in embryonic 
epithelial cells. 
 
1.2.2.2 Invasion 
 
Tumour cells invade through the basement membrane and degrade the extracellular matrix to 
invade into blood and lymphatic vessels in a process controlled by the matrix 
metalloproteinases. These are endopeptidases that are involved in normal tissue remodelling 
during growth and wound healing. Altered expression of MMPs has been identified in 
colorectal cancer (79). Normally, cells detaching from the extracellular matrix lose cell-
matrix interactions and consequently undergo programmed cell death in a process known as 
anoikis but successfully metastasising cancer cells are able to evade anoikis.  
 
1.2.2.3 Migration 
 
Migration is stimulated by scatter factors including hepatocyte growth factor (HGF). Initially 
recognised as a promoter of hepatocyte cell growth, HGF is now understood to play an 
important role in cell growth and cell motility for a range of epithelial cells (80). The activity 
of hepatocyte growth factor increases after injury, suggesting an important role in normal 
wound healing and organ regeneration and higher levels of the HGF receptor (cMet) have 
been found in metastatic lesions compared with primary tumours (80). As the tumour 
progresses, it will encounter normal blood vessels and new vessel growth is induced by 
angiogenic factors. Tumour cells invade the blood vessels and are transported through the 
circulatory system until they reach an appropriate microenvironment. Angiogenesis is 
important in order for tumour cells to become established at this metastatic site and to enable 
subsequent growth. 
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1.2.2.4 Haematogenous and lymphatogenous spread 
 
As they spread, tumour cells migrate and invade into local tissues including local blood or 
lymphatic vessels (intravasation) and the development of new blood and lymphatic vessels 
(angiogenesis and lymphangiogenesis) is induced by angiogenic and lymphangiogenic 
factors. Tanigawa et al (1997) found that the degree of new vessel formation around 
colorectal tumour was the most important predictor of haematogenous metastatic 
development (81).   
 
Angiogenesis is the biological process by which new capillaries are formed (82). It is 
essential in normal embryological development and post-embryonic angiogenesis is minimal 
in adult life though certain sites retain angiogenic activity, such as the corpus lutea in the 
ovaries, the endometrium of the uterus and there are high levels of angiogenic activity during 
the proliferative phase of wound healing (83, 84). However, inappropriate angiogenesis may 
occur in pathological states such as in rheumatoid arthritis, diabetic retinopathy and in cancer.  
 
Angiogenic factors are secreted by tumours, resulting in the stimulation of new vessel growth, 
improving the delivery of nutrients and oxygen to the growing tumour (85, 86). These new 
vessels provide nutrients to the growing tumour, are poorly developed compared to normal 
vessels facilitating penetration and embolization increasing the metastatic potential of the 
tumour, and support the survival and growth of metastatic tumour deposits. 
 
The development of the embryological vascular system involves a complex process of 
differentiation, proliferation, migration and maturation resulting in the formation of an 
organized network of vessels (87). Several molecules are involved in the regulation of 
angiogenesis including the VEGF family, Delta/Notch, Slit/Robo, neuropilin and HGF. Once 
the vascular tree is complete, the balance of stimulating and inhibiting factors stabilizes and 
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angiogenesis is usually limited to normal physiological processes like reproduction and 
wound healing. Post-embryonic angiogenesis is also induced by fibroblast growth factor 
(FGF), angiogenin, TGF-α, TGF-β, platelet derived growth factor (PDGF), TNF-α, 
interleukins, chemokines and angiopoietins (85).  
 
Bevacizumab (Avastin®) is a humanized variant of a murine anti-human monoclonal 
antibody targeting VEGF-A; a prime angiogenic molecule involved in the development of 
blood supply for both the primary tumour and secondary tumour deposits. The FDA has 
approved bevacizumab for the first- and second-line treatment of metastatic colorectal cancer 
in combination with chemotherapy (88). However, current NICE guidelines do not 
recommend bevacizumab for patients with metastatic colorectal cancer who have not been 
previously treated with the drug. 
 
Lymphangiogenesis is the process of lymphatic system development. The lymphatic system 
comprises a network of thin-walled, blind-ending vessels lines with a single layer of 
lymphatic endothelial cells. They originate from the same embryological tissue as the 
arteriovenous system. They collect extravasated fluid, proteins and electrolytes from 
extracellular fluid, returning this lymphatic fluid back to the arteriovenous system. The 
lymphatic system is also part of the immunosurveillance system, presenting foreign antigens 
to lymphocytes in lymph nodes scattered along the lymphatic vascular chain.  
 
In 1902, Sabin proposed a mechanism of lymphangiogenesis whereby lymphatic vessel 
development is subsequent to blood vessel development and which involved the sprouting of 
lymphatic vessels from venous endothelium of nearby veins. Subsequent work found that the 
expression of Prox-1 by venous endothelial cells within the embryo reflects the site of 
budding and sprouting of lymphatic cells that give rise to the primary lymphatic system.  
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1.2.2.5 Development of distant metastases 
 
Once the cancer cell reaches a suitable metastatic site, they leave the blood/lymphatic system 
(extravasation) and lodge in the target organ. They may then enter a period of metastatic 
dormancy for months or even years before subsequent growth and progression.  
 
There are two major theories relating to tumour invasion and the development of metastases. 
Firstly, Paget’s seed and soil theory, which states that a specific organ microenvironment is 
required for the development of metastases. Secondly, Ewing’s anatomical theory states that 
invasion and metastases depend on the regional lymphovascular system. In practice, both of 
these factors play a role. Regional metastases usually follow the anatomy of the regional 
blood and lymphatic vessels whilst distant metastases often show a preference for certain 
organ microenvironments. Furthermore, the ability of the cancer cell to establish metastases 
depends not only on the tumour cell itself but also on factors relating to the microenvironment 
of the potential metastatic site. For example, the release of chemokines by host tissues may 
aid tumour cell migration.  
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1.3 The Dok proteins  
 
Tyrosine phosphorylation of proteins by protein tyrosine kinases (PTKs) is a reversible 
process that plays an important role in the regulation of a variety of cellular functions 
including cell growth, differentiation and cell motility. Activation of PTKs by extracellular 
stimuli results in the phosphorylation of both the PTK as well as other substrates including 
trans-membrane receptors and downstream adaptor proteins (89). These proteins then either 
recruit or inhibit further downstream molecules, thereby regulating tyrosine kinase signalling 
pathways (89, 90). Aberrations in this process of tyrosine phosphorylation and downstream 
signal transduction are associated with many types of cancer. Consequently, there has been an 
effort to investigate and understand this complex process in order to evaluate its potential as a 
target for therapeutic intervention.  
 
Downstream of kinase (Dok) proteins possess structural characteristics typical of adapter 
proteins and, like other adapter molecules, they associate with activated cell-surface receptors 
and aid in the docking of downstream signalling molecules, facilitating intracellular signal 
transduction.  
 
1.3.1 Introduction to the Dok protein family 
 
The first of the downstream of kinase (Dok) protein family, Dok-1, was identified by Ellis et 
al in 1990 (91). Since then, a total of seven members of this family of enzymatically inert 
adaptor proteins have been identified, so called Dok-1-7, which are subdivided into three 
subgroups (Dok-1-3, Dok-4-6 and Dok-7). All of the Dok proteins share structural 
characteristics typical of adapter proteins and, like other adapter molecules, they associate 
with activated cell-surface receptors and aid in the docking of downstream signalling 
molecules, facilitating intracellular signal transduction (90, 92, 93). 
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The discovery of Dok-1 occurred in 1990 when Ellis et al identified a 62kDa protein that co-
precipitated with p21rasGTPase-activating protein (GAP) and acted as a target for activated 
protein tyrosine kinases including v-Abl and v-Src (91). This protein, initially called p62, was 
found to be tyrosine phosphorylated by tyrosine kinases in response to extracellular stimuli 
such as epidermal growth factor (EGF) and the extent of its phosphorylation was associated 
with cellular transformation (91).  Later, Carpino et al reported that a constitutively tyrosine 
phosphorylated 62kDa protein, corresponding to the protein identified by Ellis et al, 
associates with GAP in p210 (bcr-abl) expressing haematopoietic progenitor cells isolated 
from chronic myeloid leukaemia (CML) patients (94). They found that activation of the 
receptor tyrosine kinase c-Kit resulted in tyrosine phosphorylation of this protein and its 
subsequent association with GAP, with affinity dependent on the degree of tyrosine 
phosphorylation (94, 95). They named the protein p62 (dok) due to its role in signal 
transduction pathways downstream of receptor tyrosine kinases, and this later became known 
as Dok-1 (94).  
 
The discovery of the Dok-1 occurred in the context of CML, a disease characterized by the 
t(9;22) Philadelphia chromosome (Ph1) and its resultant fusion oncogene, Bcr-Abl (94). This 
oncogene expresses a chimeric protein p210(bcr-abl) that has enhanced tyrosine kinase 
activity resulting in the activation of several downstream signalling pathways including 
mitogen-activated protein kinase (MAP)/Extracellular-signal-regulated kinases (ERK), Myc, 
Jun, STAT, PI3K and NF-κB (96).  
 
Later work established that Dok-1 was the major phosphorylation substrate not only for 
p210bcr-abl oncoprotein, but also for many other receptor and cytoplasmic tyrosine kinases, 
including v-Abl, v-Src, EGF receptor (EGFR), insulin/insulin-like growth factor 1 (IGF-1) 
receptors and platelet derived growth factor receptor (PDGFR) (91, 94, 95, 97-100). Within 
the next decade, Dok-2 (Dok-R/p56 (dok-2)), a 56kDa protein comprising 412 amino acids 
with 35% homology to Dok-1, and Dok-3 (Dok-L) were subsequently identified (101, 102). 
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Owing to structural and functional similarities, Dok-1, Dok-2 and Dok-3 form a subgroup 
within the Dok protein family (102, 103).  
 
Dok-4 and Dok-5 were discovered in 2001 by Grimm et al, followed by Dok-6, which was 
discovered by Crowder et al in 2004 and these three Dok family members form a subgroup, 
which appears to be phylogenetically distinct from Dok-1, Dok-2 and Dok-3 on the basis of 
differences in expression and function (104, 105). 
 
The most recent member of the Dok protein family, Dok-7, was identified by Okada et al in 
2006 (106). They found that this cytoplasmic adaptor protein plays an essential role in 
neuromuscular junction (NMJ) formation, a process which is organised by the tyrosine kinase 
muscle specific kinase (MuSK) and its extracellular activator, agrin (107). Dok-7 is both a 
substrate of MuSK and an essential activator of MuSK kinase activity as well as being 
required for acetylcholine receptor (AChR) clustering (89, 106, 108). Moreover, Dok-7 is 
required by agrin to activate MuSK and is also necessary for the correct localisation of MuSK 
in muscle (107). Therefore, NMJ formation requires agrin, derived from neurons, as well as 
MuSK, Dok-7 and a protein called low-density lipoprotein receptor-related protein 4 (Lrp4), 
all of which arise from muscle (108-110). Other authors subsequently demonstrated that 
overexpression of Dok-7 is associated with increased activation of MuSK and NMJ formation 
and that in agrin deficient mice; Dok-7 expression enhances MuSK activation and restores 
NMJ formation (107, 109, 110). 
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1.3.2 Dok protein structure  
 
The Dok proteins share a common structure, shown in Figure 1.5, that bears some similarity 
to the insulin receptor substrate (IRS) family of proteins, which act downstream of the insulin 
and IGF-1 receptors mediating signal transduction to the phosphatidylinositol 3-kinase (PI3K) 
and mitogen-activated protein kinase (MAPK) pathways (102).  
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A. 
 
 
 
B. 
 
 
 
Figure 1.5 Protein structure of DOKs. A. Function domains of DOK protein family members 
1-5. PH (grey) and PTB (black) domains are shown and positions of tyrosine residues (Y) and 
PXXP motifs (P) are indicated. Illustration taken from Grimm et al (104) B. Phylogenetic tree 
of human DOK proteins. The phylogenetic analysis was performed using the ClustalW 
(http://www.ebi.ac.uk/clustalw/), and the dendrogram tree was plotted using the Treeview 
(Version 1.6.6, http://taxonomy.zoology.gla.ac.uk/rod/treeview.html). 
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The MAP kinase pathway is a signalling cascade initiated by the binding of a ligand, such as 
epidermal growth factor (EGF) to the extracellular binding site of a receptor tyrosine kinase 
(RTK). Binding of the ligand results in the dimerization of two subunits of the RTK. This in 
turn catalyses the phosphorylation of the intracellular portion of each RTK subunit and 
enables growth factor receptor bound protein 2 (GRB2) to bind to the phosphorylated RTK, 
which in turn binds the protein SOS. SOS can then bind onto the membrane-bound protein 
RAS, which in its inactive form is bound to GDP. Binding of SOS to Ras catalyses the 
conversion of GDP into GTP and the activation of the Ras protein. Once activated, Ras is able 
to bind to several effector proteins, including the kinase B-Raf. Active B-Raf phosphorylates 
and activates kinases MEK1 and MEK2, which in turn, phosphorylate and activate ERK1 and 
ERK2. Ultimately this cascade of phosphorylation and activation results in the activation of 
activator protein 1 (AP-1) transcription factors, including jun and fos. These transcription 
factors then form a heterodimer in the cell nucleus and bind to AP-1 motifs in the DNA 
resulting in the expression of genes involved in cell proliferation.         
 
The Dok family proteins, like other docking/scaffolding proteins, characteristically contain 
protein-protein interaction motifs such as multiple tyrosine residues (111). When 
phosphorylated, these tyrosine residues act as binding sites for Src homology 2 (SH2) domain 
containing signalling proteins, such as growth factor receptor-bound protein 2 (Grb2), PI3K 
and the SHP-2 tyrosine phosphatase (111).  
 
Initial work investigating the structure of Dok-1 revealed prominent tyrosine residues and 
nearby SH2 binding sites, suggesting its likely role as a signalling molecule (94, 95). Since 
then, the structure of the Dok family proteins has been elucidated and is characterized by 
three distinct regions: an amino (N-) terminal pleckstrin homology (PH) domain, a central 
phosphotyrosine-binding (PTB) domain and a carboxyl (C-) terminal, which contains 
multiple sites for tyrosine phosphorylation and proline-rich (PxxP) motifs which may enable 
the docking of SH2 and SH3 containing proteins (89, 101-103, 112).  
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The N-terminal PH domain is a region containing around 120 amino acids. This domain is 
found in many proteins involved in cell signalling and is thought to regulate signal 
transduction by mediating the association of the PH domain containing protein with the cell 
membrane (113).  Studies of Dok-1 isoforms suggest that the N-terminal plays an important 
role in determining the cellular localization of Dok-1 throughout the cytoplasm, and in Dok-2, 
the PH domain acts to stabilise Dok-2-EGFR binding and tyrosine phosphorylation of Dok-2 
(93, 114). Phosphorylation of Dok-4 by receptor tyrosine kinase RET or cytosolic tyrosine 
kinase Fyn requires both its PH and PTB domains and results in the inhibition of Elk-1 
activation (115). This effect, as well as the negative regulation of T cell activation, requires 
the PH domain of Dok-4 (116). The PH domain has also been shown to be important for the 
constitutive localization of Dok-4 and Dok-6 at the cell membrane (117). Itoh et al found that 
the mitochondrial location of Dok-4, and c-Src with which it associates, is dependent on the 
N-terminal and PTB domains and identified a putative mitochondrial targeting sequence in 
the N terminal of Dok-4 and Dok-5 (118). Expression of Dok-4 in endothelial mitochondria 
enhances TNF-α-induced reactive oxygen species (ROS) production and NF-κB production 
(118). In Dok-7, the N-terminal PH domain enables the nuclear import of Dok-7 (119). 
 
Phosphotyrosine-binding (PTB) domains are found in a range of signalling and cytoskeletal 
proteins (120). Previous authors have shown that Dok-1 and Dok-2 associate with activated 
EGFR via their PTB domains and that the inhibition of Src tyrosine kinase-induced cellular 
transformation by Dok-1 is dependent on the Dok-1 PTB domain as well as the presence of 
C-terminal tyrosine phosphorylation sites (especially residues 336-363) (93, 112, 121). Upon 
tyrosine phosphorylation, Dok-1 and Dok-2 interact homotypically and heterotypically to 
form oligomers via the PTB domain and this oligomerisation is essential for Dok 
phosphorylation and function (122). For example, the PTB domain and the amino terminal 
tyrosine 146 (Tyr (146)) residue enable Dok-1 to form homodimers, which are essential for 
the inhibition of Src transformation (112). 
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The PTB domain of the Dok proteins has also been shown to play a key role in the formation 
of Dok-1 and Dok-5 homomeric and heteromeric associations, the interactions of Dok-1, 
Dok-2 and Dok-3 with SH2-containing inositol 5’-Phosphatase (SHIP)-1, the interaction of 
Dok-2 with receptor tyrosine kinases such as erbB-2 (HER2/neu) and Tek (Angiopoietin-1 
receptor), and for the recruitment and phosphorylation of Dok-2 by activated EGFR, an 
interaction that is stabilized by the PH domain (93, 103, 123-126).  
 
Dok-3 binds to, and is phosphorylated by, Abl tyrosine kinase via its PTB domain (102). 
Overexpression of Dok-3 reduces v-Abl-induced MAPK activation in a PTB dependent 
fashion but has no effect on constitutively activated Ras- and EGF-induced MAPK activation 
(102).  
 
Unlike Dok-1, the PTB domain of Dok-4 and Dok-5 does not bind tyrosine phosphorylation 
sites in EGFR and when compared to Dok-1, the PTB domain of Dok-4 binds poorly to Ret 
with additional C-terminal residues being required for its binding (121, 125). However, the 
PTB domain of Dok-4 does bind SHIP-1, via phosphorylated NPXY motifs and SHIP-1 
facilitates coupling of Abl to Dok-4 (125). In Dok-5, the PTB domain interacts with 
Tropomyosin receptor kinase (Trk) B/C resulting in the activation of the MAPK pathway and 
in Dok-6, the PTB domain binds to the NPQY motif of TrkC (127, 128). TrkC is involved in 
nervous system development and this interaction with Dok-6 promotes neurotrophin 3 (NT-3) 
mediated neurite outgrowth in cortical neurons (105, 128). Dok-7 interacts with the 
juxtamembrane region of MuSK via its PTB domain and both PH and PTB domains are 
required for MuSK activation (106, 119, 129).  
 
The C-terminal of Dok-1 and Dok-2 (but not Dok-3) contains repeated YxxP motifs, which 
are involved in the interaction of the Dok proteins with SH domain-containing molecules, as 
well as providing multiple sites for tyrosine phosphorylation (102, 130). It is here that Dok-1 
is tyrosine phosphorylated by p210 (bcr-abl) and specifically, Tyr (362) and Tyr (398) are 
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major sites for phosphorylation and for interaction of Dok-1 with GAP (131, 132). Tyr (362) 
is also involved in the interaction between Dok-1 and non-catalytic region of tyrosine kinase 
adaptor protein 1 (Nck) (132), whilst Tyr (336) and Tyr (340) are necessary for the negative 
regulation of Ras-Erk signalling and cellular transformation, though they are not required for 
p210rasGAP (RasGAP) binding (133). Dok-2 interacts with c-Abl in an interaction that is 
mediated by SH3 and a PMMP motif in the proline-rich tail of Dok-2 and which is enhanced 
by the SH2 domain (134). Through this interaction, the tyrosine phosphorylation and kinase 
activity of c-Abl is increased, with a corresponding increase in activity relating to cytoskeletal 
reorganization (134).  
 
Hamuro et al found that the C-terminal region of Dok-7 contains a chromosome region 
maintenance 1-dependent nuclear export signal (NES) and that the NES-mediated 
cytoplasmic location of Dok-7 is necessary for regulating its interaction with MuSK (119). 
The C-terminal of Dok-7 contains SH2 target motifs required for MuSK activation, and 
phosphorylation of tyrosine residues in this region by agrin results in the recruitment of the 
adapter proteins Crk and Crk-L which are required for normal NMJ formation (119, 129). Crk 
also contains N-terminal SH2 and C-terminal SH3 domains implicated in the positive and 
negative regulation of cellular transformation respectively (135). Overall, the PH, PTB, SH2 
motifs and C-terminal NES are all important for Dok-7/MuSK signalling and disruption in 
these elements may give rise to NMJ synaptopathy (119).  
 
1.3.3 Genetic loci of DOK genes 
 
DOK1 has been mapped to human chromosome 2p13, in a region that is translocated in 
chronic lymphocytic leukaemia (CLL), B-cell acute lymphoblastic leukaemia (B-ALL), basal 
cell papilloma and keratoacanthoma (136-140). DOK2 has been localised to chromosome 
8p21.3, DOK3 to chromosome 5q35.3, DOK4 to chromosome 16q21, DOK5 to chromosome 
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20q13.2 and DOK6 to chromosome 18q22.2. DOK7 is located on the short arm of 
chromosome 4 at position 16.3 extending from base pair 3,463,305 to base pair 3,494,481. It 
comprises 7 exons (141). 
 
1.3.4 Expression profile of DOKs 
 
The expression profile of DOKs in the human body by tissue type is shown in Table 1.12.  
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Table 1.12 Expression profile of DOKs by tissue type (TPM, transcripts per million) 
 
 
DOK1 DOK2 DOK3 DOK4 DOK5 DOK6 DOK7 
Adipose tissue 155 233 0 77 77 0 0 
Adrenal gland 30 0 0 30 0 0 0 
Ascites 0 0 0 50 0 0 0 
Bladder 0 0 0 0 0 0 0 
Blood 114 139 302 0 0 0 8 
Bone 13 13 0 69 27 0 0 
Bone marrow 41 0 61 41 0 0 0 
Brain 10 1 16 153 83 25 10 
Cervix 41 0 0 20 0 0 0 
Connective tissue 67 114 33 60 67 20 0 
Ear 0 0 0 0 0 124 0 
Embryonic tissue 14 0 4 61 18 0 0 
Eye 9 19 4 19 14 28 9 
Heart 33 0 33 33 11 0 33 
Intestine 25 4 12 116 8 0 0 
Kidney 23 4 9 66 18 4 4 
Larynx 0 0 0 0 0 0 0 
Liver 4 9 0 19 0 0 0 
Lung 14 29 20 38 2 0 5 
Lymph 0 0 203 0 0 0 0 
Lymph node 44 0 178 11 0 0 0 
Mammary gland 39 0 13 19 0 0 19 
Mouth 15 15 15 0 0 0 30 
Muscle 9 0 0 56 18 9 9 
Nerve 0 0 0 0 0 0 0 
Oesophagus 0 0 0 0 0 0 0 
Ovary 9 9 0 49 226 9 29 
Pancreas 28 14 0 84 0 4 14 
Parathyroid 0 0 0 0 0 48 0 
Pharynx 0 49 0 49 0 0 0 
Pituitary gland 0 0 0 60 0 0 60 
Placenta 42 28 10 14 0 28 0 
Prostate 5 0 0 21 0 0 0 
Salivary gland 0 0 0 0 0 0 0 
Skin 18 0 0 42 9 0 4 
Spleen 18 74 468 37 0 0 37 
Stomach 0 20 10 52 0 0 0 
Testis 6 2 16 64 0 11 4 
Thymus 12 50 125 25 12 0 0 
Thyroid 0 0 21 21 0 0 0 
Tonsil 58 0 763 0 0 0 0 
Trachea 0 0 19 0 0 0 0 
Umbilical cord 72 0 0 0 0 0 0 
Uterus 25 21 25 43 4 0 17 
Vascular 19 0 0 116 19 0 0 
Note: TPMs in bold are top three organs/tissues which express higher levels of the DOKs. This is a summative table adapted 
from approximate expression pattern from the EST profile at http://www.ncbi.nlm.nih.gov/UniGene. 
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Although Dok-1, Dok-2 and Dok-3 are preferentially expressed in several haematopoietic 
cells, immune cells, the spleen and the lung, they are also found in other tissues (90, 94, 101, 
130, 142-144).  
 
Dok-1 is abundantly expressed in all layers of the primate dorsolateral prefrontal cortex, both 
in neurons and in the endothelial cells of cerebral blood vessels (145). Since its distribution is 
similar to that of the IGF-1 receptor, Smith et al suggest that Dok-1 may be a downstream 
target of IGF signalling in this area of the brain, which is involved in learning and memory 
(145). Dok-1 is also expressed in stem cell factor (SCF)/erythropoietin (Epo)-dependent 
erythroid progenitor cells from cord blood where it is implicated in signalling downstream of 
the c-kit/SCF receptor (146). Dok-2 is highly expressed in lymphoid tissues whilst Dok-3 is 
highly expressed in bone marrow and haematopoietic cell types including B cells, 
macrophages, mast cells and myeloid cells (102, 130, 147). Dok-4 and Dok-5 are expressed in 
human T cells (148).  
 
Dok-4 is also expressed in many non-haematopoietic tissues including the brain, heart, 
intestine, liver, kidney and lung (115). Both Dok-4 and Dok-5 are found in neuronal tissue 
and Dok-5 is highly expressed in skeletal muscle and brain tissue (104, 149, 150). Dok-6 is 
highly expressed in the developing central nervous system whilst Dok-7 is preferentially 
expressed in muscle tissue and, like MuSK, it co-localises with AChRs at the postsynaptic 
area of NMJs (105, 106). 
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1.3.5 Role of Dok proteins in normal physiological processes and benign disease 
 
1.3.5.1 Role of Dok proteins in allergy/inflammation 
 
Dok-1 plays an important role in the regulation of airway inflammation and may, therefore, 
present a potential therapeutic target in asthma and other atopic diseases (151). In the 
ovalbumin-induced murine model of asthma, overexpression of Dok-1 is associated with a 
reduction in inflammatory cell number, airway hyper-responsiveness, Th2 cytokine 
expression and mucus response (151). Furthermore, Dok-1 overexpression is associated with 
stimulation of Signal Transducer and Activator of Transcription 4 (STAT-4) and T-bet 
transcription factors and inhibition of STAT-6 and GATA-3 transcription factors (151). 
Consistent with these findings, Dok-1/Dok-2/Dok-3 triple knockout mice exhibit increased 
airway hyper-responsiveness and Th2 cytokine expression in response to methacholine 
inhalation suggesting that Dok-1, Dok-2 and Dok-3 play an anti-inflammatory role in the lung 
(152).  
 
Consistent with this, treatment of mast cells with dexamethasone is associated with 
upregulation of Dok-1 expression and phosphorylation, increased recruitment of RasGAP by 
Dok-1 and reduced activation of the MAPK pathway in antigen stimulated mast cells 
suggesting that Dok-1 may mediate the anti-allergic effects of dexamethasone (153).  
 
Work by Abramson et al found that Dok-1 and Dok-2 play a role in the signalling cascade 
downstream of type 1 Fcepsilon receptors (FcepsilonRI) which ultimately results in the 
production of inflammatory mediators as well as changes in cell adhesion and morphology 
(154). Phosphorylation of Dok-1 by Fcepsilon results in its association with RasGAP and 
overexpression of Dok-1 results in reduced Ras/Raf/Erk signalling and reduced de novo 
synthesis of the cell signalling protein Tumour Necrosis Factor-alpha (TNF-α) (154). 
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Aggregation of FcepsilonRIs allows Dok-1 and Dok-2 to act as a scaffold for the association 
of further molecules including Nck, Crk-L and Cas, which are known to play a role in 
cytoskeletal rearrangement (154). Furthermore, the formation of Dok-Grb2-SHIP complexes 
inhibits mast cells and may therefore play a role in the modulation of human allergic diseases 
(155).  
 
1.3.5.2 Role of Dok proteins in bone disease 
 
Interestingly, a previous study by Kawamata et al has suggested that Dok-1 and Dok-2 may 
play a role in bone homeostasis (156). Their study found that deficiency of Dok-1 and Dok-2 
was associated with a reduction in trabecular and cortical bone mass, increased periosteal and 
endosteal perimeters of the mid shaft of long bones and enhanced osteoclast number and 
activity, with resultant osteopenia (156).  
 
1.3.5.3 Role of Dok proteins in haemostasis 
 
The Dok proteins have also been implicated in platelet function and thrombosis. Dok-1 is one 
of several signalling proteins phosphorylated in activated platelets and both Dok-1 and Dok-3 
are involved in platelet signalling downstream of the integrin alpha(IIb)beta(3), which is 
required for platelet aggregation (157, 158). Platelet spreading on fibrinogen is associated 
with increased tyrosine phosphorylation of Dok-1 and Dok-3, resulting in their interaction 
with Grb2 and SHIP-1 (158). Dok-2 is also thought to play a role in platelet adhesion, 
haemostasis and thrombosis signalling cascades and Dok-2 deficiency has been linked with 
accelerated thrombus formation (159, 160).  
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1.3.5.4 Role of Dok proteins in embryological development 
 
In Drosophila flies, a homolog of Dok has been shown to play a crucial role in embryonic 
dorsal closure and loss of Dok is associated with defects in this process, suggesting that Dok 
may play a potential role in embryonic development (161).  
 
1.3.5.5 Role of Dok proteins in endometrial physiology 
 
Dok-1 has been found in the endometrium at all stages of the menstrual cycle, with higher 
levels seen during the proliferative phase than during the secretory phase (162).  
 
1.3.5.6 Role of Dok proteins in neuromuscular disorders 
 
Congenital myasthenic syndromes (CMS) arise as a result of genetic defects in the NMJ 
resulting in muscle weakness and other symptoms including fatigue (163). Mutations in the 
Dok-7 gene result in abnormal NMJ structure and give rise to a specific subtype of CMS 
characterised by “limb girdle” pattern fatiguable muscle weakness that accounts for 10-15% 
of CMS (89, 164-168).  
 
Patients with Dok-7 CMS show great phenotypic variability, though most have small NMJs 
and end plate structural abnormalities (169, 170). Although Dok-7 plays a role in the 
organization of AChRs, the density and phosphorylation of AChR in Dok-7 CMS is normal 
(170). In the normal NMJ, each motor nerve impulse results in the release of neurotransmitter 
molecules from the presynaptic bouton, the effect of which is amplified by voltage-gated 
sodium channels in the highly folded postsynaptic membrane (171). Patients with Dok-7 
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CMS have abnormally small NMJs with reduced postsynaptic folding resulting in impaired 
neurotransmission (89, 171).  
 
Most patients with Dok-7 CMS have at least one allele with a frameshift mutation in DOK7 
exon 7 that causes truncation of the C-terminal of Dok-7 and impairs Dok-7 induced MuSK 
activation (89, 119, 167). Recently, however, mutations in the N-terminal PH or central PTB 
domains have also been identified (89, 119).  
 
Unlike other forms of CMS, patients with Dok-7 CMS do not usually respond clinically to 
acetylcholine esterase (AChE) inhibitors but ephedrine is an effective treatment (165, 172). 
Interestingly, recent studies have shown that treatment with salbutamol, a selective B2-
adrenergic agonist, is effective in patients with Dok-7 CMS (173, 174).  
 
Furthermore, an exciting recent study by Arimura et al showed that in a mouse model of Dok-
7 myasthenia, administration of DOK7 gene therapy resulted in enlargement of NMJs and an 
increase in muscle strength and survival (175).  
 
Previous work by Jang et al has also found that the region of the motor neuron degeneration 2 
(mnd2) mutation on mouse chromosome 6, and the corresponding region on human 
chromosome 2, encodes three genes, one of which is Dok-1 suggesting that this Dok family 
member may also play a potential role in neuromuscular disorders (176).  
 
1.3.6 Tyrosine kinase signalling in cancer 
 
Protein kinases, named from the Greek κινειν meaning “to move”, are protein enzymes that 
catalyse the movement of phosphate molecules from ATP to a target protein. The first protein 
kinase was identified in 1959 and since then, protein phosphorylation has come to be 
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recognized as one of the most important mechanisms regulating protein activity and, by 
extension, a variety of cellular processes, including cell differentiation, migration, 
transformation, transduction of intracellular signals and the cell cycle (177). In fact, we now 
know that over 30% of mammalian cell proteins can be modified by phosphorylation (178). 
Protein kinases can be sub-divided into a number of groups including the protein tyrosine 
kinases (PTKs), which catalyse the transfer of phosphate molecules to tyrosine residues in 
target proteins. 
 
Tyrosine phosphorylation of proteins by PTKs is a reversible process that plays an important 
role in the regulation of a variety of cellular functions, including cell proliferation, 
differentiation and cell motility. These effects are mediated by the binding of other proteins to 
the phosphorylated protein and the initiation of downstream signalling cascades. The signals 
downstream of PTKs can be upregulated or downregulated depending on the signalling 
proteins involved and this positive or negative regulation is crucial to normal cell physiology 
and the maintenance of homeostasis (179). 
 
Protein tyrosine kinases can be further sub-divided into the receptor tyrosine kinases (RTKs), 
which are involved in trans-membrane signalling, and the cytoplasmic/non-receptor tyrosine 
kinases (CTKs), which participate in intracellular signal transduction. Following stimulation, 
PTKs become activated resulting in autophosphorylation and the phosphorylation of other 
molecules such as cytoplasmic adapter proteins. This leads to the recruitment or inhibition of 
other downstream signalling proteins (89). 
 
Currently, 58 RTKs have been identified and these are grouped into 20 subfamilies, shown in 
Table 1.13. Each RTK contains an extracellular domain for ligand binding, a trans-membrane 
helix and a cytoplasmic portion containing the tyrosine kinase domain, a C-terminal and a 
juxtamembrane regulatory region (180). RTKs play an important regulatory role in numerous 
cellular processes including cell survival, cell proliferation, differentiation, cell migration and 
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cell cycle control (181, 182). Deregulation of RTKs occurs in a range of human diseases and 
aberrant RTK activation (due to autocrine activation, chromosomal translocations, 
overexpression of RTKs or gain-of-function mutations) is associated with cancer (180). The 
CTKs, shown in Table 1.14, contain SH2 and/or SH3 domains, which enable them to bind to 
phosphorylated tyrosines on other proteins, including the RTKs (183). 
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Table 1.13 Receptor tyrosine kinase subfamilies and their family members 
 
Subfamily Family members 
ErbB EGFR, ErbB2, ErbB3, ErbB4 
Ins InsR, IGF1R, InsRR 
PDGF PDGFRα, PDGFRβ, CSF1R/Fms, Kit/SCFR, Flt3/Flk2 
VEGF VEGFR1/Flt1, VEGFR2/KDR, VEGFR3/Flt4 
FGF FGFR1, FGFR2, FGFR3, FGFR4 
PTK7 PTK7/CCK4 
Trk TrkA, TrkB, TrkC 
Ror Ror1, Ror2 
MuSK MuSK 
Met Met, Ron 
Axl Axl, Mer, Tyro3 
Tie Tie1, Tie2 
Eph EphA1-8, EphA10, EphB1-4, EphB6 
Ret Ret 
Ryk Ryk 
DDR DDR1, DDR2 
Ros Ros 
LMR LMR1, LMR2, LMR3 
ALK ALK, LTK 
STYK1 SuRTK106/STYK1 
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Table 1.14 Cytoplasmic/non-receptor tyrosine kinase (CTK) subfamilies and their family 
members  
 
Subfamily Family members 
Src Src, Fyn, Yes, Blk, Yrk, Frk/Rak, Fgr, Hck, Lck, Srm, Lyn 
Csk Csk 
Tec Tec, Btk, Itk/Emt/Tsk, Bmx, Txk/Rlk 
Abl Abl, Abl2/Arg 
Syk Syk, Zap-70 
Ack Ack1/Tnk2, Ack2, DACK, Tnk1, ARK-1, DPR2, Kos1 
JAK JAK1, JAK2, JAK3, Tyk2 
FAK FAK, PYK2/CAK-β/RAFTK/CADTK 
FER Fer, Fes 
 
 
So-called docking, or adaptor proteins, play a key role in the transduction of signals from 
activated tyrosine kinases (103). These docking proteins, including the Dok family, typically 
have an N-terminal PH domain, which mediates interaction with the cell membrane, and a 
PTB domain that binds an autophosphorylation site in the RTK. The docking protein is thus 
recruited to the RTK and becomes tyrosine phosphorylated by its kinase domain. As a 
consequence of this, binding sites become available to recruit additional SH2 containing 
signalling molecules and thus the adapter protein functions as a ‘scaffold’ for the formation of 
protein complexes (184, 185). 
 
Aberrant tyrosine phosphorylation is associated with many types of cancer and other human 
diseases and provides a potential target for therapeutic intervention.  The epidermal growth 
factor receptor (EGFR) is an RTK belonging to the ErbB family. Binding of a ligand, such as 
epidermal growth factor (EGF), results in dimerization of EGFR either with another EGFR 
monomer or with another ErbB family monomer and consequently autophosphorylation of its 
intracellular portion (186). This results in the activation of numerous downstream signalling 
pathways including PI3K and the MAPK pathway resulting in increased cell survival, 
invasion, proliferation, migration, adhesion and angiogenesis (186, 187). 
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The Ras proteins are involved cell signal transduction in the MAPK pathway downstream of 
EGFR and are known to play a role in cell growth, differentiation and survival (31-33). They 
were discovered as a result of observations made by Jennifer Harvey in 1964, that the 
injection of mice with Moloney’s leukaemogenic virus resulted in the development of 
tumours (34). The three human Ras genes, HRAS, KRAS and NRAS, are all oncogenes 
commonly implicated in human cancer and previous studies have shown that they are 
important in the development of pancreatic, thyroid and lung cancer, amongst other human 
malignancies (32, 35, 36).  
 
The first studies of the Ras oncogenes in colorectal cancer date back to the early 1980s when 
Feinberg and Vogelstein reported the hypomethylation of HRAS and KRAS in colonic 
adenocarcinomas (37). Later, in 1984, Spandidos and Kerr confirmed that KRAS and HRAS 
are overexpressed in pre-malignant adenomatous polyps and malignant colorectal tumours 
(38). We now know that RAS gene mutations are found in over a third of colorectal cancers, 
as well as in over 50% of adenomas over 1cm in size suggesting that they may play a role in 
tumourigenesis (33, 39, 40). However, RAS gene mutations are less common in small 
adenomas less than 1cm, where prevalence is less than 10% (40). KRAS, which activates 
MAPK via the oncogene BRAF to promote cell growth and survival, is mutated in 45% of 
colorectal cancers and, in metastatic colorectal cancer; KRAS status has been shown to 
predict treatment resistance to anti-EGFR monoclonal antibodies (31, 188, 189). The BRAF 
oncogene, which encodes the B-Raf protein that occurs downstream of Ras in the 
Ras/Raf/MAPK pathway, is itself mutated in around 10-15% of colorectal cancers (188).  
 
Activation of the PI3K pathway plays a key role in the promotion of cancer cell proliferation 
and survival both via the activation of Akt and Akt-independent pathways such as Bruton 
tyrosine kinase (Btk), the PTK Tec, serum- and glucocorticoid-regulated kinases and small 
GTPase regulators (190). PI3K signalling may be aberrantly activated in cancer as a result of 
RTK activation or as a result of somatic mutations in genes coding for proteins involved in 
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the signalling pathway (190). For example, mutations in PI3K pathway genes occur in almost 
40% of colorectal tumours (191). Previous analysis of human colorectal cancers has identified 
mutations in several genes encoding PI3K pathway proteins, including the serine/threonine 
kinases 3-phosphoinositide-dependent protein kinase 1 (PDK1), Akt2 and p21-activated 
kinase 4 (Pak 4), the non-serine/threonine kinases insulin-related receptor (INSRR), the RTK 
ErbB4, phosphatase and tensin homolog (PTEN), IRS2 and phosphatidylinositol-4,5-
bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), which encodes the p110α catalytic 
subunit (191). Mutations in PIK3CA are found in around 30% of colorectal cancers, but in 
few adenomas (and then generally in advanced tubulovillous adenomas measuring over 5cm 
diameter), suggesting that they arise late in the process of colorectal tumourigenesis (192). 
PTEN is a protein tyrosine phosphatase that functions as a tumour suppressor. Mutations of 
PTEN occur in approximately 20% of colorectal cancers, with a higher frequency (30%) 
found in tumours with microsatellite instability (MSI), compared to that found in tumours that 
are microsatellite stable (MSS) (9%) (193).  
 
Monoclonal antibodies against RTKs approved by the FDA for colorectal cancer therapy 
include cetuximab (Erbitux) and panitumumab (Vectibix), which both target EGFR, and 
bevacizumab (Avastin®), which targets VEGF and inhibits angiogenesis (180). The clinical 
effectiveness of monoclonal anti-TKR antibodies is limited by the fact that patients may 
develop drug resistance (180). Therapeutic agents targeted at the PI3K-Akt signalling 
pathway present a potential solution to this problem and include the PI3K inhibitors, the Akt 
inhibitors, the mechanistic target of rapamycin (mTOR) inhibitors and drugs that work via a 
combination of these methods and may in the future include novel agents targeting other 
signalling molecules such as the adaptor proteins (180, 190).  
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1.3.7 Dok protein-coordinated signal transduction and cellular functions 
 
The main interacting partners of the Dok proteins are shown in Table 1.15.  
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Table 1.15 Main interacting partners of the DOK proteins  
 
 Interacting proteins 
DOK1 RASA1, ABL1, NCK1, TEC, SRC, LCK, GRB10, KIT, FYN, SHC1 
DOK2 TEK, RASA1, NCK1, CRK, LCK, ABL1, IL4R, SRC, LYN, IL2RA 
DOK3 GRB2, CSK, LYN, INPP5D, SRC, ABL1, FYN, LCK, RET, DOK7 
DOK4 RET, FYN, RAP1A, GDNF, TEK, GFRA1, CRK, NDUFA9, SRC, COX5A 
DOK5 RET, GDNF, NTRK3, GFRA1, IGFBP5, INSR, FYN, IGF1R, NTRK2, 
COX5A 
DOK6 SRC, RET, GDNF, GFRA1, NTRK3, COX5A, TMX3, CCDC102B, 
OSBPL1A, DOK7 
DOK7 MUSK, RAPSN, AGRN, FLAD1, DRAGT1, FLVCR2, NTRK3, NTRK2, 
RRP7A, ACHE 
Note: RASA1 (RAS p21 protein activator (GTPase activating protein) 1); ABL1, c-abl oncogene 1; 
NCK1, NCK adaptor protein 1; TEC, tec protein tyrosine kinase; SRC, v-src sarcoma (Schmidt-Ruppin 
A-2) viral oncogene homolog; LCK, lymphocyte-specific protein tyrosine kinase; GRB10, growth 
factor receptor-bound protein 10; KIT, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog; FYN, FYN oncogene related to SRC, FGR, YES; SHC1, SHC (Src homology 2 domain 
containing) transforming protein 1; TEK, TEK tyrosine kinase; CRK, v-crk sarcoma virus CT10 
oncogene homolog; IL4R, interleukin 4 receptor; LYN, v-yes-1 Yamaguchi sarcoma viral related 
oncogene homolog; IL2RA, interleukin 2 receptor, alpha; GRB2, growth factor receptor-bound protein 
2; CSK, c-src tyrosine kinase; INPP5D, inositol polyphosphate-5-phosphatase; RET, ret proto-
oncogene; RAP1A, a member of RAS oncogene family ; GDNF, glial cell derived neurotrophic factor; 
TEK, TEK tyrosine kinase; GFRA1, GDNF family receptor alpha 1; NDUFA9, NADH dehydrogenase 
(ubiquinone) 1 alpha subcomplex, 9; COX5A, cytochrome c oxidase subunit Va; NTRK3, neurotrophic 
tyrosine kinase, receptor, type 3; IGFBP5, insulin-like growth factor binding protein 5; INSR, insulin 
receptor; IGF1R, insulin-like growth factor 1 receptor; NTRK2, neurotrophic tyrosine kinase, receptor, 
type 2; TMX3, thioredoxin-related transmembrane protein 3; CCDC102B, coiled-coil domain 
containing 102B; OSBPL1A, oxysterol binding protein-like 1A; MUSK, muscle, skeletal, receptor 
tyrosine kinase; RAPSN, receptor-associated protein of the synapse; AGRN, agrin; FLAD1,  FAD1 
flavin adenine dinucleotide synthetase homolog; DRAGT1, dolichyl-phosphate (UDP-N-
acetylglucosamine) N-acetylglucosaminephosphotransferase 1; FLVCR2, feline leukaemia virus 
subgroup C cellular receptor family, member 2; RRP7A, ribosomal RNA processing 7 homolog A; 
ACHE, acetylcholinesterase. 
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Dok-1, Dok-2 and Dok-3 comprise a subfamily of Dok proteins with overlapping functions 
that are substrates for a wide variety of RTKs. They are tyrosine phosphorylated in response 
to a variety of growth factors and cytokines, such as EGF, allowing them to bind SH2 domain 
containing proteins such as Nck, Src homology region 2 domain containing phosphatase-1 
(SHP-1), SHIP-1 and RasGAP phosphatases (93, 101, 134, 194, 195). RasGAP is a GTPase 
activating protein that exerts a negative regulatory role in the Ras/Raf/MEK/MAPK 
signalling pathway (94, 101, 124). Dok-1, Dok-2 and Dok-3 are therefore able to negatively 
regulate signalling pathways downstream of RTKs and CTKs and are consequently 
implicated in a range of physiological and pathological cellular processes. 
  
Many studies have shown that Dok-1 is highly phosphorylated in many cells containing 
activated tyrosine kinases, suggesting that it is a substrate of several tyrosine kinases, 
including EGFR, c-Kit, EphB2 and v-Abl (91, 95, 196). Once phosphorylated, Dok-1 has 
been shown to interact with a number of downstream signalling proteins including RasGAP, 
Crk-L and Nck (94, 95, 196, 197). Tyrosine phosphorylation of Dok-1 is also induced by 
insulin (which also promotes the association of phosphorylated Dok-1 with RasGAP and 
Nck) and by cell adhesion to extracellular matrix proteins (198).  
    
In terms of their impact on cell function, initial studies of the Dok proteins in found that they 
negatively regulated cell growth; either through inhibition of EGF induced ERK activation or 
via the inhibition of c-Src induced cell transformation (112, 124, 147). In addition, Dok-1 has 
also been shown to be a negative regulator of growth factor induced cell proliferation, 
differentiation and transformation (94, 95, 97, 112, 199-202). Despite these negative effects, 
however, overexpression of Dok-1 is actually associated with enhanced cell migration (198).  
 
Since then, numerous studies have confirmed that Dok-1, Dok-2 and Dok-3 negatively 
regulate Ras/Raf/MEK/MAPK signalling downstream of protein tyrosine kinases (203). All 
three interact with SHIP1, an SH2 domain containing inositol-5-phosphatase that regulates 
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levels of lipid second messengers, and Csk, which negatively regulates c-Src family kinases 
(99, 103, 177, 204-206). SHIP1 negatively regulates haematopoiesis and associates with 
BCR/ABL, PI3K and Crk-L adaptor protein, all of which are involved in the regulation of cell 
migration (207). The expression of SHIP1 is reduced by BCR/ABL tyrosine kinase oncogene 
(207).  
 
Phosphorylation of Dok-2 by EGFR occurs in response to EGF stimulation and results in the 
subsequent binding of SH2 domain containing molecules such as RasGAP and Nck (93). The 
recruitment of RasGAP and SHIP1 by Dok-2 leads to the subsequent inhibition of the 
Ras/Raf/MEK/MAPK and PI3K/Akt signalling pathways and consequently affects cytokine 
expression (93, 94, 142-144, 194, 208, 209).  
 
In endothelial cell lines, Dok-2 is co-expressed with Tek, an endothelial cell-specific RTK 
that is crucial in murine embryonic vascular development and which plays a key role in 
angiogenesis and cell migration (124, 210, 211). Following the activation of Tek by 
Angiopoietin-1 (Ang-1), Dok-2 interacts with Tek via its PTB domain and is phosphorylated, 
resulting in the recruitment of RasGAP, Nck, Pak and Crk to the activated Tek receptor at the 
cell membrane (124, 210). Overexpression of Dok-2 has been shown to increase endothelial 
cell migration via this mechanism (210). The binding and phosphorylation of Dok-2 is 
mediated by an Ang1-dependent autophosphorylation site Tyr (1106) on Tek, as well as the 
PTB and PH domains of Dok-2 (211). 
 
Dok-2 acts as a signalling molecule in activated platelets and has been found in platelet-
derived microparticles (PMPs) obtained from thrombin activated platelets (212, 213). PMPs 
are microvesicles generated in response to platelet activation which are found in elevated 
levels in a range of diseases, including cancer, where they increase expression of adhesion 
molecules, stimulate cytokine release and induce angiogenesis and metastasis (214). Dok-2 is 
also involved in collagen receptor, glycoprotein VI (GPVI) signalling in human platelets 
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stimulated by thrombin receptor activating peptide (TRAP), suggesting a potential role in 
platelet aggregation and activation (212). Dok-2 also interacts with the RTK HER2, an 
EGFR, the overexpression of which is associated with poor prognosis in human breast cancer 
(123). In macrophages, Dok-2 has been shown to negatively regulate c-myc signal 
transduction and cytokine induced cell proliferation (195). C-Myc is a phosphoprotein 
involved in cell proliferation, cellular transformation and apoptosis and has been shown to be 
mutated in many cancers (215).   
 
Previous studies have shown that attenuation of MAPK activation can occur independently of 
RasGAP (93, 201). Phosphorylation of Dok-2 in response to EGF stimulation attenuates 
MAPK and Akt activity via Dok-2’s SH3-dependent interaction with (and inhibition of) c-Src 
and the recruitment of Csk, a negative regulatory kinase (99, 103). Dok-2, therefore, acts as a 
scaffold molecule for c-Src and Csk to negatively regulate EGFR signalling (103). Further 
evidence for a tumour suppressor role of the Dok proteins is offered in the finding that Dok-2 
in association with c-Src and Csk can abolish the protective effect of c-Src in facilitating 
breast cancer cell evasion of anoikis (103). Moreover, Dok-1 inhibits PDGF-induced 
mitogenesis by tethering signalling molecules to the cell membrane, firstly by attenuating c-
myc induction through the recruitment of Csk to active Src kinases and secondly, by 
inhibiting Ras/Raf/MEK/MAPK activation by interaction with RasGAP (216). Dok-1 also 
increases activin A-induced B-cell apoptosis via its association with Smads, inhibits 
activation of the c-fos proto-oncogene promoter, inhibits cellular transformation by Src 
tyrosine kinase and also binds to RET proto-oncogene negatively regulating downstream 
pathways including RasGAP/ERK and Nck/ Jun N-terminal protein kinase (JNK) pathways 
(112, 149, 217, 218). Overall, these studies suggest that Dok-1 and Dok-2 act as negative 
regulators of growth-factor induced cell proliferation and are likely tumour suppressors (216).  
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Consistent with this negative role in cell signalling pathways, previous studies in both 
haematopoietic and non-haematopoietic cells have shown that loss of Dok-1 is associated 
with increased cell proliferation in response to growth factor treatment, sustained Ras and 
Ras/Raf/MEK/MAPK activation after removal of growth factor treatment and the promotion 
of oncogenic cellular transformation (97, 202). However, on the contrary, Hosooka et al 
found that inhibition of endogenous Dok-1 tyrosine phosphorylation in metastatic mouse 
melanoma cells resulted in reduced cell spreading, migration, growth and Ras activation (77).  
 
Unlike Dok-1 and Dok-2, Dok-3 does not bind RasGAP to negatively regulate Ras-Erk 
pathway (102, 203). Upon tyrosine phosphorylation, Dok-3 binds Grb2 via SH2 domains, 
inhibiting the ability of Grb2 to form complexes with Sos, a Ras activator (203). Therefore, 
by sequestering Grb2, Dok-3 inhibits the Ras-Erk pathway independently of RasGAP (203). 
Dok-3 also regulates JNK and calcium mobilization via its interaction with SHIP-1 and Grb2 
(144). In CML, Grb2/Grb 2-associated-binding protein (Gab2)/Src homology domain-
containing transforming protein 1 (Shc1) and Dok-1/Dok-2 complexes assemble on the BCR-
ABL1 core in a phosphorylation-dependent fashion (219). These can then interact with SH2 
domain containing molecules to influence downstream pathways including PI3K, ERK and 
Akt. Overexpression of Dok-3 is associated with reduced v-Abl induced MAPK activation 
and reduced v-Abl associated transforming activity but has no effect on constitutively 
activated Ras- or EGF-induced MAPK activation (102).  
 
Dok-4 also inhibits tyrosine kinase signalling in epithelial cells (115). Phosphorylated Dok-4 
associates with RasGAP, Crk, Src and Fyn but not PI3K p85, Grb2, Shp-2, Nck or 
phospholipase C gamma Src homology 2 domains (150). Dok-5 does not associate with 
RasGAP, Nck or Src homology 2 domains nor does it activate MAPK (104, 149, 150). Both 
Dok-4 and Dok-5 are substrates for the IGF-1 receptors and the RTK c-Ret, with which they 
are co-expressed in neuronal tissues, but are not phosphorylated by PDGFR beta or IGF-IR 
(104, 115). By comparison, although Dok-6 is phosphorylated in response to Ret activation, 
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the affinity of the Dok-6 PTB domain for c-Ret is much lower with correspondingly less 
impact on Ret signalling (105, 117). Activation of c-Ret is associated with neuronal 
differentiation, resulting in axonal outgrowth and activation of MAPK (104). Consequently, 
both Dok-4 and Dok-6 promote GDNF-dependent neurite outgrowth during neuronal 
development (220). Dok-4 is also a substrate for non-receptor tyrosine kinases Fyn, Src and 
Jak2 (115).   
 
The Dok proteins act mainly to negatively regulate signalling downstream of kinases, but 
Dok-4 has both positive as well as negative regulatory functions and Baldwin et al 
hypothesised that the N-terminus and C-terminus of Dok-4 exerts opposing inhibitory and 
stimulatory properties respectively (221).  
 
The expression of Dok-5 in cardiac muscle increases significantly during cardiomyocyte 
differentiation (222). In mice studies they identified that Dok-5 expression is associated with 
enhanced cardiomyocyte differentiation and that FOXO3a, a downstream substrate of 
PI3K/PKB, inhibits Dok-5 expression by transcriptional repression (222).  In mouse spinal 
tissues, Dok-5 is involved in NT-3 signalling that blocks TrkC-induced apoptosis (223). 
 
1.3.8 Dok proteins in immune function 
 
Immunoreceptors mediate their effects by inducing tyrosine phosphorylation of target 
intracellular proteins either via intrinsic PTK activity or via recruitment and activation of 
CTKs, such as the Src family (130). Src family kinases phosphorylate tyrosine residues 
within the intracellular motif enabling spleen tyrosine kinase (Syk)/Zap-70-related PTKs to 
bind to the immunoreceptor, activating further downstream signalling molecules including 
phospholipase C (PLC)-γ, PI3K and Ras and ultimately activating immune functions (130). 
These functions are negatively regulated by protein tyrosine phosphatases (PTPs) such as 
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SHP-1, SHP-2, Csk and the Src homology 2 domain-containing inositol 5’-phosphatase 
(SHIP) (130). 
 
Signals transduced by the B cell antigen receptor (BCR) control B cell development and 
function (224). Antigen binding to BCR results in BCR phosphorylation and the recruitment 
and activation of Syk via SH2 domains (224). This results in the subsequent phosphorylation 
of adapter protein SLP-65 and recruitment of Btk and PLC- γ2 (224). Another tyrosine kinase 
important to BCR signal transduction is the Ick/yes-related novel protein tyrosine kinase 
(Lyn), which has been shown to have both positive and negative effects on BCR signalling 
(225-227).  
 
Several studies have shown that the Dok proteins play important roles in immune cell 
signalling (194). Dok-1 has been shown to play a role both in B cells and in T cells and 
consequently, is important in the regulation of both the humoral and cell-mediated adaptive 
immune response. In B-cells, Tec mediates signalling between BCR and Dok-1, which 
functions with SHIP to regulate BCR signal transduction (217, 228, 229). In T cells, Dok-1 is 
recruited to the plasma membrane by cluster of differentiation 45 (CD45) resulting in 
negative regulation of the Janus kinase (JAK)/STAT signalling pathway and has also been 
found to play an important role in stromal cell-derived factor-1 (SDF-1alpha/CXCL12) 
induced chemotaxis in T cells (230, 231). Both Dok-1 and SHIP are tyrosine phosphorylated 
in response to T cell stimulation and are required for the regulation of CD4+CD25+ T cell 
development (232).  
 
Dok-3 is highly expressed in B cells where it is located at the inner aspect of the plasma 
membrane (233). Following BCR activation, Dok-3 is tyrosine phosphorylated, probably by 
the Src family kinase Lyn (130). This results in the recruitment of inhibitory molecules SHIP 
and Csk leading to the negative regulation of B cell activation and downstream signalling 
pathways such as the JNK signalling cascade (130, 234, 235). Dok-3 also plays a key role in 
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the negative feedback regulation of intracellular calcium signalling downstream of BCR 
(233). Upon phosphorylation, Dok-3 binds cytosolic Grb2 via SH2 domains (224, 235). This 
in turn phosphorylates Dok-3 and results in the formation of further Dok-3/Grb2 complexes, 
decreasing PLC- γ2 activation, inositol-1,4,5-triphosphate production and mobilization of 
calcium (224, 233). Dok-3 also promotes plasma cell differentiation by regulating the 
expression of programmed cell death 1 ligands (236). Via these effects, Dok-3 is thought to 
affect cell proliferation, differentiation and apoptosis (237, 238). Previous authors have 
shown that Dok-3/Grb2 attenuates BCR signal transduction by decreasing Lyn dependent 
phosphorylation of Syk and thus attenuating its tyrosine kinase activity (224). Moreover, they 
found that Dok-3/Grb2 complex formation is necessary for the organization of BCR 
microclusters into discrete microsignalosomes and for phosphorylation of SHIP1 which is 
required for signal transduction (224).   
 
Along with Grb2 and Casitas B-lineage Lymphoma (Cbl) proto-oncogene, Dok-3 has been 
shown to play a key role firstly, in the recruitment of dynein to BCR microclusters following 
antigen recognition and secondly, in the subsequent movement of BCR microclusters on 
microtubules to gather antigen (130, 239). Dok-3, Grb2 and Cbl are recruited to antigen 
containing BCR microclusters in a Grb2 dependent fashion and localize dynein, allowing 
movement on microtubules and internalization of the microcluster (140, 239). It has been 
suggested by Schnyder et al that Lyn and Syk signalling is initiated by antigen recognition 
along with the formation of BCR microclusters and that this results in the recruitment of other 
mediators such as Vav and PLC-γ2, which are involved in the organisation of the actin 
cytoskeleton (239). Studies in mice have shown that mice lacking in Dok-3 displayed normal 
B-cell development but had a higher level of IgM antibodies in their sera, exhibited an 
enhanced humoral immune response to T cell-independent type I and II antigens, 
hyperproliferated, had an increased level of calcium signalling and enhanced activation of 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), JNK and p38MAPK 
(240). Moreover, lack of Dok-3 was associated with reduced phosphorylation of SHIP-1 
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(240). Overall, these results suggest that Dok-3 is involved in the negative regulation of BCR 
signalling (240).   
 
Dok-1 and Dok-2 (though not Dok-3) are expressed in T cells and are tyrosine 
phosphorylated following stimulation by CD2 or CD28, but not CD3, resulting in the 
negative regulation of downstream signalling (122, 130, 241, 242). CD2 induced 
phosphorylation of Dok-1 is dependent on Src family kinases, such as Lck and Fyn, and 
results in the association of Dok-1 with Crk-L (242). The latter association is dependent on 
the ZAP70/Syk family kinases (242). Overexpression of Dok-1 in immortalized T cells 
inhibits CD2 mediated signalling resulting in reduced calcium mobilisation, reduced 
phospholipase C gamma 1 phosphorylation and reduced activation of Erk1/2 (241). 
 
Dok-1 and Dok-2 negatively regulate T cell receptor for antigen (TCR) signalling, which 
plays a crucial role in the immune response, via formation of signalling complexes involving 
SHIP-1 and Grb-2 (243). These interact with linker of activated T cells (LAT) to attenuate 
TCR signalling and negatively regulate Akt and ZAP-70 (122, 241, 243, 244). Like Dok-1, 
Dok-2 also negatively regulates T cell development via its interaction with RasGAP and Nck, 
and expression of Dok-2 in bone marrow cells is associated with reduced capacity for 
cytokine-induced colony formation (245). In irradiated mice, Dok-2 expression is associated 
with reduced repopulation of lymphoid and thymic tissue and a reduction in mature peripheral 
T cells (245).  
 
Dok-1 and Dok-2 are associated with Tec, a protein tyrosine kinase expressed in T cells 
(246). They provide negative regulation of Tec via downregulation of its tyrosine 
phosphorylation and downstream signalling pathways, which include the Ras pathway (246). 
Previously, Yoshida et al found that Tec induces Dok-1 hyperphosphorylation, and that Tec 
associates with Dok-1 in a phosphorylation-dependent manner (217).  
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Stem cell factor (SCF) is a cytokine involved in cell survival, proliferation, differentiation and 
migration that binds to c-Kit, resulting in the activation of PI3-K (247). This phosphorylates 
and activates Tec and Dok-1 which form a complex with Lyn (247). Dok-1 is phosphorylated 
by both Tec and Lyn, enabling the binding of several downstream signalling molecules 
activated by SCF including Abl, Crk-L, SHIP and PLCγ-1 via SH2 binding domains (247). 
Thus, Dok-1 acts as a “scaffold molecule” in c-Kit signalling pathways (247). Previous 
studies have shown that stimulation of Mo7 cells with SCF induced PI3K dependent tyrosine 
phosphorylation of Dok-1 and the recruitment of Dok-1 to the membrane (an event that is 
essential for the ability of Dok-1 to function as a negative regulator of cell proliferation) 
(248). C-Kit associates with Dok-1 via its juxtamembrane region and C-terminal tail (248). 
Both tyrosine phosphorylation of c-Kit and the association of c-Kit with Dok-1 are promoted 
by Lyn (248).  
 
Stimulation of the T cell receptor by an antigen results in the recruitment of ZAP-70, a 
protein tyrosine kinase recruited to the T cell receptor that plays a key role in T cell activation 
(244). Both Dok-1 and Dok-2 attenuate activation of the Akt pathway and ZAP-70 (243, 
244). Lack of Dok-1 and Dok-2 is associated with elevated T cell response to TCR 
stimulation, with an increase in ZAP-70 activation and cytokine production (244). By 
contrast, forced expression of Dok-1 or Dok-2 is associated with suppression of TCR 
stimulated ZAP-70 activation (244). Murine studies have shown that mice lacking Dok-1 and 
Dok-2 have elevated antibody titres and develop lupus-like renal disease (244).  
 
Interestingly, Guittard et al found that this negative regulatory role in T cell function and the 
tyrosine phosphorylation of Dok-1 and Dok-2 depends on the presence of their PH domain 
(249). These PH domains act as lipid/protein-interacting modules, binding to the 
phosphoinositide, phosphatidylinositol 5-phosphate (PtdIns5P) to regulate T cell response 
(249). Overexpression of Dok-1 or Dok-2 inhibits ZAP-70 activation whilst overexpression of 
both Dok-1 and Dok-2 reduces IL-2 production in activated T-cells (244, 246). Double 
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knockdown of Dok-1 and Dok-2 by siRNA increases TCR-induced Il-2 secretion and 
prolongs TCR-mediated Akt activation (243). In mouse models, lack of Dok-1 and Dok-2 is 
associated with an amplified response to thymus-dependent (but not thymus-independent) 
antigens, increased T cell response to TCR stimulation and consequently, increased ZAP-70 
activation, cell proliferation and cytokine production (244). Inhibition of T cell receptor 
signal transduction by zanolimumab, an anti-CD4 monoclonal antibody, is partly due to 
activation of p56Ick, a CD4-associated tyrosine kinase which relays inhibitory signals 
downstream via Dok-1 and SHIP-1 (250).  
 
Dok-1 and Dok-2 (though not other Dok family members) are both expressed in Natural killer 
(NK) cells and act as negative regulators of NK-cell function (194). Activation of the NK cell 
results in tyrosine phosphorylation of Dok-1 and Dok-2 (194). Celis-Guitirrez et al found that 
Dok-1/Dok-2 double knockout mice had reduced peripheral NK cells and exhibited impaired 
NK-cell development compared to wild-type mice, possibly due to impaired apoptosis during 
NK cell maturation (194). They suggest that Dok-1 and Dok-2 downregulate NK cell 
activation induced by NK cell surface activating receptors but that they upregulate NK cell 
activation and interferon gamma (IFN-γ) production induced by the cytokines interleukin 
(IL)-12 and IL-18 (194). In vivo studies show that Dok-1/Dok-2 double knockout mice had 
delayed control of murine cytomegalovirus (MCMV) replication (194). Despite these 
negative regulatory roles in immune signalling events, Dok-1 has also been shown to play a 
positive regulatory role both in IL-4 signalling, increasing IL-4-induced CD4+ T cell and B 
cell proliferation and also the IgE response to T cell-dependent antigen (251). 
 
In astrocytes and microglia, toll like receptor (TLR) 2 increased Dok-1 and Dok-2 tyrosine 
phosphorylation whilst knockdown of Dok-1 and Dok-2 increased TLR2-induced ERK 
activation (208). In astrocytes, silencing of Dok-1 and Dok-2 resulted in increased NF-κB 
activation and IL-6 production suggesting that Dok-1 and Dok-2 both negatively regulate 
TLR2-induced inflammatory signalling cascades in astrocytes (208). By comparison, in 
 125 
microglia, knockdown of Dok-1 (but not Dok-2) reduced TLR2-induced NF-κB activation 
and Il-6 production suggesting that TLR2-induced pro-inflammatory signalling is 
differentially regulated by Dok-1 and Dok-2 in different types of glial cells (208).    
 
Evidence on the role of the Dok proteins in the macrophage response to infection is somewhat 
conflicting. Mashima et al found that Dok-1 and Dok-2 play a negative regulatory role in 
macrophage responses, but work by Alvarez de Celis et al suggests that Dok-1 and Dok-2 
positively regulate the response of bone marrow derived macrophages to infection with 
Leishmania (252). 
 
In mouse macrophages stimulated with bacterial lipopolysaccharide (LPS), lack of Dok-1 or 
Dok-2 was associated with increased sensitivity to LPS, increased activation of Erk (though 
not other MAP kinases or NF-κB), with consequent increase in the production of the 
proinflammatory cytokine TNF-α and nitric oxide production (253). Overexpression of Dok-1 
or Dok-2 by contrast inhibited LPS-induced Erk activation and reduced TNF-α production 
(253). Therefore, it seems Dok-1 and Dok-2 also negatively regulate innate immunity cell 
signalling downstream of TLR4 (253).  However, Dok-3 has been shown to play a positive 
role in the TLR3 signalling cascade which is also part of the innate immune system (254).  
 
1.3.9 Aberrant expression and function of Dok proteins in cancer 
 
Many of the early studies investigating the Dok proteins in relation to malignant disease 
focused on their role in leukaemia but they have subsequently been found to play a role in 
several other human cancers. The expression profile of in different tumours is shown in Table 
1.16.  
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Table 1.16 Expression profile of DOKs in different tumours (TPM, transcripts per million) 
 
 
DOK1 DOK2 DOK3 DOK4 DOK5 DOK6 DOK7 
Adrenal tumour 79 0 0 79 0 0 0 
Bladder carcinoma 0 
0 
0 0 0 0 0 
Breast (mammary gland) 
tumour 
42 0 10 10 0 0 32 
Cervical tumour 57 
0 
0 0 0 0 0 
Chondrosarcoma 60 24 12 132 36 12 0 
Colorectal tumour 17 0 8 97 0 0 0 
Gastrointestinal tumour 0 0 
8 
33 0 0 0 
Germ cell tumour 22 15 53 60 15 15 0 
Glioma 0 0 27 74 93 18 0 
Head and neck tumour 7 22 7 22 0 0 0 
Kidney tumour 14 0 14 43 14 14 14 
Leukaemia 84 63 243 
21 
0 0 0 
Liver tumour 10 0 0 10 0 0 0 
Lung tumour 19 9 19 
38 
0 0 0 
Lymphoma 0 0 263 0 0 0 0 
Oesophageal tumour 0 0 0 0 0 0 0 
Ovarian tumour 0 0 0 39 288 13 39 
Pancreatic tumour 9 0 0 57 0 0 0 
Primitive neuroendocrine 
tumour 
31 0 0 559 7 0 0 
Prostate cancer 0 0 0 9 0 0 0 
Retinoblastoma 21 0 0 0 0 43 0 
Skin tumour 31 0 0 55 0 0 7 
Soft tissue/muscle tumour 0 0 0 63 
39 
15 7 
Uterine tumour 33 11 44 44 11 0 44 
Note: TPMs in bold are top three tumours which express higher levels of DOKs. This is a summative table adapted from 
approximate expression pattern from the EST profile at http://www.ncbi.nlm.nih.gov/UniGene. 
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1.3.9.1 Role of the Dok proteins in leukaemia 
 
Several studies have shown that the Dok proteins act as leukaemia suppressors in mice, and 
both Dok-1 and Dok-2 are downregulated in CML (142, 143, 255). In experimental studies, 
Dok-1/Dok-2 double deficient mice display an increase in myeloid progenitor cells, the 
development of CML-like myeloproliferative disease, splenomegaly and hypercellularity of 
the peripheral blood and bone marrow (142, 143). At a cellular level, Dok-1 and/or Dok-2 
knockout mice exhibit increased activation of both MAPK/Erk and Akt pathways, greater 
proliferative response to cytokines and reduced apoptosis, with these effects being more 
pronounced in the double deficient, as compared with single knockout, mice (97, 143).  
 
Further murine studies performed by Niki et al have confirmed that double Dok-1/Dok-2 
knockout results in aberrant haematopoiesis, Ras/MAPK activation and the development of 
CML-like myeloproliferative disease with increased proliferation, reduced apoptosis and 
accelerated leukaemia and blast crisis onset (142). They did not however demonstrate any 
effect on haematopoiesis with single Dok-1 or Dok-2 knockout (142). 
 
In CML, the C-terminal portion of Dok-1 is constitutively phosphorylated by elevated kinase 
activity from p210 (bcr-abl) expression. This results in the inhibition of RasGAP activity, 
activation of the Ras signalling pathway and, in mouse models infected with a p210bcr-abl 
retrovirus, loss of Dok-1 was associated with a shorter latent period before the onset of fatal 
myeloproliferative disease (97, 131). Interestingly, work by Janas and Van Aelst has 
demonstrated that oncogenic tyrosine kinases including p210 (bcr-abl) and Src target Dok-1 
for degradation by the ubiquitin-proteasome pathway, thereby overcoming the Dok-1’s 
inhibitory effects to promote cell transformation (202). Treatment of CML cells with 
Imatinib, a specific BCR-ABL kinase inhibitor, results in a 90% reduction in the 
phosphorylation of BCR-ABL, SHIP-2 and Dok-2 as well as the regulation of other proteins 
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such as SHIP-1, SH2 containing protein (SHC) and Casitas B-lineage lymphoma proto-
oncogene (BBL) (177).  
 
Previous studies have shown that Dok-1 and Dok-2 are recruited by CD200R, an inhibitory 
receptor expressed on haematopoietic progenitor cells and involved in myeloid cell regulation 
(209). Knockout of CD200R does not affect myeloid progenitor number or their proliferative 
capacity suggesting that the development of leukaemia seen in Dok-1/Dok-2 double knockout 
mice is not due to absence of CD200 mediated CD200R signalling alone (209).   
 
1.3.9.2 Role of the Dok proteins in lung cancer 
 
Research published in 2010 identified Dok-1, Dok-2 and Dok-3 as lung tumour suppressors 
(90). In mouse models, loss of Dok-1, Dok-2 and Dok-3 results in aberrant proliferation of 
alveolar type II cells and bronchoalveolar stem cells with subsequent development of lung 
cancer (90). The penetrance and latency of these effects are dependent on the number of lost 
Dok alleles, with the highest penetrance, shortest latent period and poorest survival times 
witnessed in triple knockout mice (90). In humans, lung adenocarcinoma is associated with 
loss or downregulation of Dok-2 whilst in vivo and in vitro studies have shown that Dok-2 
suppresses lung cancer cell proliferation and reduced Akt and Erk phosphorylation (90). 
Moreover, Dok-2 is haploinsufficient in its tumour suppressor function so heterozygosity 
alone may promote lung cancer (90).  
 
Knockout of Dok1/Dok-2/Dok-3 in mice is associated with the development of lung 
adenocarcinomas with histological features including nuclear polymorphism, vascular 
invasion, multiple tumour nodules and inflammatory infiltrates (90). In the majority of cases, 
tumours were well differentiated and although lymph nodes were not sampled routinely, 
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incidental lymph node metastases were not found (90). In terms of intracellular signalling, the 
mutant mice also exhibited abnormal Akt and Erk phosphorylation and activation (90).  
Chromosome 8p21.3, the location of the DOK2 gene, is one of the commonest regions 
deleted in human lung cancer (256). Berger et al found that 37% of human lung 
adenocarcinoma and 33% of human non-small cell lung cancers are associated with loss of 
one copy of the DOK2 gene (90). DOK2 mRNA is significantly downregulated in primary 
lung adenocarcinoma, lymph node metastases and lung cancer cell lines compared with 
normal lung tissue whilst forced Dok-2 expression in a lung cancer cells results in reduced 
growth rate and reduced Akt and Erk phosphorylation (90). Although Dok-3 expression was 
reduced in lung cancer lymph node metastases compared with normal lung, no difference was 
observed in the level of DOK1 or DOK3 mRNA in primary lung cancer tissue (90).  
 
1.3.9.3 Role of the Dok proteins in breast cancer 
 
In breast cancer, Dok-2 and Dok-6 expression are both inversely associated with TNM stage 
and Nottingham Prognostic Index score suggesting a potential tumour suppressor role (257). 
In keeping with this, a recent study has shown that disease-free survival in breast cancer 
patients is associated with higher levels of Dok-2 and Dok-6 expression (257). In 2013, Heyn 
et al published their study which examined DNA extracted from the whole blood of 
monozygotic twin pairs who were discordant for breast cancer using high-resolution DNA 
methylation analysis (258). They found that the Dok-7 promoter region in the blood of the 
twin with breast cancer was consistently hypermethylated compared to the blood of the paired 
healthy twin and this finding was also observed in primary breast cancer tissue and breast 
cancer cell lines (258). Interestingly, they also found that hypermethylation of the Dok-7 
promoter occurs years before tumour diagnosis, suggesting that Dok-7 may have a potential 
role as a blood based biomarker of early disease or disease predisposition (258). 
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1.3.9.4 Role of the Dok proteins in colorectal cancer 
 
To date, there have been very few studies investigating the role of the Dok proteins in 
colorectal cancer. A recently published paper found that loss of Dok-2 expression was more 
common in colorectal cancer tissues than in normal colorectal tissue (259). Furthermore, the 
absence of Dok-2 expression was associated with poorer five-year overall survival rate and 
disease recurrence in patients with colorectal cancer (259). Other authors have identified 
Dok3 as a potential therapeutic target in colorectal cancer cells (94). 
 
1.3.9.5 Role of the Dok proteins in skin cancer 
 
A recent study by Huang et al identified Dok-1 among several differentially expressed 
molecular markers in melanoma compared to normal skin tissue, suggesting its potential use 
as a diagnostic or prognostic marker in skin cancer (260).  
 
1.3.9.6 Role of the Dok proteins in reticuloendothelial system cancer 
 
Histiocytic sarcoma is a rare, aggressive malignant proliferation of histiocytic cells, which is 
associated with a poor prognosis (261). In a murine model, knockout of Dok-1 and/or Dok2 
results in half of the mice developing a histiocytic sarcoma of macrophage origin (143). In 
mice experiments conducted by Mashima et al, triple knockout of Dok-1/Dok-2/Dok-3 was 
associated with the development of aggressive histiocytic sarcoma with multiple organ 
invasion and metastases, earlier mortality secondary to sarcoma as well as aberrant 
accumulation and proliferation of macrophage tumour precursor cells in the lung (261). 
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1.3.9.7 Role of the Dok proteins in ovarian cancer 
 
Mercier et al found that a 5’-non-coding DNA region upstream of the DOK1 translation start 
codon was hypermethylated in primary serous epithelial ovarian cancer compared to normal 
ovarian tissue (262). Despite this, Dok-1 expression was not reduced and was in fact 
overexpressed in these tumours with the level of expression significantly correlated with 
improved progression-free survival and response to a cisplatin (262). Functional studies 
performed by the same group found that Dok-1 expression was associated with increased 
proliferation and migration of epithelial ovarian cancer cells (262). 
 
1.3.10 Novel potential application of Dok proteins 
 
The Dok family proteins are a group of structurally related adapter proteins that play a key 
role in cell signalling pathways downstream of PTKs. Consequently, they have been shown to 
play diverse roles in the control of cell functions including cell growth, differentiation and 
cell motility, and aberrations in Dok-protein co-ordinated cell signalling have been implicated 
in a range of both benign and malignant human diseases. A recent study by Heyn et al has 
suggested that the Dok proteins may have a potential role as blood based biomarkers in 
human cancer providing a compelling reason to investigate the role of these proteins and their 
potential use as diagnostic and therapeutic targets further. This thesis is concerned with the 
expression and role of Dok-7 in colorectal cancer.  
 
Table 1.12 and Table 1.16 provide an overview of DOK7 expression and distribution in 
different tissues/organs and tumours but there are limitations of using this information due to 
technical bias and the limited number of samples being tested and included in the database. 
The work in this thesis is based on the initial determination of DOK7 expression in our 
laboratories, which suggested aberrant DOK7 expression in human colorectal cancer. This 
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initial work was provoked by the important role of receptor tyrosine kinases in cancer and 
DOK7 protein’s regulatory role in RTK signalling pathways. It is hoped that by determining 
the expression of DOK7 in colorectal cancer we might determine its potential use as a 
diagnostic or prognostic marker and through developing a greater understanding of its links 
with candidate RTKs and signalling pathways, we may determine whether it has any further 
value as a therapeutic target, for example through gene therapy or antibody therapy.  
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Aims and objectives 
 
 
The aim of this clinically oriented PhD is to determine the expression profile and role of 
DOK7 in human colorectal cancer. The central hypothesis of the study is that DOK7 has an 
important role in colorectal cancer and that it is likely to play a tumour suppressive role.  
 
The objectives of the PhD are as follows: 
• To evaluate the existing literature relating to the DOK family proteins, particularly in 
relation to human cancers 
• To determine the expression profile of DOK7 in human colorectal cancer cell lines 
• To determine whether DOK7 expression is associated with tumour pathology and 
clinical outcome data obtained from a clinical cohort 
• To determine the functional role of DOK7 in colorectal cancer cells through 
functional assay analysis of transgenic cells.  
• To evaluate DOK7 coordinated cell signalling in colorectal cancer focusing on 
altered signalling events in colorectal cancer cells with altered DOK7 expression and 
to determine relevant signalling pathways and responsive genes. Therefore, we aim to 
propose an action model of DOK7 in colorectal cancer highlighting its diagnostic and 
therapeutic value. 
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Chapter 2: Materials and Methods 
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2.1 Materials 
 
2.1.1 Cell lines 
 
Human cancer cell lines were freshly acquired from the European Collection of Authenticated 
Cell Cultures (ECACC, Salisbury, UK) or the American Type Culture Collection (ATCC, 
Middlesex, UK). All cell lines were verified at source for identity and were low passage on 
acquisition. This study used four colorectal cancer cell lines: RKO, HT-115, HRT-18 and 
Caco-2. These cell lines were chosen because they are commonly used in studies of human 
colorectal cancer, there is considerable experience in their use within the host laboratories, 
and because this panel of cell lines includes both colonic and rectal cancer cells and well and 
poorly differentiated cell types.   
 
Full details of the cells used in the study are shown in Table 2.1. Human endothelial cell line 
(HECV) was purchased from Interlab (Milan, Italy). 
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Table 2.1. Details of colorectal cancer cell lines used in this study 
 
 RKO HT-115 HRT-18 Caco-2 
Species Human Human Human Human 
Tissue Colon Colon Rectum Colon 
Gender - - Male Male 
Age - - 67 72 
Morphology Epithelial Epithelial Epithelial 
like 
Epithelial 
Growth mode Adherent Adherent Adherent Adherent 
Characteristics Poorly 
differentiated 
Highly 
invasive 
- Moderately well differentiated 
adenocarcinomas consistent with 
colonic primary grade II 
Country UK UK UK UK 
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2.1.2 General compounds  
 
The general compounds used in this study and their sources are listed in Table 2.2 (See 
Appendix 1). 
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2.1.3 General plastic consumables, hardware and software 
 
The general plastic consumables, hardware and software used in this study and their sources 
are listed in Table 2.3 (See Appendix 2). 
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2.1.4 Antibodies 
 
The primary and secondary antibodies used in this study are shown in Table 2.4 and Table 2.5 
respectively (See Appendix 3). 
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2.1.5 Primers 
 
The primers used in this study were designed using the Beacon Design software programme 
(Biosoft International, Palo Alto, CA, USA) and synthesised by either Invitrogen (Paisley, 
UK) or Sigma (Poole, UK). The sequences of the primers used for conventional RT-PCR and 
qPCR are shown in Table 2.6 (See Appendix 4). 
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2.1.6 Preparation of reagents, buffers and standard solutions 
 
2.1.6.1 Solutions used in cell culture 
 
2.1.6.1.1 Preparation of complete cell culture medium 
 
Cell lines were cultured and maintained in the specific cell culture media recommended by 
the ECACC/ATCC. 
 
For RKO and HECV cells, 50ml of heat inactivated foetal calf serum (FCS) and 5ml 
antibiotics were added to 500ml DMEM/F12 with 2mM L-glutamine. For HT115 cells, 75ml 
of heat inactivated FCS and 5ml antibiotics were added to 500ml DMEM/F12 with 2mM L-
glutamine. HRT-18 cells were maintained in RPMI media supplemented with 50ml of heat 
inactivated FCS and 5ml antibiotics. All media were stored at 4°C and used within one month 
of preparation. 
 
2.1.6.1.2 Antibiotics 
 
An antibiotic solution for use in cell culture was prepared by dissolving 3.3g penicillin, 5g 
streptomycin and 12.5mg Amphotericin B in dimethyl sulfoxide (DMSO) in 500ml Balanced 
Salt Solution (BSS). The solution was filtered prior to use and stored at -20°C. Five millilitres 
of this antibiotic solution were added to each 500ml of culture media as described above. 
 
  
 142 
2.1.6.1.3 Balanced Salt Solution (BSS)     
 
A stock solution of BSS (137mM NaCl, 2.6mM KCl, 1.7mM Na2HPO4 and 8mM KH2PO4) 
was prepared by dissolving 79.5g NaCl, 2.2gKCl, 1.1g Na2HPO4 and 2.1g KH2PO4 in 10 
litres of distilled water (dH2O). The pH was adjusted to 7.2 with 1M NaOH and the solution 
was stored at room temperature until use.  
 
2.1.6.1.4 Ethylenediaminetetraacetic acid (EDTA) 
 
A 0.05M stock solution was prepared by dissolving 40g NaCl, 1g KCl, 5.72g Na2HPO4, 1g 
KH2PO4 and 1.4g EDTA in 5 litres of dH2O. The pH was adjusted to 7.4 using 1M NaOH and 
the solution was autoclaved before use.  
 
2.1.6.1.5 Trypsin/EDTA solution 
 
A 25mg/ml stock solution of trypsin/EDTA solution was prepared by dissolving 500mg 
trypsin in 20ml 0.05M EDTA. The solution was filtered through a 0.2µm mini-start filter and 
stored at -20°C. A working solution was prepared by further dissolving 250µl of the stock 
trypsin/EDTA solution in 10ml of 0.05M EDTA. The working solution was stored at 4°C 
until use.   
 
2.1.6.1.6 Phosphate-buffered saline (PBS) 
 
To prepare 1L of 1 x PBS, (137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 1.8mM KH2PO4) 
was prepared by dissolving 8g NaCl, 0.2g KCl, 1.44g Na2HPO4 and 0.24g KH2PO4 in 800ml 
of H2O. The pH was adjusted to 7.4 with HCl and H2O added to make up the volume to 1L. 
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The solution was then alliquoted and sterilized by autoclaving for 20 minutes at 15psi 
(1.05kg/cm
2
) on a liquid cycle before being stored at room temperature.  
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2.1.6.2 Solutions used in molecular biology 
 
2.1.6.2.1 Tris-Boric acid-EDTA (TBE) electrophoresis buffer 
 
A five-times concentration stock solution of TBE (1.1M Tris; 900mM Borate; 25mM EDTA) 
was prepared by dissolving 540g Tris-Cl, 275g boric acid and 46.5g EDTA in 10 litres of 
dH2O. The pH was adjusted to 8.3 using 1M NaOH and the solution was stored at room 
temperature until use. A working solution was prepared by diluting 200ml of the stock 
solution in 800ml of dH2O. 
 
2.1.6.2.2 Diethylpyrocarbonate (DEPC) water 
 
Diethylpyrocarbonate (DEPC) is used to inactivate RNase enzymes that may contaminate 
water or laboratory equipment, thereby reducing the risk of RNA degradation. A stock 
solution of DEPC water was prepared by dissolving 500µl of DEPC in 9500µl dH2O. The 
solution was autoclaved prior to use. 
 
2.1.6.2.3 Loading buffer 
 
Loading buffer was prepared by dissolving 25mg bromophenol blue and 4g sucrose in 10ml 
of dH2O. The buffer was stored at 4°C until use.  
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2.1.6.3 Solutions used for gene transfer techniques 
 
2.1.6.3.1 LB agar 
 
LB agar was prepared by dissolving 10g tryptone, 5g yeast extract, 15g agar and 10g NaCl in 
1 litre of dH2O. The pH was adjusted to 7.0 and the media was autoclaved and stored at 4°C 
until use.   
 
2.1.6.3.2 Preparation of LB agar dishes 
 
In order to prepare LB agar dishes the LB agar was first melted in a microwave. Upon 
reaching a liquid state, the agar was allowed to cool to approximately 65°C and the 
appropriate antibiotic for colony selection was added. The agar solution was then poured into 
10cm
2
 Petri dishes, which were left to cool. Once the agar had solidified, the plates were 
stored at 4°C until required.  
 
2.1.6.3.3 LB broth 
 
LB broth was prepared by dissolving 10g tryptone, 10g NaCl and 5g yeast extract in 1 litre of 
dH2O. The pH was adjusted to 7.0 and then the media was autoclaved prior to storage at 4°C 
until use. Appropriate antibiotics for colony selection were added prior to use.  
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2.1.6.4 Solutions used for protein extraction and Western blotting 
 
2.1.6.4.1 Protease and phosphatase inhibitors 
 
The protease and phosphatase inhibitors used in this study are shown in Table 2.7. 
 
Table 2.7. Protease and phosphatase inhibitors and their stock concentrations 
 
Name Protease/phosphatase 
inhibited 
Stock concentration 
Phenylmethylsulfonyl fluoride (PMSF) 
100mM in isopropanol, stored at -20°C 
Serine, cysteine 
proteases 
100mM 
Leupeptin 
1mg/ml in H2O, stored at -20°C 
Lysosomal 1mg/ml 
EDTA Metalloproteases 
requiring Mg2+ and 
Mn2+ 
 
Sodium fluoride Serine/threonine 
phosphatases 
 
Aprotinin 
1mg/ml in H2O, stored at -20°C 
Trypsin, 
chymotrypsin, 
plasmin 
1mg/ml 
Sodium orthovanadate (Na3VO4) Tyrosine 
phosphatases 
200mM 
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2.1.6.4.2 Inhibitor buffer 
 
A (x3) solution of inhibitor buffer was prepared by mixing 2.76g sodium nitrate, 630g sodium 
fluoride, 5.58g EDTA, 10g Na2H2PO4 and 3x10
5
 units aprotinin made up to 1L with dH2O. 
The solution was stored at 4°C until use. 
 
2.1.6.4.3 Cell lysis buffer 
 
A stock solution of cell lysis buffer was prepared by dissolving 2mM CaCl2, 0.5% Triton X-
100, 1mg/ml aprotinin, 1mg/ml leupeptin and 10mM sodium orthovanadate in 50ml dH2O . 
The solution was stored at 4°C until use. A working solution was prepared by diluting 10ml 
stock solution in 6.6ml inhibitor buffer, 200µl PMSF, 80µl 10mM CaCl2, 3ml of 10% Triton 
X-100 made up to 20ml with dH2O.  
 
2.1.6.4.4 Tris Buffered Saline (TBS) 
 
A (x10) stock solution (200mM Tris; 1.37M NaCl) was prepared by dissolving 24.228g Tris-
Cl and 80.06g NaCl in 1 litre dH2O. The pH was adjusted to 7.4 using hydrochloric acid 
(HCl) and the solution was stored at room temperature until use.   
 
2.1.6.4.5 Ammonium Persulphate (APS) 
 
A 10% APS solution was prepared by dissolving 1g APS in 10ml dH2O. The solution was 
stored at 4°C until use. 
 
 148 
2.1.6.4.6 Running buffer 
 
A (x10) stock solution was prepared by dissolving 303g Tris, 100g SDS and 1.44kg glycine 
in 10 litres dH2O. The pH was adjusted to 8.3 using NaOH and the solution was stored at 
room temperature. A working solution was prepared by diluting 100ml of the stock solution 
with 900ml dH2O prior to use.  
 
2.1.6.4.7 Transfer buffer 
 
Transfer buffer was prepared by dissolving 15.15g Tris, 72g glycine and 1L methanol in 4 
litres dH2O.  
 
2.1.6.4.8 Preparation of 0.1% Coomassie blue 
 
This was prepared by dissolving 1g coomassie blue, 400ml methanol and 100ml acetic acid 
and making the volume up to 1 litre with dH2O. The solution was filtered and stored at room 
temperature until use. 
 
2.1.6.5 Preparation of SDS-PAGE gels 
 
2.1.6.5.1 Resolving gel 
 
A 10% resolving gel for SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was prepared 
using 7.9ml dH2O, 6.7ml 30% acrylamide mix, 5ml 1.5M Tris (pH 8.8), 200µl 10% SDS, 
200µl APS and 8µl Tetramethylethylenediamine (TEMED) per gel. 
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2.1.6.5.2 Stacking gel 
 
A 5% stacking gel for SDS-PAGE was prepared using 6.8ml dH2O, 1.7ml 30% acrylamide 
mix, 1.25ml 1.5M Tris (pH 6.8), 100µL 10% SDS, 100µL APS and 10µL TEMED per gel. 
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2.2 Methods 
 
2.2.1 Cell culture 
 
2.2.1.1 Preparation of cell media 
 
Cell lines were cultured and maintained according to ECACC/ATCC recommendations. RKO 
cells were maintained in Dulbecco’s Modified Eagle’s Medium/Nutrient F-12 Ham (DMEM-
F12, Sigma-Aldrich, Dorset, UK) media supplemented with 10% heat-inactivated foetal calf 
serum (FCS, PAA Laboratories, Coelbe, Germany) and antibiotics. HT-115 cells were 
maintained in DMEM-F12 media supplemented with 15% FCS and antibiotics. HRT-18 cells 
were maintained in Roswell Park Memorial Institute (RPMI, Sigma-Aldrich, Dorset, UK) 
media supplemented with 10% FCS and antibiotics. HECV cells were maintained in DMEM-
F12 media supplemented with 10% FCS and antibiotics. For the purposes of this thesis, these 
media will be referred to as ‘normal media’ throughout.   
 
2.2.1.2 Cell maintenance and storage 
 
Cells were cultured in 25cm
2
 or 75cm
2
 tissue culture flasks depending on the required 
application. The flasks were placed horizontally in an incubator humidified to 98% with a 
water tray at a temperature of 37°C with 5% CO2 in air. The flask caps were loosened to 
facilitate gaseous exchange. 
 
Transfected cell lines were cultured in normal media for 24 hours following transfection and 
then transferred into blasticidin selection media (normal media supplemented with 5µg/ml 
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blasticidin S). Following selection of transfected cells, cells were maintained in blasticidin 
maintenance media (normal media supplemented with 0.5µg/ml blasticidin S).   
Cells were inspected regularly using the light microscope to assess viability, confluence and 
to monitor for infection. Cells were routinely passaged once confluence exceeded 80%. All 
experimental work in this study was carried out using cells with a total passage number of 20 
or less. 
 
All cell work was carried out in a Class II Laminar Flow Cabinet with disposable sterile 
and/or autoclaved equipment.   
 
2.2.1.3 Cell detachment and cell counting 
 
The tissue culture flask was removed from the incubator and the waste medium was removed 
using a glass pipette and vacuum aspirator. The flask was washed briefly with 2ml of PBS 
buffer to remove any remaining FCS as this may inhibit the action of trypsin. 
 
Approximately 500µl trypsin/EDTA solution (Trypsin 0.01% (w/v) and EDTA 0.05% (w/v) 
in HBSS buffer) per 25cm
2
 of tissue culture flask surface area was added to the flask and the 
flasks were capped and returned to the incubator for 5-10 minutes at 37°C to facilitate cell 
detachment. Flasks were visually inspected under the light microscope to ensure complete 
cell detachment.   
 
Following cell detachment, 5ml of the appropriate media was added to each flask to neutralise 
the trypsin and wash the detached cells from the flask surface. This cell/medium mixture was 
transferred to a sterile 30ml universal container and centrifuged at 1,800rpm for 10 minutes. 
The media was then aspirated and discarded and the cell pellet re-suspended in media for re-
culturing or immediate use in experimental work.  
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Cell counts were performed using the Tali™ Image-based cytometer. The Tali™ Image-based 
cytometer is a benchtop assay platform that uses optics and image analysis to perform cell 
counting assays as well as apoptosis and cell viability assays. In order to perform a cell count, 
25µl sample was pipetted into the sample loading area of a disposable Tali™ cellular analysis 
slide and the slide was inserted into the slide port of the Tali™ cytometer. The image 
adjustment knob was used to focus the cells prior to image capture. Multiple repeat cell 
counts were taken from each sample to reduce error.      
 
2.2.1.4 Storage of cell lines in liquid nitrogen and cell resuscitation 
 
In order to prepare cells for storage, they were detached from the flask as described above, 
centrifuged and the cell pellet was re-suspended in the appropriate medium with 10% 
dimethylsulphoxide (DMSO) at a density of 1x10
6
 cells/ml. This cell suspension was rapidly 
transferred into 1ml labelled cryotubes and frozen down to -80°C using a Mr. Frosty™ 
Freezing container which uses 100% isopropyl alcohol to cool cells at a rate of approximately 
-1°C per minute. For longer-term storage, cells were transferred to dewars containing liquid 
nitrogen maintained at -196°C.  
 
To resuscitate frozen cells, a cryotube was removed from liquid nitrogen and thawed rapidly 
in a 37°C water bath. The cell suspension was then transferred into a 30ml universal container 
containing 5ml of pre-warmed medium and then centrifuged at 1800rpm for 8 minutes. The 
medium was removed by vacuum aspiration to remove any DMSO and the cell pellet 
resuspended in 5ml normal media. Centrifugation and resuspension in fresh media was 
repeated once more prior to seeding in a 25cm
2
 tissue culture flask. The flask cap was 
loosened to facilitate gaseous exchange and the flask was placed horizontally in an incubator 
at 37°C, 98% humidification and 5% CO2.  
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2.2.2 Methods for RNA isolation and quantification 
 
2.2.2.1 Total RNA isolation 
 
Isolation of total RNA was performed according to the manufacturer’s instructions provided 
with TRI Reagent® as described below. 
 
2.2.2.1.1 Preparation of tissue samples 
 
Tissue samples were homogenized in TRI Reagent® (1ml per 50-100mg of tissue) in a 
homogeniser.  
 
2.2.2.1.2 Preparation of monolayer cells 
 
Cells were cultured in a monolayer to a confluence of approximately 80% (5-10x10
5
 cells). 
The medium was removed with a vacuum aspirator and the cells washed gently with BSS 
solution, which was aspirated before 1ml TRI Reagent® per 10cm2 culture flask surface area 
was added to lyse the cells. The cell lysate was passed through a pipette several times to form 
a homogenous lysate and then transferred to a 1.8ml eppendorf tube.  
 
2.2.2.1.3 Phase separation 
 
The sample was then left to stand for 5 minutes at room temperature to ensure dissociation of 
nucleoprotein complexes.  
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Two hundred microliters of chloroform (per 1ml TRI Reagent®) was then added to each tube. 
The tube was closed tightly and shaken vigorously for 15 seconds before being allowed to 
stand for 2-15 minutes at room temperature. The mixture was then centrifuged at 12,000 x g 
for 15 minutes at 4°C, separating the sample into three phases: a red organic phase containing 
protein, a white interphase containing DNA and a colourless upper aqueous phase containing 
RNA. 
 
2.2.2.1.4 Isolation of RNA 
 
The upper aqueous phase was carefully removed and transferred to a fresh eppendorf tube. 
Five hundred microliters of 2-propanol (per 1ml TRI Reagent®) was then added to the 
sample, mixed and then left to stand for 5-10 minutes at room temperature. The sample was 
then centrifuged at 12,000 x g for 10 minutes at 4°C resulting in an RNA pellet forming at the 
bottom of the tube. The white interphase and red organic phase were discarded unless 
required for subsequent DNA isolation for cell identity verification.  
 
The supernatant was removed using a pipette and the RNA pellet was washed by adding 1ml 
75% ethanol in DEPC water (per 1ml TRI Reagent®). The sample was vortexed then 
centrifuged at 7,500 x g for 5 minutes at 4°C. The RNA pellet was briefly air dried at 55°C 
for 5-10 minutes in a drying oven to evaporate most of the ethanol without drying the pellet 
completely in order to aid solubility. Finally, 30-50µL of DEPC water was added to the RNA 
pellet and the pellet dissolved by repeated pipetting for 10-15 minutes. The RNA was then 
quantified prior to storage at -80°C. 
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2.2.2.2 Quantification of RNA 
 
The resulting single stranded RNA (ssRNA) in µg/µg was quantified by measuring its 
absorbance at a wavelength of 260nm using a Uv1101 Biotech spectrophotometer (WPA, 
Cambridge, UK) set to detect single strand RNA (ssRNA) with a dilution factor of 1:10. The 
photometer was calibrated between samples using DEPC water as a blank. 
 
The concentration of RNA samples was then standardised to 0.5µg/µl using DEPC water to 
make up the total volume and the samples were stored at -80°C until further use. 
 
2.2.2.3 Synthesis of cDNA using reverse transcription of RNA 
 
Reverse transcription (RT) is a process whereby complementary DNA (cDNA) is generated 
from an RNA template enabling subsequent analysis by polymerase chain reaction (PCR). 
Together, these processes are known as RT-PCR. 
 
Single stranded cDNA was synthesised from total RNA using a High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, Paisley, UK). 
 
2.2.2.3.1 Preparation of 2X RT Master Mix 
 
The 2X RT Master Mix was prepared on ice using the kit components described in Table 2.8.  
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Table 2.8. Components for 2xRT Master mix (per 20µL reaction)  
 
Component Volume per reaction (µL) 
10x RT Buffer 2µL 
25xdNTP mix (100nM) 0.8µL 
10xRT Random primers 2µL 
MultiScribe™ Reverse Transcriptase 1µL 
RNase Inhibitor 1µL 
Nuclease-free H20 3.2µL 
Total volume per reaction 10µL 
 
2.2.2.3.2 Preparation of cDNA RT reactions 
 
The cDNA RT reactions were prepared by mixing 10µL 2xRT Mastermix and 0.5µg of total 
RNA diluted in 10µL DEPC water in a 200µL PCR tube to give a total reaction volume of 
20µL. The tube/plate was then sealed, briefly centrifuged to spin down the contents and 
eliminate air bubbles and placed on ice prior to performing reverse transcription.  
 
2.2.2.3.3 Performing reverse transcription 
 
The reaction was carried out in a T-Cy Thermocycler using the conditions shown in Table 
2.9, which are optimized for use with the High Capacity cDNA Reverse Transcription kits. 
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Table 2.9 Thermal cycler conditions for reverse transcription 
 
 Temperature  
(°C) 
Time  
(minutes:seconds) 
Step 1 25 10:00 
Step 2 37 80:00 
Step 3 85 05:00 
Step 4 4 ∞ 
 
 
The resulting 20µl of cDNA product was diluted 1:4 with 60µl PCR water and either used 
immediately for PCR or stored at -20°C until required.  
 
2.2.2.4 Polymerase chain reaction (PCR) 
 
Polymerase chain reaction (PCR) is a technique, first developed by Kary Mullis in 1983, that 
is used to amplify a single or a few copies of DNA, producing thousands or millions of copies 
of a the DNA sequence.  
 
The components required for a PCR reaction include a DNA template containing the target 
DNA that is to be amplified, a heat resistant DNA polymerase such as Taq polymerase which 
synthesizes DNA from nucleotides, short DNA fragments called primers which contain 
complementary sequences to the 3’ ends of the sense and anti-sense strand of the target DNA 
and which act as a starting point for DNA formation by the DNA polymerase, 
deoxynucleoside triphosphates (dNTPs) from which the polymerase can synthesis new DNA 
strands and a thermal cycler, which provides repeated cycles of heating and cooling to 
provide the required temperatures for each step of the reaction. The DNA produced by the 
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PCR acts as a further template for replication resulting in a chain reaction and the exponential 
amplification of DNA.  
 
2.2.2.4.1 Steps of PCR  
 
The steps in a typical PCR procedure are shown in Table 2.10. 
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Table 2.10 Steps in a typical PCR procedure 
 
Step Temperature 
(°C) 
Time 
 
Purpose 
Initialisation 94 1-9 min  Only required for DNA 
polymerases needing heat 
activation 
Denaturation 94 20-30 
seconds 
Disrupts hydrogen bonds in 
dsDNA template resulting in 
single stranded DNA 
Annealing 55 20-40 
seconds 
Allows specific hybridization of 
the primer to the ssDNA 
template enabling the 
polymerase to bind  
Extension/elongation ~ 72 20-40 
seconds 
Synthesis of new DNA strand 
complementary to template by 
DNA polymerase leading to 
exponential amplification 
Final elongation 72 5-15 
minutes 
 
Final hold 4 ∞ For short-term storage 
Notes: Denaturation + annealing + elongation = one cycle. Multiple cycles (usually 20-40) 
are used. Temperatures used and length of cycle vary and depend in part on the enzyme used 
for DNA synthesis and the melting temperature (Tm) of the primers. 
* Only required for DNA polymerases that require heat activation 
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2.2.2.4.2. Components and conditions for PCR 
 
Conventional PCR was performed using a total reaction volume of 12µL. The components in 
each PCR reaction are shown in Table 2.10 and the conditions used are shown in Table 2.11.  
 
Table 2.11. Components in PCR reaction 
 
Component 
 
Volume 
2xGoTaq® Green Master Mix (Promega, USA) 
 
6µL 
Forward primer (1µM) 
 
1µL 
Reverse primer (1µM) 
 
1µL 
cDNA 
 
1µL 
PCR water 
 
3µL 
Total volume per reaction 12µL 
 
 
A negative control containing no cDNA template (volume replaced with PCR water) was run 
with each set of test samples and all cDNA samples were simultaneously screened for 
GAPDH (a house keeping gene) as an internal loading control to check uniformity of sample 
cDNA levels.  
 
The reaction was set up in individual PCR tubes or 96 well PCR plates which were sealed and 
placed in an Applied Biosystems® 2720 PCR Thermal Cycler. The conditions used for 
conventional PCR in this study are shown in Table 2.12. 
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Table 2.12. Conditions used for conventional PCR 
 
Step Temperature 
(°C) 
Time 
(minutes:seconds) 
Number of cycles 
Initialisation 94 05:00  
Denaturation 94 00:20  
32 cycles Annealing 55 00:20 
Extension/elongation 72 00:40 
Final extension 72 10:00  
Final hold 4 ∞  
 . 
2.2.2.5 Agarose gel electrophoresis and DNA visualisation 
 
Agarose gel electrophoresis uses electricity to move negatively charged DNA towards a 
positive electrode through an agarose gel matrix. The speed with which DNA moves through 
the agarose gel depends on the length of the DNA fragments. Electrophoresis therefore, 
separates DNA by size allowing DNA to be visualized and purified. A DNA ladder 
containing different DNA fragments of known lengths can be run alongside samples on the 
gel enabling the size of the DNA in the samples to be determined.  
 
Size separation of PCR products was performed using 1-2% agarose gel depending on the 
size of the PCR products. A higher agarose percentage was used for small PCR products and 
a lower percentage was used for larger products. Agarose gel was prepared by adding the 
appropriate amount (1-2g) of agarose powder to 100ml 1xTBE buffer in a heat resistant flask. 
The mixture was placed into a microwave and heated until the agarose had completely 
dissolved. The solution was allowed to cool for 5 minutes before being stained 1:10,000 using 
SYBR®Safe DNA gel stain (Life Technologies Ltd, Paisley, UK) and poured into 
electrophoresis gel tray. Well forming combs were lowered into the gel and the gel was 
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covered to protect the gel from light and left to set at room temperature for approximately 30-
45 minutes until the gel was completely solidified. 
 
Once the gel was set, the well forming combs were removed and the agarose gel was placed 
into the electrophoresis unit. The gel was then immersed in 1xTBE to ensure the gel was 
completely covered with 5mm fluid. A molecular weight ladder (5µL, PCR DNA ladder, 
GenScript®, Piscataway, USA) was then loaded into the first lane of the gel with a pipette 
and then 8µL of each sample was added using the additional wells of the gel. The lid 
containing the electrodes was then placed onto the unit ensuring the correct orientation and 
the gel was run at 80-150V, 100mA and 50W using a Gibco BRL Electrophoresis power 
supply (model 250EX Life Technologies Ltd, Paisley, UK) or 45 minutes to 1 hour, or until 
the dye line had moved 75-80% of the way down the gel. The electrodes were then 
disconnected, the gel removed and the DNA fragments visualised using Syngene U:Genius3 
fluorescence UV transilluminator (Synoptics Ltd, Cambridge, UK). Images were saved 
electronically and printed using a thermal printer.  
 
2.2.2.6 Real-time/quantitative PCR (qPCR) 
 
Real-time (or quantitative) PCR is a very sensitive gene analysis technique, which measures 
PCT amplification as it occurs (i.e. in “real-time”) and not just at the end of the reaction, as 
occurs in conventional PCR. As data is collected during the log phase of PCR (when the 
quantity of PCR product is proportional to the amount of template), qPCR also provides 
quantitative data, allowing the exact concentration of amplified DNA in the sample to be 
calculated. Quantitative PCR has a number of advantages when compared to conventional 
PCR, it is quick, does not involve a separate DNA separation and visualisation step, it allows 
high throughput, it is very sensitive, is repeatable, has a broad dynamic range of 
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quantification and provides more informative results. It is however, more costly and can be 
sensitive to errors in technique. 
 
2.2.2.6.1 Principles of qPCR 
 
Quantitative PCR is based on the same principles as conventional PCR but a fluorescent label 
is added to the amplified DNA and the level of fluorescence is measured throughout the PCR 
cycle. During amplification, the amount of fluorescence produced is directly proportional to 
the amount of amplified DNA and samples with higher initial copy number of the DNA target 
will produce a faster rise in fluorescence and the cycle in which the fluorescence is detected 
(the quantitation cycle, Cq) will occur sooner than for samples with a lower initial copy 
number. 
 
2.2.2.6.2 Components and conditions for qPCR 
 
Quantitative PCR in the current study was performed using the Amplifluor ™ Universal 
Detection System (Intergen®, New York, USA). This system is based on molecular energy 
transfer from an excited fluorophore (fluorescein) to an acceptor moiety (4-(4’-
dimethylaminophenylazo) sulfonic acid (DABSYL)) that quenches the fluorescence emission. 
The fluorophore and acceptor are tethered together via an oligonucleotide primer called 
UniPrimer™. Amplifluor™ UniPrimer™ hairpin primers are designed in such a way that a 
fluorescent signal is only generated when the primer is unfolded during its incorporation into 
an amplification product. The fluorescent signal is generated during unfolding due to the fact 
that quenching is no longer possible because of the increased distance between the fluorescein 
and DABSYL moieties. The level of fluorescence directly correlates with the amount of PCR 
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product during each cycle and can be measured during the reaction (real-time) or at the end of 
the reaction (endpoint) to give a quantification of PCR product. 
 
Contained within the UniPrimer™ is a 3’ 18 base oligonucleotide tail called a Z sequence, 
which acts as a universal PCR primer. The fluorophore and acceptor are located at the 5’ end. 
In order to use the UniPrimer™, the Z sequence is added to the 5’ end of a target-specific 
primer. The UniPrimer™ can then anneal to the Z’ sequence in an amplicon generated in the 
initial cycles of the PCR reaction. As the UniPrimer™ is incorporated, the hairpin becomes 
unfolded, quenching can no longer occur and then a fluorescence signal that directly 
correlates to the amount of amplified DNA is produced. An illustration showing how the 
Amplifluor™ Universal detection system using UniPrimer™ detection system works is 
shown in Figure 2.1.  
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Figure 2.1 Amplifluor™ Universal detection system using UniPrimer™ 
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The components of each qPCR reaction are shown in Table. 2.13. Each sample was loaded 
into a 96 well plate (Applied Biosystems™, Life Technologies Ltd, Paisley, UK), covered 
with MicroAmp® Optical Adhesive film (ThermoFisher Scientific, Life Technologies Ltd, 
Paisley, UK) and run alongside a podoplanin (PDPL) standard of a known transcript number  
(ranging from 10
8
 to 10
1
). PDPL is a lymphangiogenesis marker, which acted as a reference 
control gene to ensure any differences observed were not due to technical errors and allowed 
normalization of results.  The 96 well plate was placed in an iCycler Thermal Cycler which 
uses a light source to excite the fluorescent molecules in the wells and an image intensifier 
and a 350,000 pixel charge-coupled device (CCD) detector to image all 96 wells every second 
and detect fluorescent light. The conditions used for qPCR are shown in Table 2.14. 
 
Table 2.13 Components in each qPCR reaction 
 
Component Volume 
2x iQ™ Supermix 5µL 
Forward primer (10pmol/µL) 0.3µL 
Reverse primer (1pmol/µL) 0.3µL 
Amplifluor™ probe (10pmol/µL) 0.3µL 
cDNA 1µL 
PCR H20 3µL 
Total volume per reaction 10µL 
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Table 2.14. Conditions for qPCR 
 
Step Temperature 
(°C) 
Time 
(minutes:seconds) 
Number of cycles 
Initial denaturation 94 05:00  
Denaturation 94 00:10  
80-90 cycles Annealing 55 00:35 
Extension 72 00:20 
 
Software was used to analyse the data in order to determine the threshold cycle (Ct). The Ct is 
the number of cycles taken to detect fluorescence (above background fluorescence levels) 
from the sample in a given well. The Ct value is inversely proportional to the amount of 
nucleic acid in the sample. The procedure was repeated at least three times.  
An example of the amplification plot and standard curve produced using qPCR is shown in 
Figure 2.2 
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Figure 2.2 Amplification plot and standard curve produced using qPCR and pCR2.1 standard 
with known transcript numbers from 10
1
 to 10
8
. A. Amplification plot showing exponential 
increase in transcript copy number with cycle number B. Standard curve produced by plotting 
starting copy number against cycle threshold (Ct). From ThermoFisher Scientific 
https://www.thermofisher.com/order/catalog/product/11733038. 
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2.2.3 Methods for protein detection 
 
2.2.3.1 Extraction of protein and preparation of cell lysates 
 
The first step in protein extraction and analysis is to collect and lyse cells. Once cells had 
reached an appropriate confluence, the medium was removed with a vacuum aspirator and the 
cell monolayer was washed with BSS buffer. A sterile cell scraper was then used to scrape the 
cells from the flask surface and the resultant suspension was collected in a universal 
container. The universal container was placed in a centrifuge and the suspension centrifuged 
at 1,800rpm for 8 minutes to deposit cells in a cell pellet. The supernatant was then removed 
with a vacuum aspirator and the cell pellet was resuspended in BSS and centrifuged twice. 
After removal of the supernatant, the cell pellet was resuspended in 200-300µL lysis buffer 
(depending on pellet size) and transferred to a 1.8ml eppendorf tube. The tube was placed on 
a Labinco rotating wheel (Woolf laboratories, York, UK) and rotated at room temperature. 
 
After 1 hour, the resulting suspension was centrifuged at 13,000rpm for 15 minutes separating 
the sample into a supernatant containing proteins, which was transferred to a fresh microfuge 
tube, and a cell pellet containing cell debris, which was discarded. The protein containing 
supernatant was then either quantified immediately or stored at -20°C until further use.  
 
2.2.3.2 Quantification of proteins and preparation of protein samples 
 
In order to standardize the concentration of the protein samples prior to their analysis using 
SDS-PAGE and Western blotting, the protein samples were then quantified using the Bio-Rad 
DC Protein Assay kit (Bio-Rad Laboratories, Hemel Hempstead, UK). This is a colourimetric 
assay based on the reaction of protein with an alkaline copper tartrate solution (Reagent A) 
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and Folin reagent (Reagent B) and is used for the determination of protein concentration 
following detergent solubilisation. The protein reacts with copper in the alkaline medium 
resulting in the subsequent reduction of the Folin reagent and the production of a 
characteristic blue colour with an absorbance between 405-750nm). Bovine serum albumin 
was used as a standard.   
 
The working reagent (Reagent A’) was prepared by adding 20µL of reagent S to each 1ml of 
reagent A. In a 96-well plate, serial dilutions of a protein standard were prepared using 
50mg/ml bovine serum albumin (BSA) and the same lysis buffer that was used for the sample 
proteins in order to produce standards with a protein concentration gradient of 0.78mg/ml to 
50mg/ml. Five microliters of either protein sample or standard were pipetted into fresh wells 
on a 96 well plate and 25µL of Reagent A’ was added to each well followed by 200µL 
Reagent B. The plate was gently agitated to mix the reagents and then left to rest for 15 
minutes at room temperature until the colourimetric reaction had occurred. Absorbances were 
then read at 750nm using the ELx800 plate reading spectrophotometer (Bio-Tek, Wolf 
Laboratories, York, UK). A standard curve of protein concentration was prepared by plotting 
a graph of the BSA standards protein concentration versus absorbance and this was then used 
to determine the protein concentration of the protein samples. The protein samples were then 
standardised to a final concentration of 1-2mg/ml using the appropriate amount of lysis 
buffer. Finally, 2x Lamelli sample buffer concentrate was added 1:1 to each standardised 
protein sample prior to denaturation by boiling at 100°C for 5-10 minutes. The boiled samples 
were either used immediately for SDS-PAGE or stored at -20°C    
 
2.2.3.3 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
The percentage gel required depends on the size of the protein of interest. The gel percentages 
required for different protein sizes are shown in Table 2.15. 
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Table 2.15 SDS-PAGE gel percentage required for different sizes of proteins. Adapted from 
‘Western blot protocol” by Abcam (http://www.abcam.com/protocols/general-western-blot-
protocol) 
 
Protein size Gel percentage 
4-40kDa 20% 
12-45kDa 15% 
10-70kDa 12.5% 
15-100kDa 10% 
25-100kDa 8% 
 
A molecular weight marker was loaded into the first well of the SDS-PAGE gel and equal 
volumes of the protein samples were loaded into each of the remaining wells. The gel was 
then run at 100V for 1-2 hours. 
 
2.2.3.4 Transferring proteins from gel to nitrocellulose membrane (Western blotting) 
 
During SDS-PAGE, the equipment required for transferring the proteins from gel to 
nitrocellulose membrane was prepared. Six sheets of filter paper cut to the same size as the 
gel were soaked in 1x transfer buffer. Once SDS-PAGE was complete, three of these sheets 
were then placed one at a time onto the bottom graphite base electrode of a SD20 SemiDry 
Maxi System blotting unit (SemiDRY, Wolf Laboratories, York, UK). Air bubbles between 
the sheets were removed by rolling a roller gently over each layer in the stack. A sheet of 
similarly sized Hybond nitrocellulose membrane (Amersham Biosciences Ltd, Bucks, UK) 
was placed on top of the filter paper. The SDS-PAGE gel cassette was removed from the cell 
and the glass plates pried open to expose the gel. The stacking gel was discarded and the 
resolving gel was carefully placed on top of the nitrocellulose membrane. The remaining 
three sheets of pre-soaked filter paper were then placed on top of the gel to complete the 
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stack. The lid of the blotter was then placed on top of the stack and electroblotting was carried 
out at 15V, 500mA and 8W for 20-60 minutes depending on protein size. The arrangement of 
paper, gel and nitrocellulose membrane is shown in Figure 2.3. 
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Figure 2.3. Sandwich arrangement of filter paper, nitrocellulose membrane and gel used for 
Western blotting. Figure taken from the PhD thesis of Dr. L. Ye. 
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2.2.3.5 Protein staining and blocking of nitrocellulose membrane 
 
Successful transfer of the proteins from gel to membrane was confirmed using Ponceau S 
staining.  
 
A 10% milk solution was prepared using 10% milk powder and 0.1% polyoxyethylene (20) 
sorbitanmonolaurate (Tween 20) (Sigma-Aldrich, St. Louis, USA) in 50ml TBS. The 
nitrocellulose membrane was placed in a 50ml falcon tube (Fisher Scientific, Leicester, UK) 
with the side of the membrane that had been facing the gel towards the lumen of the tube and 
filled with 10% milk solution. The tube was left overnight at 4°C for the milk solution to 
block the membrane.  
 
2.2.3.6 Protein detection using specific immuno-probing 
 
A 3% milk solution was prepared using 3% milk powder and 0.1% Tween 20 in 50ml TBS. A 
primary antibody solution was prepared using 3% milk solution containing primary antibody 
diluted 1:500. Secondary antibody solution was prepared using 3% milk solution containing 
1:1000 horseradish peroxidase (HRP) conjugated secondary antibody. Tween TBS solution 
was prepared using 0.2% Tween 20 in TBS.   
 
Following overnight blocking, the nitrocellulose membrane was transferred into a fresh 50ml 
falcon tube and fresh 10% milk solution was added. The tube was then placed on a roller 
mixer for one hour at room temperature. Following this, the 10% milk solution was removed 
and replaced with 10ml 3% milk solution and the tube was returned to the roller mixer for 15 
minutes. The 3% milk solution was then poured off and replaced with 5ml primary antibody 
solution. The tube was returned to the roller mixer to incubate the membrane with the primary 
antibody for one hour at room temperature. The primary antibody solution was then removed 
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and the membrane washed twice by adding fresh 3% milk solution and placing the tube on the 
roller for 15 minutes at room temperature. The membrane was then incubated with 5ml 
secondary antibody solution for one hour on the roller mixer at room temperature. The 
membrane was then removed from the secondary antibody solution and washed with 10ml 
3% milk solution twice for 15 minutes each time followed by two washes each lasting 15 
minutes with Tween TBS solution. Finally, the membrane was washed twice for 15 minutes 
per wash in TBS to remove any residual detergent.  
 
2.2.3.7 Protein visualization using chemiluminescence 
 
Protein detection was performed using Luminata™ Forte Western HRP chemiluminescence 
substrate (Millipore, Billerica, MA, USA). This substrate works on the principle that 
horseradish peroxidase catalyses the oxidation of luminol in the presence of peroxide 
releasing photons (chemiluminescence) that can be captured by a CCD camera. 
 
The blot was placed protein side up in a plastic weighing boat and 0.1ml of HRP substrate per 
cm2 of membrane area was added (i.e. for a 7 x 8.4cm blot, 6ml HRP substrate was required). 
The blot was incubated for 2-5 minutes at room temperature. The excess substrate was then 
poured off and the blot was transferred using forceps into a fresh weighing boat. The 
chemiluminescent signal was detected using a UVITEC Imager (UVITEC, Cambridge, UK), 
which comprises a darkroom and a camera to detect chemiluminescence attached to a 
computer. Images were viewed and analysed using the UVI band software package 
(UVITEC, Cambridge, UK).     
 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a commonly used human 
“housekeeping gene”, the expression of which should not differ between samples. It is used as 
a reference or endogenous control against which quantification of a gene in tissues can be 
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normalised to avoid bias caused by RNA extraction and quantification, sample loading (i.e. to 
ensure there is an equal amount of template), variation in RT efficiency, degradation of RNA, 
presence of inhibitors in the RNA sample and differences in sample handling. Each Western 
blot was carried out a minimum of three times.  
 
2.2.4 Antibody based protein microarrays 
 
Antibody based protein microarray was performed using the Kinex™ KAM-880 antibody 
microarray (Kinexus Bioinformatics Ltd, Canada). This microarray identifies the differential 
binding of dye-labelled proteins in lysates prepared from cells or tissues in order to provide 
information on differences in protein expression, phosphorylation and protein-protein 
interactions. This enables targeted protein work using Western blot to be undertaken and 
signalling pathway analysis to be performed.  
 
2.2.4.1 Principles of antibody based protein microarrays 
 
The Kinex™ KAM-880 antibody microarray uses 877 antibodies to identify differences in the 
protein expression levels (using 518 pan-specific antibodies) and phosphorylation states 
(using 359 phosphosite-specific antibodies) of a range of proteins involved in cell signal 
transduction. The classes of protein targets on the KAM-880 Antibody Microarray chip are 
shown in Table 2.16.  
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Table 2.16 Classes of targeted proteins and phosphosites on the Kinex™ KAM-880 Antibody 
Microarray chip. Information obtained from Kinex™ KAM-880 Antibody Microarray 
Service Customer Information Package March 2015 (Kinexus Bioinformatics Ltd, 
Vancouver, Canada)   
 
Content Total % Total N 
Total number of pan-specific antibodies 60% 518 
Total number of phospho-specific antibodies 40% 359 
Total number of antibodies 100% 877 
Total number of protein kinase pan-specific antibodies 35% 307 
Total number of protein kinase phospho-specific antibodies 23% 200 
Total number of protein phosphatase pan-specific antibodies 7% 65 
Total number of protein phosphatase phospho-specific antibodies 0.5% 4 
N = number 
 
These antibodies are covalently immobilised onto a glass surface coated with a three-
dimensional polymer material to ensure high binding efficiency and specificity. In order to 
ensure consistency in quantity of protein across all fields, each microarray has loading and 
antibody controls. Semi-quantitative analysis of protein expression and phosphorylation state 
in two samples (control vs. treated) is provided by duplicate measurements of the strength of 
the fluorescence signals for each target protein. In order to reduce the number of false positive 
results and to eliminate differential binding that may occur with the use of different dyes, the 
same fluorescent dye is used to label both the control and test lysate samples and they are 
analysed simultaneously on the same chip at the same time.   
 
One of the inherent limitations of antibody based protein microarrays is the high rate of false 
positives due to the fact that non-denaturing conditions are used, giving rise to the possibility 
that changes observed are due to protein-protein interactions rather than differences in protein 
expression and phosphorylation. In order to reduce the possibility of false positives, the 
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Kinex™ KAM-880 antibody microarray uses a chemical digestion step that fragments 
proteins, disrupting protein complexes without destroying the epitopes recognized by the 
antibodies. An image of the microarray chip is shown in Figure 2.4. 
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Figure 2.4 Close up scanned image of 4 of 32 grids on a Kinex™ KAM-880 Antibody 
Microarray chip. High signal intensity is shown in red/orange with lower signal intensities 
represented by green/blue. Image from Kinex™ KAM-880 Antibody Microarray Service 
Customer Information Package March 2015 (Kinexus Bioinformatics Ltd, Vancouver, 
Canada)   
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Kinex™ KAM-880 Antibody microarray is based on the binding and detection of control and 
test cell lysate proteins to antibodies. The methodology used in the microarray is illustrated in 
Figure 2.5. 
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Figure 2.5 Methodology used in Kinex™ KAM-880 Antibody Microarray. Taken from 
Kinex™ KAM-880 Antibody Microarray Service Customer Information Package March 2015 
(Kinexus Bioinformatics Ltd, Vancouver, Canada)   
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2.2.4.2. Preparation of cell lysate samples for Kinex™ KAM-880 Antibody Microarray 
 
2.2.4.2.1 Preparation of lysis buffer 
 
Lysis buffer was prepared using the ingredients shown in Table 2.17. SDS-PAGE sample 
buffer was not used as non-denatured proteins are required for analysis. Final pH of the lysis 
buffer was corrected to 7.2 prior to use. 
 
Table 2.17 Ingredients of lysis buffer for Kinex™ Antibody Microarray 
 
Ingredients Purpose 
20mM MOPS, pH 7.0 Buffer 
2mM EGTA Binds calcium 
5mM EDTA Binds magnesium and manganese 
30mM sodium fluoride  Inhibits protein-serine phosphatases 
60mM β-glycerophosphate, pH 7.2 Inhibits protein-serine phosphatases 
20mM sodium pyrophosphate Inhibits protein-serine phosphatases 
1mM sodium orthovanadate Inhibit protein-tyrosine phosphatases 
1% Triton X-100 Cellular fractionation 
 
Immediately before use, a number of protease inhibitors and DTT were added to the lysis 
buffer. These are shown in Table 2.18. 
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Table 2.18 Protease inhibitors and DTT added to lysis buffer for Kinex™ Antibody 
Microarray 
 
Ingredient Purpose 
1mM phenylmethylsulfonylfluoride Inhibit proteases 
3mM benzamidine Inhibit proteases 
5µM pepstatin A Inhibit proteases 
10µM leupeptin Inhibit proteases 
1mM dithiothreitol Disrupt disulphate bonds 
 
2.2.4.2.2 Preparation of cell lysates 
 
Verified transfected cells were maintained in blasticidin maintenance medium until required. 
Once cell culture flasks containing approximately 1-2 x10
6
 cells reached approximately 80% 
confluence, the medium was removed by vacuum aspiration and replaced with normal media 
supplemented with 5% FCS. The flasks were then returned to the incubator for overnight 
culture. The following morning, the medium was replaced with fresh normal medium 
supplemented with 5% FCS and the flasks were returned to the incubator for a further three 
hours culture prior to harvesting the cells for protein extraction.  
 
At the time of harvest, the medium was removed with vacuum aspiration and the cells were 
washed twice with 5ml PBS, firstly at room temperature and secondly, with PBS kept 
refrigerated at 4°C. The cells were then scraped into a universal container and the suspension 
was pelleted using a centrifuge at 1600 rpm for 5 minutes. The supernatant was discarded and 
600µL of the lysis buffer prepared as described in Section 2.2.4.2.1 was added to the cell 
pellet. The pellet/buffer mix was transferred to a 1.5ml eppendorf tube and rotated on a blood 
wheel at 4°C for 1 hour.   
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The lysates were then centrifuged at maximum speed (15,000-17,000 x g) in a benchtop 
Eppendorf microcentrifuge for 30 minutes at 4°C. The supernatant was then transferred to a 
1.5ml microcentrifuge tube and protein quantification using a BSA standard was performed to 
determine the protein concentration. A minimum of 100µg protein for each lysate with a 
minimum concentration of 2mg/ml was then transferred into a fresh tube, frozen immediately 
and shipped by a courier on dry ice to Kinexus in Canada on a Monday. Any remaining lysate 
was stored at -20°C for future use.  
 
2.2.4.2.3 Analysis of antibody based protein microarray data 
 
Once the intensities of dye-bound proteins on the KAM-880 chip are scanned and quantified 
by Kinex™, software is used to calculate the average intensities recorded for each pair of 
antibody spots to calculate the differences between the control and test lysate samples. Data is 
normalized to account for any differences in lysate protein loading and Z scores and percent 
changes from control (%CFC) are calculated. Kinexus also undertake a mapping analysis of 
the results and allow access to the KiNET™ Antibody Microarray (KiNET-AM) Database so 
that data can be compared with lysates from other model systems analysed with the same 
methodology.  
 
Using the data report provided by Kinexus, the results of the control and test cell lysates were 
compared using the Globally Normalised Signal Intensity, %CFC and Z-scores. 
 
  
 185 
2.2.5 Manipulation of gene expression 
 
2.2.5.1 Steps in gene transfer  
 
The manipulation of gene expression by gene transfer involves a number of steps shown in 
Figure 2.6.  
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Determine strategy for PCR: Design of expression primers or ribozymes 
! 
Produce PCR product using touchdown PCR and either expression primers or ribozymes 
! 
Clone PCR product: mixing of PCR product and vector 
! 
Transformation: vector is transformed into E.coli 
! 
Colony selection and orientation checking 
! 
Preparation of purified plasmid 
! 
Transfection into mammalian cells 
! 
Selection of transfectants 
! 
Maintenance of stable transfectants 
! 
Verification using RT-PCR and Western blot 
 
Figure 2.6 Steps in gene transfer 
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2.2.5.2 Determining the strategy for PCR: Design of expression primers and ribozymes 
 
Ribozymes are RNA molecules capable of cleaving a sequence leading to loss of the 
molecule at transcript level. 
 
Ribozyme primers based on the secondary structure of the gene transcripts were designed 
using Zuker’s RNA mFold programme and transgenes were created using touchdown PCR.  
 
2.2.5.3 Production of PCR products 
 
Ribozyme transgenes for the knockdown of DOK7 at mRNA level were created using 
ribozyme primers and touchdown PCR. The components for the reaction are shown in Table 
2.19 and the conditions for the PCR are shown in Table 2.20.  
 
Table 2.19 Components used for ribozyme transgene generation 
 
Component Volume 
2xGoTaq® Green Master Mix (Promega, 
USA) 
10µl 
Forward primer (1µM) 1µl 
Reverse primer (1µM) 
 
1µl 
PCR H2O 8µl 
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Table 2.20 Conditions used for touchdown PCR  
 
Step Temperature Time Cycle 
Initialisation 94°C 5 minutes 1 
Denaturation 94°C 10 seconds 48 
Annealing 70°C 
65°C 
60°C 
55°C 
50°C 
15 seconds 
15 seconds 
15 seconds 
15 seconds 
15 seconds 
Extension 72°C 20 seconds 
Final extension 72°C 7-10 minutes 1 
 
Following PCR, agarose gel electrophoresis using a 2% agarose gel was used to confirm the 
presence and size of the resulting transgenes prior to their use in TOPO-TA gene cloning. 
 
2.2.5.4 TOPO-TA gene cloning 
 
Cloning was carried out using the pEF6/V5-His TOPO ® TA Expression Kit (Invitrogen, CA, 
USA) according to the manufacturers protocol. 
 
2.2.5.4.1 Anatomy of the pEF6/V5-His-TOPO® vector 
 
A schematic representation of the pEF6/V5-His-TOPO® vector illustrating the important 
regions for gene cloning is shown in Figure 2.7.  
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A. 
 
B. 
 
Figure 2.7 Schematic representation of the pEF6/V5-His-TOPO® vector. A. Complete view 
showing important regions within vector. B. View of PCR product binding site. 
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2.2.5.4.2 TOPO® cloning reaction 
 
The components of the TOPO® cloning reaction are shown in Table 2.21. These reagents 
were mixed together in an eppendorf tube and incubated at room temperature for 5 minutes 
prior to being placed on ice. 
 
Table 2.21 Components of TOPO® cloning reaction 
 
Reagent Volume 
PCR product 4µL 
Salt solution 1µL 
TOPO® vector 1µL 
 
2.2.5.5 Transformation of chemically competent E.coli 
 
Five microlitres of the TOPO® cloning reaction was added to one 50µL vial of OneShot® 
TOP10 chemically competent E.coli (Life Technologies Ltd, Paisley, UK) and tapped gently 
to mix. The vial was then incubated on ice for 30 minutes. A heat shock of 42°C for 30 
seconds was then applied by placing the vial into a pre-heated water bath. The vial was then 
removed from the water bath, placed on ice and 250µL of pre-warmed S.O.C medium was 
added to the vial. The vial was then placed in a tube holding foam pad and placed on an 
orbital shaker in an incubator and shaken at 225-250rpm for 1 hour at 37°C. 
 
Meanwhile, ampicillin selection plates were prepared using LB agar with 100µg/ml 
ampicillin in a Class II laminar flow cabinet. Refrigerated autoclaved LB agar was placed into 
a microwave and heated for approximately 10 minutes with occasional agitation until it had 
become liquid. It was then placed into the cabinet and allowed to cool slightly before use. 
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Sterile culture dishes, autoclaved LB broth and stock concentration ampicillin (100mg/ml) 
were placed into the cabinet and the dishes labelled accordingly. Twenty millilitres of LB 
broth were then added to 30ml of LB agar in a Falcon tube and 50µL of the ampicillin was 
added to the tube. The tube was tipped back and forth to mix the contents and then 
approximately 15ml was poured into each culture dish. The dishes were tipped to evenly coat 
them with the mixture and a sterile pipette tip was used to dispel any bubbles. The dishes 
were then left to set in the cabinet. 
 
The vial was removed from the incubator and one third of the transformed E.coli were then 
pipetted onto the top of the plate with the remaining two-thirds pipetted onto the bottom of 
the plate. The bacteria were then spread over the plate using a zig-zag pattern to obtain high 
and low seeding densities. The lids were placed on the dishes, they were inverted to prevent 
condensation build up and placed in an incubator at 37°C overnight.  
 
Any remaining transformed bacteria were stored at -80°C until further use. 
 
2.2.5.6 Selection of correctly oriented colonies 
 
After overnight incubation at 37°C, plates were examined for colony growth. Owing to the 
ampicillin in the selection plate agar, surviving colonies should be those that have 
successfully taken up the vector, which carries resistance to ampicillin.  
 
2.2.5.6.1 Orientation checking 
 
Orientation checking was performed to ensure the PCR product was inserted into the plasmid 
with the correct orientation. Using a clean pipette tip, a small sample was taken from each of 
the 10 selected colonies and orientation was checked by performing three PCR reactions. 
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The first reaction used a T7F primer and a reverse primer specific to the insert. The T7F 
primer starts at around 90bp upstream of the inserting site and therefore, if the insert is 
correctly oriented, the resulting PCR product should be around 100bp bigger than the 
predicted product size.  
 
The second reaction used T7F primer and a forward primer specific to the inserted sequence. 
If a PCR product was generated in this reaction, it indicated incorrect insert orientation. If a 
PCR product was generated for both reactions, it indicated that the colony contained a 
mixture of plasmids with both correctly and incorrectly inserted sequences.  
 
A final reaction using T7F and BGHR primers was used to verify that the full sequence has 
been inserted without degradation. All PCR products were visualised using agarose gel 
electrophoresis to confirm presence and size of PCR product.  
 
The conditions used for the PCR are shown in Table 2.22. 
 
Table 2.22 Conditions for orientation checking PCR 
 
Step Temperature Time Cycle 
Initialisation 94°C 10 minutes 1 
Denaturation 94°C 20 seconds 25 
Annealing 55°C 30 seconds 
Extension 72°C 40 seconds 
Final extension 72°C 7 minutes 1 
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Following orientation checking, a sterile pipette tip was used to inoculate 10ml fresh LB 
broth containing 100µg/ml ampicillin with the correctly oriented colonies and these were 
cultured overnight on an orbital shaker in an incubator at 37°C.  
 
2.2.5.7 Purification and amplification of plasmids 
 
The following day, the universal container was taken from the incubator and checked for 
turbidity to confirm E.coli growth. Plasmids were isolated using the GenElute™ Plasmid 
Miniprep kit (Sigma-Aldrich Ltd, Dorset, UK), which isolates plasmid DNA from 
recombinant E.coli cultures. 
 
Cells were first harvested by transferring 5ml of the overnight recombinant E.coli culture to a 
2ml microcentrifuge tube and pelleting the cells using centrifugation at ≥ 12,000 x g for 1 
minute. The supernatant was discarded. The bacterial cell pellet was then resuspended with 
200µL of the Resuspension solution and the tube was vortexed to produce a homogeneous 
solution. Cells were then lysed by adding 200µL of the lysis solution and the contents of the 
tube were immediately mixed by gentle inversion 6-8 times until the solution became clear 
and viscous. Cell debris was then precipitated by adding 350µL of the Neutralisation/Binding 
solution and the tube was inverted 4-6 times to mix gently. The cell debris was then pelleted 
by centrifuging at ≥ 12,000 g for 10 minutes to produce a cleared lysate. 
 
A GenElute™ Miniprep binding column was prepared by inserting it into a microcentrifuge 
tube and adding 500µL of column preparation solution to the column. The tube was then 
centrifuged at ≥ 12,000 x g for 1 minute. The flow-through liquid was discarded and the 
cleared lysate was transferred to the column and centrifuged at ≥ 12,000 x g for 1 minute. The 
flow-through liquid was discarded and the column was washed by adding 750µL of the 
diluted wash solution to the column and centrifuging at ≥ 12,000 x g for 1 minute. The flow 
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through liquid was discarded and the tube centrifuged again at ≥ 12,000 x g for 2 minutes to 
remove excess ethanol. The column was transferred to a fresh collection tube and 100µL 
Elution solution was added prior to centrifuging at ≥ 12,000 x g for 1 minute. The eluate 
containing DNA was either used immediately or stored at -20°C until further use. 
 
The presence and correct size of plasmid was confirmed using agarose gel electrophoresis 
using a 1% agarose gel and 3µL product mixed with 2µL loading dye per well.  
 
2.2.5.8 Sequencing of inserts 
 
Where necessary, inserts were submitted for analysis by sequencing using the T7 primer. 
 
2.2.5.9 Transfection of cells using electroporation 
 
Transfection is the process by which foreign DNA is introduced into the nucleus of 
eukaryotic cells. There are a variety of methods by which transfection can occur, including 
physical methods, such as electroporation, microinjection and sonoporation, and chemical 
methods, such as lipofection and co-precipitation. In this study, transfection was performed 
using electroporation, whereby transfection is induced using a high voltage electrical shock. 
This shock temporarily destabilizes the cell membrane rendering it highly permeable to 
exogenous molecules in the surrounding media. Plasmids can therefore move into the cell via 
pores, which close when the electrical field is turned off. 
 
The components required for transfection are immortalised mammalian cell lines and a 
mammalian expression vector which contains a bacterial plasmid, the gene of interest, a 
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mammalian promoter and a selectable marker which allows the selection of stable 
transfectants in mammalian cells.  
 
The cell lines used for transfection were low passage, free of contamination, grown in 
appropriate medium according to optimum conditions recommended by the supplier and were 
transfected when they were approximately 70-80% confluent to optimize gene uptake. 
 
Following plasmid extraction and verification, the plasmids containing transgenes were used 
to transfect colorectal cancer cells and empty plasmid vectors (pEF) were also transfected into 
wild type colorectal cancer cells using the same technique in order to provide a control cell 
line.  
 
Cells were cultured until approximately 80% confluent, harvested, counted and 1x10
6
 cells 
were resuspended in 1ml normal media. Five hundred microlitres of this cell suspension 
(500,000 cells in 500µL) was transferred to an electroporation cuvette and 3-5µL of plasmid 
was added. The solution was gently mixed using a pipette tip and left at room temperature for 
5 minutes. The cuvette was then placed into the electroporator and a pulse of 290-310V at 
1200vF capacitance and ∞Ω was applied to the cuvette. The transfected cell solution was then 
immediately seeded into a fresh cell culture flask containing pre-warmed normal media 
supplemented with FCS and antibiotics as appropriate for the cell line. These were then 
placed in an incubator at 37°C with 5% CO2 for 24-48 hours.  
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2.2.5.10 Establishing stable transfected mammalian cell lines 
 
Following 24-48 hours incubation of the transfected cells, the medium was removed with a 
vacuum aspirator and blasticidin selection media (media containing 5µg/ml blasticidin) added 
to the flask. The selective media was changed every 3-4 days for around 1-2 weeks until 
distinct blasticidin resistant colonies were seen. Once selected, stable transfectants were 
maintained in blasticidin maintenance media (media containing 0.5µg/ml blasticidin) until 
further use. Cells were maintained in this media thereafter and cultured for use in in vitro 
functional assays. Cells transfected with empty plasmid vector (pEF) were selected and 
maintained in the same fashion. 
 
Following selection, successful gene manipulation was verified using PCR.  
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2.2.6 In vitro functional assays 
 
The stable transfected cell lines produced by gene transfer were used to explore the effect of 
altered gene expression on mammalian cell function using in vitro cell function assays. 
 
2.2.6.1 In vitro growth assay 
 
In vitro growth assays were performed according to the protocol described by Jiang et al. in 
2005 (263).   
 
Two hundred microlitres of media containing 2,000 cells was seeded into each well of five 96 
well plates using at least six repeats for each cell line. The plates were incubated at 37°C and 
5% CO2 for a period of 24, 48, 72, 96 and 120 hours respectively. On the appropriate day of 
analysis, the media was removed from the wells using vacuum aspiration and the cells were 
fixed with 4% formalin for 10-20 minutes before being stained with 0.5% crystal violet for 10 
minutes. The dye was then washed off with water and the plates left to air dry. 
 
Cell growth was assessed by counting the number of cells under a light microscope prior to 
solubilisation of the dye with 200µL acetic acid and measuring the absorbance at 540nm 
using an absorbance reader (BioTek® ELx800, Swindon, UK). Growth was calculated as a 
percentage using the 24-hour plate as a baseline measurement to control for any seeding 
differences.  
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2.2.6.2 In vitro Matrigel® adhesion assay 
 
In vitro adhesion assays were performed according to the protocol described by Jiang et al 
(264). Each well of a 96 well plate was coated with 100µl of serum free media containing 5µl 
(stock concentration 0.05µg/µl) Matrigel® (Corning®, Tewksbury, MA, USA). The plate was 
then left to dry in a drying cabinet at 55°C for 2 hours until the Matrigel® was completely 
dry. 
 
The Matrigel® was then rehydrated with 200µl of sterile water and left for 30 minutes at 
room temperature. The liquid in each well was then removed with a vacuum aspirator leaving 
the layer of rehydrated Matrigel® at the base of each well. A cell suspension of 20,000 cells 
in 200µl media was then seeded into each well and the plate was placed in an incubator for 45 
minutes at 37°C with 5%CO2 to allow time for cells to adhere. 
 
After this incubation time, the media was removed using vacuum aspiration and the plate was 
gently washed with BSS to remove any non-adherent cells. The adherent cells were then fixed 
with 4% formalin for 10-20 minutes before being stained with 0.5% crystal violet for 10 
minutes. The dye was washed off and the plate left to air-dry before capturing images under 
the microscope and counting cell number.  
 
In order to ensure the same areas of each well were compared, a gridlines 2mm apart were 
drawn on the underside of each 96 well plate. This divided each well (internal diameter 6mm) 
into nine areas. Photographs were then taken from three of these nine areas for each well 
using a microscope-mounted camera with a 160/0.17 AP10PL 0.25 x 10 lens. Each image 
was then analysed and the number of cells per photograph counted using Image J software. 
The average cell count across the three images was then calculated using Excel and used to 
compare adhesion across different cell lines.  
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Following photography, the grid was removed from the underside of each 96 well plate using 
70% ethanol and 200µL acetic acid was added to each well to solubilise the crystal violet dye. 
The absorbance was measured at 540nm using an absorbance reader (BioTek® ELx800, 
Swindon, UK).  
 
2.2.6.3 In vitro Matrigel® invasion assay 
 
The inner bases of trans-well inserts with an 8µm pore size (Corning™ Falcon™, 
ThermoFisher Scientific, Loughborough, UK) were each coated with a solution containing 
100µl serum free media and 50µg Matrigel® (stock concentration 0.5µg/µl). The inserts were 
suspended over the wells of a 24 well plate (Nunc™, ThermoFisher Scientific, 
Loughborough, UK) using sterile forceps and left to dry in a drying oven for 2 hours at 55°C. 
The Matrigel® was then rehydrated with 200µl sterile water and left for 30 minutes at room 
temperature until the Matrigel® was completely rehydrated. The water was removed using 
vacuum aspiration taking care not to damage the Matrigel® layer and 20,000 cells in 200µl 
media were seeded into each insert. Six hundred microlitres of media were then pipetted into 
the well surrounding the insert and the plates were placed in an incubator for 72 hours at 37°C 
with 5%CO2. The in vitro Matrigel® invasion assay is illustrated in Figure 2.8. 
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Figure 2.8 In vitro Matrigel® invasion assay. (The figure was adapted from MRes thesis of 
Carly Bunston). 
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After 72 hours incubation, the Matrigel® layer was carefully removed from the inside of the 
insert using a cotton bud and cells that had invaded through to the other side of the membrane 
as well as those that had reached the base of the surrounding well were fixed with 4% 
formalin for 10-20 minutes prior to staining with 0.5% crystal violet for 10 minutes. The 
crystal violet was then washed off and the inserts left to air dry. Images were captured of the 
stained cells and cell counting performed using absorbance as previously described.  
 
2.2.6.4 In vitro cell motility assay 
 
Each well of a 24 well plate was seeded with 600µL DMEM-F12 medium containing 10% 
FCS and antibiotics and 500,000 cells. The plate was incubated at 37C and 5% CO2 overnight 
to allow cells to adhere to the plate in a confluent monolayer. The following day, each cell 
monolayer was wounded in a linear fashion with a sharp sterile pipette tip and photos of the 
same area of the wounded cells were taken periodically after wounding using the EVOS® 
Cell Imaging system (Life Technologies, Paisley, UK). Migration distances were measured 
using Image J software (National Institute of Health, USA).   
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2.2.7 Clinical cohort study 
 
2.2.7.1 Colorectal cancer cohort patient selection and tissue collection 
 
Primary human colorectal cancer tissue (n=94) and normal colorectal tissue (n=80) were 
collected during surgery from informed, consenting patients. Of these, 69 pairs of colorectal 
cancer and normal colorectal tissue were available from the same patient. Tissue was 
recovered from the operating theatre during the procedure by a researcher and delivered 
immediately to a Consultant Histopathologist. The Consultant Histopathologist examined the 
operative specimens and fresh samples of colorectal carcinoma, normal matched colorectal 
tissue (>10cm away from tumour margin) and mesenteric tissue were obtained. Tissue 
samples were placed in labelled universal containers, frozen in liquid nitrogen and stored in 
the research laboratory at -80°C until required. The remaining surgical specimen was fixed 
and examined by the same Consultant Histopathologist and the subsequent report was 
obtained for data stratification.   
   
Patients underwent routine clinical, colonoscopic and radiological follow up after the surgery 
and results were obtained using the hospital clinical portal system and CANISC data. The 
median follow up period was 65 months. 
 
Ethical approval for the use of tissue was obtained from the South East Wales Local Research 
Ethics Committee (Reference: 05/WSE03/92). 
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2.2.7.2 Preparation of tissue samples 
 
Frozen tissue samples were sectioned into 8-10µm sections using a Leica CM1900 Cryostat 
(Leica Biosystems, Newcastle Upon Tyne, UK). Sections were homogenized to allow RNA 
extraction. 
 
2.2.7.3 Quantitative PCR analysis of mRNA expression in colorectal cancer tissue 
 
Once extracted, RNA was quantified using a UV spectrophotometer and cDNA was 
generated as previously described. The quantity of target mRNA transcripts was determined 
using qPCR as described previously. 
 
2.2.8 Statistical analysis 
 
Mann-Whitney U test for non-parametric data was used to analyse qPCR results. Kruskal-
Wallis test was used to analyse the association between T stage and DOK7 level. Survival 
analyses were performed using Kaplan-Meier survival analysis. Differences were considered 
to be statistically significant at p<0.05.  
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Chapter 3: Initial assessment of DOK7 in colorectal cancer 
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3.1 Introduction 
 
Dok-7 is a cytoplasmic adaptor protein that was first identified in 2006 by Okada et al. In 
common with other Dok family members, Dok-7 has SH2 domain target motifs in the C-
terminal region along with PH and PTB domains in the N-terminal region (141). The PTB 
binding domain enables Dok-7 to interact with MuSK resulting in agrin-independent 
neuromuscular synaptogenesis. Dok-7 is preferentially expressed in skeletal muscle and in the 
heart and is localised at the post-synaptic neuromuscular junction (141). 
 
The discovery of the Dok proteins and much of the early research on their role occurred in the 
context of CML but subsequent work has shown that they play a role in a variety of other 
human cancers, including lung cancer, breast cancer, skin cancer, ovarian cancer and in 
neurological malignancy. Thus far, the role of Dok-7 in colorectal cancer has not been 
investigated. However, a recently published study by Heyn et al, which investigated DNA 
methylation in identical twins discordant for breast cancer diagnosis found that the Dok-7 
promoter region was hypermethylated in the peripheral blood of twins with breast cancer 
(265). Moreover, they also found Dok-7 promoter hypermethylation in primary breast cancer 
tissue and breast cancer cell lines (265). Intriguingly, the authors also reported that 
hypermethylation of the Dok-7 promoter could be found in peripheral blood years before 
tumour diagnosis, suggesting that Dok-7 may have potential use as a blood based biomarker 
(265).  
 
In relation to colorectal cancer, a recent study has demonstrated that Dok-2 expression is 
reduced in colorectal cancer tissue compared to normal colorectal tissue and that lack of Dok-
2 expression is associated with poorer five-year survival and an increased risk of disease 
recurrence (259). This suggests that the Dok family may play a tumour suppressor role in 
colorectal cancer but, to date, there have been no studies looking at the expression of Dok-7 
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in colorectal cancer or its association with clinical and pathological characteristics of the 
disease or patient outcomes.  
 
The study presented in this chapter aimed to examine the mRNA expression profile of DOK7 
in colorectal cancer tissues obtained from a clinical cohort and in colorectal cancer cell lines, 
with the subsequent aim of developing in vitro cell models that would allow us to explore the 
effect of DOK7 expression on colorectal cancer cell function. Moreover, we analysed the 
association between DOK7 expression and clinicopathological features of colorectal cancer 
and patient outcomes using qPCR in order to determine whether DOK7 may have any 
potential role as a biomarker in colorectal cancer. 
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3.2 Materials and methods 
 
3.2.1 Materials and methods for determination of DOK7 expression in colorectal cancer 
patient cohort tissue samples 
 
3.2.1.1 Patient selection  
 
Colorectal cancer tissue and normal colorectal tissue were obtained from patients undergoing 
curative surgery for colorectal cancer in three hospitals in South Wales; University Hospital 
of Wales, Llandough Hospital and the Royal Gwent Hospital over the 1 year collection phase 
of the study.  
 
In order to be included in the study, patients had to meet all of the following criteria; proven 
colorectal cancer, deemed suitable for surgery with curative intent following MDT discussion 
and informed pre-operative consent obtained from the patient and the Consultant Surgeon 
responsible for their care. Lt. Col. Mansel Davies, a research fellow working in the laboratory 
at the time, identified patients fulfilling these criteria at the time of MDT discussion.  
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3.2.1.2 Collection of tissue samples 
 
The collection of tissue samples is described in Section 2.2.7.1. 
 
3.2.1.3 Isolation of RNA and cDNA from tissue samples 
 
Frozen tissue samples were sectioned into 8-10µm sections using a Leica CM1900 Cryostat 
and homogenized. RNA was isolated from the homogenized tissue using TRI Reagent® as 
described in Section 2.2.2.1, quantified as described in Section 2.2.2.2 and converted into 
cDNA by reverse transcription using a High Capacity cDNA Reverse Transcription kit as 
described in Section 2.2.2.3.  
 
3.2.1.4 Quantitative PCR  
 
Quantitative PCR to determine the level of DOK7 mRNA expression was simultaneously 
performed on all of the cDNA samples obtained from the patient cohort using the DOK7F1 
and DOK7ZR1 primers, details of which are listed in Table 2.6. The components and 
conditions used for qPCR are provided in Section 2.2.2.6.2.  
 
3.2.1.5 Statistical analysis  
 
Data obtained from qPCR was analysed using the Mann-Whitney test for non-parametric data 
and Kruskal-Wallis test. Survival analysis was performed using Kaplan-Meier survival 
analysis. The threshold for statistical significance was p<0.05. Multivariate analysis was not 
performed as it was felt that this was not appropriate given the nature of the data. 
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3.2.2 Materials and methods for determination of DOK7 expression in colorectal cancer 
cell lines 
 
3.2.2.1 Colorectal cancer cell lines 
 
The details of the colorectal cancer cell lines used in this study are shown in Section 2.1.1. All 
cells were maintained according to the supplier’s instructions. Details of the media used for 
cell culture are provided in Section 2.1.6.1 and the methods of cell culture used are described 
in Section 2.2.1.  
 
HECV, a cell line originating from human umbilical cord tissue, was used as a positive 
control. 
 
3.2.2.2 Primers 
 
The primers used in this study are shown in Table 3.1. Full details of these primers are shown 
in Table 2.6.  
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Table 3.1. Primers used for determination of DOK7 expression in colorectal cancer tissues 
and colorectal cancer cell lines, DOK7 expression, ribozyme synthesis and orientation 
checking 
 
Gene  Primer 
DOK7 DOK7F1 
DOK7ZR1 
DOK7 DOK7F8 
DOK7R8 
DOK7 DOK7F9 
DOK7R9 
DOK7 DOK7exF2 
DOK7exR4 
DOK7 DOK7rib1F 
DOK7rib1R 
DOK7 DOK7rib2F 
DOK7rib2R 
pEF/His TOPO TA plasmid vector T7F 
BGHR 
GAPDH GAPDHF10 
GAPDHR10 
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3.2.2.3 RNA isolation and cDNA synthesis 
 
RNA was isolated from cells using TRI Reagent® (Sigma-Aldrich Inc., Poole. UK) as 
described in Section 2.2.2.1, and quantified using a spectrophotometer as described in Section 
2.2.2.2. Reverse transcription using a High Capacity cDNA Reverse transcription kit was 
used to synthesis cDNA as described in Section 2.2.2.3.  
 
3.2.2.4 PCR 
 
The synthesised cDNA was screened for DOK7 expression using PCR. The components and 
conditions used for PCR are described in Section 2.2.2.4.2.  
 
Size separation of the resulting PCR products was performed using 2% agarose gel 
electrophoresis and visualized using SYBR® Safe DNA gel stain (Life Technologies Ltd, 
Paisley, UK) and UV transillumination as described in Section 2.2.2.5.  
 
3.2.2.5 qPCR 
 
Quantitative PCR to determine the level of DOK7 mRNA expression was performed on the 
cDNA samples obtained from the colorectal cell lines using the Amplifluor™ Universal 
Detection system (Intergen®, New York, USA) as described in Section 2.2.2.6 using the 
DOK7F1 and DOK7ZR1 primers, details of which are listed in Table 2.6. The components 
and conditions used for qPCR are described in Section 2.2.2.6.2.  
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3.2.3 Materials and methods used for the knockdown and overexpression of DOK7 
 
The manipulation of gene expression was performed using techniques described in Section 
2.2.5.  
 
3.2.3.1 Generation of DOK7 ribozyme transgenes 
 
Hammerhead ribozymes targeting DOK7 were designed using Zuker’s mRNA Fold 
programme and used to generate primers. Ribozymes were then synthesised using touchdown 
PCR using the components and conditions described in Section 2.2.5.3.  
 
The PCR products obtained were then run on a 2% agarose gel to verify their presence and 
size prior to being cloned into a plasmid vector.    
 
3.2.3.2 Generation of DOK7 expression constructs 
 
A DOK7 expression construct was created using the DOK7 expression primers listed in Table 
2.6 using the techniques described in Section 2.2.5. The PCR products obtained were then run 
on a 2% agarose gel to verify their presence and size prior to being cloned into a plasmid 
vector.    
   
3.2.3.3 TOPO TA cloning of DOK7 transgenes into a pEF6/His TOPO plasmid vector 
 
The verified DOK7 ribozyme/expression inserts were cloned into a pEF6/V5-His-TOPO 
plasmid (Invitrogen, Paisley, UK) as described in Section 2.2.5.4 and then transformed into 
chemically competent E.coli, as described in Section 2.2.5.5.  
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3.2.3.4 Orientation checking  
 
Following overnight incubation, orientation checking and selection of correctly oriented 
colonies was performed as described in Section 2.2.5.6 using T7F and BGHR primers, the 
details of which are given in Table 2.6.  
 
3.2.3.5 Amplification and purification of correctly oriented colonies  
 
The correctly oriented colonies (DOK7expCol3, DOK7rib1Col4, DOK7rib2Col3) were then 
amplified and purified using the GenElute™ Plasmid Miniprep Kit (Sigma-Alrich, St.Louis, 
MO, USA) as described in Section 2.2.5.7. Plasmids were verified using agarose gel 
electrophoresis as described previously in Section 2.2.2.5. . 
 
3.2.3.6 Transfection of colorectal cancer cells and generation of stable transfectants  
 
Transfection of colorectal cancer cells using electroporation was performed as described in 
Section 2.2.5.9. An empty pEF plasmid vector was used to transfect colorectal cancer cells 
using the same technique in order to provide a control cell line. Stable transfected colorectal 
cancer cell lines were established as described in Section 2.2.5.10.   
  
3.2.3.7 Verification of DOK7 knockdown using RT-PCR and Q-PCR 
 
Verification of transfection was carried out using PCR and qPCR as previously described. 
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3.2.4 Materials and methods for determination of DOK7 expression in other human 
cancers  
 
3.2.4.1 Additional cancer cell lines 
 
3.2.4.1.1 Breast cancer cell lines 
 
Three breast cancer cell lines were used in this study: ZR-751, MCF-7 and MDA-MB-231. 
These cell lines were acquired from the ECACC (Salisbury, UK) or ATCC (Middlesex, UK) 
and their characteristics are listed in Table 3.2. 
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Table 3.2 Details of breast cancer cell lines used in this study 
 
 ZR-75-1 MCF-7 MDA-MB-231 
Species Human Human Human 
Tissue Breast 
adenocarcinoma, 
established from 
malignant ascites 
Breast 
adenocarcinoma, 
established from a 
malignant pleural 
effusion 
Breast 
adenocarcinoma, 
established from a 
malignant pleural 
effusion 
Gender Female Female Female  
Age  63 years 69 years 51 years  
Morphology Epithelial Epithelial Epithelial 
Growth mode Adherent Adherent Adherent 
Characteristics Ductal carcinoma 
ER+, PR+, HER2+ 
Ductal carcinoma 
ER+, PR+, HER2- 
ER-, PR-, HER2- 
Country  USA  
 
These breast cancer cell lines were screened for DOK7 expression using the same methods 
described for colorectal cancer cells in Section 3.2.2.  
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3.2.4.2 Additional clinical cohort data 
 
3.2.4.2.1 Gastric cancer clinical cohort 
 
3.2.4.2.1.1 Patient selection  
 
Gastric adenocarcinoma and Siewert type III gastro-oesophageal junction adenocarcinoma 
tissues (n = 245) with matched adjacent background tissues (n = 158) were collected 
immediately after surgical resection at the Beijing Cancer Hospital from informed, consented 
patients. All patients underwent surgery without any prior treatment. The tissue samples were 
stored at -80
o
C at the Tissue Bank of Peking University Oncology School with a record of the 
relevant clinical and histopathological data. All protocols were reviewed and approved by the 
Beijing Cancer Hospital Research Ethics Committee (MTA10062009). 
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3.2.4.2.1.2. Collection of tissue samples  
 
Tissue was recovered from the operating theatre during the procedure by a researcher and 
delivered immediately to a Consultant Histopathologist. The surgical specimen was examined 
by the Consultant Histopathologist, who obtained fresh samples of gastric carcinoma, normal 
matched gastric tissue and mesenteric tissue. Tissue samples were placed in labelled universal 
containers, frozen in liquid nitrogen and were stored in the research laboratory at -80°C prior 
to use. The remaining surgical specimen was fixed and examined by the same Consultant 
Histopathologist and the subsequent report was obtained for data stratification.   
 
3.2.4.2.1.3 Isolation of RNA and cDNA from tissue samples 
 
Frozen tissue samples were sectioned into 8-10µm sections using a Leica CM1900 Cryostat 
and homogenized. RNA was isolated from the homogenized tissue using TRI Reagent® as 
described in Section 2.2.2.1, quantified as described in Section 2.2.2.2 and converted into 
cDNA by reverse transcription using a High Capacity cDNA Reverse Transcription kit as 
described in Section 2.2.2.3.  
 
3.2.4.2.1.4 Quantitative PCR  
 
Quantitative PCR to determine the level of DOK7 mRNA expression was simultaneously 
performed on the cDNA samples obtained from the gastric cancer patient cohort using the 
Amplifluor™ Universal Detection system (Intergen®, New York, USA) as described in 
Section 2.2.2.6 using the DOK7F1 and DOK7ZR1 primers, details of which are listed in 
Table 2.6. The components and conditions used for qPCR are described in Section 2.2.2.6.2.  
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3.2.4.2.1.5 Statistical analysis  
 
Data obtained from qPCR was analysed using the Mann-Whitney test for non-parametric data 
and Kruskal-Wallis test. Survival analysis was performed using Kaplan-Meier survival 
analysis. The threshold for statistical significance was p<0.05. Data was normalized by RNA 
concentration. 
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3.3 Results 
 
3.3.1 Cohort data 
 
3.3.1.1 Patient demographics 
 
A total of 94 samples were obtained from primary colorectal cancer tissue and 80 samples 
were obtained from normal background colorectal tissue (See Section 2.2.7.1). Paired cancer 
and normal samples were available for 68 patients, enabling both overall and paired (within 
patient) comparisons to be undertaken.  
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3.3.1.2 Histopathological features of cohort colorectal cancers 
 
The histopathological features of the tumours included in this study are shown in Table 3.3. 
All tumour samples included in the current study were confirmed adenocarcinomas. 
Metastatic status of the tumour was defined as the presence of metastases either at the time of 
surgery or the development of metastases in the follow up period.  
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Table 3.3 Histopathological features of colorectal cancer tissue samples 
 
   Number (Percentage) 
Anatomical location Colon Right colon 28 (29.8%) 
  Transverse colon 2 (2.1%) 
  Left colon 22 (23.4%) 
 Rectum  22 (23.4%) 
 Location unknown  20 (21.3%) 
Tumour grade 1 (well differentiated)  2 (2.1%) 
 2 (moderately differentiated)  54 (57.4%) 
 3 (poorly differentiated)  14 (14.9%) 
 Grade unknown  24 (25.5%) 
Dukes’ stage A  7 (7.4%) 
 B  33 (35.1%) 
 C  32 (34.0%) 
 Dukes’ stage unknown  22 (23.4%) 
T stage T1  2 (2.1%) 
 T2  10 (10.6%) 
 T3  40 (42.6%) 
 T4  18 (19.1%) 
 T stage unknown  24 (25.5%) 
Overall tumour stage I  9 (9.6%) 
 II  30 (31.9%) 
 III  26 (27.7%) 
 IV  6 (6.4%) 
 Overall stage unknown  23 (24.5%) 
Nodal status Node negative (N0)  39 (41.5%) 
 1-3 lymph nodes positive 
(N1) 
 16 (17.0%) 
 ≥4 lymph nodes positive (N2)  15 (16.0%) 
 Nodal status unknown  24 (25.5%) 
Metastatic status Distant metastases  19 (20.2%) 
 No distant metastases  50 (53.2%) 
 Metastatic status unknown  25 (26.6%) 
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3.3.1.3 DOK7 expression is significantly reduced in colorectal cancer compared to 
normal colorectal tissue 
 
The expression of DOK7 is significantly reduced in colorectal cancer compared to normal 
colorectal tissue. Median DOK7 mRNA expression per 50µg of total cellular RNA was 148.9 
copies for colorectal carcinoma tissue samples (n = 94, IQR = 41-525) compared with 342.3 
for normal colorectal tissue (n = 80, IQR = 63-1104, p = 0.0199) for the whole cohort and 
121.2 (n = 68, IQR = 42-407) vs. 342.3 copies (n = 68, IQR = 73-1104) respectively for the 
paired tissue samples (p = 0.0090). Data is shown in Figure 3.1. 
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Figure 3.1. DOK7 expression in colorectal cancer and normal colorectal tissue. In this figure 
and in all subsequent figures in this chapter * indicates p < 0.05. 
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3.3.1.4 DOK7 expression is not related to degree of colorectal tumour differentiation 
 
The expression of DOK7 in relation to the grade of tumour differentiation is shown in Figure 
3.2. The median copy number per 50µg of total cellular RNA was reduced in grade 1 (median 
copy number 106.0, n = 2, IQR not calculated due to sample size), grade 2 (median copy 
number 138.1, n = 54, IQR = 43-525) and grade 3 colorectal cancer samples (median copy 
number 140.0, n = 14, IQR = 18.6 – 444.8) compared to normal colorectal tissue (median 
copy number 342.3, n = 80, IQR = 63-1104). Median copy number was significantly reduced 
in Grade 2 cancer samples compared to normal colorectal tissue (p = 0.0312) and for Grade 2 
and Grade 3 samples combined vs. normal tissue (p = 0.0124) but failed to reach significance 
for Grade 1 samples vs. normal (p = 0.2859) and Grade 3 samples vs. normal (p = 0.0639). 
Analysis using the Kruskal-Wallis test did not reveal a significant difference in median copy 
number between different grades of tumour differentiation (p = 0.714). 
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Figure 3.2 DOK7 expression by degree of tumour differentiation 
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3.3.1.5 DOK7 expression is significantly decreased in node negative colorectal cancer 
compared with normal colorectal tissue 
 
DOK7 expression was significantly decreased in node negative colorectal cancer samples 
compared with normal colorectal tissue (median copy number 131.5, n = 39, IQR = 28-451 
vs. 342.3, n = 80, IQR = 63-1104 respectively, p = 0.0159). By comparison, there was a trend 
towards increased median copy number in colorectal cancer samples from patients with N1 
disease (median copy number 399.8, n = 16, IQR = 123-680). DOK7 expression was 
decreased in N2 colorectal cancer samples compared to normal (median copy number 74.8, n 
= 15, IQR = 18-298). 
 
There was no significant difference in median copy number between patients with node 
negative and node positive disease (131.5 vs. 144.6, p = 0.5906). DOK7 expression in relation 
to nodal status of colorectal cancer tissue samples is shown in Figure 3.3. 
 
  
 227 
  
Figure 3.3 DOK7 expression by nodal status of colorectal cancer 
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3.3.1.6 DOK7 expression is significantly reduced in Dukes’ stage B colorectal cancer 
compared to normal colorectal tissue 
 
DOK7 expression was reduced across all Dukes’ stages of colorectal cancer compared to 
normal colorectal tissue (Dukes’ A median copy number 153.2, n = 7, IQR = 59-1308; 
Dukes’ B median copy number 119.6, n = 33, IQR = 27-382; Dukes’ C median copy number 
168.9, n = 32, IQR = 57-568 vs. median copy number 342.3, n = 80, IQR 63-1104 for normal 
colorectal tissue) but did not reach statistical significance except for the Dukes’ B group (p = 
0.0068). DOK7 expression in relation to Dukes’ stage is shown in Figure 3.4.  
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Figure 3.4 DOK7 expression and Dukes’ stage of colorectal cancer 
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3.3.1.7 DOK7 expression is inversely associated with T stage in colorectal cancer 
 
The level of DOK7 expression decreases with increasing T stage. Median DOK7 mRNA 
expression per 50µg of total cellular RNA was 2560.5 for T1 disease (n = 2, IQR not 
calculated due to sample size), 466.6 for T2 disease (n = 10, IQR = 111-1248), 120.3 for T3 
disease (n = 40, IQR = 30-388) and 134.8 for T4 disease (n = 18, IQR = 25.2-419.1). In 
comparison with normal colorectal tissue (median copy number 342.3, n = 80, IQR = 63-
1104), the median copy number was not significantly different for T1 (p = 0.0952) or T2 
disease (p = 0.9693) but was significantly reduced in both T3 (0.0048) and T4 (p = 0.0287) 
disease.  
 
When T stages were combined, median copy number was significantly reduced in T2/3 
cancers (median copy number 130.8, p = 0.0161), T3/4 cancers (median copy number 120.3, 
p = 0.0013) and T2/3/4 cancers (median copy number 130.8, p = 0.0043) in comparison with 
normal colorectal tissue. 
 
Further analysis of the colorectal cancer samples using the Kruskal-Wallis test revealed a 
significant difference in DOK7 expression between T stages (p = 0.038). DOK7 expression in 
relation to T stage in colorectal cancer is shown in Figure 3.5. 
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Figure 3.5 DOK7 expression and T stage of colorectal cancer 
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3.3.1.8 DOK7 expression is significantly reduced in Stage II colorectal cancer 
 
Compared to normal colorectal tissue (median copy number 342.3, n = 80, IQR = 63-1104), 
DOK7 expression was increased in Stage I disease (median copy number 531.4, n = 9, IQR = 
93-1322, p = 0.7133), decreased in Stage II disease (median copy number 113.9, n = 30, IQR 
= 24-329, p = 0.0023), decreased in Stage III disease (median copy number 137.4, n = 26, 
IQR = 67.6-566.8, p =0.1778) and decreased in Stage IV disease (median copy number 238.5, 
n = 6, IQR = 15-1703, p = 0.4924). However, only the difference in DOK7 median copy 
number between normal colorectal tissue and Stage II disease reached statistical significance. 
Between-group comparison revealed that there was a significant difference in DOK7 
expression between Stage I and Stage II colorectal cancer (p = 0.0404) but not between other 
stages. Kruskal-Wallis test did not reveal a significant difference between different stages of 
disease (p = 0.206). DOK7 expression in relation to the overall stage of disease is shown in 
Figure 3.6.  
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Figure 3.6 DOK7 expression and overall stage of colorectal cancer 
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3.3.1.9 DOK7 expression is significantly reduced in right sided colonic tumours and in 
rectal cancers 
 
When analysed by anatomical location, DOK7 expression was significantly reduced in right-
sided colonic cancers (median copy number 94.8, n = 28, IQR = 21-381, p = 0.0183) and in 
rectal cancers (median copy number 157.1, n = 22, IQR = 49.7-411.1, p = 0.0419) when 
compared with normal colorectal tissue (median copy number 342.3, n = 80, IQR = 63-1104). 
DOK7 expression in left sided colonic cancers was also reduced compared to normal 
colorectal tissue but failed to reach statistical significance (median copy number 136.4, n = 
22, IQR = 58-557, p = 0.2223). In transverse colonic tumour samples, median copy nmber 
was 350 (n = 2, IQR not calculated due to sample size). There was no significant difference 
between median copy number between cancer samples at different sites. DOK7 expression in 
relation to anatomical location of tumour is shown in Figure 3.7. 
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Figure 3.7 DOK7 expression and anatomical location of colorectal cancer 
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3.3.1.10 DOK7 expression is not associated with neoadjuvant/adjuvant treatment status 
 
DOK7 expression was significantly lower in colorectal cancer tissue obtained from patients 
who had not undergone, or did not undergo neoadjuvant or adjuvant treatment respectively 
compared to normal colorectal tissue (median copy number 129.8, n = 42, IQR = 43-495 vs. 
342.3, n = 80, IQR = 63-1104 respectively, p = 0.0417). DOK7 expression was also lower in 
colorectal cancer tissue obtained from patients who underwent adjuvant chemotherapy 
(median copy number 144.6, n = 13, IQR = 35-636) and neoadjuvant chemoradiotherapy 
(median copy number 90.0, n = 5, IQR = 50.7-358.2) but this failed to reach statistical 
significance (p = 0.2086 and p = 0.2247 respectively). In the sole patient who had 
radiotherapy, the median copy number was 1.2609 (IQR not calculated due to sample size). 
There was no significant difference in the level of DOK7 expression between those 
undergoing no additional treatment and those undergoing either adjuvant chemotherapy or 
neoadjuvant chemoradiotherapy.  
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3.3.1.11 DOK7 expression is not associated with invasiveness of tumour 
 
Compared to normal colorectal tissue, DOK7 expression in colorectal cancer tissue was 
significantly reduced in both invasive (median copy number 125.5, p = 0.0367) and non-
invasive (142.4, p = 0.0319) disease. There was no significant difference in level of DOK7 
expression found in colorectal cancer samples from patients with invasive and non-invasive 
disease (p = 0.7550).   
 
3.3.1.12 DOK7 expression and disease-free survival 
 
The level of DOK7 expression was significantly reduced in colorectal cancer tissue samples 
taken from both patients who remained disease-free (median copy number 108.2, p = 0.0321) 
and in those in who did not (median copy number 153.2, p = 0.0359). There was no 
significant difference in level of DOK7 expression between those who remained disease-free 
and those who did not (p = 0.6794). 
 
3.3.1.13 DOK7 expression and survival status 
 
The level of DOK7 expression was significantly lower in colorectal cancer tissue samples 
obtained from both patients who were alive (median copy number 79.5, p = 0.0109) at the end 
of follow up and those who died (median copy number 165.4, p = 0.0373). There was no 
significant difference in level of DOK7 expression between survivors and those who died (p = 
0.3089).  
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3.3.1.14 DOK7 expression and presence of metastatic status 
 
The level of DOK7 expression was observed to be lower in colorectal cancer tissue samples 
obtained from both patients with distant metastases (median copy number 193.2, p = 0.0984), 
and those without (median copy number 114.8, p = 0.0526) compared to normal colorectal 
tissue but this was not found to be statistically significant. There was no significant difference 
in level of DOK7 expression between those patients with distant metastases and those without  
(p = 0.7625).  
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3.3.1.15 DOK7 expression and local recurrence disease 
 
The level of DOK7 expression was significantly lower in colorectal cancer tissue samples 
obtained from patients who did not subsequently go on to have local recurrence (median copy 
number 136.4, p = 0.0435). Although the level of DOK7 expression was reduced in colorectal 
cancer tissue samples from patients who did have subsequent disease recurrence, this 
difference was not statistically different (median copy number 177.6, p = 0.2119). The level 
of DOK7 expression was not significantly different between those patients who had local 
recurrence of their disease and those who did not (p = 0.7270).  
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3.3.1.16 DOK7 expression and patient survival 
 
The Kaplan-Meier survival curve for DOK7 expression in colorectal cancer (dichotomized 
according to the median DOK7 transcript number for the whole cohort) is shown below. Low 
DOK7 expression is associated with significantly reduced survival (p = 0.011) when 
compared with the survival of patients with high levels of DOK7 expression. Data is shown in 
Figure 3.8.  
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Figure 3.8 Kaplan-Meier survival curve for DOK7 expression in colorectal cancer cohort 
dichotomized according to the median value of DOK7 expression for the whole cohort. Blue 
line represents low DOK7 mRNA expression (n = 62); green line represents high DOK7 
expression (n = 12). 
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3.3.2 Colorectal cell line data 
 
3.3.2.1 DOK7 is variably expressed in colorectal cancer cell lines 
 
The expression of DOK7 was examined in four colorectal cancer cell lines: HT-115, RKO, 
HRT-18 and Caco-2. HECV cell line was used as a control. Screening PCR revealed that 
DOK7 expression in colorectal cancer cell lines is variable. Expression of DOK7 is highest in 
HRT-18 cells with weaker expression seen in Caco-2 cells and little or no expression seen in 
HT-115 and RKO cells. Data is shown in Figure 3.9. Three cell lines were chosen for further 
analysis: HRT-18, HT-115 and RKO. 
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Figure 3.9 DOK7 expression in human colorectal cancer cell lines 
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3.3.2.2 Expression of DOK7 in HRT-18 ribozyme transgenic cell lines 
 
Two ribozyme transgenes were used to attempt knockdown of DOK7 in HRT-18 cells: rib1 
and rib2 which were used singly and in combination to produce three transgenic cell lines: 
HRT-18rib1, HRT-18rib2 and HRT-18rib1+2. Expression of DOK7 in these transgenic cell 
lines was examined using PCR. There was no reduction in DOK7 expression in HRT-18rib1 
cell line. Expression of DOK7 in HRT-18rib2 and HRT-18rib1+2 appeared to be reduced but 
was not completely knocked out. Data is shown in Figure 3.10. 
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Figure 3.10 DOK7 expression in HRT-18rib1, HRT-18rib2 and HRT-18rib1+2 transgenic cell 
lines 
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3.3.2.3 Attempted DOK7 overexpression in HT-115 and RKO cells 
 
A DOK7 expression insert was used to forcibly overexpress DOK7 in HT-115 and RKO cells 
to produce two transgenic cell lines: HT115exp and RKOexp. 
 
Expression of DOK7 in these transgenic cell lines was examined using PCR. There was no 
reduction in DOK7 expression in HRT-18rib1 cell line. DOK7 expression was not 
convincingly increased in either HT-115exp or RKOexp cells compared to the pEF control. 
Data is shown in Figure 3.11 and 3.12. 
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Figure 3.11 DOK7 expression in HT-115exp cell line 
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Figure 3.12 DOK7 expression in RKOexp cell line 
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3.3.2.4 Analysis of transgenic cell lines using qPCR 
 
Analysis using qPCR showed increased DOK7 expression in RKOexp transfected cells 
compared to pEF cells but failed to show increased expression in HT115exp or reduced 
expression in HRT18 knockdown cells.  
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3.3.3 DOK7 expression in other human cancers 
 
3.3.3.1 Breast cancer cell line data 
 
See Appendix 5. 
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3.3.3.2 Gastric cancer clinical cohort data 
 
See Appendix 6. 
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3.4 Discussion 
 
To our knowledge, this is the first study to attempt to characterise the expression of DOK7 in 
colorectal cancer and our data show a number of interesting findings. DOK7 mRNA 
expression is significantly reduced in colorectal cancer compared to normal colorectal tissue, 
both across the whole dataset and when paired data is analysed separately. This is in keeping 
with previous (unpublished) findings in the host laboratories that show reduced levels of 
DOK7 expression in breast cancer tissue compared to normal breast tissue, suggesting a 
potential tumour suppressor role for DOK7.  
 
Furthermore, DOK7 expression is inversely related to colorectal cancer T stage and DOK7 
expression is low in T3/T4 and Dukes’ B cancers, suggesting a possible role in primary 
tumour growth and bowel wall invasion. Whilst there was no significant difference in DOK7 
expression by nodal status or metastatic status, survival analysis shows that low DOK7 
expression is associated with poorer survival compared to high DOK7 mRNA expression, in 
keeping with a potential tumour suppressor role. 
 
Analysis of DOK7 mRNA expression in human colorectal cancer cell lines revealed that 
DOK7 is variably expressed in colorectal cancer cells. DOK7 is strongly expressed by HRT-
18 colorectal cancer cells with weaker levels of expression seen in Caco-2 and little or no 
DOK7 expression seen in HT-115 and RKO cells, the more poorly differentiated and highly 
aggressive colorectal cancer cell lines. In breast cancer cell lines, DOK7 expression was 
reduced or absent in MDA-MB-231, a poorly differentiated metastatic breast 
adenocarcinoma. However, analysis of DOK7 mRNA expression in our gastric cancer cohort 
failed to demonstrate any significant difference in expression between gastric cancer and 
normal gastric tissue. Furthermore, there was no significant difference in DOK7 mRNA 
expression between gastric cancer samples when analysed by T stage, nodal status, distant 
metastases, overall stage, location within the stomach, disease free status and overall survival.   
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A search of online gene array data identified a cohort of 585 colorectal cancer samples with 
19 non-tumour tissues (gene array cohort data shown in Appendix 7). Interestingly, analysis 
of this cohort revealed that DOK7 mRNA expression was increased in colorectal cancer 
compared to normal colorectal tissue (median DOK7 value 4.493 vs. 4.358, p = 0.037), the 
opposite to what was found in our dataset. Moreover, when this cohort of colorectal cancers 
were divided into subgroups representing different molecular subtypes as identified by Marisa 
et al and analysed for level of DOK7 expression there was a significant difference in DOK7 
expression in different molecular subtypes (p = 0.05) (266).  
 
Again, in contrast to our findings, analysis of this cohort failed to show any association 
between DOK7 mRNA expression and T stage (p = 0.616) but showed that DOK7 mRNA 
expression was significantly reduced in node positive disease compared to node negative 
colorectal cancers (median DOK7 value 4.416 vs. 4.525, p = 0.001) and was significantly 
reduced in Stage III tumours compared to Stage II (p < 0.01) and Stage IV tumours (p < 
0.05). In keeping with our findings, DOK7 mRNA expression was not affected by presence of 
distant metastases (p = 0.171). Finally, survival analysis revealed that high DOK7 expression, 
defined by expression levels over the 75% centile, was associated with significantly poorer 
overall survival (p = 0.033). There are many possible explanations for the differences seen 
between our own data and that from the online gene array – there were very few non-tumour 
tissues included in the gene array cohort, there is no information provided as to how the gene 
array data was collected and it is not possible to check that the primers used were similar to 
those used in our laboratories, leading to significant limitations in the ability to compare our 
results with that of the gene array data set.  
 
Aberrations in cell signalling pathways downstream of tyrosine kinases have been associated 
with many types of human cancer. Previous studies have shown that the Dok proteins act as 
tumour suppressors in a range of human cancers including leukaemia (142, 143, 255), lung 
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cancer (90), breast cancer (257) and histiocytic sarcoma (261). Conflicting results have been 
shown in relation to ovarian cancer (267).  
 
In colorectal cancer, previous studies have shown that Dok-2 expression is reduced in 
colorectal cancer tissue compared with normal colorectal tissue and that loss of Dok-2 
expression is associated with disease recurrence and poorer five-year overall survival (259). 
 
There is currently a lack of information regarding the role of DOK7 in cancer. In 2013, Heyn 
et al investigated DNA methylation in identical twins who were discordant for breast cancer 
diagnosis (258). They found hypermethylation of the DOK7 promoter region in the peripheral 
blood of the twins with breast cancer, in primary breast cancer tissue and breast cancer cell 
lines (258). However, there are, to-date, no published studies on the role of DOK7 in 
colorectal cancer.  
 
Following verification of DOK7 mRNA expression in the clinical cohort and colorectal 
cancer cells, we had planned to use gene transfer techniques to create cells with knockdown 
or overexpression of DOK7. However, PCR failed to show successful DOK7 expression in 
transfected RKO and HT-115 cells and there was incomplete knockdown of DOK7 in 
transfected HRT-18 cells despite repeating the PCR several times with freshly prepared 
primers, running check PCR of expression plasmids and optimizing the conditions of the 
expression primers.  
 
Further investigation revealed that DOK7 has several different variants, which code for Dok7 
isoforms. A diagrammatic representation of the structures of DOK7 variants 1-3 is shown in 
Figure 3.13.  
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Figure 3.13 Diagrammatic representation of the structure of DOK7 isoforms 1-3 coded for by 
DOK7 variants 1-3 (DOK7V1-3) 
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The software programme Primer 3 was used to assess the product sizes that would be 
produced using the existing DOK7 primers for variants 1-3. This revealed similar/identical 
product sizes for more than one transcript variant of DOK7 across the range of primers used 
as shown in Table 3.4. It therefore became apparent that due to overlaps in the structure of 
these variants, the existing plasmids and primers had not been able to distinguish between 
these variants resulting in our inability to confirm successful knockdown. 
 
Table 3.4 Product sizes produced with DOK7 primers for DOK7V1, DOK7V2 and DOK7V3 
demonstrating lack of specificity of DOK7 primers for DOK7 variants 
 
Primers DOK7V1 DOK7V2 DOK7V3 
Dok7F8R8 409bp 409bp 409bp 
Dok7F9R9 479bp 468bp - 
Dok7exF2R4 1512bp 1501bp - 
Dok7F1ZR1 129bp 129bp - 
Dok7F2ZR2 115bp 115bp 115bp 
 
These variants and isoforms present an interesting challenge and may explain the differences 
in DOK7 mRNA expression seen in our own cohort compared to the cohort of 585 colorectal 
cancer cases, though this difference may also be due to the limitations already described 
above. A review of the previous literature did not yield any reference to the existence of these 
variants and isoforms in previous laboratory studies and thus there is no advice on how these 
variations should be accommodated for in the design of primers or antibodies nor any 
preceding data on the expression of these variants or the role of their corresponding isoforms. 
This discovery led us to develop new DOK7 variant specific qPCR primers and the 
development of these and the variant specific expression profiles obtained using these are the 
subject of the next chapter. 
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In summary, our data suggest that DOK7 expression is reduced in colorectal cancer, 
particularly in T3/4 disease and that low DOK7 expression is associated with poorer patient 
survival. These results are consistent with the pattern of DOK protein expression found in 
relation to other Dok family members in a range of human cancers and to the expression of 
Dok-2 in relation to colorectal cancer. We therefore suggest that DOK7 may play a potential 
tumour suppressor role in relation to colorectal cancer.  
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Chapter 4: Expression of DOK7 variant-1, -2 and -3 (V1, V2 
and V3) in colorectal cancer clinical cohort 
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4.1 Introduction 
 
The downstream of tyrosine kinase (DOK) protein family has seven members, DOK1-7. The 
precise role of these proteins is not entirely clear although some authors have suggested a 
potential tumour suppressor role. The aim of this clinically oriented PhD is to determine the 
role of DOK7 in colorectal cancer and to establish if there is an association between DOK7 
expression and clinical outcome. 
 
During initial investigations, analysis of three human colorectal cancer cell lines (HRT18, 
HT115 and RKO) revealed high DOK7 expression in HRT18 and little or no expression in 
HT115 and RKO cells. Analysis of tissue obtained from a cohort of patients with colorectal 
cancer revealed that DOK7 expression was significantly reduced in colorectal cancer tissue 
compared with normal colorectal tissue (p=0.0199) and that DOK7 level was significantly 
negatively correlated with increasing T stage (p = 0.038).  
 
Initial attempts to knockdown DOK7 using ribozyme transgenes in HRT18 colorectal cancer 
cells were partly successful. However, attempts to overexpress DOK7 in HT115 and RKO 
cells failed. Further investigations revealed that DOK7 has several isoforms encoded by 
several transcript variants. 
 
Having established the relative structures of DOK7 variant 1 (DOK7V1), DOK7 variant 2 
(DOK7V2) and DOK7 variant 3 (DOK7V3), the aim of the work presented in this chapter 
was to produce variant specific DOK7 primers and to determine the expression of DOK7V1-3 
in both the clinical cohort and the colorectal cancer cell lines. It was hoped that this would 
potentially allow variant specific in vitro cell models to be subsequently developed that would 
allow the effect of DOK7 variant expression on colorectal cancer cell function to be explored.  
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4.2 Materials and methods 
 
4.2.1 Materials and methods for determination of DOK7V1/V2/V3 expression in 
colorectal cancer patient cohort tissue samples 
 
4.2.1.1 Patient selection  
 
The selection of patients has previously been discussed in Section 3.2.1.1.  
 
4.2.1.2 Collection of tissue samples 
 
The collection of tissue samples is described in Section 2.2.7.1. 
 
4.2.1.3 Isolation of RNA and cDNA from tissue samples 
 
Frozen tissue samples were sectioned into 8-10µm sections using a Leica CM1900 Cryostat 
and homogenized. RNA was isolated from cells using TRI Reagent® (Sigma-Aldrich Inc., 
Poole. UK), as described in Section 2.2.2.1, and quantified using a spectrophotometer as 
described in Section 2.2.2.2. Reverse transcription using a High Capacity cDNA Reverse 
transcription kit was used to synthesis cDNA as described in Section 2.2.2.3.  
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4.2.1.4 Quantitative PCR  
 
Quantitative PCR to determine the level of DOK7 V1/V2/V3 mRNA expression was 
simultaneously performed on all of the cDNA samples obtained from the patient cohort using 
the variant specific primers shown in Table 4.1, which were designed using an online primer 
design tool (Primer blast, https://www.ncbi.nlm.nih.gov/tools/primer-blast/). The full details 
of these primers are shown in Table 2.6.  
 
The components and conditions used for qPCR are provided in Section 2.2.2.6.2.  
 
Table 4.1 Variant specific qPCR primers  
 
Gene Primer 
DOK7V1 DOK7V1F1 
DOK7V1ZR1 
DOK7V2 DOK7V2F1 
DOK7V2ZR1 
DOK7V3 DOK7V3F1 
DOK7V3ZR1 
 
4.2.1.5 Statistical analysis  
 
Data obtained from qPCR was analysed using the Mann-Whitney test for non-parametric data 
and Kruskal-Wallis test. Survival analysis was performed using Kaplan-Meier survival 
analysis. The threshold for statistical significance was p<0.05. Data was normalized by RNA 
concentration. 
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4.2.2 Materials and methods for determination of DOK7V1/V2/V3 expression in 
colorectal cancer cell lines 
 
4.2.2.1 Colorectal cancer cell lines 
 
The details of the colorectal cancer cell lines used in this study are shown in Section 2.1.1. All 
cells were maintained according to the supplier’s instructions. Details of the media used for 
cell culture are provided in Section 2.1.6.1 and the methods of cell culture used are described 
in Section 2.2.1.  
 
4.2.2.2 Primers 
 
The variant specific primers used in this study are shown in Table 4.2. Full details of these 
primers are shown in Table 2.6. 
 
Table 4.2 Variant specific primers and product sizes 
 
  Product sizes obtained with DOK7 variant (bp) 
Gene Primer pair Variant 1 Variant 2 Variant 3 
DOK7V1 DOK7V1 F8R8 595 - - 
 DOK7V1 F9R9 609 - - 
DOK7V2 DOK7V2 F8R8 - 597 - 
DOK7V3 DOK7V3 F8R8 - - 229 
 DOK7V3 F9R9 - - 227 
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4.2.2.3 RNA isolation and cDNA synthesis 
 
RNA was isolated from cells using TRI Reagent® (Sigma-Aldrich Inc., Poole. UK), as 
described in Section 2.2.2.1, and quantified using a spectrophotometer as described in Section 
2.2.2.2. Reverse transcription using a High Capacity cDNA Reverse transcription kit was 
used to synthesis cDNA as described in Section 2.2.2.3.  
 
4.2.2.4 PCR 
 
The synthesised cDNA was screened for DOK7V1/V2/V3 expression using PCR. The 
components and conditions used for PCR are described in Section 2.2.2.4.2.  
 
Size separation of the resulting PCR products was performed using 1-2% agarose gel 
electrophoresis and visualized using SYBR® Safe DNA gel stain (Life Technologies Ltd, 
Paisley, UK) and UV transillumination as described in Section 2.2.2.5.  
 
4.2.2.5 qPCR 
 
Quantitative PCR to determine the level of DOK7V1/V2/V3 mRNA expression was 
performed on the cDNA samples obtained from the colorectal cell lines using the 
Amplifluor™ Universal Detection system (Intergen®, New York, USA) as described in 
Section 2.2.2.6 and the variant specific qPCR primers listed in Table 4.1.   
 
The components and conditions used for qPCR are described in Section 2.2.2.6.2.  
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4.3 Results 
 
4.3.1 Cohort data 
 
4.3.1.1 Patient demographics 
 
The patient demographics are shown in Section 3.3.1.1. 
 
4.3.1.2 Tumour histopathological features 
 
The histopathological features of the colorectal tumours of patients included in this study are 
shown in Table 3.3.   
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4.3.1.3 DOK7V1 expression 
 
4.3.1.3.1 DOK7V1 expression is significantly reduced in colorectal cancer compared to 
normal colorectal tissue 
 
The expression of DOK7V1 is significantly reduced in colorectal cancer compared to normal 
colorectal tissue. Median DOK7V1 mRNA expression per 50µg of total cellular RNA (copy 
number) was 0.4 (IQR = 0.0-5.8) copies for colorectal carcinoma tissue (n = 94) compared 
with 18.1 (IQR = 9.3-638.5) for normal colorectal tissue (n = 80) (p = 0.0000) for the whole 
cohort, and 0.2 (IQR = 0.0-3.4) vs. 17.6 (IQR = 8-768) copies for paired tissue samples (n = 
68 in each group) respectively (p = 0.0000). Data is shown in Figure 4.1 below. 
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Figure 4.1 DOK7V1 mRNA expression in colorectal cancer and normal colorectal tissue. In 
this figure and all subsequent figures in this chapter, * indicates p < 0.05, ** indicates p < 
0.01 and *** indicates p < 0.001.  
  
N
o
rm
a
l
T
u
m
o
u
r
0
200
400
600
800
C
o
p
y
 n
u
m
b
e
r 
p
e
r 
5
0
μ
g
 R
N
A ***
P
a
ir
e
d
 n
o
rm
a
l
P
a
ir
e
d
 t
u
m
o
u
r
0
200
400
600
800
1000
C
o
p
y
 n
u
m
b
e
r 
p
e
r 
5
0
μ
g
 R
N
A
***
 267 
4.3.1.3.2 DOK7V1 expression is not related to degree of colorectal tumour 
differentiation 
 
The expression of DOK7V1 in relation to degree of tumour differentiation is shown in Figure 
4.2. The median copy number per 50µg of total cellular RNA was significantly reduced in 
Grade 1 (1.2 copies, n = 2, IQR not calculated due to sample size, p = 0.0183), Grade 2 (0.2 
copies, n = 54, IQR = 0.0-4.8, p = 0.0000) and Grade 3 (2.0 copies, n = 14, IQR = 0-35, p = 
0.0004) colorectal cancer tissue compared to normal colorectal tissue (18.1 copies, n = 80, 
IQR = 9.3-638.5). Analysis using the Kruskal-Wallis test did not reveal a significant 
difference in median copy number between different grades of tumour differentiation (p = 
0.264). 
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Figure 4.2 DOK7V1 expression by degree of tumour differentiation 
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4.3.1.3.3 DOK7V1 expression is not related to colorectal cancer nodal status 
 
DOK7V1 expression was significantly decreased in node negative colorectal cancer samples 
compared with normal colorectal tissue (median copy number 0.5, n = 39, IQR = 0.0-4.7 vs. 
18.1, n = 80, IQR = 9.3-638.5) respectively, p = 0.0000). Median DOK7V1 mRNA 
expression per 50µg of total cellular RNA (copy number) was 1.3 (IQR = 0.1-15.2) in 
colorectal cancer tissue obtained from patients with N1 disease (n = 16) and 0.2 (0-9) in 
colorectal cancer tissue obtained from patients with N2 disease (n = 15). There was no 
significant difference in median copy number between patients with node negative and node 
positive disease (0.5 vs. 0.2, p = 0.4854). DOK7V1 expression in relation to colorectal cancer 
nodal status is shown in Figure 4.3. 
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Figure 4.3 DOK7V1 mRNA expression by nodal status of colorectal cancer 
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4.3.1.3.4 DOK7V1 expression is significantly reduced across all Dukes’ stage colorectal 
cancer 
 
DOK7V1 expression was significantly reduced across all Dukes’ stages of colorectal cancer 
compared to normal colorectal tissue (median copy number 1.7 (IQR = 0.355-3.699), 0.1 
(IQR = 0.0-5.9) and 0.2 (IQR = 0.1-15.4) for Dukes’ A (n = 7), Dukes’ B (n = 33) and Dukes’ 
C (n = 32) tumours respectively compared to 18.1 (IQR = 9.3-638.5) in normal colorectal 
tissue, p values = 0.0000 for all three comparisons). DOK7V1 expression in relation to 
Dukes’ stage is shown in Figure 4.4. 
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Figure 4.4 DOK7V1 mRNA expression and Dukes’ stage of colorectal cancer 
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4.3.1.3.5 DOK7V1 expression and T stage of colorectal cancer 
 
The level of DOK7V1 expression decreased with increasing T stage, with median copy 
numbers of 6.8 (n = 2, IQR not calculated due to sample size) for T1 disease, 3.6 (n = 10, IQR 
= 0-22) for T2 disease, 0.2 (n = 40, IQR = 0.0-2.7) for T3 disease and 0.1 (n = 18, IQR = 0.0-
8.5) for T4 disease. In comparison with normal colorectal tissue (n = 80, median DOK7V1 
mRNA expression 18.1, IQR = 9.3-638.5), the median copy number was not significantly 
different for T1 (p = 0.0952) but was significantly reduced in T2 (p = 0.0125), T3 (p = 
0.0000) and T4 (p = 0.0000) disease. DOK7V1 expression in relation to T stage is shown in 
Figure 4.5  
 
When T stages were combined, median copy number was significantly reduced in T2/3 
cancers (median copy number 0.5, p = 0.0000), T3/4 cancers (median copy number 0.2, p = 
0.0000) and T2/3/4 cancers (median copy number 0.2, p = 0.0000) in comparison with normal 
colorectal tissue. 
 
Further analysis of the colorectal cancer samples using the Kruskal-Wallis revealed that the 
difference in DOK7V1 expression between T stages was not significant (p = 0.072). 
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Figure 4.5 DOK7V1 expression and T stage of colorectal cancer 
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4.3.1.3.6 DOK7V1 expression is significantly associated with overall stage of colorectal 
cancer 
 
Compared to normal colorectal tissue (median copy number 18.1, n = 80, IQR = 9.3-638.5), 
DOK7V1 expression was reduced in Stage I disease (median copy number 2.5, n = 9, IQR = 
0.44-7.30, p = 0.0001), decreased in Stage II disease (median copy number 0.1, n = 30, IQR = 
0.0-3.6, p = 0.0000), decreased in Stage III disease (median copy number 0.2, n = 26, IQR = 
0.0-5.7, p =0.0000) and increased in Stage IV disease (median copy number 60.0, n = 6, IQR 
= 1.6-259.1, p = 0.3827), though the latter failed to reach statistical significance. Between-
group comparisons using the Kruskal-Wallis test revealed that there was a significant 
difference in DOK7V1 expression between different stages of disease (p = 0.041). DOK7V1 
expression in relation to overall stage of colorectal cancer is shown in Figure 4.6.   
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Figure 4.6 DOK7V1 expression and overall stage of colorectal cancer 
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4.3.1.3.7 DOK7V1 expression and anatomical location of colorectal cancer 
 
When analysed by anatomical location, DOK7V1 expression was significantly reduced in 
right-sided colonic cancers (median copy number 0.2, n = 28, IQR = 0-6, p = 0.0000), left-
sided colonic cancers (median copy number 0.8, n = 22, IQR = 0.1-4.9, p = 0.0000) and 
transverse colonic cancers (median copy number 0.0, n = 2, IQR not calculated due to sample 
size, p = 0.0169) when compared with normal colorectal tissue (median copy number 18.1, n 
= 80, IQR = 9.3-638.5). DOK7V1 expression in rectal cancers was also significantly reduced 
compared to normal colorectal tissue (median copy number 0.1, n = 22, IQR = 0.0-1.3, p = 
0.0000). There was no significant difference in DOK7V1 expression between cancer samples 
at different sites. DOK7V1 expression in relation to anatomical site of colorectal tumour is 
shown in Figure 4.7. 
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Figure 4.7 DOK7V1 expression and anatomical location of colorectal cancer 
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4.3.1.3.8 DOK7V1 expression and neoadjuvant/adjuvant treatment status 
 
DOK7V1 expression was significantly lower in colorectal cancer tissue obtained from 
patients who did not undergo any additional therapy compared to normal colorectal tissue 
(median copy number 0.3, n = 42, IQR = 0.0-3.0 vs. 18.1, n = 80, IQR = 9.3-638.5 
respectively, p = 0.0000). DOK7V1 expression was also significantly lower in colorectal 
cancer tissue obtained from those patients who underwent adjuvant chemotherapy (median 
copy number 0.2, n = 13, IQR = 0.02-0.42, p = 0.0000) and neoadjuvant chemoradiotherapy 
(median copy number 0.0, n = 5, IQR = 0.003 – 0.409, p = 0.0002) compared to normal 
colorectal tissue. In the one patient who underwent adjuvant radiotherapy, median DOK7V1 
expression was 0 (IQR not calculated due to sample size). There was no significant difference 
in the level of DOK7V1 expression between those who received no additional treatment and 
those who had either undergone adjuvant chemotherapy or neoadjuvant chemoradiotherapy. 
DOK7V1 expression in relation to neoadjuvant/adjuvant treatment status is shown in Figure 
4.8. 
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Figure 4.8 DOK7V1 expression and neoadjuvant/adjuvant treatment status 
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4.3.1.3.9 DOK7V1 expression and tumour invasiveness 
 
Compared to normal colorectal tissue, DOK7V1 expression in colorectal cancer tissue was 
reduced in both invasive (median copy number 0.2, p = 0.0000) and non-invasive disease 
(median copy number 0.3, p = 0.0000). There was no significant difference in level of 
DOK7V1 expression between colorectal cancer samples from those with invasive and those 
with non-invasive disease (p = 0.7508). 
 
4.3.1.3.10 DOK7V1 expression and disease-free status 
 
The level of DOK7V1 expression was significantly reduced in colorectal cancer tissue 
samples taken from both patients who remained disease-free (median copy number 0.6, p = 
0.0000) and those who did not (median copy number 0.1, p = 0.0000) patients. The level of 
DOK7V1 expression was significantly lower in colorectal cancer samples from patients did 
not remain disease-free compared to those who remained disease-free (p = 0.0230).    
 
4.3.1.3.11 DOK7V1 expression and survival status 
 
The level of DOK7V1 expression was significantly lower in colorectal cancer tissue samples 
obtained from both patients who were alive (median copy number 0.2, p = 0.0000) at the end 
of follow up and those who died (median copy number 0.1, p = 0.0000). There was no 
significant difference in the level of DOK7V1 expression in colorectal cancer samples 
obtained from patients who were alive compared to those who had died (p = 0.1239). 
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4.3.1.3.12 DOK7V1 expression and metastatic status 
 
The level of DOK7V1 expression was observed to be lower in colorectal cancer tissue 
samples obtained from both patients with distant metastases (median copy number 0.1, p = 
0.0000), and those without (median copy number 0.4, p = 0.0000) compared to normal 
colorectal tissue. There was no significant difference in the level of DOK7V1 expression in 
colorectal cancer samples obtained from patients with distant metastases compared to those 
with without (p = 0.1564).  
 
4.3.1.3.13 DOK7V1 expression and local recurrence of disease 
 
The level of DOK7V1 expression was significantly lower in colorectal cancer tissue samples 
obtained both from patients who did and did not subsequently go on to have local recurrence 
(median copy number 0.0 vs. 0.2, p = 0.0000 and p = 0.0000). There was no significant 
difference in level of DOK7V1 expression between colorectal cancer samples obtained from 
patients with local recurrence compared to those obtained from patients without (p = 0.1010). 
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4.3.1.3.14 DOK7V1 expression and overall patient survival 
 
The Kaplan-Meier survival curve for DOK7V1 expression in colorectal cancer (dichotomized 
according to the median value of DOK7V1 expression for the whole cohort) is shown below 
in Figure 4.9. Low DOK7V1 expression (n = 26) is associated with reduced overall survival 
when compared with the overall survival of patients with high levels of DOK7V1 expression 
(n = 48) but this difference failed to reach statistical significance (p = 0.093).  
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Figure 4.9 Overall patient survival in patients with high (green) DOK7V1 expression (n = 48) 
compared to those with low (blue) DOK7V1 expression (n = 26) 
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4.3.1.3.15 DOK7V1 expression and disease-free patient survival 
 
The Kaplan-Meier disease-free survival curve for DOK7V1 expression in colorectal cancer 
(dichotomized according to the median value of DOK7V1 expression for the whole cohort) is 
shown below in Figure 4.10. Low DOK7V1 expression (n = 26) is associated with 
significantly reduced disease-free survival when compared with the disease-free survival of 
patients with high levels of DOK7V1 expression (n = 48) (p = 0.036).  
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Figure 4.10 Disease-free patient survival in patients with high (green) DOK7V1 expression (n 
= 48) compared to those with low (blue) DOK7V1 expression (n = 26) 
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4.3.1.4 DOK7V2 expression 
 
4.3.1.4.1 DOK7V2 expression is significantly increased in colorectal cancer compared to 
normal colorectal tissue 
 
The expression of DOK7V2 is significantly increased in colorectal cancer compared to 
normal colorectal tissue. Median DOK7V2 mRNA expression per 50µg of total cellular RNA 
was 0.9 copies (n = 94, IQR = 0-15) for colorectal carcinoma tissues compared with 0.0 
copies (n = 80, IQR = 0.0-3.983) for normal colorectal tissue (p = 0.0000) for the whole 
cohort, and 0.7 (n = 68, IQR = 0.1-11.7) vs. 0.0 (n = 68, IQR = 0.0-4.846) copies for paired 
colorectal carcinoma and paired normal colorectal tissue samples respectively (p = 0.0003). 
Data is shown in Figure 4.11.  
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Figure 4.11 DOK7V2 expression in colorectal cancer and normal colorectal tissue 
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4.3.1.4.2 DOK7V2 expression is not related to degree of colorectal tumour 
differentiation 
 
The expression of DOK7V2 in relation to degree of tumour differentiation is shown in Figure 
4.12. The median copy number of DOK7V2 per 50µg of total cellular RNA was increased in 
Grade 1 (10.7 copies, n = 2, IQR not calculated due to sample size, p = 0.1910), Grade 2 
(median copy number 0.4, n = 54, IQR = 0.1-12.4, p = 0.0020 copies) and Grade 3 (median 
copy number 8.5, n = 14, IQR = 0.55-18.08, p = 0.0016) colorectal cancers compared to 
normal colorectal tissue (median copy number 0.0, n = 80, IQR = 0.0-3.983). Analysis using 
the Kruskal-Wallis test did not reveal a significant difference in DOK7V2 median copy 
number between different grades of tumour differentiation (p = 0.316). 
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Figure 4.12 DOK7V2 expression by degree of tumour differentiation 
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4.3.1.4.3 DOK7V2 expression and colorectal cancer nodal status 
 
DOK7V2 expression was significantly increased in node negative colorectal cancer samples 
compared with normal colorectal tissue (median copy number 0.7, n = 39, IQR 0.1-20.1 vs. 
0.0, n = 80, IQR = 0.0-3.983 respectively, p = 0.0006). Median DOK7V2 mRNA expression 
per 50µg of total cellular RNA (copy number) was 4.3 in colorectal cancer samples obtained 
from patients with N1 disease (n = 16, IQR = 0.2-17.69) and 0.1 in colorectal cancer samples 
obtained from patients with N2 disease (n = 15, IQR = 0.0-10.61). There was no significant 
difference in median copy number between patients with node negative and node positive 
disease (0.7 vs. 0.6, p = 0.5704). DOK7V2 expression in relation to colorectal cancer nodal 
status is shown in Figure 4.13. 
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Figure 4.13 DOK7V2 expression by nodal status of colorectal cancer 
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4.3.1.4.4 DOK7V2 mRNA expression is significantly increased across all Dukes’ stages 
of colorectal cancer 
 
DOK7V2 mRNA expression was significantly increased across all Dukes’ stages of 
colorectal cancer compared to normal colorectal tissue. Median copy number for Dukes’ A 
was 3.4 (n = 7, IQR = 0.23-21.03, p = 0.0272), Dukes’ B was 0.6 (n = 33, IQR = 0.1-19.3, p = 
0.0029) and Dukes’ C was 1.2 (n = 32, IQR = 0.08-15.45, p = 0.0038) compared to 0.0 in 
normal colorectal tissue (n = 80, IQR = 0.0-3.983). DOK7V2 mRNA expression in relation to 
Dukes’ stage is shown in Figure 4.14. 
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Figure 4.14 DOK7V2 mRNA expression and Dukes’ stage of colorectal cancer 
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4.3.1.4.5 DOK7V2 expression and T stage of colorectal cancer 
 
DOK7V2 expression was significantly increased in T2 (median copy number 8.3, n = 10, IQR 
= 0.21-26.51, p = 0.0028), T3 (median copy number 0.5, n = 40, IQR = 0.1-11.3, p = 0.0036) 
and T4 (median copy number 1.1, n = 18, IQR = 0.0-23.6, p = 0.0480) colorectal cancer 
tissue compared to normal colorectal tissue (median copy number 0.0, n = 80, IQR = 0.0-
3.983). DOK7V2 mRNA expression was increased in T1 colorectal cancers compared to 
normal colorectal tissue (median copy number 9.9 vs. 0.0, p = 0.1216), although this 
difference was not statistically significant. DOK7V2 mRNA expression in relation to T stage 
of colorectal cancer is shown in Figure 4.15.  
 
When T stages were combined, median copy number was significantly increased in T2/3 
cancers (median copy number 0.6, p = 0.0003), T3/4 cancers (median copy number 0.5, p = 
0.0014) and T2/3/4 cancers (median copy number 0.6, p = 0.0002) in comparison with normal 
colorectal tissue. 
 
Further analysis of the colorectal cancer samples using the Kruskal-Wallis revealed that there 
was no significant difference in DOK7V2 expression between T stages (p = 0.407). 
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Figure 4.15 DOK7V2 expression and T stage of colorectal cancer 
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4.3.1.4.6 DOK7V2 expression and overall stage of colorectal cancer 
 
Compared to normal colorectal tissue, DOK7V2 expression was significantly increased in 
Stage I disease (median copy number 7.1, n = 9, IQR = 0.24-21.15 vs. 0.0, n = 80, IQR = 0.0-
3.983, p = 0.0042), Stage II disease (median copy number 0.5, n = 30, IQR = 0.0-18.8, p = 
0.0083), Stage III disease (median copy number 0.4, n = 26, IQR = 0.05 – 7.21, p =0.0450) 
and Stage IV disease (median copy number 16.5, n = 6, IQR = 9.06 – 23.56, p = 0.0028). 
Between-group comparisons using the Kruskal-Wallis test revealed that there was no 
significant difference in DOK7V2 expression between different stages of disease (p = 0.072). 
DOK7V2 mRNA expression in relation to overall stage of colorectal cancer is shown in 
Figure 4.16.  
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Figure 4.16 DOK7V2 mRNA expression and overall stage of colorectal cancer 
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4.3.1.4.7 DOK7V2 expression and anatomical location of colorectal cancer 
 
When analysed by anatomical location, DOK7V2 mRNA expression was significantly 
increased in right-sided colonic cancers (median copy number 0.3, n = 28, IQR = 0.03-12.48, 
p = 0.0364) and left-sided colonic cancers (median copy number 6.2, n = 22, IQR = 0.4-18.8, 
p = 0.0001) compared to normal colorectal tissue (median copy number 0.0, n = 80, IQR 0.0-
3.983). The level of DOK7V2 expression was also increased in transverse colonic cancers 
(median copy number 0.2, n = 2, IQR not calculated due to sample size, p = 0.5885) and 
rectal cancers (median copy number 0.5, n = 22, IQR = 0.07-7.43, p = 0.0678) but this 
difference did not reach statistical significance. DOK7V2 expression was significantly higher 
in left colonic cancers compared to right colonic cancers (p = 0.0411) and rectal cancers (p = 
0.0378) but was not significantly different to levels found in transverse colonic tumours (p = 
0.0848). DOK7V2 mRNA expression in relation to anatomical location of colorectal cancer is 
shown in Figure 4.17. 
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Figure 4.17 DOK7V2 expression and anatomical location of colorectal cancer 
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4.3.1.4.8 DOK7V2 expression and neoadjuvant/adjuvant treatment status 
 
DOK7V2 mRNA expression was significantly higher in colorectal cancer tissue obtained 
from patients who underwent no additional therapy compared to normal colorectal tissue 
(median copy number 0.7, n= 42, IQR = 0.1-16.6 vs. 0.0, n = 80, IQR = 0.0-3.983, p = 
0.0007). DOK7V2 expression was also higher in colorectal cancer tissue obtained from 
patients who had adjuvant chemotherapy (median copy number 0.2, n = 13, IQR = 0.040 – 
2.370, p = 0.4218) and neoadjuvant chemoradiotherapy (median copy number 0.1, n = 5, IQR 
= 0.044-0.515, p = 0.9404) but was not significantly different to the levels in normal 
colorectal tissue. Median DOK7V2 mRNA expression in the single patient who underwent 
radiotherapy was 0.0 copies (IQR not calculated due to sample size). There was no significant 
difference in the level of DOK7V2 expression between patients who underwent no additional 
therapy and those who underwent either adjuvant chemotherapy or neoadjuvant 
chemoradiotherapy. The level of DOK7V2 mRNA expression in relation to 
neoadjuvant/adjuvant treatment status is shown in Figure 4.18. 
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Figure 4.18 DOK7V2 expression and neoadjuvant/adjuvant treatment status 
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4.3.1.4.9 DOK7V2 expression and tumour invasiveness 
 
Compared to normal colorectal tissue, DOK7V2 mRNA expression in colorectal cancer tissue 
was significantly increased in both invasive (median copy number 1.2, p = 0.0045) and non-
invasive (median copy number 0.6, p = 0.0021) disease. There was no significant difference 
in level of DOK7V2 expression between colorectal cancer samples taken from patients with 
invasive and non-invasive disease (p = 0.7550).   
 
4.3.1.4.10 DOK7V2 expression and disease-free status 
 
The level of DOK7V2 mRNA expression was significantly increased in colorectal cancer 
tissue samples taken from patients who remained disease-free (median copy number 0.6, p = 
0.0008) compared to normal colorectal tissue. The level of DOK7V2 expression was also 
increased in patients who suffered further disease but this difference did not reach statistical 
significance (median copy number 0.2, p = 0.3320) patients. The level of DOK7V2 
expression was not significantly different between colorectal cancer samples obtained from 
patients who remained disease free vs. those who did not (p = 0.1119). 
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4.3.1.4.11 DOK7V2 expression and survival status 
 
The level of DOK7V2 expression was significantly higher in colorectal cancer tissue samples 
obtained from patients who were alive (median copy number 0.4, p = 0.0057) compared to 
normal colorectal tissue. Although DOK7V2 expression levels were higher in patients who 
died compared to normal colorectal tissue, this difference was not significant (median copy 
number 0.2 vs. 0.0, p = 0.1271). There was no significant difference in DOK7V2 expression 
between colorectal cancer samples obtained from patients who were alive at the end of 
follow-up compared to those who had died (p = 0.4908).  
 
4.3.1.4.12 DOK7V2 expression and metastatic status 
 
The level of DOK7V2 mRNA expression was significantly higher in colorectal cancer 
samples obtained from patients without distant metastases compared to normal colorectal 
tissue (median copy number 0.7 vs. 0.0, p = 0.0003). The level of DOK7V2 expression was 
higher in colorectal cancer samples obtained from patients with distant metastases compared 
to normal colorectal tissue, but this difference did not reach statistical significance (median 
copy number 0.2 vs. 0.0, p = 0.2119). There was no significant difference in DOK7V2 
expression between colorectal cancer samples obtained from patients with distant metastases 
and those without (p = 0.1685). 
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4.3.1.4.13 DOK7V2 expression and local recurrence of disease 
 
The level of DOK7V2 mRNA expression was significantly higher in colorectal cancer 
patients without local recurrence compared to normal colorectal tissue (median copy number 
0.5 vs. 0.0, p = 0.0009). The level of DOK7V2 expression was the same in colorectal cancer 
samples obtained from patients with local recurrence compared to normal colorectal tissue 
(median copy number 0.0 vs. 0.0, p = 0.9502). There was no significant difference in level of 
DOK7V2 expression between colorectal cancer samples obtained from patients with local 
recurrence compared to those without (p = 0.3973).  
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4.3.1.4.14 DOK7V2 expression and overall patient survival 
 
The Kaplan-Meier survival curve for DOK7V2 mRNA expression in colorectal cancer 
(dichotomized according to the median value of DOK7V2 expression for the whole cohort) is 
shown in Figure 4.19. Low DOK7V2 expression (n = 11) is associated with reduced overall 
survival when compared with the overall survival of patients with high levels of DOK7V2 
expression (n = 63) but this difference failed to reach statistical significance (p = 0.064). 
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Figure 4.19 Overall patient survival in patients with high (green) DOK7V2 expression (n = 
63) compared to those with low (blue) DOK7V2 expression (n = 11) 
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4.3.1.4.15 DOK7V2 expression and disease-free patient survival 
 
The Kaplan-Meier disease-free survival curve for DOK7V2 expression in colorectal cancer 
(dichotomized according to the median value of DOK7V2 expression for the whole cohort) is 
shown below in Figure 4.20. Low DOK7V2 expression (n = 11) is associated with 
significantly reduced disease-free survival when compared with the disease-free survival of 
patients with high levels of DOK7V2 expression (n = 63) (p = 0.009). 
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Figure 4.20 Disease-free patient survival in patients with high (green) DOK7V2 expression (n 
= 63) compared to those with low (blue) DOK7V2 expression (n = 11) 
 
 
  
 310 
4.3.1.5 DOK7V3 expression 
 
4.3.1.5.1 DOK7V3 mRNA expression is increased in colorectal cancer compared to 
normal colorectal tissue across the whole cohort but not for paired samples 
 
The level of DOK7V3 expression is increased in colorectal cancer compared to normal 
colorectal tissue. Median DOK7V3 mRNA expression per 50µg of total cellular RNA was 
significantly higher in colorectal carcinoma tissues (median copy number 15.1, n = 94, IQR = 
1-512) compared with normal colorectal tissue (median copy number 2.4, n = 80, IQR = 0-
391, p = 0.0263) for the whole cohort. Paired tumour vs. normal comparison (median copy 
number 8.1, n = 68, IQR  = 1-465 vs. median copy number 2.1, n = 68, IQR = 0-391 
respectively) showed a similarly increased level of DOK7V3 in colorectal cancer, but this 
difference did not reach statistical significance (p = 0.0765). Data is shown in Figure 4.21. 
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Figure 4.21 DOK7V3 mRNA expression in colorectal cancer and normal colorectal tissue 
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4.3.1.5.2 DOK7V3 expression is not related to degree of colorectal tumour 
differentiation 
 
The expression of DOK7V3 mRNA in relation to degree of tumour differentiation is shown in 
Figure 4.22. The median copy number of DOK7V3 per 50µg of total cellular RNA was 
increased in well differentiated (median copy number 1520.2, n = 2, IQR not calculated due 
to sample size vs. 2.4, n = 80, IQR = 0-391, p = 0.5377) and moderately differentiated 
(median copy number 6.0, n = 54, IQR = 1-252, p = 0.4181 copies) colorectal cancer samples 
compared to the level in normal colorectal tissue but these differences were not statistically 
significant. DOK7V3 expression was significantly higher in poorly differentiated colorectal 
cancer samples compared to normal colorectal tissue (median copy number 211.8, n = 14, 
IQR = 12-1430, p = 0.0140). Analysis using the Kruskal-Wallis test did not reveal a 
significant difference in median copy number between different grades of tumour 
differentiation (p = 0.085).  
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Figure 4.22 DOK7V3 expression by degree of tumour differentiation 
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4.3.1.5.3 DOK7V3 expression and colorectal cancer nodal status 
 
DOK7V3 expression is increased in node negative colorectal cancer samples compared with 
normal colorectal tissue but this difference was not statistically significant (median copy 
number 11.3, n = 39, IQR = 1-366 vs. 2.4, n = 80, IQR = 0-391 respectively, p =0.1620). 
Median DOK7V3 expression was 12.6 copies (n = 16, IQR = 1-944) in colorectal carcinoma 
tissue obtained from patients with N1 disease and 5.7 copies (n = 15, IQR = 1-55) in 
colorectal carcinoma tissue obtained from patients with N2 disease. There was no significant 
difference in level of DOK7V3 expression between colorectal cancer samples obtained from 
patients with node negative and node positive disease (11.3 vs. 8.4, p = 0.8361). The level of 
DOK7V3 mRNA expression in relation to colorectal cancer nodal status is shown in Figure 
4.23. 
 
  
 315 
 
Figure 4.23 DOK7V3 expression by nodal status of colorectal cancer 
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4.3.1.5.4 DOK7V3 expression and Dukes’ stage  
 
DOK7V3 expression was increased across all Dukes’ stages of colorectal cancer compared to 
normal colorectal tissue (Dukes’ A median copy number 35.8, n = 7, IQR = 1-279, Dukes’ B 
median copy number 6.3, n = 33, IQR = 1-677 and Dukes’ C median copy number 11.7, n = 
32, IQR = 1-610 compared to median copy number 2.4, n = 80, IQR = 0-391 in normal 
colorectal tissue) but these differences were statistically non-significant (p = 0.2579, p = 
0.2691 and p = 0.1955 respectively). DOK7V3 mRNA expression in relation to Dukes’ stage 
is shown in Figure 4.24. 
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Figure 4.24 DOK7V3 expression and Dukes’ stage of colorectal cancer 
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4.3.1.5.5 DOK7V3 expression and T stage of colorectal cancer 
 
DOK7V3 expression was increased, though not significantly, in T1 (median copy number 
712.8, n = 2, IQR not calculated due to sample size, p = 0.1622), T2 (median copy number 
157.4, n = 10, IQR = 1-2397, p = 0.0754), T3 (median copy number 7.4, n = 40, IQR = 1-192, 
p = 0.4796) and T4 (median copy number 4.7, n = 18, IQR = 1-654, p = 0.2810) colorectal 
cancer tissue compared to normal colorectal tissue (median copy number 2.4, n = 80, IQR = 
0-391). There was no significant difference in DOK7V3 expression compared to normal 
colorectal tissue when T2/3, T3/4 and T2/3/4 were grouped. DOK7V3 expression in relation 
to T stage of colorectal cancer is shown in Figure 4.25.  
 
Further analysis of the colorectal cancer samples using the Kruskal-Wallis revealed that there 
was no significant difference in DOK7V3 expression between T stages (p = 0.263). 
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Figure 4.25 DOK7V3 expression and T stage of colorectal cancer 
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4.3.1.5.6 DOK7V3 expression and overall stage of colorectal cancer 
 
Compared to normal colorectal tissue (median copy number 2.4, n = 80, IQR = 0-391), 
DOK7V3 expression was increased, though not significantly, in Stage I disease (median copy 
number 243.5, n = 9, IQR = 14-1816, p = 0.0559), Stage II disease (median copy number 5.0, 
n = 30, IQR = 1-256, p = 0.4768) and Stage III disease (median copy number 4.4, n = 26, IQR 
= 1-122, p = 0.6542). The level of DOK7V3 expression was significantly increased in Stage 
IV disease compared to normal colorectal tissue (median copy number 660.4, n = 6, IQR = 
158-1218, p = 0.0180). Between-group comparisons using the Kruskal-Wallis test revealed 
that there was no significant difference in DOK7V3 expression between different stages of 
disease (p = 0.143). DOK7V3 expression in relation to overall stage of colorectal cancer is 
shown in Figure 4.26.  
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Figure 4.26 DOK7V3 expression and overall stage of colorectal cancer 
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4.3.1.5.7 DOK7V3 expression and anatomical location of colorectal cancer 
 
When analysed by anatomical location, DOK7V3 expression was significantly increased in 
left-sided colonic cancers compared to normal colorectal tissue (median copy number 108.6, 
n = 22, IQR = 2-733 vs. 2.4, n = 80, IQR = 0-391, p = 0.0258). Compared to normal 
colorectal tissue samples, there was no significant difference between the level of DOK7V3 
expression in colorectal cancer samples obtained from right colonic cancers (median copy 
number 12.2, n = 28, IQR = 1-574, p = 0.4061), transverse colonic cancers (median copy 
number 6.8, n = 2, IQR not calculated due to sample size, p = 0.9401) or rectal cancers 
(median copy number 1.6, n = 22, IQR = 0-20, p = 0.7852). The level of DOK7V3 expression 
was significantly higher in left colonic cancer samples compared to those obtained from rectal 
cancers (p = 0.0089) but comparisons of other tumour sites did not reveal statistically 
significant differences. DOK7V3 mRNA expression according to anatomical location is 
shown in Figure 4.27.  
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Figure 4.27 DOK7V3 expression and anatomical location of colorectal cancer 
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4.3.1.5.8 DOK7V3 expression and neoadjuvant/adjuvant treatment status 
 
The level of DOK7V3 mRNA expression was higher in colorectal cancer samples obtained 
from patients who underwent no additional therapy compared to normal colorectal tissue but 
this difference was not statistically significant (median copy number 11.6, n = 42, IQR = 1-
301 vs. 2.4, n = 80, IQR = 0-391, p = 0.1341). By comparison, the level of DOK7V3 
expression was decreased in colorectal cancer samples obtained from patients who underwent 
adjuvant chemotherapy (median copy number 2.3, n = 13, IQR = 0.3-12.5, p = 0.6697) and 
neoadjuvant chemoradiotherapy (median copy number 1.0, n = 5, IQR = 0.317 – 1.647, p = 
0.2913) but was not statistically significant for either comparison. The sole patient who 
underwent radiotherapy had a DOK7V3 median copy number of 0.3 (IQR not calculated due 
to sample size). When treatment groups were compared, the level of DOK7V3 expression 
was significantly higher in colorectal cancer samples obtained from patients who did not 
undergo additional therapy compared to the neoadjuvant chemoradiotherapy group (p = 
0.0324) but did not reach significance when the patients with no additional therapy were 
compared to patients who underwent adjuvant chemotherapy (p = 0.0714). DOK7V3 
expression in relation to neoadjuvant/adjuvant treatment status is shown in Figure 4.28.  
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Figure 4.28 DOK7V3 expression and neoadjuvant treatment status 
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4.3.1.5.9 DOK7V3 expression and tumour invasiveness 
 
The level of DOK7V3 mRNA expression was higher in colorectal cancer samples obtained 
from patients both with invasive (median copy number 13.5 vs. 2.4, p = 0.1686) and non-
invasive (median copy number 6.3 vs. 2.4, p = 0.2935) disease but the difference did not 
reach statistical significance for either group. There was no significant difference in the level 
of DOK7V3 expression in colorectal cancer samples obtained from patients with or without 
invasive disease (p = 0.5954).  
 
4.3.1.5.10 DOK7V3 expression and disease-free status 
 
The level of DOK7V3 mRNA expression was higher in colorectal cancer samples obtained 
from patients who remained disease-free (median copy number 8.4 vs. 2.4, p = 0.1872) and 
those who did not (median copy number 6.3 vs. 2.4, p = 0.7635) but the difference did not 
reach statistical significance for either group. There was no significant difference in level of 
DOK7V3 expression between colorectal cancer samples obtained from patients who remained 
disease-free compared to patients who developed further disease (p = 0.4455).  
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4.3.1.5.11 DOK7V3 expression and survival status 
 
Compared to normal colorectal tissue, the level of DOK7V3 mRNA expression was higher in 
colorectal cancer samples obtained from patients both who survived (median copy number 
6.3 vs. 2.4, p = 0.2632) and died (median copy number 4.7 vs. 2.4, p = 0.7789) from their 
disease but these differences did not reach statistical significance. There was no significant 
difference in DOK7V3 expression between colorectal cancer samples obtained from patients 
who survived compared to those obtained from those who died of their disease (p = 0.6479).  
 
4.3.1.5.12 DOK7V3 expression and metastatic status 
 
The level of DOK7V3 mRNA expression was higher in colorectal cancer samples obtained 
from both patients with distant metastases (median copy number 6.3 vs. 2.4, p = 0.4528) and 
those without (median copy number 8.1 vs. 2.4, p = 0.1532) metastatic disease, compared to 
normal colorectal tissue but these differences did not reach statistical significance. There was 
no significant difference in DOK7V3 expression between colorectal cancer samples obtained 
from patients with distant metastatic disease compared to those obtained from patients 
without distant metastatic disease (p = 0.7018).  
 
4.3.1.5.13 DOK7V3 expression and local recurrence of disease 
 
The level of DOK7V3 expression was higher in colorectal cancer samples obtained from both 
patients with (median copy number 6.3 vs. 2.4, p = 0.9440) and without (median copy number 
6.3 vs. 2.4, p = 0.1920) local recurrence compared to normal colorectal tissue but these 
differences did not reach statistical significance. There was no significant difference in 
DOK7V3 expression between colorectal cancer samples obtained from patients with and 
without local disease recurrence (p = 0.5606).  
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4.3.1.5.14 DOK7V3 expression and overall patient survival 
 
The Kaplan-Meier survival curve for DOK7V3 expression in colorectal cancer (dichotomized 
according to the median value of DOK7V3 expression for the whole cohort) is shown in 
Figure 4.29. Low DOK7V3 expression (n = 48) is associated with reduced overall survival 
when compared with the overall survival of patients with high levels of DOK7V3 expression 
(n = 26) but this difference failed to reach statistical significance (p = 0.228).  
 
  
 329 
 
Figure 4.29 Overall patient survival in patients with high (green) DOK7V3 expression (n = 
26) compared to those with low (blue) DOK7V3 expression (n = 48) 
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4.3.1.5.15 DOK7V3 expression and disease-free patient survival 
 
The Kaplan-Meier disease-free survival curve for DOK7V3 expression in colorectal cancer 
(dichotomized according to the median value of DOK7V3 expression for the whole cohort) is 
shown in Figure 4.30. Low DOK7V3 expression (n = 48) is associated with reduced disease-
free survival when compared with the disease-free survival of patients with high levels of 
DOK7V3 expression (n = 26) but the difference did not reach statistical significance (p = 
0.102).  
 
 
  
 331 
 
Figure 4.30 Disease-free patient survival in patients with high (green) DOK7V3 expression (n 
= 26) compared to those with low (blue) DOK7V3 expression (n = 48) 
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4.3.2 Colorectal cell line data 
 
4.3.2.1 Expression of DOK7V1-3 in colorectal cancer cell lines: PCR data 
 
Data from PCR shows that DOK7V1 is strongly expressed by HRT-18 cells with reduced 
expression in HT-115 cells and very little expression in RKO cells.  
 
DOK7V2 shows a similar pattern of expression to DOK7V1 with high levels of DOK7V2 
expression in HRT-18 cells, lower levels of expression in HT-115 cells and low levels of 
expression in RKO cells.  
 
The expression of DOK7V1-3 in colorectal cancer cell lines is shown in Figure 4.31. 
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Figure 4.31 Expression of DOK7V1-3 in colorectal cancer cell lines – qPCR results 
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4.3.2.2 Expression of DOK7V1-3 in colorectal (RKO, HT115 and HRT18), endothelial 
(HECV) and breast (ZR751, MCF7, MDA-MB-231) cancer cell lines: qPCR data 
 
Focusing on colorectal cancer cell lines, data obtained using qPCR shows a similar pattern of 
expression to DOK7V1 with high levels of DOK7V2 expression in HRT-18 cells, lower 
levels of expression in HT-115 cells and low levels of expression in RKO cells. These results 
suggest that RKO colorectal cancer cell line would be the optimal cell line for creating 
overexpression models of DOK7V1 and DOK7V2. Data is shown in Figure 4.32.  
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A. 
 
B. 
 
C. 
 
Figure 4.32 Expression of DOK7V1-3 in colorectal (RKO, HT115, HRT18), endothelial 
(HECV) and breast (ZR751, MCF&, MDA-MB-231) cancer cell lines – qPCR results. A. 
Expression of DOK7V1 in colorectal, endothelial and breast cancer cell lines. B. Expression 
of DOK7V2 in colorectal, endothelial and breast cancer cell lines. C. Expression of DOK7V3 
in colorectal, endothelial and breast cancer cell lines 
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4.4 Discussion 
 
To our knowledge, this is the first study to characterise the expression of DOK7 variants 1, 2 
and 3 in human cancer and specifically, in a colorectal cancer clinical cohort and cell lines. 
Our data show a number of interesting findings.  
 
Firstly, the expression of DOK7V1 is significantly reduced in colorectal cancer compared to 
normal colorectal tissue. Furthermore, DOK7V1 expression is significantly associated with 
overall stage of disease and is significantly reduced in patients who suffered further disease 
events compared to those who remained disease free. Low DOK7V1 expression was also 
associated with significantly reduced length of disease free survival compared to that of 
patients with high DOK7V1 expression.  
 
We found no association between DOK7V1 expression and degree of colorectal cancer 
differentiation, Dukes’ stage, anatomical location, treatment status or nodal status. DOK7V1 
expression was not a significant predictor of local invasion, the development of distant 
metastases, local recurrence rate or overall survival. DOK7V1 expression decreased with 
increasing T stage but Kruskal Wallis analysis revealed that the difference in DOK7V1 
expression between T stages was not statistically significant.  
 
By comparison, the expression of DOK7V2 is significantly increased in colorectal cancer 
compared to normal colorectal tissue. The level of DOK7V2 expression is significantly 
higher in left-sided colonic cancers compared to right-sided colonic cancer and rectal cancers. 
Low DOK7V2 expression was associated with significantly reduced disease-free survival 
when compared to that of patients with high DOK7V2 expression.  
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No association was found between level of DOK7V2 expression and degree of tumour 
differentiation, nodal status, Dukes’ stage, T stage, overall stage, treatment status, tumour 
invasiveness, disease-free status and overall survival. 
 
DOK7V3 expression was significantly increased in colorectal cancer compared to normal 
colorectal tissue across the whole cohort data, but not for paired samples. DOK7V3 
expression was significantly higher in left-sided colonic cancer samples compared to those 
obtained from rectal cancers. DOK7V3 expression was also significantly higher in patients 
who did not require any neoadjuvant/adjuvant treatment compared to those who underwent 
chemoradiotherapy. 
 
There was no association between DOK7V3 expression and the degree of tumour 
differentiation, nodal status, Dukes’ stage, T stage or overall stage of disease. Dok7V3 was 
not associated with the likelihood of metastatic disease development, local recurrence, tumour 
invasiveness, disease-free survival or overall survival.   
 
The expression of DOK7 variants 1,2 and 3 also differed between different colorectal cancer 
cell liens. DOK7V1 and DOK7V2 are strongly expressed by HRT-18 cells with reduced 
levels seen in RKO and HT-115 cells. DOK7V3 expression is highest in HT-115 cells with 
lower levels of expression seen in RKO and HRT-18 cells. 
 
Cossins et al investigated the mutations seen in DOK7 congenital myasthenic syndrome in 
their 2012 publication. In addition to identifying 34 different mutations, they found 27 
additional variants, which they believed were non-pathogenic. These are illustrated in Figure 
4.33. 
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Figure 4.33 Schematic diagram of DOK7 showing the exons and positions of 27 exonic 
variants identified during routine DNA screening likely to be non-pathogenic. Predicted 
amino acid changes are indicated. Figure taken from Cossins et al ‘The spectrum of mutations 
that underlie the neuromuscular junction synaptopathy in DOK7 congenital myaesthenic 
syndrome’ Hum Mol Genet 2012 Sep 1;21(17):3765-75.   
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In their paper, they comment on three additional pathogenic silent nucleotide variants in the 
N-terminal portion of DOK7 that can alter the splicing of the DOK7 RNA transcript. One of 
these is in exon 1 (c.48C>T, p.G16G) and the other two are located in exon 4 (c.414C>T, 
p.L138L and c.513C>T, p. G171G). The first of these variants produces a shorter transcript 
that misses out exon 1 resulting in an in-frame deletion of 18 amino acid residues 
MTEAALVEGQVKLRDGKK. The second variant produced two different sized transcripts – 
a longer correctly spliced transcript and a shorter transcript with a deletion of 94 nucleotides 
at the 5’ end of exon 4 resulting in a frameshift. The last of the variants resulted in a truncated 
exon 4, which had lost the last 21 nucleotides of the exon. The gel electrophoresis of the 
amplicons generated by Cossins et al using vector-specific primers and the sequencing data 
and aberrant splicing due to the variants are shown in Figure 4.34. 
  
 340 
  
Figure 4.34. Silent nucleotide variants in N-terminal portion of DOK7 resulting in altered 
splicing of the DOK7 RNA transcript. (A) Gel electrophoresis of amplicons generated using 
vector-specific primers. All three silent variants produce different sized transcripts compared 
to wild-type. (B-D) Sequencing data and schematic diagrams showing aberrant splicing 
arising due to the variants. Figure taken from Cossins et al ‘The spectrum of mutations that 
underlie the neuromuscular junction synaptopathy in DOK7 congenital myaesthenic 
syndrome’ Hum Mol Genet 2012 Sep 1;21(17):3765-75.   
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Our data show that not only does the expression of different DOK7 variants differ between 
normal and cancer tissue, but that the expression of DOK7V1 appears to be diametrically 
opposed to the expression of DOK7V2 and, to a lesser extent, DOK7V3. Specifically, we 
have shown that the expression of DOK7V1 is significantly reduced in colorectal cancer 
tissue compared to normal colorectal tissue whilst the expression of DOK7V2 and DOK7V3 
are significantly increased in colorectal cancer compared to normal colorectal tissue. 
 
Attempts to confirm Dok7 expression at the protein level failed. The antibodies available and 
the DOK7 isoforms detected by them are shown in Table 4.3. Despite several attempts to 
confirm Dok7 Isoform 1, 2 and 3 expression at the protein level we were unable to do so. As 
demonstrated in the table, this may in part be due to the fact that the antibodies are not 
specific for different isoforms of Dok7. Owing to the limited time available for the current 
study and the cost and time required to raise isoform specific antibodies in animals, it was 
decided to focus on the mRNA expression of DOK7 and its variants and to assess the effects 
on protein expression and interactions using protein microarray. 
 
Overall, the results discussed in this chapter suggest that the expression of individual DOK7 
variants differs in colorectal cancer compared to normal colorectal tissue and that individual 
DOK7 variants may play different roles in human cancer. Further work is necessary to 
elucidate the effects of DOK7 variant expression on colorectal cancer cell function. 
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Table 4.3 DOK7 antibodies available for use in this study and isoforms detected by them 
 
Antibody Product 
number 
Dok7 Isoform 1 
(53kDa) 
Dok7 Isoform 2 
(37kDa) 
Dok7 Isoform 3 
(27kDa) 
pDok7 
(Tyr 395) 
SC-68691 ✔ ✔ ✖ 
Dok7 
(N-terminal) 
AP-13568a ✔ ✖ ✔ 
Dok7 SC-50463 ✔ ✔ ✖ 
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Chapter 5: Creation of DOK7 variant overexpression and 
knockdown constructs and creation of transgenic cell lines 
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5.1 Introduction 
 
In the first results chapter, we analysed the expression profiles of DOK7 in a cohort of 
patients with colorectal cancer and colorectal cancer cell lines and examined the association 
between DOK7 expression and the clinical and pathological features of colorectal cancer as 
well as patient outcomes. We found that DOK7 mRNA expression is significantly reduced in 
colorectal cancer tissue compared with normal colorectal tissue and that DOK7 mRNA 
expression is inversely associated with T stage. Moreover, we found that DOK7 mRNA 
expression is significantly associated with overall survival in patients with colorectal cancer. 
In colorectal cancer cell lines, we found that the expression of DOK7 is variable and that 
DOK7 is highly expressed in HRT-18 colorectal cancer cells with little or no expression in 
HT-115 and RKO cells.  
 
In the second results chapter, we analysed the expression profiles of DOK7V1, DOK7V2 and 
DOK7V3 in the same clinical cohort and colorectal cell lines and once again, examined the 
association between the expression of these DOK7 variants and clinicopathological features 
of colorectal cancer and patient outcomes. Our data revealed a number of interesting findings. 
Firstly, the expression of DOK7V1 is significantly reduced in colorectal cancer compared to 
normal colorectal tissue and is significantly associated with overall stage of disease and 
disease-free survival. In contrast, DOK7V2 expression is significantly increased in colorectal 
cancer compared to normal colorectal tissue, is higher in left-sided colonic cancers compared 
to right-sided cancers and is significantly associated with disease-free survival. Finally, 
DOK7V3 expression is also increased in colorectal cancer compared to normal colorectal 
tissue and is higher in left-sided colonic cancers compared to rectal cancers. Furthermore, 
DOK7V3 expression is significantly higher in patients who did not require any adjuvant 
treatment compared to those who underwent chemoradiotherapy. 
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Therefore, our results suggest that the expression of individual DOK7 variants differs in 
colorectal cancer compared to normal colorectal tissue and that individual DOK7 variants 
may play different roles in human cancer. In this chapter, we discuss how DOK7 variant 
specific transgenic cell lines were created. 
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5.2 Materials and methods  
 
The manipulation of gene expression was performed using techniques described in Section 
2.2.5. 
 
5.2.1 Materials and methods used for the overexpression of DOK7 variants 
 
5.2.1.1 Colorectal cancer cell lines 
 
RKO colorectal cell line was used in this study. Details of this cell line are shown in Section 
2.1.1. Cells were maintained according to the supplier’s instructions. Wild type cells were 
maintained in the appropriate media for cell culture as described in Section 2.1.6.1 and the 
methods of cell culture used are described in Section 2.2.1. Stable transfected cells were 
maintained in the same media treated with 0.5µg/ml blasticidin as described in Section 
2.2.5.10. 
 
5.2.1.2 Primers 
 
The variant specific primers used in this study are listed in Table 4.1.  
 
5.2.1.3 Generation of synthetic DOK7V1-3 sequences 
 
Synthetic DOK7 variant 1 (DOK7V1), DOK7 variant 2 (DOK7V2) and DOK7 variant 3 
(DOK7V3) genes were assembled by Life Technologies Ltd (Paisley, UK) using synthetic 
oligonucleotides and/or PCR products. The sequence of DOK7V1 construct is shown in 
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Figure 5.1, the sequence of DOK7V2 construct is shown in Figure 5.2 and the sequence of 
DOK7V3 is shown in Figure 5.3.   
 
The DOK7V1 fragment was cloned into pMK (kanR) vector using PacI and AscI cloning 
sites, the DOK7V2 fragment was cloned into pMA-T vector using Sfil and Sfil cloning sites 
and the DOK7V3 fragment was cloned into pMK (kanR) vector. Plasmid DNA was purified 
from transformed bacteria, quantified using UV spectroscopy and the final construct was 
verified by sequencing. Sequence congruence within the used restriction sites was 100% for 
all constructs and sequence identity was confirmed as 100% for all three variants. Life 
Technologies Ltd supplied 5µg of lyophilized plasmid DNA for each variant. These were 
dissolved in 50µl of distilled water on receipt and stored at -20°C until use. The plasmid map 
for DOK7V1 is shown in Figure 5.4, DOKV2 is shown in Figure 5.5 and DOK7V3 is shown 
in Figure 5.6. 
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Figure 5.1. Sequence of DOK7V1 (Provided by Life Technologies) 
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Figure 5.2.  Sequence of DOK7V2 (Provided by Life Technologies) 
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Figure 5.3 Sequence of DOK7V3 (Provided by Life Technologies) 
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Figure 5.4. Plasmid map for DOK7V1 (Provided by Life Technologies) 
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Figure 5.5 Plasmid map for DOK7V2 (Provided by Life Technologies) 
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Figure 5.6 Plasmid map for DOK7V3 (Provided by Life Technologies) 
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5.2.1.4 Extraction and amplification of synthesised sequences 
 
The synthesised plasmids containing DOK7V1, DOK7V2 and DOK7V3 were not suitable for 
immediate use in mammalian cells owing to the nature and number of antibiotic resistance 
sites. Primers that would enable the extraction of the synthesised sequences from the plasmids 
were designed and are shown in Table 5.1.  
 
Table 5.1 Primers used for extraction of synthesised DOK7V1, DOK7V2 and DOK7V3 
sequences from plasmids supplied by Life Technologies. 
 
Primer Primer type Sequence 
DOK7V2exF1 Forward primer atgaccgaggcggcgctggtgga 
DOK7V3exF1 Forward primer atggtgggtgcctcaaggccac 
DOK7V2exR1 Reverse primer tcatcccctccactgcccggcct 
DOK7V2exR1b Reverse primer tcccctccactgcccggcct 
DOK7V3exR1 Reverse primer tcaaggaggggggtttaccttga 
DOK7V3exR1b Reverse primer aggaggggggtttaccttga 
 
Two types of reverse primer were designed: R1 primers which contained a stop codon and no 
His tag, and R1b primers which did not contain a stop codon but instead contained a His tag. 
The purpose of the latter was to facilitate potential future targeting of the sequence using His 
antibodies during protein analysis, Western blot and immunohistochemistry.  
 
The combinations of the primers used to extract each individual variant of DOK7 are shown 
in Table 5.2 along with their expected product sizes. 
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Table 5.2 Primer pairs used for extraction of DOK7V1, DOK7V2 and DOK7V3 with product 
sizes 
 
Target sequence Primer pair used PCR product  Product size 
DOK7V1 DOK7V2exF1 
DOK7V3exR1 
DOK7V1Stop 1515bp 
 DOK7V2exF1 
DOK7V3exR1b 
DOK7V1His 
DOK7V2 DOK7V2exF1 
DOK7V2exR1 
DOK7V2Stop 767bp 
 DOK7V2exF1 
DOK7V2exR1b 
DOK7V2His 
DOK7V3 DOK7V3exF1 
DOK7V3exR1 
DOK7V3Stop 585bp 
 DOK7V3exF1 
DOK7V3exR1b 
DOK7V3His 
 
 
The components used in each PCR reaction undertaken to generate products from the 
synthesised vectors are shown in Table 5.3 and the conditions used are shown in Table 5.4. 
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Table 5.3 Components of PCR reactions used to extract synthesised DOK7V1, DOK7V2 and 
DOK7V3 from synthesised plasmids 
 
Component Volume 
2x High fidelity PCR mix 25µL 
Forward primer 2µL 
Reverse primer 2µL 
Plasmid (0.025ng/ µL 1:100 in PCR H20) 2µL 
PCR H20 19µL 
Total volume per reaction 50µL 
 
 
Table 5.4 Conditions used for PCR reactions for extraction of synthesised DOK7V1-3 
sequences from plasmids 
 
Step Temperature  
(°C) 
Time  
(minutes: seconds) 
Number of cycles 
Initialisation 94 05:00  
Denaturation 94 00:20  
30 cycles Annealing 55 00:20 
Extension/elongation 72 02:00 
Final extension 72 10:00  
Final hold 4 ∞  
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Following the PCR, 10µL of each sample was mixed with 2µL loading dye . A 1% agarose 
gel was prepared and 5µL of a PCR ladder was loaded into the first well with 8µL of each 
sample pipetted into the consecutive remaining wells. The gel was run at 100V, 100mA and 
50W for 45 minutes and then visualised using the Syngene U: Genius 3 fluorescence UV 
transilluminator (Synoptics Ltd, Cambridge, UK) in order to confirm the presence and correct 
size of the PCR products. The remaining 15µL of the PCR product was mixed with 2µL of 
Red Mastermix and the final extension step was run again at 72°C for 10 minutes followed by 
4°C for infinity. The PCR products were then stored at -20°C until further use. 
 
Bands of the correct size were excised from the agarose gel and elution to obtain the products 
was performed using GenElute™ Gel Extraction kit as described below.  
 
5.2.1.5 Extraction of bands from agarose gel and product separation using gel elution kit 
 
The GenElute™ Gel Extraction kit was used to purify the DOK7V1, DOK7V2 and DOK7V3 
linear DNA fragments from the agarose gel. Briefly, the principles of elution are that DNA 
fragments are extracted from the agarose gel and solubilised to dissolve the agarose gel. The 
extracted DNA fragments are then selectively absorbed onto a silica membrane, contaminants 
are removed and finally, the DNA is eluted in a buffer. This isolated DNA can then be used 
for PCR, cloning and other purposes. The manufacturers state that typical DNA recovery is 
50-55% and can be as high as 80%. Each column can process up to 3.5g agarose and can bind 
up to 10µg of DNA.  
 
The DNA fragment of interest (DOK7V1/DOK7V2/DOK7V3) was excised from the agarose 
gel using a sterile, sharp disposable scalpel taking care to trim away any excess agarose gel 
outside of the band of interest. The gel was then weighed prior to adding 3 gel volumes of the 
Gel Solubilisation solution to the gel slice. The gel mixture was incubated at 50-60°C for 10 
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minutes, vortexing briefly every 2-3 minutes, until the gel slice was completely dissolved and 
the mixture was yellow in colour. 
 
Meanwhile, a binding column was prepared by placing the GenElute™ Binding Column G 
into a 2ml collection tube. Five hundred microlitres of Column Preparation solution was 
added to each binding column and the tube was centrifuged for 1 minute. The flow-through 
liquid was then discarded. One gel volume of 100% isopropanol was added to the gel mixture 
and mixed until the contents of the tube were homogenous. The solubilised gel solution (up to 
a maximum of 700µL) was loaded into the binding column and centrifuged for 1 minute. The 
flow through liquid was discarded. If the solubilised gel solution exceeded 700µL volume this 
step was repeated until all the solution had been used. 
 
Seven hundred microlitres of wash solution was then added to the binding column and the 
tube centrifuged for 1 minute. The flow-though liquid was discarded and then the tube 
containing the binding column was centrifuged again for 1 minute to remove any excess 
ethanol.  
 
Finally, the binding column was transferred to a new collection tube and 50µL Elution 
Solution pre-heated to 65°C was added to the centre of the membrane. The tube was 
incubated for 1 minute and then centrifuged for 1 minute. The eluted solution was then 
poured off and stored at -20°C.  
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5.2.1.6 Confirmation of extracted DOK7 variant sequences 
 
The DOK7 variant sequences obtained using the elution kits were verified using PCR. The 
components used for each reaction are shown in Table 5.5 and the conditions used are shown 
in Table 5.6. 
 
Table 5.5 Components used in PCR reaction to confirm extracted DOK7 variant sequences 
 
Component Volume 
2x Green GoTaq Mastermix 6µL 
Forward primer (1:10) 1µL 
Reverse primer (1:10) 1µL 
DNA/Vector/Plasmid (1:100) 1µL 
PCR H2O 3µL 
Total volume 12µL 
 
Table 5.6 Conditions used in PCR reaction to confirm extracted DOK7 variant sequences 
 
Step Temperature 
(°C) 
Time  
(minutes:seconds) 
Number of cycles 
Initialisation 94 05:00  
Denaturation 94 00:20  
25-32 cycles Annealing 55 00:20 
Extension/elongation 72 00:40 
Final extension 72 10:00  
Final hold 4 ∞  
 
The PCR products were then run on a 1-2% agarose gel at 120V, 100mA and 50W for 45 
minutes. The gel was visualised using a UV transilluminator. Following the PCR, the variant 
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specific plasmids were quantified and 10µL of plasmid at a concentration of 100ng/µL was 
prepared and submitted for sequencing.  
 
5.2.1.7 TOPO TA cloning of DOK7V expression constructs into a pEF/His TOPO 
plasmid vector 
 
The PCR products obtained from the previous steps are shown in Table 5.7.   
 
Table 5.7 PCR products used for cloning 
 
Variant Primers used PCR fragment cloned 
DOK7V1 DOK7V2exF1 
DOK7V3exR1 
DOK7V1stop 
 DOK7V2exF1 
DOK7V3exR1b 
DOK7V1His 
DOK7V2 DOK7V2exF1 
DOK7V2exR1 
DOK7V2stop 
 DOK7V2exF1 
DOK7V2exR1b 
DOK7V2His 
DOK7V3 DOK7V3exF1 
DOK7V3exR1 
DOK7V3stop 
 DOK7V3exF1 
DOK7V3exR1b 
DOK7V3His 
Note: stop = stop codon included in sequence, His = stop codon removed, His tag inserted. 
 
The verified DOK7V1/V2/V3 expression constructs were cloned into a pEF6/V5-His-TOPO 
plasmid (Invitrogen, Paisley, UK) as described in Section 2.2.5.4 and then transformed into 
chemically competent E.coli, as described in Section 2.2.5.5.  
 364 
5.2.1.8 Orientation checking 
 
Following overnight incubation, the ampicillin selection agar plates were removed from the 
incubator and colonies were identified.  
 
Orientation checking was performed using conventional PCR using forward primers paired 
with either T7F or BGHR primers. The components for the PCR reaction are shown in Table 
5.8 and the conditions used are shown in Table 5.9. 
 
Table 5.8 Components used in PCR reaction for orientation checking 
 
Component Volume 
2x Green GoTaq Mastermix 6µL 
PCR H2O 4µL 
Forward variant specific primer (1:10) 1µL 
T7F/BGHR primer 1µL 
E.coli colony Touch with sterile pipette tip 
Total volume 12µL 
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Table 5.9 Conditions used in PCR reaction for orientation checking 
 
Step Temperature  
(°C) 
Time 
(minutes:seconds) 
Number of cycles 
Initialisation 94 10:00  
Denaturation 94 00:30  
25-30 cycles Annealing 55 00:30 
Extension/elongation 72 01:30 
Final extension 72 10:00  
Final hold 4 ∞  
 
Products were visualised using agarose gel electrophoresis and UV transillumination as 
described in Section 2.2.2.5 and subsequently purified and amplified as described in Section 
2.2.5.7.  
 
5.2.1.9 Quantification of plasmid DNA 
 
The plasmids were quantified using a spectrophotometer set to a double stranded DNA setting 
using PCR water as a blank. Ideal values were determined as being between 0.2-1µg.  
 
5.2.1.10 Confirmation of plasmid DNA using sequencing 
 
The isolated plasmids were submitted for sequencing along with T7F primer (concentration 
100pmol/µL). The plasmids and their expected product sizes are shown in Table 5.10. 
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Table 5.10 Plasmids submitted for sequencing and their expected product sizes 
 
Plasmid Expected product size Expected product size with T7F 
5.1 (DOK7V2Stop) 768bp 868bp 
4.1 (DOK7V2His) 768bp 868bp 
Note: Plasmid numbers identify original plate number and colony from which plasmid was extracted, purified and amplified. 
 
5.2.1.11 Transfection of colorectal cancer cells and generation of stable transfectants 
 
Colorectal cancer cells were transfected using electroporation as described in Section 2.2.5.9 
and stable transfected cell lines were established as described in Section 2.2.5.10.  
 
5.2.1.12 Isolation of RNA and cDNA synthesis  
 
RNA was isolated from cells using TRI Reagent® (Sigma-Aldrich Inc., Poole. UK), as 
described in Section 2.2.2.1, and quantified using a spectrophotometer as described in Section 
2.2.2.2. Reverse transcription using a High Capacity cDNA Reverse transcription kit was 
used to synthesis cDNA as described in Section 2.2.2.3.  
 
5.2.1.13 Verification of DOK7 variant overexpression in transfected cells using PCR 
 
Verification of successful DOK7 variant overexpression in stable transfected cells was 
performed using PCR. 
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5.3 Results 
 
5.3.1 Extraction of DOK7V2 sequences from synthesised vectors 
 
The DOK7V2 sequences were extracted from the synthesised vectors supplied by Life 
Technologies Ltd as shown in Figure 5.7. It was decided to focus on DOK7V2 sequences 
owing to the non-specific bands seen for DOK7V1 and the weaker bands seen for DOK7V3.  
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Figure 5.7 Synthesised DOK7V1, DOK7V2 and DOK7V3 sequences visualised following gel 
electrophoresis. V1 = DOK7V1 with stop codon, V1His = DOK7V1 without stop codon and 
with His Tag, V2 = DOK7V2 with stop codon, V2His = DOK7V2 without stop codon and 
with His tag, V3 = DOK7V3 with stop codon, V3His = DOK7V3 without stop codon and 
with His tag. 
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5.3.2 Confirmation of extracted DOK7V2 sequences 
 
The extracted DOK7V2 sequences were confirmed using variant specific qPCR primers. 
Representative confirmation PCR results for DOK7V2 are shown in Figure 5.8. 
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Figure 5.8 Confirmation of DOK7V2 vector shown on agarose gel using UV trans 
illumination using DOK7V2 F1ZR1 primers. V2 = vector, Neg = negative control.  
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5.3.3 Confirmation of correct orientation of PCR products 
 
Following transformation of DOK7V2Stop and DOK7V2His plasmids into chemically 
competent E.coli, each colony was checked using PCR, firstly to verify the orientation of the 
inserted transgene as shown in Figure 5.9 and secondly to verify the presence and correct size 
of the products. 
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Figure 5.9 Confirmation of correct orientation of PCR products. Following transformation of 
DOK7V2Stop and DOK7V2His plasmids into chemically competent E.coli, each colony was 
checked using PCR, firstly to verify the orientation of the inserted transgene and secondly to 
verify the presence and correct size of the products. 
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5.3.4 Successfully obtained plasmids following extraction, cloning and orientation 
checking 
 
A summary of the correctly oriented successfully inserted PCR products following extraction, 
amplification, cloning and colony orientation checking are shown in Table 5.11. 
 
Table 5.11. Successfully obtained plasmids following extraction, cloning and orientation 
checking 
 
Plate/colony number 
(Date grown) 
DOK7 variant Originating primer pair PCR product 
5/1 
(04/09/2014) 
V2 DOK7V2exF1 
DOK7V2exR1 
DOK7V2Stop 
4/1 
(12/06/2014) 
V2 DOK7V2exF1 
DOK7V2exR1b 
DOK7V2His 
 
5.3.5 Confirmation of plasmid DNA using sequencing 
 
Results from formal sequencing analysis were entered into Nucleotide BLAST 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch), which confirmed they 
matched the known sequences for DOK7 Variant 2 with ≥99% identity of sequence 
alignment.    
 
 
  
 374 
5.3.6 Verification of DOK7V2 overexpression in RKO cells 
 
Successful overexpression of DOK7V2 in RKO cells at the mRNA level was confirmed using 
PCR as shown in Figure 5.10. 
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Figure 5.10 Verification of DOK7V2 overexpression in RKO cells. Compared to RKO WT 
and RKO pEF cells, the expression of DOK7V2 is increased in DOK7V2Stop expression 
(V2S) and, to a lesser extent, in the DOK7V2His expression (V2H) cells.  
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5.4 Discussion 
 
In order to create DOK7 variant specific transgenic cell lines we used ribozyme transgenes 
and overexpression constructs. The latter were created using synthesised DOK7V1-3 obtained 
from Life Technologies Ltd. Owing to the nature and number of antibiotic resistance sites, the 
plasmids supplied by Life Technologies Ltd were not suitable for immediate use in 
mammalian cells. This made using the synthesised sequences somewhat more complicated 
since the sequences had to be extracted from the plasmids and amplified prior to cloning into 
the more suitable pEF/His TOPO plasmid vector. 
 
Firstly, primers that would enable the extraction of the synthesised sequences were designed. 
In addition, two reverse primers were designed; one that contained a stop codon and a second 
for each variant sequence that contained no stop codon but instead contained a His tag. The 
purpose of the His tag was to enable potential future targeting of the sequence using His 
antibodies during protein analysis, Western blot and immunohistochemistry. The products 
produced using PCR were then separated using gel electrophoresis and bands of the correct 
sizes were excised from the agarose gel. In order to extract the DNA fragments from the 
agarose gel a GenElute™ Gel extraction kit was used. The products thereby obtained were 
then verified by PCR prior to their cloning into a pEF/His TOPO plasmid vector. Following 
orientation checking, the resulting plasmids were quantified and verified using formal 
sequencing analysis. These plasmids were then used to transfect colorectal cancer cells and 
successful overexpression at the mRNA level in the resulting stable transfectants was 
confirmed using PCR.  
 
One of the limitations of the work discussed in this chapter is that unfortunately, despite good 
GAPDH bands being seen on protein analysis, no bands were seen using DOK7 antibodies 
and therefore, manipulation of DOK7 variant expression at the protein level could not be 
directly verified using Western blot. 
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The transgenic cell lines produced as a result of the work discussed in this chapter will enable 
the role of DOK7 variants and their interacting protein partners and interaction with cell 
signalling pathways to be analysed in the subsequent chapters. Since the DOK7V2 
overexpression constructs produced more convincing results than the other constructs created, 
it was decided to focus the work of the remaining chapters on DOK7V2 overexpression.  
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Chapter 6: Effect of DOK7V2 overexpression on colorectal 
cancer cell function 
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6.1 Introduction 
 
Most, if not all, cancer cells share a number of characteristic acquired capabilities, listed by 
Hanahan and Weinberg as  (i) self-sufficiency in growth signals, (ii) insensitivity to anti-
growth signals, (iii) evasion of apoptosis, (iv) limitless replicative potential, (v) sustained 
angiogenesis and (vi) tissue invasion and metastasis (76). Alterations in oncogenes and 
tumour suppressor genes may enable cells to acquire these characteristic capabilities resulting 
in modulation of key cell signalling pathways and ultimately, changes in cell behaviour. Such 
changes may manifest as alterations in cancer cell proliferation, tumour growth, cell adhesion, 
invasion, migration and rate of apoptosis.  
 
The DOK7 gene is highly variable in the human population with multiple sequence variants 
encoding different protein isoforms (268). Our data suggest that the expression of these 
variants may differ between colorectal cancer tissue and normal colorectal tissue. Moreover, 
DOK7V1 expression is significantly lower in colorectal cancer tissue compared to normal 
colorectal tissue whilst DOK7V2 expression is significantly higher, suggesting that the 
different variants may play opposing roles. 
 
The role of different DOK7 mRNA splice variants and the expression of their corresponding 
protein isoforms have not previously been investigated in relation to cancer. However, the 
role of DOK7 gene mutations in congenital myasthenic syndrome has recently been explored 
by Beeson and his team in Oxford (268, 269). They report that around 18% of genetically 
diagnosed CMS cases in the UK have mutations in DOK7 and from 72 patients studied, 34 
different pathogenic mutations and 27 rare, but non-pathogenic, mutations were identified by 
examining the number and complexity of AChR clusters in C2C12 mouse myotubes (268, 
269). In over 50% of DOK7 CMS patients, the exon 7 frameshift mutation 
1124_1127dupTGCC is found in at least one allele resulting in aberrant AChR clustering 
(268, 269). In several patients there is truncation of, or mutation in, the large 3’exon of DOK7 
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resulting in the loss of C-terminal region function, though MuSK binding is retained (268). 
However, mutations may also occur towards the N-terminal region of the protein where the 
PH and PTB domains are found (268).  
 
Previous studies have identified a key role for Dok-7 in the development of the 
neuromuscular junction. Yamanashi et al found that Dok-7 overexpression in skeletal muscle 
resulted in an increase in the total area of AChR clustering in the central region of the muscle 
as well as an increased number of AChR clusters suggesting increased NMJ formation (270). 
Despite this work investigating the role of Dok-7 in skeletal muscle, there is nothing in the 
currently published literature regarding the effect of Dok-7 on cancer cell proliferation, 
tumour growth, cell adhesion, cell invasion, cell motility/migration or apoptosis.  
 
The functional role of the other Dok proteins is somewhat better understood. Several previous 
authors have shown that Dok-1-4 are negative regulators of cell proliferation (94, 95, 97, 99, 
103, 112, 116, 199-202, 216). Negative regulation of cell growth by the Dok proteins may 
occur due to inhibition of epidermal growth factor (EGF) induced ERK activation or via the 
inhibition of c-Src induced cell transformation (112, 124, 147). Accordingly, loss of Dok-1-3 
has been shown to result in increased cell proliferation (90, 97, 142, 202, 244, 261).  
  
Contrary to these findings, however, other authors have found that Dok-1 plays a positive 
regulatory role with regard to cell proliferation (77, 251, 262). For example, Inoue et al 
demonstrated in mice that lack of Dok-1 was associated with decreased proliferation of 
splenic CD4+ T cell and splenic B cells in response to IL-4 (251). Furthermore, IL-4 induced 
surface expression of CD23 was significantly reduced in B cells prepared from Dok-1-
deficient mice (251). Moreover, forced expression of Dok-1 in a myeloid cell line led to 
increased IL-4 induced proliferation (251). The authors suggest that the increased 
proliferative response to IL-4 associated with Dok-1 may be due to sustained phosphorylation 
of Stat6 and IL-4Rα (251). Dok-4, Dok-5 and Dok-6 have all been shown to play a role in 
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neurite outgrowth in mouse cortical neurons (104, 105, 128, 220). Consequently, knockdown 
of Dok-6 is associated with an approximate 25% reduction in neurite outgrowth in mouse 
primary cortical neurons (128)   
     
The Dok proteins have also been implicated in cell adhesion. Noguchi et al found that 
tyrosine phosphorylation of Dok-1 is induced by cell adhesion to extracellular matrix proteins 
and that this is dependent on Src family kinases and the Dok-1 PH domain (198). Work by 
Abramson et al established that Dok-1 and Dok-2 are associated with CrkL, Cas and Nck, 
three proteins that are implicated in the regulation of actin-cytoskeletal reorganization, which 
is known to play a role in cell adhesion and migration (154). Dok-2 has also been found in 
PMP, which are associated with increased expression of adhesion molecules, angiogenesis 
and metastasis in cancer (212-214). Deficiency of Dok-2 has been associated with increased 
platelet-fibrinogen and platelet-platelet adhesion in discoid platelets and was associated with 
increased thrombus accumulation in vivo (160).  
  
Other studies have suggested a potential role for the Dok proteins in cancer cell invasion and 
migration. Mashima et al found that loss of Dok-1, Dok-2 and Dok-3 in mice was associated 
with increased tumour invasiveness and multiple organ spread (261). Meanwhile, Dok-1 has 
been shown to play a positive regulatory role with regard to cell spreading and migration and 
has been shown to play an important role in SCF-1alpha/CXCL12 induced chemotaxis in T 
cells (77, 198, 231, 262). Sattler et al suggested that Dok-1 might mediate its effect on cell 
migration via the interaction of its PTB domain with multiple tyrosine residues on SHIP1 
(207). Master et al found that overexpression of Dok-2 was associated with increased Ang1-
mediated migration in endothelial cells via its association with Tek, Nck and Pak/Pak1 and 
the subsequent activation of Pak kinase (210).  
 
Finally, the evidence regarding the Dok proteins and apoptosis is somewhat conflicting. Di 
Cristofano et al found no association between Dok-1 activation and growth factor 
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deprivation-induced apoptosis (97). However, Yamakawa et al found that overexpression of 
Dok-1 in B cells resulted in increased activin A-induced apoptotic responses and postulated 
that this occurs due to Dok-1 acting as an adaptor protein linking activin receptors with 
Smads (218). Moreover, Van Slyke et al found that Dok-2 potentiates anoikis, which is 
apoptosis induced by cell detachment (103). Consistent with this, Yasuda et al and Niki et al 
both found that mice lacking Dok-1 and Dok-2 displayed reduced apoptosis (143, 271). Pan et 
al concluded that Dok-5 is required for the blockade of TrkC-induced apoptosis by NT-3 
signalling and that it mediates this action via the regulation of caspase-3 activity (223). 
 
The aim of this chapter was to determine whether DOK7 variant overexpression resulted in 
altered colorectal cancer cell behaviour focusing on DOK7V2. Plasmids constructed from 
synthesised DOK7V2 sequences were used to create colorectal cancer cells that 
overexpressed DOK7V2 respectively. The effect of DOK7V2 expression on colorectal cancer 
cell behaviour was then investigated using functional assays to assess cell proliferation, 
adhesion, invasion and migration. 
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6.2 Materials and methods 
 
6.2.1 Cell lines 
 
RKO wild type (RKOWT), empty plasmid control (RKO pEF) and V2 overexpression cell 
lines (RKOV2Stop/5.1 and RKOV2His/4.1) were used in this study. The creation of these 
transgenic cell lines is described in Chapter 5 and the cell line used was the same cell line 
verified in Section 5.3.6.  
 
6.2.2 Functional assays 
 
6.2.2.1 In vitro growth assay  
 
The methodology used for the in vitro growth assay has previously been described in Section 
2.2.6.1.  
 
6.2.2.2 In vitro cell Matrigel® matrix adhesion assay 
 
The methodology used for the in vitro Matrigel® adhesion assay has previously been 
described in Section 2.2.6.2.  
 
6.2.2.3 In vitro cell Matrigel® matrix invasion assay 
 
The methodology used for the in vitro Matrigel® invasion assay has previously been 
described in Section 2.2.6.3.  
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6.2.2.4 In vitro cell motility assay 
 
The methodology used for the in vitro cell motility assay has previously been described in 
Section 2.2.6.4.  
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6.3 Results 
 
6.3.1 Effect of DOK7V2 overexpression on growth of RKO cells 
 
The effect of DOK7V2 overexpression on the growth of RKO cells was analysed using an in 
vitro growth assay comparing the growth of RKO
DOK7V2stopexp 
cells with the growth of RKO
pEF
 
control cells. Overexpression of DOK7V2 was associated with a decrease in the growth rate 
of RKO cells, but this difference failed to reach statistical significance. Data is shown in 
Figure 6.1. 
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Figure 6.1. Effect of DOK7V2 overexpression on colorectal cancer cell growth. Growth rate 
was decreased in the RKO DOK7V2stopexp cells compared to RKO pEF control cells. 
Growth rate was measured by recording absorbance measured after fixing and staining cells 
with crystal violet after 1-4 days of incubation and is shown as a percentage of Day 1 growth. 
Data shown is representative of at least three independent repeats and was normalised by 
using the day 1 growth plate as a baseline. Lines correspond to growth rate (%) and error bars 
represent the standard error of the mean (SEM).  
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6.3.2 Effect of DOK7V2 overexpression on in vitro cell-matrix adhesion 
 
The effect of DOK7V2 overexpression on the adhesive capacity of RKO cells was analysed 
using an in vitro Matrigel® matrix adhesion assay comparing the adhesion of RKO
DOK7V2exp
 
cells and RKO
DOK7V2stopexp
 cells with the adhesion of RKO
pEF
 control cells. Overexpression of 
DOK7V2 was associated with a decrease in the adhesive capacity of RKO cells but this 
difference failed to reach statistical significance (average absorbance 1.95 vs. 1.88, p = 
0.745). Data is shown in Figure 6.2.  
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Figure 6.2 Effect of DOK7V2 overexpression on colorectal cancer cell adhesion. Cell 
adhesion to the Matrigel® matrix was decreased in the RKO
DOK7V2stopexp
 cells compared to 
RKO
pEF 
control cells after 45 minutes incubation. Graph illustrates absorbance measured after 
fixing and staining cells after 45 minutes incubation. There was a decrease in the 
adhesiveness of RKO DOK7V2stopexp cells (mean ± SEM = 1.88 ± 0.23) compared to RKO 
pEF control cells (1.96 ± 0.02), but this difference was not statistically significant (p = 0.745). 
Data shown is representative of at least three independent repeats and was normalized by 
using the corresponding day 1 growth plate as a baseline. Bar corresponds with mean 
absorbance and error bars represent SEM. 
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6.3.3 Effect of DOK7V2 overexpression on invasion by RKO cells 
 
The effect of DOK7V2 overexpression on the invasive capacity of RKO cells was analysed 
using an in vitro Matrigel® matrix invasion assay comparing the invasion through a 
Matrigel® layer of RKO
DOK7V2stopexp
 cell compared with RKO
pEF
 control cells. Overexpression 
of DOK7V2 was associated with an increase in the invasiveness of RKO cells but this 
difference failed to reach statistical significance (mean absorbance 0.48 vs. 0.49, p = 0.938). 
Data is shown in Figure 6.3. 
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Figure 6.3 Effect of DOK7V2 overexpression on colorectal cancer cell invasion. Cell 
invasion through the Matrigel® matrix was slightly increased in the RKO DOK7V2expstop 
cells compared to RKO pEF control cells after 3 days incubation. Graph illustrates the 
absorbance measured from fixed and stained cells on the well side of the well insert and the 
bottom of the well combined. There was a slight increase in the invasiveness of RKO 
DOK7V2expstop cells (mean ± SEM = 0.49 ± 0.09) compared to RKO pEF control cells 
(0.48 ± 0.03) but this difference was not statistically significant (p = 0.938). Data shown is 
representative of at least three independent repeats and was normalized by seeding density in 
a control well without insert. Bar corresponds with mean number of adhered cells and error 
bars represent standard error of the mean.  
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6.3.4 Effect of DOK7V2 overexpression on cell motility analysed by scratch assay 
 
Attempts to determine the effect of DOK7V2 overexpression on RKO cell motility using a 
scratch assay failed due to the fact that the monolayer of all RKO experimental cell lines 
became detached from the well base when the media was changed or when the scratch was 
made with the pipette tip. 
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6.4 Discussion 
 
The current study utilized verified overexpression DOK7V2 constructs to investigate the 
effect of DOK7V2 on colorectal cancer cell function. 
 
Our data demonstrate no significant effect of DOK7V2 overexpression on colorectal cancer 
cell growth. Although there was a trend towards reduced colorectal cancer cell adhesion and 
towards increased colorectal cancer cell invasion with DOK7V2 overexpression, the 
differences did not reach statistical significance. Despite several attempts to analyse the effect 
of DOK7V2 overexpression on colorectal cancer cell migration using a scratch assay, 
technical difficulties resulted in failure of the experiments.   
 
Overall, despite the differences observed in DOK7V2 expression between colorectal cancer 
cells and normal colorectal tissue, we did not find any significant differences in colorectal 
cancer cell function with modulation of DOK7V2 expression at the mRNA level. One 
explanation for these findings is the limited capability of a simplified functional assay and 
culture media to replicate the complexity of the tumour in vivo. 
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Chapter 7: Identification of potential interacting proteins 
and signalling pathways associated with DOK7V2 
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7.1 Introduction 
 
The results discussed in the previous chapters suggest that DOK7V2 may be implicated in the 
development of colorectal cancer and may be associated with the survival of patients with 
colorectal cancer.  
 
Dok-7 is a cytoplasmic adapter protein involved in the formation of the neuromuscular 
junction and it is required for MuSK localization and activation as well as AChR clustering. 
Adaptor proteins typically contain protein binding sites that mediate protein-protein 
interactions resulting in the formation of signalling complexes and although previous studies 
have shed light on how Dok-7 functions in relation to NMJ formation, there is little 
information available regarding its role in cancer cell signalling.  
 
STRING analysis identifies a number of predicted functional partners of Dok-7 but it is 
interesting to note that, of these, experimental evidence exists only for its predicted 
interaction with MuSK, with other predicted interactions based on textmining data. The top 
10 predicted functional partners of Dok-7, as identified by STRING are shown in Table 7.1 
and the top 50 predicted functional partners of Dok-7 are illustrated in Figure 7.1. 
Table 7.1 Top 10 predicted functional partners of Dok-7 according to STRING 
 
Name  Length (aa) Evidence Confidence score 
Muscle, skeletal, receptor tyrosine kinase MUSK 869 Experimental 
Textmining 
Highest 
Receptor-associated protein of the synapse RAPSN 412 Textmining High 
Agrin  AGRN 2045 Textmining High 
FAD1 flavin adenine dinucleotide synthetase homolog FLAD1 587 Textmining High 
Dolichyl-phosphate (UDP-N-acetylglucosamine) N-
acetylglucosaminephosphotransferase 1 
DPAGT1 408 Textmining High 
Feline leukaemia virus subgroup C cellular receptor family, member 2 FLVCR2 526 Textmining High 
Neurotrophic tyrosine kinase, receptor, type 3  NTRK3 839 Textmining Medium 
Neurotrophic tyrosine kinase, receptor, type 2 NTRK2 838 Textmining Medium 
Ribosomal RNA processing 7 homolog A  RRP7A 280 Textmining Medium 
Acetylcholinesterase  ACHE 617 Textmining Medium 
 
Figure 7.1 Top 50 predicted functional partners of Dok-7 according to STRING analys
illustrating links between proteins 
 
 
  
 397 
Dok-7 forms a dimer and interacts with the cytoplasmic portion of MuSK, resulting in its 
phosphorylation and activation. The interaction of Dok-7 with MuSK is mediated via the PTB 
domain, although the PH domain is also required for MuSK activation. The C-terminal of 
Dok-7 contains a nuclear export signal necessary for the cytoplasmic localisation of Dok-7, 
SH2 target motifs required for MuSK activation and tyrosine residues, which are 
phosphorylated by agrin, resulting in the recruitment of the adapter proteins Crk and Crk-L. 
Meanwhile, the PH domain in the N-terminal of Dok-7 enables the nuclear import of Dok-7. 
 
There is currently no published literature on the protein interactions of Dok-7, or indeed its 
isoforms, in relation to human cancer. Our hypothesis for the experimental work discussed in 
this chapter is that DOK7V2 interacts with other cell signalling proteins implicated in the 
development and progression of colorectal cancer. Therefore, the aim of the experimental 
studies described in this chapter was to investigate protein expression in RKOpEF and 
RKODOK7V2 overexpression cells to determine whether DOK7V2 expression is associated 
with changes in downstream protein expression and to establish potential interacting proteins 
and signalling pathways associated with DOK7V2. In order to address these questions, we 
used an established antibody based protein microarray to firstly, identify changes in protein 
expression associated with DOK7V2 expression and secondly, identify changes in 
phosphorylation of proteins involved in key cell signalling pathways.  
 
One of the potential benefits of identifying signalling pathways involved in Dok signalling is 
the possibility of identifying targets for therapy. Although there have been no reports of 
therapeutic interventions in relation to Dok-7 in cancer, it is notable that in CMS associated 
with DOK7 mutation, treatment with ephedrine or salbutamol is effective (268). Currently, 
the mechanism of action of these drugs is not fully understood but it has been suggested that 
the β2-agonsts compensate for the destabilized postsynaptic apparatus via second messenger 
pathways (268). 
  
 398 
7.2 Materials and methods 
 
7.2.1 Cell lines 
 
The following cell lines were used in the experiments discussed in this chapter: RKO pEF, 
containing an empty plasmid control, and RKO DOK7V2Stop/5.1 cell line, containing 
DOK7V2 full coding sequence. These cell lines were established as previously detailed in 
Chapter 5.   
 
7.2.2 Preparation of lysis buffer for protein microarray 
 
The preparation of the lysis buffer has previously been described in Section 2.2.4.2. 
 
7.2.3 Preparation and quantification of protein samples for protein microarray 
 
Protein samples were prepared for protein microarray and quantified as described in Section 
2.2.4.2.2. 
 
7.2.4 Protein microarray technique 
 
The principles of the Kinex™ KAM-880 antibody microarray used in this study are discussed 
in Section 2.2.4.1.  
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7.2.5 Statistical analysis of protein microarray data 
 
The results of the protein microarray were provided in an Excel spreadsheet containing the 
following data: 
 
Target protein name/full target protein name 
Phospho Site 
Flag (Control/Treated) 
Globally normalized median (Control/Treated) 
% error range (Control/Treated) 
Log2 (Intensity Corrected) (Control/Treated) 
% CFC (Treated from Control) 
 
Z score (Control/Treated): Measures the relationship of the signal intensity to the mean, 
indicates its positive or negative relationship to the mean and its variation from the mean in 
terms of standard deviation. 
 
Z-score difference (Treated-Control): Calculated as the difference between Z scores for the 
control vs. treated group. 
 
Z-ratio (Treated, Control): Potential candidate proteins affected by Dok7V2 expression were 
identified by the following criteria: z ratio ≥ 1.96 or ≤-1.96.  
 
Antibodies with good read were defined as those with flag = 0 in both of the physical 
replicates and these were included in analysis. Antibodies with poor reads (flag = 1 for either 
or both of the physical replicates) were excluded from further analysis. 
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7.3 Results 
 
7.3.1 Analysis of protein microarray data 
 
The microarray chip is shown in Figure 7.2 
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Figure 7.2 Image of microarray chip. Sample ID C15 = RKO pEF control cell protein lysate, 
Sample ID C16 = RKO DOK7V2stopexp cell protein lysate. 
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Of the 877 antibodies tested, 874 had good reads (Flag = 0). The three antibodies with poor 
reads (flag = 1) shown in Table 7.2 below were excluded from further analysis.  
 
Table 7.2 Antibodies with poor read (flag = 1) excluded from analysis 
 
Antibody code Target protein  Full target protein name Phospho Site 
NN042 FAS Tumour necrosis factor superfamily 
member 6 (Apo1, CD95) 
Pan-specific 
NK117-3 Nek2 NIMA (never-in-mitosis)-related protein-
serine kinase 2 
Pan-specific 
PN070 Rb Retinoblastoma-associated protein 1 T821 
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7.3.2 Expression/activation of predicted functional partners in RKO
pEF
 and 
RKO
DOK7V2exp
 cells 
 
The STRING output data for predicted functional partners of Dok-7 was compared with the 
list of antibodies analysed by protein microarray. The top 50 predicted functional partners 
identified using STRING analysis are shown in Figure 7.1. Of these, the evidence for the 
predicted association was obtained from experimental evidence for 1 of the predicted partners 
and by textmining for 50 of the predicted functional partners. 
 
Of the 50 predicted functional partners identified using STRING analysis, 14 were included 
in the microarray analysis. The relative expression/activation of these proteins in RKO 
DOK7V2pEF and RKO DOK7V2 overexpression cells is shown in Table 7.3. 
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Table 7.3 Expression/phosphorylation of STRING predicted functional partners in control vs. 
DOK7V2 overexpressing RKO cells as determined by protein microarray analysis.  
 
Target 
protein 
Panspecific/ 
Phosphosite 
RKO 
pEF 
median 
RKODOK7V2 
median 
%CFC Z-ratio 
AAK1 S637 4612 3667 -21 -0.70 
Abl Pan 895 687 -23 -0.91 
Abl Pan 6300 5438 -14 -0.39 
Abl Y393 438 347 -21 -0.84 
CDK5 Pan 6907 8557 24 0.93 
CDK5 Pan 6946 6180 -11 -0.27 
CDK5 Pan 4395 4215 -4 -0.02 
DOK2 Y142 6362 3567 -44 -1.96  
DOK2 Y142 5263 3301 -37 -1.56 
EGFR Pan 7861 6891 -12 -0.32 
EGFR Pan 11848 9236 -22 -0.73 
EGFR Pan 17331 20287 17 0.77 
EGFR Pan 8839 8865 0 0.17 
EGFR T693 684 784 14 0.53 
EGFR Y1068 224 280 25 0.80 
EGFR Y1110 1679 2018 20 0.75 
EGFR Y1148 1063 945 -11 -0.37 
EGFR Y1148 716 1016 42 1.31 
EGFR Y1197 133 206 55 1.55 
EGFR Y998 4420 3197 -28 -1.05 
ErbB2 Pan 2860 3082 8 0.38 
ErbB2 Pan 12100 11309 -7 -0.07 
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ErbB2 Pan 4028 6209 54 1.70 
ErbB2 T686 7892 7127 -10 -0.21 
ErbB2 Y1248 7194 4545 -37 -1.52 
JAK2 Pan 739 726 -2 -0.02 
JAK2 Pan 9212 7945 -14 -0.37 
JAK2 Pan 6853 6471 -6 -0.06 
JAK2 Pan 7665 8432 10 0.50 
JAK2 Y1007 & 
Y1008 
106 80 -24 -1.08 
JAK2 Y1007/ 
Y1008 
1105 1085 -2 -0.01 
SG2NA Pan 4857 3900 -20 -0.67 
Shc1 Y239/Y240 4619 3507 -24 -0.87 
Shc1 Y349 143 172 20 0.63 
Src Pan 6008 4839 -20 -0.64 
Src Pan 3312 3529 6 0.35 
Src Pan 1053 1204 14 0.55 
Src Y418 283 410 45 1.34 
Src Y529 410 562 37 1.16 
Striatin Pan 13257 18531 40 1.41 
TEC Y519 10404 8890 -15 -0.40 
TrkA Pan 1805 1315 -27 -1.07 
TrkB Pan 3573 5067 42 1.39 
TrkB Y705 160 369 131 3.02 
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7.3.3 Effect of DOK7V2 manipulation on protein expression 
 
7.3.3.1 Proteins overexpressed in RKO
DOK7V2exp
 cells compared to RKO
pEF
 cells 
 
Proteins overexpressed in RKO
DOK7V2exp
 cells compared to RKO
pEF
 cells were found by 
identifying pan-specific antibodies with increased normalized median values in RKO
DOK7V2exp
 
cells compared to RKO
pEF
 cells (z-ratios exceeding 1.96). There were a total of 20 proteins 
that were overexpressed in RKO
DOK7V2exp
 cells compared to RKO
pEF
 cells and these are 
shown, in order of decreasing Z-ratio, in Table 7.4.  
 
  
 407 
Table 7.4 Overexpressed proteins in RKO
DOK7V2exp
 cells compared to RKO
pEF
 cells identified 
by protein antibody-based microarray, organised in order of decreasing Z-ratio. 
 
Target 
protein 
Phospho site RKO
pEF
 
normalized 
median 
RKO
DOK7V2exp
 
normalised 
median 
%CFC Z-ratio 
VGFR2 Pan 4477 12035 168 3.73 
JAK3 Pan 5649 13305 135 3.26 
PRKDC Pan 6476 14894 130 3.18 
MEK5 Pan 3972 8490 113 2.89 
mTOR Pan 7981 16629 108 2.83 
Catenin b Pan 2003 4172 108 2.76 
WNK2 Pan 5831 11889 104 2.74 
DUSP4 Pan 9349 18193 94 2.59 
Cdc25C Pan 9139 17120 87 2.45 
ERK1 Pan 10495 19478 85 2.43 
MKK4 Pan 10073 18180 80 2.32 
Grp94 Pan 4583 8310 81 2.30 
PDGFRB Pan 4003 7208 80 2.27 
PDK4 Pan 8092 14416 78 2.26 
4E-BP1 Pan 151 282 87 2.24 
Ros Pan 7024 12404 76 2.22 
MKK6 Pan 6945 12037 73 2.16 
ErbB4 Pan 10178 17237 69 2.09 
DUSP3 Pan 12805 21521 68 2.07 
PTEN Pan 83 146 76 1.99 
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7.3.3.2 Proteins underexpressed in RKO
DOK7V2exp
 cells compared to RKO
pEF
 cells 
 
Proteins underexpressed in RKO
DOK7V2exp
 cells compared to RKO
pEF
 cells were found by 
identifying pan-specific antibodies with decreased normalized median values in RKO
DOK7V2exp
 
cells compared to RKO
pEF
 cells (z-ratios below -1.96). There were a total of 12 proteins that 
were underexpressed in RKO
DOK7V2exp
 cells compared to RKO
pEF
 cells and these are shown, in 
order of increasing Z-ratio, in Table 7.5 below.  
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Table 7.5 Underexpressed proteins in RKO
DOK7V2exp
 cells compared to RKO
pEF
 cells identified 
by protein antibody-based microarray, organised in order of increasing Z-ratio. 
 
Target 
protein 
Phospho site RKO pEF 
normalized 
median 
RKODOK7V2 
normalised 
median 
%CFC Z-
ratio 
PTP1D/SHP2 Pan 299 102 -66 -3.92 
PDK3 Pan 334 145 -57 -3.04 
GNB2L1 Pan 3015 1502 -50 -2.43 
Haspin Pan 1659 839 -50 -2.40 
STI1 Pan 252 131 -48 -2.38 
Smad2/3 Pan 335 176 -48 -2.34 
PCTK1 Pan 1966 1013 -49 -2.33 
ROCK-
I/ROKb 
Pan 304 165 -46 -2.23 
MEK1 Pan 305 167 -45 -2.20 
PTP-PEST Pan 73 42 -42 -2.06 
DRAK2 Pan 4425 2456 -45 -2.02 
BMX (Etk) Pan 537 311 -42 -1.97 
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7.3.4 Effect of DOK7V2 manipulation on protein phosphorylation 
 
7.3.4.1 Proteins activated in RKO
DOK7V2exp
 cells compared to RKO
pEF
 cells 
 
Proteins activated in RKO
DOK7V2exp
 cells compared to RKO
pEF
 cells were found by identifying 
phosphosite-specific antibodies with increased normalized median values in RKO
DOK7V2exp
 
cells compared to RKO
pEF
 cells (z-ratio exceeding 1.96, p = 0.05). There were a total of 12 
proteins that were activated in RKO
DOK7V2exp
 cells compared to RKO
pEF
 cells detected by 13 
phosphosite-specific antibodies. There are shown in order of decreasing Z-ratio in Table 7.6.   
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Table 7.6 Activated proteins in RKO
DOK7V2exp
 cells compared to RKO
pEF
 cells identified by 
protein antibody-based microarray, organised in order of decreasing Z-ratio. 
 
Target 
protein 
Phospho site RKO pEF 
normalized 
median 
RKODOK7V2 
normalised 
median 
%CFC Z-ratio 
TrkB Y705 160 369 131 3.02 
CREB1 S133 5376 11217 108 2.82 
Cyclin B1 S147 535 1139 113 2.78 
BRCA1 S1497 960 2007 109 2.74 
CDK1/2 Y15 191 388 103 2.55 
IKKa T23 287 572 99 2.50 
4E-BP1 T45 158 316 99 2.47 
ATF2 S94/S112 257 502 95 2.42 
PLCg1 Y783 80 152 90 2.27 
PLCg1 Y771 354 636 79 2.13 
Connexin 
43 
S367 797 1409 76 2.12 
ERK5 T218+Y220 630 1091 73 2.03 
Cofilin 2 S3 3236 5402 67 1.98 
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7.3.4.2 Proteins functionally suppressed in RKO
DOK7V2exp
 cells compared to RKO
pEF
 cells 
 
Proteins functionally suppressed in RKO
DOK7V2exp
 cells compared to RKO
pEF
 cells were found 
by identifying phosphosite-specific antibodies with decreased normalized median values in 
RKO
DOK7V2exp
 cells compared to RKO
pEF
 cells (z-ratio below -1.96). There were a total of 5 
proteins that were inhibited in RKO
DOK7V2exp
 cells compared to RKO
pEF
 cells. There are shown 
in order of increasing Z-ratio in Table 7.7.   
 
  
 413 
Table 7.7 Inhibited proteins in RKO
DOK7V2exp
 cells compared to RKO
pEF
 cells identified by 
protein antibody-based microarray, organised in order of increasing Z-ratio. 
 
Target 
protein 
Phospho site RKO pEF 
normalized 
median 
RKODOK7V2 
normalised 
median 
%CFC Z-
ratio 
IRAK4 T345+S346 75 37 -51 -2.67 
Met Y1003 4405 2210 -50 -2.38 
CDK1 Y19 3652 2032 -44 -2.02 
Dok2 Y142 6362 3567 -44 -1.96 
VAV1 Y826 1432 820 -43 -1.96 
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7.3.5 Analysis of interacting proteins to determine related signalling pathways 
 
7.3.5.1 Analysis of proteins overexpressed in RKO
DOK7V2exp
 cells compared to RKO
pEF
 
cells 
 
In order to determine the role of proteins overexpressed in RKO
DOK7V2exp 
cells compared to 
RKO
pEF
 cells, a literature review was undertaken. The summarized results are shown in Table 
7.8. 
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Table 7.8 Role of proteins overexpressed in RKO
DOK7V2exp 
cells compared to RKO
pEF
 cells and 
their related signalling pathways 
 
Target 
protein 
Type of protein Related 
signalling 
pathway(s) 
Role Ref 
VGFR2 Type III 
receptor 
tyrosine kinase 
PI3K-Akt 
MAPK1/ERK2 
MAPK3/ERK1 
MAPK 
AKT1 
Phosphorylates 
PLCG1 
When activated VGFR2 recruits 
Shc, GRB2, PI3K, Nck, SHP-1 
and SHP-2. Promotes VEGF-
induced endothelial proliferation, 
survival, migration and 
differentiation. Negatively 
regulates apoptosis. Promotes 
cytoskeletal reorganization. Key 
role in regulation of angiogenesis. 
(272) 
(273) 
JAK3 Non-receptor 
tyrosine kinase 
JAK-STAT  
PI3K-Akt 
GPCR 
 
Involved in cell growth, migration 
and differentiation.  
Activating mutations are found in 
acute megakaryoblastic leukaemia 
(274) 
(275) 
(276) 
PRKDC Catalytic 
subunit of 
DNA-
dependent 
serine/threonine 
protein kinase 
of PI3/PI4-
kinase family 
Akt 
ERK 
ErbB/HER 
G2/M DNA 
damage 
checkpoint 
Sensor for DNA damage.  
Required for double strand DNA 
break repair and recombination. 
Implicated in cell proliferation  
 
(277) 
(278) 
(276) 
(279) 
 
MEK5 Dual specificity ErbB/HER, Activates ERK5 and MAPK. (280) 
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protein kinase, 
member of 
MAP kinase 
family 
MAPK, IL6  Inhibits NF-κB. Involved in 
growth factor stimulated cell 
proliferation and muscle cell 
differentiation 
mTOR Atypical 
serine/threonine 
kinases 
Downstream of 
PI3K/Akt 
pathway,  
mTOR 
Promotes cell growth. Central 
regulator of cellular metabolism, 
growth and survival. Directly or 
indirectly regulates the 
phosphorylation of >800 proteins 
(276) 
Catenin 
b 
Part of protein 
complex that 
constitute 
adherens 
junctions (AJs) 
Wnt/Beta-
catenin, 
ErbB/HER  
Involved in the regulation of cell 
adhesion and growth between 
cells. May play a role in contact 
inhibition. Mutations are 
associated with colorectal 
adenomatous polyposis 
(281) 
WNK2 Serine-
threonine 
kinase 
belonging to 
protein kinase 
superfamily 
MEK 
ERK 1/2 
Regulated electrolyte homeostasis, 
cell signalling survival and 
proliferation. Negatively regulates 
EGF-induced activation of 
ERK/MAPK pathway 
(282) 
DUSP4 Dual specificity 
protein 
phosphatase 
Negatively 
regulates 
MAPK, 
SAPK/JNK  
Negatively regulate MAP kinase 
superfamily (MAP/ERK, 
SAPK/JNK, p38) 
(283) 
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Cdc25C Tyrosine 
phosphatase 
belonging to the 
Cdc25 
phosphatase 
family 
G2/M DNA 
damage 
checkpoint, 
MAPK 
Regulation of cell division, 
suppresses p53-induced growth 
arrest 
(284) 
ERK1 Serine/threonine 
kinase 
Angiogenesis, 
apoptosis 
regulation, 
ErbB/HER, 
MAPK, IL6, 
mTOR, TGF-
beta 
Involved in the regulation of cell 
growth and differentiation. Plays a 
key role in MAPK cascades.  
(285) 
MKK4 Dual specificity 
kinase of the 
STE7 family 
B cell receptor, 
ErbB/HER, 
IL6, MAPK, 
SAPK/JNK, T 
cell receptor, 
TGF-beta 
Phosphorylates and activates 
JNK1, JNK2 and p38. Mediates 
cell responses to stress and 
inflammatory cytokines. 
Inactivated or deleted in 
approximately of 5% tumours 
(276) 
(286) 
Grp94 Chaperone 
protein 
Akt   Regulation of innate and adaptive 
immunity. Promotion of tumour 
proliferation and metastasis 
(287) 
  
 418 
PDGFRB Receptor 
tyrosine kinase 
Angiogenesis Recruits SH2-containing proteins 
such as Grb2, Src, GAP, PTPN11, 
PI3K PLC-gamma and Nck. 
Regulates cell proliferation, 
survival, differentiation, 
chemotaxis and migration. 
Overexpressed in metastatic 
medulloblastoma. Activating 
translocations found in 
myeloproliferative disorders and 
cancers 
(276) 
(288) 
 
PDK4 Atypical 
protein kinase 
Insulin 
receptor, 
regulation of 
fatty acid 
biosynthesis 
and oxidation 
Regulation of glucose metabolism. 
Involved in cell response to 
starvation, insulin receptor 
signalling, regulation of fatty acid 
biosynthetic process and oxidation, 
pH regulation 
(289) 
(289) 
4E-BP1 Translation, 
translation 
initiation 
Angiogenesis, 
Insulin 
receptor, 
mTOR, 
PI3K/Akt  
Sequesters eIF4E repressing the 
initiation of translation of proteins 
involved in cell proliferation, 
survival, angiogenesis, EMT and 
metastatic progression (290). 
Underexpressed or phosphorylated 
in most tumours, loss of 4E-BP1 
function is associated with 
increased EMT and metastatic 
capability (290).  
(290) 
(291) 
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Ros Proto-
oncogenic 
receptor 
tyrosine kinase 
TOR Aberrant expression in CNS 
tumours. Upregulated in human 
glioma. Plays a role in 
differentiation, growth, 
proliferation.  
(276) 
MKK6 Dual 
specificity 
protein kinase 
of the STE7 
family 
TGFβ, B cell 
receptor, 
ErbB/HER, 
IL6, MAPK  
Activates p38 MAPK activity, 
involved in cell cycle arrest and 
DNA damage induced protein 
phosphorylation 
(292) 
ErbB4 Receptor 
tyrosine kinase, 
member of the 
epidermal 
growth factor 
receptor 
subfamily 
Akt, 
ErbB/HER  
Involved in mitogenesis and 
differentiation 
May function as a tumour 
suppressor but expression varies 
between tumours from different 
locations.  
(276) 
(293) 
DUSP3 Non receptor, 
dual specificity 
protein 
phosphatase 
Negatively 
regulates 
MAPK, JNK 
cascade, T cell 
receptor, T cell 
activation. 
Positively 
regulates 
mitotic cell 
cycle 
Phosphorylated by ZAP-70. (294) 
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PTEN Phosphoinositide 
3-phosphatase 
Negatively 
regulates 
PI3K/Akt. Key 
modulator of 
AKT-mTOR. 
Also involved 
in T cell 
receptor 
signalling, 
Wnt, B cell 
receptor and 
insulin receptor 
signalling 
Tumour suppressor. Plays a role in 
negative regulation of migration, 
proliferation, cell size, focal 
adhesion formation, organ growth, 
Implicated in many cancers.  
(295) 
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7.3.5.2 Analysis of proteins activated in RKO
DOK7V2exp
 cells compared to RKO
pEF
 cells 
 
In order to determine the role of proteins upregulated in RKO
DOK7V2exp 
cells compared to 
RKO
pEF
 cells, a literature review was undertaken. The summarized results are shown in Table 
7.9. 
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Table 7.9 Role of proteins activated in RKO
DOK7V2exp 
cells compared to RKO
pEF
 cells and their 
related signalling pathways 
 
Target 
protein 
Type of protein Signalling 
pathway 
Role Ref 
TrkB Transmembrane 
Receptor with 
intracellular tyrosine 
receptor activity. Acts 
as a receptor for brain-
derived neurotrophic 
factor (BDNF), 
neurotrophin-4 (NT4) 
and neurotrophin-3 
(NT3) (296). 
MAPK, Ras-
PI3K-AKT1 
pathway, 
PLCG1 and 
protein kinase 
C, NF-κB  
Cell differentiation 
Growth and survival 
Synaptic plasticity 
Suppresses anoikis 
Two point mutations found 
in colon tumours and cell 
lines 
Enhances metastases in rats 
Associated with poor 
prognosis in neuroblastoma 
and may play a role in 
chemoresistance 
(297) 
(276) 
CREB1 Transcription factor of 
the leucine zipper 
family 
cAMP, PI3K-
AKT , B cell 
receptor, 
ErbB/HER, T 
cell receptor, 
MAPK 
Phosphorylated by several 
protein kinases. Involved in 
cell differentiation. 
Positively regulates 
transcription.  
(298, 
299) 
Cyclin 
B1 
Cyclin family protein AMPK, G2/M 
DNA damage 
checkpoint 
Activator protein involved 
in cell cycle regulation. 
Regulates CDK kinases. 
Involved in mitosis. 
(300) 
(301) 
BRCA1 Nuclear phosphoprotein Negatively Involved in transcription, (302) 
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with E3 ubiquitin-
protein ligase activity  
regulates 
oestrogen 
receptor 
signalling 
pathway, 
G2/M DNA 
damage 
checkpoint 
DNA repair, ubiquitination, 
transcriptional regulation 
and maintains genomic 
stability. Required for 
normal cell cycle 
progression from G2 to 
mitosis 
Acts as a tumour 
suppressor. Plays a role in 
apoptosis, angiogenesis and 
proliferation. Mutations are 
associated with breast and 
ovarian cancers 
(303) 
CDK1/2 Serine/Threonine 
protein kinases 
MAPK, PI3K-
AKT, 
ErbB/HER, 
G2/M DNA 
damage 
checkpoint, 
apoptosis, Rb, 
G1/S 
checkpoint, 
Ras signal 
transduction  
Involved in cell cycle 
regulation. CDK1 is 
involved in cell migration, 
DNA damage response, 
epithelial cell 
differentiation, negative 
regulation of apoptosis.  
CDK2 is involved in DNA 
damage response, positive 
regulation of cell 
proliferation and cell cycle 
regulation. 
(304) 
(305) 
(276) 
(306) 
(307) 
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IKKa Serine/threonine 
protein kinase 
PI3K/AKT 
and PI-3K 
cascade, NF-
κB , T and B 
cell receptor, 
TNF 
Phosphorylates inhibitors 
of NF-κB. Involved in 
inflammatory and immune 
responses and the 
regulation of apoptosis. 
(308) 
(309) 
4E-BP1 Translation initiation MAPK, 
mTOR, 
PI3K/AKT, 
AMPK, 
angiogenesis, 
insulin 
receptor, 
Signalling by 
GPCR  
Negatively regulates 
translation. Positively 
regulates mitotic cell cycle 
at G1/S transition.  
(310) 
(311) 
(291) 
ATF2 Transcription factor, 
member of leucine 
zipper family of DNA 
binding proteins 
PI3K-AKT, 
MAPK, 
SAPK/JNK, B 
cell receptor  
Transcriptional activator of 
genes involved in anti-
apoptosis, cell growth and 
DNA damage. Evokes 
oncogenic or tumour 
suppressor events 
depending on the tissue. 
(312) 
(313) 
(314) 
PLCg1 Calcium dependent 
phosphatidylinositol-
specific phospholipase 
C 
PI-3K cascade, 
FGFR, 
MAPKK, 
calcium 
signalling, 
Regulation of intracellular 
signalling cascades. 
Involved in reorganization 
of actin and cell migration. 
Involved in activation of 
(315) 
(316) 
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EGFR, T cell 
receptor, 
angiogenesis, 
ErbB/HER 
MAPKK activity, positive 
regulation of angiogenesis 
and cell migration 
Connexi
n 43 
Gap junction protein I-κB 
kinase/NF-κB 
cascade 
Negative regulation of cell 
growth, positively regulates 
I-κB kinase/NF-κB cascade  
(317) 
(318) 
ERK5 Protein kinase of the 
MAPK family 
ErbB/HER 
signalling, 
GPCR 
signalling to 
MAPKs, IL6 
signalling, 
mTOR 
Involved in angiogenesis. 
May block apoptosis in 
endothelial cells. 
Transduces EGF growth 
signal. Activated in ErbB2 
overexpressing breast 
cancer and downstream of 
MEK5 in metastatic 
prostate cancer. Negatively 
regulates cell-cell adhesion. 
(276) 
(319) 
Cofilin 2 Cytoskeletal protein Actin and 
microtubule 
dynamics, 
TGF-β 
signalling 
Regulation of actin-
filament dynamics. 
Mutations are associated 
with congenital myopathy 
(320) 
(321) 
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7.3.5.3 Analysis of proteins underexpressed in RKO
DOK7V2exp
 cells compared to RKO
pEF
 
cells 
 
In order to determine the role of proteins underexpressed in RKO
DOK7V2exp 
cells compared to 
RKO
pEF
 cells, a literature review was undertaken. The summarized results are shown in Table 
7.10. 
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Table 7.10 Role of proteins underexpressed in RKO
DOK7V2exp 
cells compared to RKO
pEF
 cells 
and their related signalling pathways 
 
Target protein Type of protein Signalling 
pathway 
Role Ref 
PTP1D/ 
SHP2 
SH2-containing 
tyrosine-
specific protein 
phosphatase 
GPCR, PAK, 
EGFR, ephrin 
receptor, B cell 
receptor, 
ErbB/HER, 
FGFR, IL-6, 
insulin, receptor, 
phosphoinositide
-mediated and 
PI3K signalling 
pathways 
Involved in the regulation 
of cell growth, 
differentiation, migration 
and death. Also involved 
in the regulation of 
integrin-mediated cell 
adhesion  
(322) 
(323) 
(324) 
PDK3 Atypical 
protein kinase 
Pyruvate 
dehydrogenase 
pathway 
Regulates glucose 
metabolism and aerobic 
respiration 
(325) 
(326) 
GNB2L1 G-beta like 
scaffold protein 
that links 
protein kinase 
C to its 
substrates 
ERK, CREB 
pathway. 
Negatively 
regulates protein 
kinase B and 
Wnt signalling 
Regulates calcium release 
and IGF-1-mediated Akt 
activation. Involved in 
repression of translation. 
Negatively regulates cell 
growth, phagocytosis, and 
translation. Positively 
regulates apoptosis and 
cell migration.  
(327) 
(328) 
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Haspin Serine/threonin
e protein kinase 
 Cell cycle regulation (329) 
STI1 Chaperone 
protein 
 Involves in stress response. 
Interacts with Hsp70 and 
Hsp90. 
(330) 
(331) 
Smad2 Transcription 
factor 
Activin receptor, 
TGF-β, BMP 
and angiogenesis 
signalling 
pathways 
Mediates TGF-beta 
signalling. Regulates 
proliferation, 
morphogenesis, apoptosis 
and differentiation 
 
(332) 
(333) 
(334) 
Smad3 Transcription 
factor 
Activin receptor, 
angiogenesis, 
G1/S checkpoint 
and TGF-β 
signalling 
pathways  
Mediates TGF-beta 
signalling. Negatively 
regulates cell growth, 
mitotic cell cycle Inhibits 
wound healing 
 
(332) 
(333) 
(335) 
PCTK1/ 
PCTAIRE-1 
protein-serine 
kinase/CDK16 
Member of 
cdc2/cdkx 
subfamily of 
serine/threonin
e family of 
protein kinases 
 Signal transduction in 
terminally differentiated 
cells, exocytosis, transport 
of secretory cargo from 
endoplasmic reticulum 
(336) 
(337) 
ROCK-I/ROKb Serine/threonin
e kinase 
RhoGDI, ephrin 
receptor, NF-κB, 
PI3K/AKT, 
TGF-β, VEGFR 
Regulates actin 
cytoskeleton and cell 
polarity. Regulate smooth 
muscle contractility, stress 
(276) 
(338) 
(339) 
 429 
and death 
receptor 
signalling 
pathways 
fibre and focal adhesion, 
cell adhesion and motility. 
Negatively regulates 
inflammatory cell 
migration and VEGF-
induced angiogenic 
endothelial cell activation 
Regulates PTEN 
phosphorylation and 
stability 
MEK1 Dual specificity 
protein kinase 
of STE7 kinase 
family 
MAPK/ERK, 
angiogenesis, B 
cell receptor, 
ErbB/HER, IL6, 
insulin receptor, 
T cell receptor, 
PI3K-AKT and 
PI3K signalling 
cascades 
Induces MAPK activity. 
Regulates proliferation, 
differentiation, 
transcription, motility and 
chemotaxis. 
Overexpressed/overactivat
ed in many tumour types. 
Involved in colon cell 
growth and motility 
(276) 
(340) 
(341) 
PTP-
PEST/PTPN12 
Protein tyrosine 
phosphatase 
GPCR, PAK and 
EGFR signalling 
pathways 
May regulate protein 
intracellular half-life, 
oncogenesis, cell shape 
and motility 
(342) 
(343) 
DRAK2/STK17
B 
Calmodulin-
dependent 
serine/threonin
e kinase of the 
 Positive regulator of 
apoptosis 
(344) 
(345) 
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DAPK family 
BMX (Etk) Non-receptor 
tyrosine kinase 
of the Tec 
family 
AKT, 
STAT 
Involved in IL-6-induced 
differentiation and the 
growth and differentiation 
of haematopoietic cells. 
Involved in TNF-induced 
angiogenesis and 
signalling of TEK and 
FLT1 receptors 
Required for 
phosphorylation and 
activation of Stat3-induced 
cell differentiation. Also 
involved in IL-6 induced 
differentiation 
Involved in adaptive 
cellular response to 
extracellular stress 
(346) 
(347) 
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7.3.5.4 Analysis of proteins functionally suppressed in RKO
DOK7V2exp
 cells compared to 
RKO
pEF
 cells 
 
In order to determine the role of proteins functionally suppressed in RKO
DOK7V2exp 
cells 
compared to RKO
pEF
 cells, a literature review was undertaken. The summarized results are 
shown in Table 7.11. 
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Table 7.11 Role of proteins downregulated in RKO
DOK7V2exp 
cells compared to RKO
pEF
 cells 
and their related signalling pathways 
 
Target 
protein 
Type of protein Signalling 
pathway 
Role Ref 
IRAK4 Serine/threonine 
protein kinase 
Toll-like 
receptor 
(TLR), T-cell 
receptor 
(TCR), NF-κB, 
and IL1R 
signalling 
pathways  
Activates NF-kappaB 
Initiates innate immune 
response  
(348) 
(349) 
Met/ 
Hepatocyte 
growth 
factor 
receptor 
Proto-oncogenic 
receptor tyrosine 
kinase 
PI3K-AKT, 
RAS-ERK, 
PLCgamma-
PKC signalling 
pathways 
Regulates proliferation, 
chemotaxis, morphogenesis and 
survival. Involved in embryonic 
development, wound healing 
and tissue remodelling. 
Necessary for invasive growth 
and EMT. 
Mutations seen in renal 
carcinoma and hepatocellular 
carcinoma.  
Upregulation in carcinomas 
correlates with metastases and 
poor outcome 
(350) 
(276) 
(351) 
 
CDK1 Cyclin-
dependent 
MAPK, PI-3K, 
apoptosis, 
Involved in cell cycle control, 
essential for G1/S and G2/M 
(352) 
(304) 
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kinase, member 
of 
serine/threonine 
protein kinase 
family 
ErbB/HER and 
G2/M DNA 
damage 
checkpoint  
cascades 
phase transitions and cell 
migration. Activated in many 
cancers. Negatively regulates 
apoptosis. 
(306) 
Dok2 Adaptor protein ErbB/HER  Attenuates EGF-induced 
MAPK activation 
Constitutively tyrosine 
phosphorylated in 
haematopoietic progenitors 
from CML patients in the 
chronic phase 
Substrate for p210(bcr/abl) 
Attenuates EGF-stimulated 
MAP kinase activation 
(353) 
(354) 
Vav 1 
guanine 
nucleotide 
exchange 
factor 1 
Proto-oncogenic 
guanine 
nucleotide 
exchange factor 
(GEF) of the 
Dbl family 
Actin 
dynamics, B 
cell and T cell 
receptor, 
ErbB/HER, 
VEGFR and 
PI-3K cascades  
Involved in cell differentiation, 
proliferation, actin cytoskeletal 
rearrangement and 
transcriptional alteration. 
Involved in T-cell and B-cell 
development and activation. 
Positively regulates apoptosis,  
(355) 
(356) 
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7.3.6 Analysis of interacting proteins for a potential role in colorectal cancer 
 
7.3.6.1 Analysis of proteins overexpressed in RKO
DOK7V2exp
 cells compared to RKO
pEF
 
cells: review of the literature for role in cancer 
 
In order to determine the role of proteins overexpressed in RKO
DOK7V2exp 
cells compared to 
RKO
pEF
 cells, a literature review was undertaken. The summarized results are shown in Table 
7.12. 
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Table 7.12 Role of proteins overexpressed in RKO
DOK7V2exp 
cells compared to RKO
pEF
 cells in 
cancer 
 
Target protein Role in Cancer 
VGFR2 Expressed by endothelial cells and in the malignant epithelium of 
colorectal cancers with strongest expression at the invasive tumour edge 
(357). Expressed to a lesser degree in colorectal lymph node and liver 
metastases (357). Phosphorylated VEGFR2/KDR expression in colorectal 
cancer cells is associated with larger tumour size and poor differentiation 
(358).  
VEGFR2 tyrosine kinase inhibitors inhibit tumour growth in vivo, have 
an anti-angiogenic effect and inhibit the development of hepatic 
metastases (359, 360). 
JAK3 JAK3 mRNA is expressed in colon cancer cell lines and primary tumours 
(361). Inhibition of JAK3 in SW480 and HT29 colorectal cancer cell 
lines downregulates phosphorylated pSTAT3 and reduces colon cancer 
cell viability as a result of apoptosis and cell cycle arrest (361). STAT3 
and JAK3 are frequently expressed in stage II and stage IV colon cancer 
(361). The intensity of JAK3 immunostaining is significantly associated 
with tumour differentiation, pT stage and TNM stage (362).  
PRKDC/DNAPK DNA-PK activity is significantly upregulated in colorectal cancer tissue 
compared with adjacent normal colorectal tissue (363). Increased 
expression of DNA-PK catalytic subunit is associated with clinical stage, 
lymphatic invasion and distant metastases and adverse survival outcomes 
in colorectal cancer patients (364). Plays a role in cellular resistance to 
oxidative stress and may influence the responsiveness of cells to 
radiotherapy (365, 366). 
MEK5 Expression of phosphorylated MEK5 is significantly higher in colorectal 
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cancer tissues compared to normal colorectal tissue and is significantly 
correlated with depth of tumour invasion, lymph node metastases, distant 
metastases, high pre-operative CEA level, stage of disease and poorer 
survival outcomes (367). 
mTOR Inhibition of mTOR reduces the growth of colon cancer cells but 
increases the transformation and invasiveness of intestinal epithelial cells 
(368).  
Catenin b The β-catenin gene (CTNNB1) gene is frequently mutated in colorectal 
cancer and is more highly expressed in left-sided colorectal tumours 
(369-372). Its expression is associated with increased tumour 
proliferation, invasion and metastases and may be a marker of improved 
response to neo-adjuvant chemoradiotherapy in rectal cancer (369-371). 
WNK2 No literature relating to the role of WNK2 in colorectal cancer but WNK1 
is activated in colon cancer cell lines (373). However, studies 
investigating WNK2 expression in meningioma and cervical cancer cells 
have suggested that WNK2 may act as a tumour suppressor (374, 375). 
DUSP4 In colorectal cancer, high DUSP4 expression is associated with poorer 
overall survival and the presence of BRAF mutations (376).  
Cdc25C General studies of Cdc25C function suggest a mitotic function (377). 
ERK1 Although ERK1 levels are similar in colorectal cancer tissues and pared 
normal tissue, activity of ERK1 is downregulated in most colorectal 
cancer and in colorectal adenomas (378, 379). Another study has shown 
that constitutive phosphorylation of Erk1/2 is dependent on Kirsten-ras 
(380). In the human colon cancer cell line HT-29, activation of ERK1/2 
results in macroautophagy (381). Stimulation of ERK1/2 activation 
however has been demonstrated in response to GSNO, a nitric oxide 
donor, and is thought to play a role in NO-induced apoptosis (382). The 
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phosphorylation of ERK1/2 along with that of c-Met and AKT has been 
shown to be induced by HGF which also upregulates VEGF mRNA and 
protein levels (383). The main activator of ERK1 is MEK1, which is 
involved in the regulation of tumour cell proliferation and cell 
transformation (384). Activation of ERK1/2 is also thought to play a role 
in the stimulation of colon cancer cell invasion and migration (385).  
MKK4 In colorectal cancer cells, MKK4 has been shown to mediate the ROS-
stimulated phosphorylation of JNK (386). Immunohistochemical studies 
have shown that phosphorylated MKK4 is present in colorectal cancer 
tissue, and that its expression correlates with depth of tumour invasion, 
differentiation, TNM stage and the presence of metastases but was also 
associated with improved survival outcomes (387). Certain 
polymorphisms in the promoter of MKK4 have been associated with a 
reduced risk of colorectal cancer development (388). 
Grp94 Grp94 expression is associated with the expression of c-myc oncogene in 
colorectal cancer cell lines (389). The expression of Grp94 is 
significantly higher in colon cancer tissue than in adjacent background 
colonic tissue and high Grp94 expression is associated with poorer 
tumour differentiation and presence of metastases (390). 
PDGFRB The majority of human colorectal cancers express PDGFRB in the stroma 
(but not the epithelium) of colorectal cancer tissue with strongest IHC 
staining seen in vascular cells (391, 392).  However, it is not associated 
with tumour characteristics or prognosis (391). 
PDK4 Conflicting evidence regarding expression in human colorectal cancer 
(393, 394). 
4E-BP1 Expression of 4E-BP1 is upregulated in colorectal cancer cells compared 
to normal colon cells and is also upregulated in colorectal cancer tissue 
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compared to non-cancerous tissue (395). Furthermore, 4E-BP1 
expression in the liver is higher in in patients with CRC liver metastases 
compared to those without liver metastases (395). 4E-BP1 expression is 
significantly correlated with nodal status and is more frequently 
expressed in patients with an advanced stage of presentation (395). 
Moreover, 4E-BP1 expression is associated with significantly shorter 
survival time and reduced time to disease recurrence (395). Another study 
by Diab-Assaf et al found that overall 4E-BP1 expression as determined 
by immunohistochemical staining was increased in colorectal adenoma 
tissue compared to normal colorectal tissue but was decreased in 
colorectal adenocarcinoma tissue (396). Furthermore, when 4E-BP1 was 
present in colorectal adenocarcinoma, it was highly phosphorylated or 
inactivated (396). A study of patients with stage II colon cancer found 
that expression of phosphorylated-4E-BP1 was inversely associated with 
disease-free survival (397).  
Ros Mutated in non-small cell lung cancer and gastric cancer (398). 
MKK6 Upregulated in human colon cancers (399). 
ErbB4 Overexpressed in human colorectal cancer (400). Mutated in 0.6% of 
CRC (401). Genetic variations of ErbB4 are associated with increased 
colorectal cancer risk (402, 403). Phosphorylated ERbB4 is associated 
with poorer prognosis in colorectal cancer (404). ErbB4 membranous 
protein expression predicts for CRC lymph node positivity (405). 
DUSP3 Implicated in several human cancers, found to be both tumour-
suppressing and tumour-promoting (406). Upregulated in cervical cancer 
but downregulated in NSCLC (407, 408). Pro-angiogenic (409). 
PTEN Reduced PTEN expression may play a role in colorectal carcinogenesis 
and loss of PTEN is associated with shorter survival (410, 411). PTEN 
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expression correlates with differentiation, lymph node metastases, 
infiltration of the serosa and Dukes’ stage in colorectal cancers but is not 
associated with tumour size (412). Loss of function or PTEN mutation is 
a predictor of poor colorectal tumour response to anti-EGFR treatment as 
well as being a predictor of shorter progression free survival and overall 
survival (413).   
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7.3.6.2 Analysis of proteins activated in RKO
DOK7V2exp
 cells compared to RKO
pEF
 cells: 
review of the literature for role in cancer 
 
In order to determine the role of proteins activated in RKO
DOK7V2exp 
cells compared to RKO
pEF
 
cells, a literature review was undertaken. The summarized results are shown in Table 7.13. 
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Table 7.13 Role of proteins activated in RKO
DOK7V2exp 
cells compared to RKO
pEF
 cells in 
cancer 
 
Target 
protein 
Role in Cancer 
TrkB TrkB is necessary for CRC cell growth and survival (414). High TrkB is 
associated with poor prognosis in CRC and enhanced malignant potential with 
regard to proliferation, migration, invasion and anoikis (415-417). Tissue TrkB 
mRNA expression is associated with lymph node metastases and TrkB 
expression is associated with poorer prognosis (418).  
CREB1 Promotes colorectal cancer tumour aggressiveness (419). 
Cyclin B1 High levels expressed in human colorectal cancer (420).  
BRCA1 Risk of CRC is increased in female carriers of BRCA1 mutations below the age 
of 50 (421). 
CDK1/2 CDK1 is activated in many cancers including colon cancer (306).  
IKKa Nuclear IKKa is associated with malignancy (422). In murine models, elevated 
levels in the skin increase the malignant potential of skin cancers (423). 
4E-BP1 4E-BP1 has been shown to be highly activated in colorectal cancers and 
colorectal adenomas with high-grade intraepithelial neoplasia and intensity of 
IHC staining correlates with depth of tumour invasion (424). 
ATF2 Plays an important role in colorectal cancer (425). Contributes to cisplatin 
resistance in non-small cell lung cancer (426). Increases pancreatic cancer cell 
invasiveness by inducing EMT (427). Associated with poor prognosis in renal 
cell carcinoma (428). Conflicting data on role in skin cancers (429, 430). 
PLCg1 Promotes tumour cell growth and migration (431).  
Connexin 
43 
Conflicting results; some studies show connexin 43 is overexpressed in human 
colorectal cancer cells (432) whilst others have shown that connexin 43 is 
downregulated and that loss of expression is associated with shorter disease-
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free and overall survival (433). 
ERK5 Overexpressed in human adenomas and adenocarcinomas, expression correlates 
with greater invasive and metastatic potential (434). ERK5 expression 
correlates with NF-κB activation in CRC (434). Overactivation of ERK5 is 
associated with increased cell cycle progression and cell migration (434). 
Cofilin 2 Reduced expression has been found in pancreatic cancer (435). 
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7.3.6.3 Analysis of proteins underexpressed in RKO
DOK7V2exp
 cells compared to RKO
pEF
 
cells: review of the literature for role in cancer 
 
In order to determine the role of proteins underexpressed in RKO
DOK7V2exp 
cells compared to 
RKO
pEF
 cells, a literature review was undertaken. The summarized results are shown in Table 
7.14. 
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Table 7.14 Role of proteins underexpressed in RKO
DOK7V2exp 
cells compared to RKO
pEF
 cells 
in cancer 
 
Target 
protein 
Role in cancer 
PTP1D/SHP2 Downregulation of SHP2 in colorectal cancer may promote cancer metastases 
and invasion via the negative regulation of c-Src and consequently villin-
induced cell migration and invasion (436). 
PDK3 Previous studies have shown levels of PDK3 are increased in colorectal 
cancer compared to adjacent normal tissues and are positively associated with 
severity of cancer and negatively associated with disease-free survival (437).  
GNB2L1 Tumour suppressor in gastric cancer (438). Expression is correlated with 
differentiation level and lymph node metastasis in colorectal cancer (439). 
Inhibits growth and induces apoptosis of colon cells and promotes cell-cell 
adhesion and reduces the invasive potential of colon cancer cells (440, 441).  
Haspin Highly expressed during cell proliferation and in several cancers (442).  
STI1 Promotes proliferation in glioma cells via MAPK and PI3K pathways (443). 
Increases glioblastoma cell migration (444). 
Smad2/3 Smad2 mutations are implicated in colorectal and lung cancers (445). Smad2 
may act as tumour suppressor in colorectal cancer and is inactivated in LOH 
colorectal cancers (446). C-terminally phosphorylated Smad 3 (pSmad3C) 
and linter phosphorylated Smad 3 (pSmad3L) are potential biomarkers in 
colorectal cancer (447). 
PCTK1 Implicated in cancer cell proliferation and anti-apoptosis (448). siRNA 
treatment targeting PCTAIRE1 reduces tumour volume and weight and 
results in increased apoptosis in human colorectal cancer cells (448). 
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ROCK-
I/ROKb 
ROCK1 genetic polymorphisms may modify susceptibility to colorectal 
cancer (449). 
MEK1 Deregulation of the MEK pathway is implicated in melanoma, pancreatic, 
lung, colorectal and breast cancers (450). MEK is recognized as a potential 
therapeutic target in colorectal cancer and several MEK inhibitors are under 
evaluation by clinical trials (451). 
PTP-PEST Downregulation of PTP-PEST in colorectal cancer may promote cancer 
metastases and invasion via the negative regulation of c-Src and consequently 
villin-induced cell migration and invasion (436).  
DRAK2 Implicated in the regulation of apoptosis in colorectal cancer cells (452). 
BMX (Etk) Implicated in prostate cancer (453). Contributes to tumour angiogenesis and 
growth in colon, lung and melanoma tumour deposits (454). 
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7.3.6.4 Analysis of proteins functionally suppressed in RKO
DOK7V2exp
 cells compared to 
RKO
pEF
 cells: review of the literature for role in cancer 
 
In order to determine the role of proteins functionally suppressed in RKO
DOK7V2exp 
cells 
compared to RKO
pEF
 cells, a literature review was undertaken. The summarized results are 
shown in Table 7.15. 
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Table 7.15 Role of proteins functionally suppressed in RKO
DOK7V2exp 
cells compared to 
RKO
pEF
 cells in cancer 
 
Target 
protein 
Role in cancer 
IRAK4 Increased phosphorylation state found in melanoma patients (455). Inhibition 
of IRAK4 inhibits tumour growth and increases cell death (455).  
Met/ 
Hepatocyte 
growth 
factor 
receptor 
HGFR activation promotes colorectal cancer cell survival, invasion and 
resistance to apoptosis and its expression in colon cancer correlates with depth 
of tumour invasion and is a marker of metastatic disease (456-458). 
CDK1 High nuclear/cytoplasmic ratio of Cdk1 expression predicts poor prognosis in 
colorectal cancer patients (459). High level of phosphorylated CDK1 is 
associated with prolonged disease-free survival in colorectal cancer patients 
(460). 
Dok2 Loss of DOK2 found in 1/3 of CRC specimens (259). Loss of DOK2 is 
associated with CRC recurrence and poorer 5-year overall survival rate (259). 
Vav 1  Overexpression is associated with advanced cancer stage or lymph node 
metastases (461). 
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7.4 Discussion 
 
Data obtained from qPCR analysis of our cohort tissues demonstrates that DOK7V2 
expression is increased in colorectal cancer tissue compared with normal colorectal tissue.  
 
Here, we have shown that, overexpression of DOK7V2 in colorectal cancer cells is associated 
with changes in the expression and phosphorylation (activation) of numerous proteins in RKO 
cells. 
 
Of the predicted functional partners identified using STRING analysis, two proteins were 
found to be differently phosphorylated in DOK7V2 overexpression RKO cells. Firstly, 
functional suppression of DOK2 at phosphosite Y142 was observed in RKO DOK7V2 cells 
compared to RKO pEF control cells. Secondly, increased activation of TrkB at phosphosite 
Y705 was observed in RKO DOK7V2 cells compared to RKO pEF control cells. 
 
The microarray data reveals a number of interesting findings. Notable proteins overexpressed 
in DOK7V2 overexpression cells include the receptor tyrosine kinase VGFR2, the non-
receptor tyrosine kinase JAK3 and the atypical serine/threonine kinase mTOR. VGFR2 is a 
receptor tyrosine kinase which plays a key role in the regulation of angiogenesis and which 
has been shown to promote endothelial proliferation, survival, migration and differentiation 
whilst negatively regulating apoptosis (272, 273). mTOR is an atypical serine/threonine 
kinase, which promotes cell growth and is a key regulator of cell metabolism and survival. It 
regulates the phosphorylation of hundreds of proteins (276).  
 
JAK3 is involved in cell growth, migration and differentiation and has been found to be 
activated in acute megakaryoblastic leukaemia (274-276). Other proteins overexpressed in 
RKO DOK7V2 overexpression cells that have been implicated in cell proliferation are 
PRKDC, MEK5, WNK2, ERK1, Grp94 and PDGFRB. PRKDC, MEK5, catenin b, DUSP4, 
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Grp94 and 4E-BP1 have previously been linked with colorectal tumour aggressiveness and 
poorer clinical outcomes. Cell signalling pathways associated with these proteins include the 
PI-3K-Akt, MAPK, JAK-STAT, mTOR, ErbB/HER, Wnt/β-catenin and angiogenesis 
signalling pathways 
  
Notable proteins activated in the DOK7V2 overexpression cells include the transmembrane 
receptor tyrosine kinase TrkB, transcription factor CREB1, Cyclin B1, translational protein 
4E-BP1 and protein kinase ERK5, the expression of all of which have previously been linked 
with increased colorectal cancer malignant potential and poorer clinical outcomes. TrkB is a 
transmembrane receptor with intracellular tyrosine receptor activity which has been 
previously associated with cell differentiation, growth, survival and suppressed anoikis as 
well as poor prognosis and increased metastases (276, 297). CREB1 is also known to play a 
role in cell differentiation and a number of the other proteins activated in RKODOK7V2 
overexpression cells are known to play a role in cell cycle progression, including Cyclin B1, 
BRCA1 and CDK1/2 (298) (300-302). Cell signalling pathways associated with the activated 
proteins include the PI-3K-Akt, MAPK, mTOR, ErbB/HER and angiogenesis signalling 
pathways  
 
Of the proteins exhibiting reduced expression in RKO DOK7V2 overexpression cells, 
PTP1D/SHP2 and PTP-PEST are notable in that their downregulated in colorectal cancer has 
previously been associated with cancer metastasis, cell migration and invasion (436). We also 
found that there was reduced levels of phosphorylation of CDK1, a proteins whose level of 
phosphorylation has previously been associated with the length of disease-free survival of 
colorectal cancer patients (460). Reduced phosphorylation of Dok-2 was also observed, 
consistent with previous findings that Dok-2 acts as a tumour suppressor in colorectal cancer 
(259). By comparison, the hepatocyte growth factor receptor, Met, was observed to be 
downregulated in RKO DOK7V2 overexpression cells. Previous studies have linked Met 
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activation with increased colorectal cancer cell survival, invasion and evasion of apoptosis 
(458).  
 
A number of the proteins modulated by DOK7V2 expression participate in the mTOR 
signalling pathway. This important pathway regulates cell growth, proliferation and survival 
(462). Activation of the mTOR pathway is associated with tumour formation and 
angiogenesis and also occurs in insulin resistance and T-lymphocyte activation (462). This 
has led to the development of mTOR inhibitors, which are used in a variety of pathological 
conditions including cancer (462). The impact of DOK7V2 overexpression on the mTOR 
pathway is illustrated in Figure 7.3 and the impact on the Jak/STAT and angiogenesis 
pathways are illustrated in Figure 7.4 and Figure 7.5 respectively. In these diagrams, over- or 
under-expression of a protein is indicated by an arrow and an asterisk indicates protein 
activation. Where there is more than one member of a protein family, for example ERK1 and 
ETK5, the number of the protein affected is indicated in brackets. 
 
In summary, analysis of DOK7V2 overexpression in a colorectal cancer cell line compared 
with a control cell line has revealed a number of differences in the expression and activation 
of other proteins. These findings provide a useful starting point for future work to elucidate 
how DOK7 isoforms interact with other cell signalling proteins.  
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Figure 7.3 Impact of DOK7V2 overexpression on the mTOR pathway. Diagram adapted from 
Cell Signalling Technology. 
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Figure 7.4 Impact of DOK7V2 overexpression on Jak/STAT pathway. Diagram adapted from 
Cell Signalling Technology.  
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Figure 7.5 Impact of DOK7V2 overexpression on the angiogenesis pathway. Diagram 
adapted from Cell Signalling Technology.  
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Chapter 8: General Discussion 
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8.1 Dok proteins in colorectal cancer 
 
The Dok proteins are a family of cytoplasmic adaptor proteins involved in signalling 
pathways downstream of tyrosine kinase. Tyrosine phosphorylation of proteins by protein 
tyrosine kinases (PTKs) is a reversible process that plays an important role in the regulation 
of a variety of cellular functions including cell growth, differentiation and cell motility. 
Activation of PTKs by extracellular stimuli results in the phosphorylation of both the PTK as 
well as other substrates including trans-membrane receptors and the adaptor proteins. The 
latter then either recruit or inhibit further downstream molecules, thereby regulating tyrosine 
kinase signalling pathways. Aberrations in this process of tyrosine phosphorylation and 
downstream signal transduction are associated with many types of cancer. Consequently, 
there has been an effort to investigate and understand this complex process in order to 
evaluate its potential as a target for therapeutic intervention. The Dok proteins possess 
structural characteristics typical of adapter proteins and, like other adapter molecules, they 
associate with activated cell-surface receptors and aid in the docking of downstream 
signalling molecules, facilitating intracellular signal transduction. Their precise role is unclear 
but they are thought to play a possible tumour suppressor role in relation to human 
malignancies. Dok-7, the most recently identified member of this family, has mostly been 
investigated with regard to its role in musculoskeletal diseases and little is currently known 
about its role in cancer. A recently published paper looking at twin pairs discordant for breast 
cancer suggested hypermethylation of the Dok-7 promoter occurs in breast cancer and may 
occur prior to cancer diagnosis, raising the possibility that Dok-7 may have a potential role as 
a cancer biomarker. However, there has been no research to date investigating the role of 
Dok-7 in colorectal cancer, one of the commonest cancers in the UK and a significant cause 
of cancer related death.  
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8.2 Main conclusions of this study 
 
8.2.1 Expression of DOK7 in human colorectal cell lines 
 
Initial studies of DOK7 mRNA expression revealed that DOK7 is variably expressed in 
colorectal cancer cells. Interestingly, lower levels of DOK7 expression were seen in HT-115 
and RKO cell lines, which are the more poorly differentiated and highly aggressive colorectal 
cancer cell lines and this trend was also observed in breast cancer cell lines, with lowest 
levels of expression seen in MDA-MB-231, a poorly differentiated metastatic breast 
adenocarcinoma.  
 
8.2.2 Expression of DOK7 in colorectal clinical cohort and association with tumour 
pathology and clinical outcome data 
 
Preliminary results found that DOK7 mRNA expression is significantly reduced in colorectal 
cancer compared to normal colorectal tissue in keeping with a potential tumour suppressor 
role for DOK7. Our data also revealed that DOK7 expression was inversely related to 
colorectal cancer T stage and that low DOK7 expression was associated with poorer survival 
compared to high DOK7 expression, suggesting a tumour suppressive effect that may be of 
clinical importance. These results correlate with our previous (unpublished) findings in the 
host laboratories that found reduced levels of DOK7 expression in breast cancer tissue 
compared to normal breast tissue. 
 
However, our analysis of gene array data obtained from a cohort of 585 colorectal cancer 
samples found conflicting results. We found that in this cohort, DOK7 mRNA expression was 
increased in colorectal cancer compared to normal colorectal tissue and that, contrary to our 
cohort data, poor survival outcomes were associated with high DOK7 expression. 
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Although DOK7 expression has not previously been examined in relation to colorectal 
cancer, previous studies have generally suggested a tumour suppressor role for the Dok 
proteins in a range of human cancers. In relation to colorectal cancer, DOK2 expression has 
been shown to be reduced in colorectal cancer compared to normal colorectal tissue and low 
DOK2 expression is associated with poorer survival (259). A recently published study by 
Friedrich et al investigating DOK1 in a large cohort (n = 1492) of colorectal cancer patients 
found that loss of DOK1 protein was associated with poor prognosis in early stage tumours 
(463). Furthermore, they found that cytoplasmic expression of DOK1 was associated with 
better survival outcome whilst nuclear localisation of DOK1 was associated with poorer 
survival outcomes suggesting that the subcellular compartmentalization of DOK1 played a 
role in colorectal cancer progression (463).  
 
Difficulties encountered in creating cell models for DOK7 expression along with the 
conflicting results found between the two sets of cohort data led us to realise the existence of 
DOK7 variants which code for different protein isoforms. 
 
8.2.3 Expression of DOK7 variants in human colorectal cell lines 
 
The expression of DOK7 variants differed between colorectal cancer cell lines. DOK7V1 and 
DOK7V2 were both strongly expressed by HRT-18 cells with reduced levels of expression 
seen in RKO and HT-115 cells. Meanwhile, DOK7V3 expression was highest in HT-115 
cells with lower levels of expression seen in RKO and HRT-18 cells. There is no previously 
published data regarding the expression of DOK7 variants in colorectal cell lines but DOK7 
splice variants are acknowledged in research investigating DOK7 congenital myasthenic 
syndrome.  
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8.2.4 Expression of DOK7 variants in colorectal clinical cohort and association with 
tumour pathology and clinical outcome data 
 
Analysis of variant expression in our cohort revealed that the expression of DOK7V1 is 
significantly reduced in colorectal cancer compared to normal colorectal tissue. By 
comparison, the expression of DOK7V2 and DOK7V3 is significantly increased in colorectal 
cancer compared to normal colorectal tissue.  
 
In addition, we found that DOK7V1 expression is significantly associated with overall stage 
of disease and that low DOK7V1 expression is associated with reduced length of disease free 
survival. Interestingly, although the level of DOK7V2 expression was increased in colorectal 
cancer compared to normal colorectal tissue, low DOK7V2 expression was associated with 
reduced disease-free survival compared to high DOK7V2 expression. 
 
8.2.5 Functional role of DOK7 in colorectal cancer 
 
It took almost a year to develop overexpression cell models using DOK7 variant synthesised 
sequences. These enabled us to investigate the impact of DOK7V2 overexpression on some of 
the important functions of colorectal cancer cells, namely cell growth, adhesion and invasion. 
Despite the differences observed at a cohort level, in vitro functional assays revealed no 
significant differences in colorectal cancer cell growth, adhesion or invasion. This may be due 
to the inherent limitations of functional assays and culture media in replicating the complexity 
of the tumour in vivo.    
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8.2.6 Evaluation of DOK7 coordinated cell signalling in colorectal cancer 
 
Although we were unable to pursue protein analysis using Western blot due to difficulties 
with Dok-7 antibodies and a lack of isoform specific antibodies, we investigated the effect of 
DOK7V2 overexpression on protein expression and activation using an antibody based 
protein microarray. 
 
We found that DOK7V2 overexpression is associated with significant changes in the 
expression and phosphorylation (activation) of numerous proteins in RKO cells.  
 
Notable proteins significantly overexpressed in DOK7V2 overexpression cells include the 
receptor tyrosine kinase VGFR2, the non-receptor tyrosine kinase JAK3 and the atypical 
serine/threonine kinase mTOR. These and other overexpressed proteins including PRKDC, 
MEK5, catenin b, DUSP4, Grp94 and 4E-BP1 have previously been linked with colorectal 
tumour aggressiveness and poorer clinical outcomes. Cell signalling pathways associated with 
these proteins include the PI-3K-Akt, MAPK, JAK-STAT, mTOR, ErbB/HER, Wnt/β-catenin 
and angiogenesis signalling pathways.  
 
Notable proteins significantly activated in the DOK7V2 overexpression cells include the 
transmembrane receptor tyrosine kinase TrkB, transcription factor CREB1, Cyclin B1, 
translational protein 4E-BP1 and protein kinase ERK5, the expression of all of which have 
previously been linked with increased colorectal cancer malignant potential and poorer 
clinical outcomes. Cell signalling pathways associated with these proteins include the PI-3K-
Akt, MAPK, mTOR, ErbB/HER and angiogenesis signalling pathways. 
 
We have been able to illustrate the effect of DOK7V2 overexpression on the mTOR, 
Jak/STAT and angiogenesis signalling pathways, which all play an important role in 
colorectal carcinogenesis. Our findings provide a useful starting point for future work to 
 460 
elucidate how Dok 7 isoforms interact with other cell signalling proteins and to determine 
whether Dok 7 itself has the potential to be a useful therapeutic target.  
  
8.2.7 Summary of thesis findings 
 
Overall, our results suggest that DOK7 plays a role in colorectal cancer and that different 
DOK7 variants coding for different protein isoforms may be differentially expressed in 
colorectal cancer compared to normal colorectal tissue.  
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8.3 Limitations 
 
There are a number of limitations regarding the data discussed in this thesis. Firstly, the 
numbers of samples available in some subgroups of the cohort were small and therefore, the 
results should be treated with some caution. Secondly, our cohort samples were all obtained 
from patients undergoing surgery for operable colorectal cancer. Consequently, the majority 
of samples available for analysis were Dukes’ B (n=33) and Duke’s C (n = 32) cancers with 
relatively fewer Dukes’ A (n = 7). Whilst the data is representative of patients with surgically 
resectable disease, it may not necessarily be applicable to patients with early, undetected 
cancer, those undergoing endoscopic removal for early cancers or those with advanced, 
inoperable disease. Furthermore, the recent introduction of bowel screening in Wales may 
result in a change in the pathological profile of patients undergoing surgery for bowel cancer 
in Wales over the next few years towards the detection and treatment of earlier cancers.  
 
A further limitation is that the tissue samples obtained for the current study were obtained 
from a cohort of patients undergoing treatment for bowel cancer over a 1-year period from 
2005-2006. As such, the neo-adjuvant or adjuvant oncological therapy given to some of the 
patients in this study may have been superseded by newer therapies and therefore, the 
application of results relating to oncological therapies should be treated with some caution.  
 
In order to address these limitations, ethical approval is currently being sought to collect 
further operative samples to obtain a larger cohort, to enable analysis of tissue from patients 
undergoing contemporary oncological treatment and also to include lymph node tissue for 
analysis. Biopsy material from colonoscopies would also provide useful tissue from early 
cancers, and also from patients without cancer with normal and adenomatous colorectal 
mucosa. This would potentially enable more detailed analysis of DOK7 expression during the 
normal-adenoma-carcinoma sequence but limitations to this include the size of biopsy 
obtained relative to the quantity of tissue required for diagnosis and also the risks and ethical 
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considerations involved in obtaining additional biopsies for research study, particularly in 
patients who are asymptomatic or do not have proven pathology. 
 
One of the main limitations of this thesis is that we were unable to confirm our findings at the 
protein level despite multiple attempts at Western blot owing to problems with Dok-7 
antibodies. Ideally, we would have developed our own variant-specific antibodies but this was 
not practical given the time restraints of a PhD project as well as the cost and practical 
difficulties this would have posed.   
 
8.4 Future perspectives 
 
This study has demonstrated that the expression of DOK7 variants may differ in colorectal 
cancer compared to normal colorectal tissue and that changes in the expression of these 
variants may impact not only at a cellular level on cell function, but also at a clinical level by 
affecting tumour pathology and patient outcomes.  
 
This clinically oriented PhD seeks to bridge the gap between what is observed at the cellular 
level and what is seen clinically. We have identified several interesting novel findings in 
relation to DOK7 but have generated many questions and avenues for further investigation.  
Further work is now required to better our understanding of how DOK7 and its variants 
interact with other proteins, how it modulates cell signalling, how it impacts on colorectal 
cancer cell function and ultimately, how this information may be usefully applied in the 
clinical context either as a predictive or diagnostic tool, as a means of prognostication or 
treatment stratification or as a potential target for molecular therapies.  
Specific areas for future work are as follows.  
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8.4.1 Correlation of findings at the protein level 
 
Unfortunately, attempts to confirm our findings at the protein level using SDS-PAGE and 
Western blot failed due to difficulties with antibodies. Given more time, we would like to 
develop isoform specific Dok-7 antibodies that would enable us to confirm our findings at the 
protein level.  
 
8.4.2 Generation of additional cell models 
 
Owing to the time constraints of a PhD study, work was focused on DOK7V2 overexpression 
cell models in two colorectal cell lines. With more time, additional cell models would be 
helpful to correlate this study’s findings, investigate the impact of DOK7V1 and DOK7V3 
overexpression and to investigate the effects of DOK7V1-3 knockdown on colorectal cancer 
cell function.   
 
8.4.3 Investigation of additional cell functions 
 
Although this study has shed some light on the effect of DOK7V2 expression on cell growth, 
adhesion and invasion, attempts to investigate the effect on cell migration using a scratch 
assay and ECIS failed due to disruption of the RKO cell monolayer. Potential solutions to 
overcome this particular challenge may include the establishment of cell models using an 
alternative colorectal cell line or the use of alternative migration assays. 
 
Alternative migration assays include scatter assays, which monitor cell movement from 
clustered cells by adding a motogen such as HGF or FGF or alternatively, motility assays 
using a cell carrier bead, which co-culture cells with beads in a universal container overnight 
allowing cells to attach to the beads. Non-attached cells are washed off using low speed (500-
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700 rpm for 5 min) centrifuge and PBS. The beads are resuspended in a medium, added to a 
culture plate and fixed after a period of 2-4 hours incubation. 
  
8.4.4 Further elucidation of cell signalling pathways 
 
Based on the results of the functional assays and antibody-based protein microarray, some 
preliminary work has been undertaken to identify potential interacting proteins for DOK7 and 
to try to establish which cell signalling pathways are implicated.  
 
Further work is necessary firstly to localise DOK7 variants in normal and colorectal cancer 
cells and secondly, to confirm the role of DOK7V2 in the cell signalling pathways discussed 
in Figure 7.3-7.5.  
 
A recently published paper by Friedrich et al investigating the role of DOK1 in colorectal 
cancer found that cytoplasmic DOK1 activated peroxisome-proliferator-activated-receptor-
gamma (PPARγ) leading to inhibition of the c-FOS promoter and cell proliferation (463). By 
comparison, nuclear DOK1 was inactive (463). The same authors found that use of a PPARγ-
agonist increased the expression of endogenous DOK1 and its interaction with PPARγ, 
leading them to suggest that DOK1 may be a potential therapeutic target (463). 
 
8.4.5 In vivo models 
 
Finally, we plan to correlate our findings using in vivo DOK7 variant overexpression mouse 
models to further explore the impact of DOK7 variant expression on tumour growth and 
survival. Hopefully this will help us to overcome some of the limitations of cell line based 
single functional assays. 
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Appendices 
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Appendix 1: General compounds used in this study 
 
Table 2.2 General compounds used in this study and their sources 
 
Material/Reagent Supplier 
Acetic acid Fisher Scientific, Leicestershire, UK 
Acrylamide mix (30%) Sigma-Aldrich, Poole, Dorset, UK 
Agar Melford Laboratories Ltd, Suffolk, UK 
Ammonium persulphate (APS) Sigma-Aldrich, Poole, Dorset, UK  
Amphotericin B Sigma-Aldrich, Poole, Dorset, UK 
Ampicillin Sigma-Aldrich, Poole, Dorset, UK 
Amplifluor™ UniPrimer™ Intergen Inc., Oxford, United Kingdom 
Aprotinin Sigma-Aldrich, Poole, Dorset, UK 
β-glycerophosphate  Sigma-Aldrich, Poole, Dorset, UK 
Benzamidine Sigma-Aldrich, Poole, Dorset, UK 
Bio-Rad DC™ Protein Assay Bio-Rad Laboratories, Hercules, CA, USA 
Blasticidin S Melford laboratories Ltd, Suffolk, UK 
Boric acid Duchefa Biochemie, Haarlem, Netherlands 
Bovine serum albumin (BSA) Sigma-Aldrich, Poole, Dorset, UK 
Bromophenol Blue Sigma-Aldrich, Poole, Dorset, UK 
Calcium chloride (CaCl2) Sigma-Aldrich, Poole, Dorset, UK 
Chloroform Sigma-Aldrich, Poole, Dorset, UK 
Coomassie blue Sigma-Aldrich, Poole, Dorset, UK 
Crystal violet Sigma-Aldrich, Poole, Dorset, UK  
Diethylpyrocarbonate (DEPC) Sigma-Aldrich, Poole, Dorset, UK 
Dimethylsulphoxide (DMSO) Fisons Scientific Equipment, Loughborough, UK 
Disodium phosphate (Na2HPO4) BDH Chemicals Ltd, Poole, Dorset, UK 
Dithiothreitol Sigma-Aldrich Ltd, Dorset, UK 
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Dulbecco’s Modified Eagles’ 
Medium/Nutrient mixture F12 
Ham (DMEM/F-12) with 2mM L-
glutamine 
PAA Laboratories, Coelbe, Germany 
Ethylenediaminetetraacetic acid 
(EDTA) 
Duchefa Biochemie, Haarlem, Netherlands 
Ethanol Fisher Scientific, Leicestershire, UK 
Foetal calf serum (FCS) PAA Laboratories, Coelbe, Germany 
Formalin Sigma-Aldrich Ltd, Dorset, UK 
GenElute™ Plasmid Miniprep kit Sigma-Aldrich Ltd, Dorset, UK 
GenScript® PCR DNA ladder Qiagen Ltd, Manchester, UK 
Glycine  Melford Laboratories Ltd, Suffolk, UK 
GoTaq® Green Master Mix Promega 
High capacity cDNA reverse 
transcription kit  
Applied Biosciences 
Hydrochloric acid (HCl) Sigma-Aldrich, Poole, Dorset, UK 
Isopropyl alcohol/isopropanol/2-
propanol 
Sigma-Aldrich, Poole, Dorset, UK 
Leupeptin Sigma-Aldrich, Poole, Dorset, UK 
Luminata(TM0 Forte Western HRP 
chemiluminescence substrate 
Millipore, MA, USA 
Matrigel® BD Biosciences, Oxford, UK 
Mayer HTX solution Sigma-Aldrich, Poole, Dorset, UK 
Methanol Fisher Scientific, Leicestershire, UK 
Monopotassium phosphate 
(KH2PO4) 
BDH Chemicals Ltd, Poole, Dorset, UK 
3-(N-morpholino)propanesulfonic Sigma-Aldrich, Poole, Dorset, UK 
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acid (MOPS) 
Nitrocellulose membrane Ammersham, Cardiff, UK 
OneShot® TOP10 chemically 
competent E.coli  
Life Technologies, Paisley, UK 
pEF6/V5-His TOPO® TA 
Expression kit  
Invitrogen, CA, USA 
Penicillin Sigma-Aldrich, Poole, Dorset, UK 
Pepstatin A Sigma-Aldrich, Poole, Dorset, UK 
Peroxidase conjugated goat anti-
rabbit IgG 
Sigma-Aldrich, Poole, Dorset, UK 
Peroxidase conjugated rabbit anti-
mouse IgG 
Sigma-Aldrich, Poole, Dorset, UK 
Phenylmethylsulfonyl fluoride 
(PMSF) 
Sigma-Aldrich, Poole, Dorset, UK 
Ponceau S Sigma-Aldrich, Poole, Dorset, UK 
Precision qScript™ RT PCR kit Primerdesign Ltd, Southampton, UK 
Potassium chloride (KCl) Fisons Scientific Equipment, Loughborough, UK 
REDTaq® ReadyMix™ PCR 
Reaction Mix 
Sigma-Aldrich, Poole, Dorset, UK 
RPMI Sigma-Aldrich, Poole, Dorset, UK 
Serum bovine albumin Sigma-Aldrich, Poole, Dorset, UK 
SOC medium Invitrogen, CA, USA 
Sodium dodecyl sulphate (SDS) Melford Laboratories Ltd, Suffolk, UK 
Sodium chloride (NaCl) Sigma-Aldrich, Poole, Dorset, UK 
Sodium fluoride Sigma-Aldrich, Poole, Dorset, UK 
Sodium hydroxide (NaOH) Sigma-Aldrich, Poole, Dorset, UK 
Sodium nitrate Sigma-Aldrich, Poole, Dorset, UK 
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Sodium orthovanadate (NA2VO4) Sigma-Aldrich, Poole, Dorset, UK 
Sodium pyrophosphate Sigma-Aldrich, Poole, Dorset, UK 
Streptomycin Sigma-Aldrich, Poole, Dorset, UK 
Sucrose Fisons Scientific Equipment, Loughborough, UK 
SYBR®Safe DNA gel stain  Life Technologies Ltd, Paisley, UK 
Tetramethylethylenediamine 
(TEMED) 
Sigma-Aldrich, Poole, Dorset, UK 
TRI Reagent® Sigma-Aldrich, Poole, Dorset, UK 
Tris Sigma-Aldrich, Poole, Dorset, UK 
Tris-Cl Melford Laboratories Ltd, Suffolk, UK 
Triton X-100 Sigma-Aldrich, Poole, Dorset, UK 
Trypsin Sigma-Aldrich, Poole, Dorset, UK 
Tryptone Duchefa Biochemie, Haarlem, Netherlands 
Tween 20 Melford Laboratories Ltd, Suffolk, UK 
Vectastain Universal ABC kit Vector Laboratories Inc, Burlingame, CA, USA 
Yeast extract Duchefa Biochemie, Haarlem, Netherlands 
Zinc chloride (ZnCl) Sigma-Aldrich, Poole, Dorset, UK 
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Appendix 2: General plastic consumables used in this study 
 
Table 2.3 General plastic consumables, hardware and software used in this study and their 
sources 
 
Plastic consumable/Hardware/Software Supplier 
24 well plate  
 
Nunc™, ThermoFisher Scientific, 
Loughborough, UK 
96 well plate Nunc™, ThermoFisher Scientific 
Amplifluor™ detection system Intergen, England, UK 
Applied Biosystems® 2720 PCR Thermal cycler ThermoFisher Scientific 
Cell scraper ThermoFisher Scientific 
Centrifuge Woolf Laboratories, York, UK 
Class II Laminar Flow Cabinet Woolf Laboratories, York, UK 
Cryotube Woolf Laboratories, York, UK 
Drying oven Woolf Laboratories, York, UK 
Electrophoresis gel tray Scie-Plas Ltd, Cambridge, UK 
Electrophoresis unit Woolf Laboratories, York, UK 
Electroporation cuvette (4mm) Euro Gentech, Southampton, UK 
Electroporator Woolf Laboratories, York, UK 
ELx800 plate reading spectrophotometer Bio-Tek, Wolf Laboratories, York, UK 
Eppendorf tube (1.8ml) Greiner Bio-one GmbH, Bristol, UK 
Falcon tube Greiner Bio-one GmbH, Bristol, UK 
Filter paper Sigma-Aldrich, Poole, Dorset, UK 
Filtration unit (0.4µm) Sigma-Aldrich, Poole, Dorset, UK 
Gibco BRL Electrophoresis power supply (model 
250EX) 
Life Technologies, Paisley, UK 
Glass pipette ThermoFisher Scientific 
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Glass plates for SDS-PAGE Woolf Laboratories, York, UK 
Hybond nitrocellulose membrane  Amersham Biosciences Ltd, Bucks, UK 
iCycler iQ system Bio Rad, Hercules, CA, USA 
Image J https://imagej.nih.gov/ij/ 
Incubator Sanyo Electric, Japan 
Labinco rotating wheel Woolf Laboratories, York, UK 
Leica DM IRB microscope Leica GmbH, Bristol, UK 
MicroAmp® Optical Adhesive film  
 
ThermoFisher Scientific, Paisley, UK 
Microscope heated plate Leica, GmbH, Bristol, UK 
Microsoft Excel Microsoft Inc, Redmond, WA, USA 
Mini start filter (0.2µm) Sartorius, Epsom, UK 
Mr Frosty™ Freezing Container Thermo Scientific, Waltham, MA, USA  
Neubauer haemocytometer counting chamber Reichert, Austria 
Nitrocellulose membrane Hybond C, Ammersham, Cardiff 
Partec CyFlow® FloMax software Partec GmbH, Munster, Germany 
Partec CyFlow® SL flow cytometer Partec GmbH, Munster, Germany 
PCR tube (200µL) ABgene, Surrey, UK 
Petri dishes (10cm
2
) BibbySterilin Ltd, Staffs, UK 
Protein spectrophotometer BIO-TEK, Wolf Laboratories, York, UK 
RNA spectrophotometer BIO-TEK, Wolf Laboratories, York, UK 
SD20 SemiDry Maxi System blotting unit  SemiDRY, Wolf Laboratories, York, UK 
Tali® cellular analysis slide Life Technologies, Paisley, UK 
Tali® Image Cytometer Life Technologies, Paisley, UK 
Techne Hybridiser HB-1D drying oven Wolf Laboratories, York, UK 
T-Cy Thermocycler Creacon Technologies Ltd, Netherlands 
Tissue culture flasks (25cm
2
 and 75cm
2
) Greiner Labortechnik, Germany 
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Trans-well inserts 8µm pore size Corning™ Falcon™, Loughborough, UK 
Ultra-Turrax T8 homogeniser IKA Labortechnik, Staufen, Germany 
Universal container (30ml) Greiner Bio-One Ltd, Gloucestershire, 
UK 
UV1101 Biotech Photometer  WPA, Cambridge, UK 
UV light chamber  Germix 
UVI band software  UVITEC, Cambridge, UK 
UVI-doc system UVI-Tech Inc., Cambridge, England, UK 
UVITEC imager UVITEC, Cambridge, England, UK 
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Appendix 3: Antibodies used in this study 
 
Table 2.4 Primary antibodies 
 
Antibody against Species Supplier Catalogue number 
C-terminal Dok7 
(cDok7) 
Rabbit polyclonal Santa Cruz 
Biotechnology Inc. 
SC-50463 
N-terminal Dok7 
(nDok7) 
Rabbit Abgene AP13568a 
DOK7 (p-19) Goat polyclonal Santa Cruz 
Biotechnology Inc 
SC-55168 
Phosphorylated Dok7 
(pDok) 
Rabbit polyclonal Santa Cruz 
Biotechnology 
SC-68691 
His-probe Mouse monoclonal Santa Cruz 
Biotechnology Inc 
SC-53073 
His-probe Mouse monoclonal  Santa Cruz 
Biotechnology Inc 
SC-8036 
GAPDH Mouse monoclonal Santa Cruz 
Biotechnology Inc 
SC-47724 
GAPDH Mouse monoclonal Santa Cruz 
Biotechnology Inc 
SC-32233 
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Table 2.5 Secondary antibodies 
 
Antibody  Supplier Catalogue number 
Peroxidase 
conjugated Anti-
mouse IgG 
Sigma-Aldrich, 
Poole, Dorset, UK 
A9044-2ML 
Peroxidase 
conjugated Anti-
rabbit IgG 
Sigma-Aldrich, 
Poole, Dorset, UK 
A9169 
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Appendix 4: Primers used in this study 
 
Table 2.6. Sequences of primers used in this study 
 
Gene Primer Sequence Product 
size (bp) 
DOK7 DOK7F1 5'-GAGTAGGTGGCTGGTGCT 129 
DOK7ZR
1 
5'-
ACTGAACCTGACCGTACACAGATGTCCTCTAGCGT
CA 
DOK7 DOK7F8 5'-TTCTACCAGACCCAAGTCC 409 (V1, 
V2, V3 
and V4) 
DOK7R8 5'-CTGCTGGAGTAAGAGGAGTG 
DOK7 DOK7F9 5'-GCTGGTCTACAAGGACAAGT 479 (V1, 
V2 and 
V4) 
DOK7R9 5'-AGTCGAACAGGAAGCTGAT 
DOK7 
Exp 
DOK7ex
F2 
5'-ATGACCGAGGCGGCGCTGGT 1512 
(V1) 
1501 
(V2) 
DOK7ex
R4 
5'-AGGAGGGGGGTTTACCTT 
DOK7 
Rib 1 
DOK7rib
1F 
5’-
CTGCAGCTCCCCCTCGGCCGAGCTGATGAGTCCGT
GAGG 
74 
DOK7rib
1R 
5’ACTAGTACTGGGCTGGCGTCTTCTTCCTGTTTCGT
CCTCACGGACT 
DOK7 
Rib 2 
DOK7rib
2F 
5’CTGCAGGCCCCTCCTGTGACGTGCTGGCTCTGAT
GAGTCCGTGAGGA 
87 
DOK7rib 5’ACTAGTCACCGCATGGCCAGAGCAATCCTCGTCG
 476 
2R TTTCGTCCTCACGGACT 
DOK7
V1 
DOK7V1
F1 
5’-CAGTGGAAGCTGTCTGACCT 90 
DOK7V1
ZR1 
5’-
ACTGAACCTGACCGTACAGCCAGCCCAGTACCCAC
A 
DOK7
V2 
DOK7V2
F1 
5’-ATGATGTCCTCGTCTTGGCC 132 
DOK7V2
ZR1 
5’-
ACTGAACCTGACCGTACAGAAGACGCCAGCCCCTG
GT 
DOK7
V3 
DOK7V3
F1 
5’-AGGGCTTCATTCACCCCTG 95 
DOK7V3
ZR1 
5’-
ACTGAACCTGACCGTACAGTCACTGGCAGAGCGAT
G 
DOK7
V1 
DOK7V1
F8 
5’-AAAGTGACCCTGGGCTGG 595 
DOK7V1
R8 
5’-GCCCAGTACCCACACCTG 
DOK7
V1 
DOK7V1
F9 
5’-GAGCTATTTTGAAAGTGACCCTG 609 
DOK7V1
R9 
5’-CCAGCCCAGTACCCACAC 
DOK7
V2 
DOK7V2
F8 
5’-TTGAAAGTGACCCTGGGCTG 597 
DOK7V2 5’-GAAGACGCCAGCCCCTGGT 
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R8 
DOK7
V3 
DOK7V3
F8 
5’-AGGGCTTCATTCACCCCTG 229 
DOK7V3
R8 
5’-CTCGGTCATCTTTCAGGGGA 
DOK7
V3 
DOK7V3
F9 
5’-TTCATTCACCCCTGGCCG 227 
DOK7V3
R9 
5’-CTCCTCGGTCATCTTTCAGG 
pEF/H
is 
TOPO 
TA 
plasmi
d 
vector 
T7F TAATACGACTCACTATAGGG  
BGHR TAGAAGGCAGTCGAGG 
GAPD
H 
GAPDH 
F10 
5’AGCTTGTCATCAATGGAAAT 593 
GAPDH
R10 
5’CTTCACCACCTTCTTGATGT 
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Appendix 5: Breast cancer cell line data 
 
The expression of DOK7 was examined in three breast cancer cell lines – MCF7, MDA-MB-
231 and ZR751. DOK7 expression was seen in MCF7 and ZR751 cells but was not seen in 
MDA-MB-231, a poorly differentiated metastatic breast adenocarcinoma. DOK7 mRNA 
expression in breast cancer cell lines is shown in Figure a5.1 below.  
 
 
Figure a5.1 DOK7 mRNA expression in breast cancer cell lines 
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Appendix 6: Gastric clinical cohort data 
 
A total of 322 samples were obtained from primary gastric cancer tissue and 183 samples 
were obtained from normal background gastric tissue. Two hundred and thirty of the patients 
were male and 92 were female. The median follow up period was 120 months.   
 
The histopathological details of the gastric tumours included in this study are shown in Table 
a6.1. 
 
  
 480 
Table a6.1. Histopathological details of the gastric tumours included in this study 
 
   
Number (%) 
Histological type 
   
 
Adenocarcinoma Non-junctional  256 (79.5%) 
  
Junctional 51 (15.8%) 
 
Interstitial/GIST 
 
5 (1.6%) 
 
Type/location unknown 
 
10 (3.1%) 
Grade  High 
 
1 (0.3%) 
 
High-medium 
 
6 (1.9%) 
 
Medium 
 
62 (19.3%) 
 
Medium-low 
 
82 (25.5%) 
 
Low 
 
136 (42.2%) 
 
Grade unknown 
 
35 (10.9%) 
T stage T1 
  
16 (5.0%) 
 
T2 
  
26 (8.1%) 
 
T3 
 
41 (12.7%) 
 
T4 
 
231 (71.7%) 
 
T stage unknown 
 
8 (2.5%) 
Overall stage Stage I 
 
25 (7.8%) 
 
Stage II 
 
60 (18.6%) 
 
Stage III 
 
219 (68.0%) 
 
Stage IV 
 
9 (2.8%) 
 
Overall stage unknown 
 
9 (2.8%) 
Nodal status 
 
Node negative (N0) 
 
70 (21.7%) 
 
N1 
 
48 (14.9%) 
 
N2 
 
65 (20.2%) 
 N3  
133 (41.3%) 
 
Nodal status unknown 
 
6 (1.9%) 
Metastatic status Distant metastases present  41 (12.7%) 
 No distant metastases  280 (87.0%) 
 Metastatic status unknown  1 (0.3%) 
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The expression of DOK7 is not significantly different in gastric tumours compared to normal 
gastric tissue (median DOK7 mRNA expression per 50µg of total cellular RNA was 2438 vs. 
2126 respectively, p = 0.6397). Data is shown in Table a6.2. 
 
Table a6.2. DOK7 expression in gastric cancer and normal gastric tissue 
 
Tissue Number of 
samples 
analysed 
Median DOK7 mRNA expression per 50µg of 
total cellular RNA (copy number) 
Normal gastric tissue 183 2126 
Gastric tumours 322 2438 
 
There was no significant difference in DOK7 mRNA expression between gastric cancer 
samples when analysed by T stage, nodal status, distant metastases, overall stage, location 
within the stomach, disease free status and overall survival.   
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Appendix 7: Colorectal gene array data 
 
A search of gene array data identified a cohort of 585 colorectal cancer samples with 19 non-
tumour tissues. Interestingly, analysis of this cohort revealed that DOK7 mRNA expression 
was increased in colorectal cancer compared to normal colorectal tissue (median DOK7 value 
4.493 vs. 4.358, p = 0.037), the opposite to what was found in our dataset. Data is shown in 
Figure a7.1.  
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Figure a7.1 DOK7mRNA expression in colorectal cancer and normal colorectal tissue in a 
cohort of 585 colorectal cancer samples and 19 non-tumour tissues 
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Moreover, when this cohort of colorectal cancers were divided into subgroups representing 
different molecular subtypes as identified by Marisa et al and analysed for level of DOK7 
expression there was a significant difference in DOK7 expression in different molecular 
subtypes (p = 0.05) (266). Data is shown in Figure a7.2. 
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Figure a7.2 DOK7 mRNA expression in colorectal cancer in a cohort of 585 colorectal cancer 
samples analysed according to molecular subtypes 
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Again, in contrast to our findings, analysis of this cohort failed to show any association 
between DOK7 mRNA expression and T stage (p = 0.616) but showed that DOK7 mRNA 
expression was significantly reduced in node positive disease compared to node negative 
colorectal cancers (median DOK7 value 4.416 vs. 4.525, p = 0.001) and was significantly 
reduced in Stage III tumours compared to Stage II (p < 0.01) and Stage IV tumours (p < 
0.05). In keeping with our findings, DOK7 mRNA expression was not affected by presence of 
distant metastases (p = 0.171). Finally, Kaplan-Meier survival analysis revealed that high 
DOK7 expression, defined by expression levels over the 75% centile, was associated with 
significantly poorer overall survival (p = 0.033). Data is shown in Figure a7.3. 
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Figure a7.3 Kaplan-Meier survival curve showing overall survival time in months in high 
(over 75% centile) vs. low DOK7 expression in a cohort of 585 colorectal cancer samples.  
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